[
    {
        "anchor": "Table 2 Best overall response according to RECIST",
        "positive": "Table 2 displays the best overall response to treatment, as assessed using the RECIST evaluation method.",
        "negative": "TNFR2 downregulation suppresses pancreatic cancer cell migration and invasion\nWound-healing assays were used to measure cell migration changes by calculating the wound closure area (Figure 3D)."
    },
    {
        "anchor": "Trial Design\nOur trial complied with the Helsinki Declaration and was approved by the institutional review boards.",
        "positive": "The study was conducted in accordance with the Helsinki Declaration and received approval from the institutional review boards.",
        "negative": "Data Sharing Statemen\nRaw data will be provided by corresponding authors upon reasonable request."
    },
    {
        "anchor": "A total of 112 patients receiving the RP2D had PD-L1 data.",
        "positive": "The RP2D treatment group consisted of 112 patients, all of whom had PD-L1 data.",
        "negative": "Efficacy analysis\nThe median follow-up time was 9.5 (95% CI 9.3\u20139.7) months."
    },
    {
        "anchor": "For each ELISpot assay, co-culture of T cells and antigen presenting cells but without any peptides was used as negative control and a one-way ANOVA with Dunnett\u2019s multiple comparison test was used to determine if the peptide elicited reactivity relative to control.",
        "positive": "The ELISpot assays used a negative control consisting of T cells and antigen presenting cells without peptides, and a statistical test was applied to evaluate the reactivity of peptides compared to this control.",
        "negative": "Presence of T cells Recognizing Cancer Mutations\nWe sequenced whole-exomes and transcriptomes of pretreatment tumors with paired germline and human leukocyte antigen sequencing (Supplementary Table 2)."
    },
    {
        "anchor": "b, c Kinetic changes of serum AQP4-IgG detected by cell-based assay (CBA) and BCMA post-infusion.",
        "positive": "The kinetic changes in serum AQP4-IgG levels were monitored using a cell-based assay (CBA) and BCMA after infusion.",
        "negative": "Study design and oversight\nThis is an investigator-initiated, open-label, single-arm, phase 1 study, which is conducted at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China."
    },
    {
        "anchor": "Circulating Tumor Material Assays:\nPlasma cell-free DNA (cfDNA) and RNA (cfRNA) will be delivered, processed, and frozen as per SOP to the Circulating Tumor Material Center.",
        "positive": "Plasma cell-free DNA (cfDNA) and RNA (cfRNA) will be collected, processed, and stored according to standard operating procedures (SOP) and sent to the Circulating Tumor Material Center.",
        "negative": "4 | Treatment efficacy in patients with or without pathologic evidence of LN involvement."
    },
    {
        "anchor": "The DMC will include 3 clinicians experienced in Lung Cancer and 1 external statistician; this is in addition to the unblinded trial statistician who will be a non-voting member of the committee.",
        "positive": "The DMC will comprise three clinicians with lung cancer expertise, one external statistician, and the unblinded trial statistician, who will serve as a non-voting member.",
        "negative": "Survival and Toxicity\nSurvival analyses were performed on the 61 patients who accepted assignment to treatment (44 patients) or surveillance (17 patients)."
    },
    {
        "anchor": "All subjects were relapse or refractory to the last line of therapy.",
        "positive": "The study population consisted of patients who had relapsed or were refractory to the last line of therapy.",
        "negative": "Title: Phase \u2161 Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma\n\nAbstract: Background:Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell, is under investigation in patients (pts) with relapsed/refractory multiple myeloma (RRMM) of an ongoing phase 1/2 study, LUMMICAR STUDY1 (NCT03975907) in China."
    },
    {
        "anchor": "PD-L1 expression levels were scored by the percentage of PD-L1 membranous staining at any intensity on tumor cells.",
        "positive": "The level of PD-L1 expression was determined by measuring the percentage of PD-L1 staining on tumor cells.",
        "negative": "Does your paper address CONSORT subitem 12b?"
    },
    {
        "anchor": "ConclusionsA subset of neurocognitive tests in CART-NS sensitively detects early neurologic and cognitive changes that correlate with alterations in ICE score and ICANS grading.",
        "positive": "The study found that a subset of neurocognitive tests in the CART-NS group were sensitive to early changes in neurologic and cognitive function, which correlated with changes in ICE score and ICANS grading.",
        "negative": "Introduction\nThe focus of cancer therapy has shifted from the tissue to the genetic level."
    },
    {
        "anchor": "Patients who had undergone allogeneic HCT were required to have a confirmed CD19+ leukemia recurrence, defined as \u22650.01% disease, and were required to be free from active graft-versus-host disease (GVHD) and have ended immunosuppressive therapy \u22654 weeks before enrollment.",
        "positive": "Patients who received allogeneic hematopoietic cell transplantation were required to have a confirmed recurrence of CD19-positive leukemia, with a disease burden of at least 0.01%, and be free from active graft-versus-host disease and off immunosuppressive therapy for at least four weeks prior to enrollment.",
        "negative": "Description\nClass and constructor for n-dimensional ellipsoidal (<>)filter objects."
    },
    {
        "anchor": "Efficacy and safety variables will be observed during the study.",
        "positive": "Efficacy and safety will be assessed during the study period.",
        "negative": ",5%\ue003$SSURYDO\ue003\ue003\nEach investigator or group of investigators at a clinical site must obtain IRB approval for this protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office before they can be approved to enroll patients."
    },
    {
        "anchor": "P < 0.05 was considered statistically significant.",
        "positive": "A significance level of 0.05 or less was used to determine statistical significance.",
        "negative": "Standard Protocol Approvals, Registrations, and Patient Consents\nProcedures were compliant with the ethical principles of the Declaration of Helsinki and were approved by the Ethic Committee of the First Hospital of Jilin University."
    },
    {
        "anchor": "Patient PBMCs were processed by Ficoll-Hypaque gradient protocol for leukapheresis samples or cell processing tubes (BD Biosciences) for whole blood samples.",
        "positive": "Peripheral blood mononuclear cells from patients were processed using the Ficoll-Hypaque gradient protocol for leukapheresis samples or cell processing tubes from BD Biosciences.",
        "negative": "Immunogenicity analysis\nPBMCs for immunogenicity analysis were processed from leukapher-esis (baseline and week 9) or whole blood collections (all other time-points)."
    },
    {
        "anchor": "The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.",
        "positive": "A phase Ib open-label study evaluated the combination of figitumumab, an insulin-like growth factor-I receptor inhibitor, and docetaxel in patients with advanced solid tumors.",
        "negative": "Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials."
    },
    {
        "anchor": "As\u00a0PTPN2/N1 inhibition lowered the threshold for TCR signalling and T cell activation (Fig.",
        "positive": "PTPN2/N1 inhibition decreased the threshold for T cell receptor signaling and activation, as depicted in Figure.",
        "negative": "AC484 increases TCR diversity in tumours\nGiven our observation of increased antigen presentation in AC484treated tumour cells both in vitro and in vivo (Fig."
    },
    {
        "anchor": "The persistence of CAR-T cells was another index that was closely monitored.",
        "positive": "The persistence of chimeric antigen receptor T cells was a key metric that was closely tracked.",
        "negative": "Trial design\nWe conducted a phase I clinical trial to investigate the safety and efficacy of combined belapectin plus pembroli-zumab immunotherapy in patients with MM or HNSCC (NCT02575404)."
    },
    {
        "anchor": "Up to 40% of patients present with locally advanced NSCLC (stage IIIA/B, see Appendix I for TNM Classification) that is frequently inoperable.",
        "positive": "About 40% of patients with non-small cell lung cancer (stage IIIA/B) had locally advanced disease that was frequently inoperable, as detailed in Appendix I.",
        "negative": "BACKGROUND and RATIONALE\nLung cancer is the leading cause of cancer mortality in North America."
    },
    {
        "anchor": "QUANTIFICATION AND STATISTICAL ANALYSIS\n3 Sample size calculations and statistical considerations for the primary analyses have been reported previously.Patients with treatment assignment and any type of biomarker measurement (PD-L1, tTMB, bTMB, or GEP) were included in this retrospective exploratory analysis.",
        "positive": "The statistical analysis plan, including sample size calculations, has been previously published.",
        "negative": "An Open-Label, Single Arm, Multicenter Phase II Study\nHong-Yun Zhao, PhD, Gong-Yan Chen, PhD, Yan Huang, PhD, Xiao-li Li, PhD, Ji-Feng Feng, PhD, Mei-Qi Shi, MD, Ying Cheng, MD, Li-Xia Ma, MS, Yi-Ping Zhang, MD, Cui-Ping Gu, MS, Xiang-Qun Song, MD, Da Zhou, MD, and Li Zhang, MD Abstract: Preclinical studies have shown synergism between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and antifolates in solid tumors."
    },
    {
        "anchor": "Patient 15 had a CT done after CAR-T that demonstrated progression of adenopathy in the chest, abdomen, and pelvis with PD confirmed by biopsy and also developed new CSF disease post-CART.",
        "positive": "Patient 15 underwent a computed tomography scan after CAR-T cell therapy, which showed progression of lymph node enlargement in the chest, abdomen, and pelvis, with disease progression confirmed by biopsy, and also developed new central nervous system disease after CART cell therapy.",
        "negative": "3 | RESULTS\n8 Sixteen patients were treated at a target dose of 2.5 \ue001 106 cells/kg."
    },
    {
        "anchor": "External sources \u2022 No sources of support provided",
        "positive": "No external funding was received for this study.",
        "negative": "2.1 Model Design\nThis analysis evaluated lifetime costs and health outcomes of nivolumab versus docetaxel by squamous and non-squamous histologies."
    },
    {
        "anchor": "J Thorac Oncol.",
        "positive": "The Journal of Thoracic Oncology was the publication.",
        "negative": "Mohammad Farhad, MS,\nEarle A Chiles Research Institute, Portland, OR, USA"
    },
    {
        "anchor": "Increased COX-2 expression is associated with more aggressive tumor behavior and poor prognosis in NSCLC patients [5].",
        "positive": "Research has shown that increased COX-2 expression is a predictor of aggressive tumor behavior and poor prognosis in NSCLC patients.",
        "negative": "Background\nApproximately 30% of patients with non\u2013small cell lung cancer (NSCLC) have locally advanced diseases (LA-NSCLC) [1]."
    },
    {
        "anchor": "The associations between CRS grade and neurotoxicity outcomes were evaluated using the Cochran Armitage test for trend.",
        "positive": "The study analyzed the correlation between CRS grade and neurotoxicity outcomes using the Cochran Armitage test.",
        "negative": "Values less than the lower limit of detection were recorded as half the lower limit."
    },
    {
        "anchor": "Hence, IMRT has not been shown to reduce the toxicity to the esophagus, at least not with traditional dose constraints.",
        "positive": "IMRT has not been proven to reduce esophageal toxicity, regardless of traditional dose constraints.",
        "negative": "Long-term follow up\nAfter completion of the initially recommended tumor-specific therapy, routine follow up will be performed every three months up to 24 months and includes thoracic and abdominal sectional imaging as well as lung function assessment."
    },
    {
        "anchor": "However, the study has several limitations.",
        "positive": "However, the study was not without its limitations.",
        "negative": "Abstract\nBackground: This study compared the results of the application of two different chest tube management systems; a drainage ball with low negative pressure and the more commonly used chest tube with water-sealed bottle, after video-assisted thoracoscopic (VATS) lobectomy."
    },
    {
        "anchor": "Funding\nBiohaven Pharmaceuticals funded the clinical trial.",
        "positive": "Biohaven Pharmaceuticals sponsored the clinical trial.",
        "negative": "Patients\nFrom September 22, 2020, to December 24, 2021, a total of 17 patients were screened, and 14 patients were apheresed."
    },
    {
        "anchor": "MRD was assessed at a threshold of 1 tumor cell per 105 white blood cells.",
        "positive": "The study set a threshold of 1 tumor cell per 105 white blood cells to detect MRD.",
        "negative": "Cox Proportional Hazards Model for PFS with Time-varying Covariates for MRD Status."
    },
    {
        "anchor": "Patients eligible for the UC cohort had histologically or cytologically con\ufb01rmed locally advanced or metastatic transitional cell carcinoma of the urothelium (e.g.",
        "positive": "The UC cohort included patients with histologically or cytologically confirmed locally advanced or metastatic transitional cell carcinoma of the urothelium.",
        "negative": "Results\nPatients were enrolled in ALKA-372\u2013001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018 (both studies were closed on May 17, 2018); and in STARTRK-2 on Nov 19, 2015 (enrolment is ongoing)."
    },
    {
        "anchor": "Subject should not experience a significant change in performance or clinical status compared to their previous study visit that would, in the opinion of the treating physician, increase the risk of experimental cell infusion.",
        "positive": "The treating physician should not consider a significant change in performance or clinical status to increase the risk of experimental cell infusion.",
        "negative": "In brief\nKRAS mutant pancreatic tumors have poor prognosis and few therapeutic options."
    },
    {
        "anchor": "Between 0.1 and 0.9mg/kg TransCon IL-2 \u03b2/\u03b3, IL-2 \u03b2/\u03b3 exposure (both mean Cmax and AUC0-336h) increased generally dose proportionally ((<>)figure 5C).",
        "positive": "The levels of IL-2 \u03b2/\u03b3 exposure, as represented by Cmax and AUC0-336h, increased in a dose-dependent manner within the 0.1 to 0.9mg/kg TransCon IL-2 \u03b2/\u03b3 range.",
        "negative": "INCLUSION AND DIVERSITY\nWe support inclusive, diverse, and equitable conduct of research."
    },
    {
        "anchor": "For the efficacy endpoint analyses, only those subjects with complete pre- and post-intervention bronchoscopy data were included.",
        "positive": "The efficacy endpoint analysis was limited to subjects who had complete bronchoscopy data before and after the intervention.",
        "negative": "Statistical Considerations\nThe primary endpoint was defined as change in histologic grade of bronchial dysplasia, based on a per-participant analysis."
    },
    {
        "anchor": "No grade 5 surgery-related AEs were reported in either treatment arm.",
        "positive": "There were no severe surgery-related adverse events reported in either treatment group.",
        "negative": "Discussion\nThis phase Ib study showed that simotinib was well tolerated and had a favorable safety profile in patients with advanced NSCLC and EGFR mutations."
    },
    {
        "anchor": "spillRefId Object of class \"character\" \u2013 the name of the compensation object (The compensation object contains the spillover Matrix).",
        "positive": "The spillRefId is a character object that represents the name of the compensation object, which contains the spillover matrix.",
        "negative": "Slots\n.Data Object of class \"function\"."
    },
    {
        "anchor": "clinical research subjects will be informed that there will be relevant personnel to audit during the trial, but patient privacy and data will be strictly protected.",
        "positive": "Participants in the clinical trial will be notified that there will be auditors present, while ensuring that patient privacy and data remain confidential.",
        "negative": "Cynomolgus Monkeys\nThe nonclinical toxicology study was conducted at Charles River Laboratories (CRL), Mattawan, USA, in accordance with US Food and Drug Administration Good Laboratory Practice Regulations for Nonclinical Laboratory Studies (21 CFR Part 58), the US Department of Agriculture Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources."
    },
    {
        "anchor": "Patient reported Outcomes (PRO\u2019s): PRO\u2019s include standard validated questionnaires assessing general wellbeing using the 36-Item Short Form Health Survey (MOS SF-36)",
        "positive": "Patient-reported outcomes (PROs) comprise standardized, validated questionnaires that evaluate overall wellbeing using the 36-Item Short Form Health Survey (MOS SF-36).",
        "negative": "CRediT Authorship Contribution Statement\nYing Cheng, Li Zhang, Jie Hu, Donglin Wang, ChengPing Hu, Jianying Zhou, Lin Wu, Lejie Cao, Jiwei Liu, Helong Zhang, Hong Sun, Ziping Wang, Hongjun Gao, Luis Paz-Ares: Investigation, Writing - review & editing."
    },
    {
        "anchor": "Evidence before this study\nIn developing the study design and protocol, we did a systematic review of the scientific literature.",
        "positive": "Prior to designing the study, we conducted a systematic review of the existing scientific literature to inform the study protocol.",
        "negative": "Efficacy\nThe efficacy analysis included 22 patients."
    },
    {
        "anchor": "We allowed dose modifications of all study drugs according to protocol-defined criteria (appendix).",
        "positive": "Dose adjustments for all study medications were permitted based on protocol-defined guidelines (appendix).",
        "negative": "14.8  Records Retention\nAll study-related documents must be retained for the maximum period required by applicable federal regulations and guidelines or institutional policies."
    },
    {
        "anchor": "No patient received subsequent anticancer therapy.",
        "positive": "None of the patients received additional anticancer treatment.",
        "negative": "13.3 Patient Accrual\nPatient accrual is projected to be 29 patients per month."
    },
    {
        "anchor": "To our knowledge, this represents the first use of this pan-tumor pathologic scoring system in a phase 3 registrational trial for any tumor type and provides evidence to support pathologic assessment of %RVT in both the PT and LNs for patients receiving neoadjuvant regimens that include immunotherapy.",
        "positive": "To our knowledge, this study is the first to utilize this pan-tumor pathologic scoring system in a phase 3 registrational trial for any tumor type, providing evidence for the pathologic assessment of %RVT in both the PT and LNs for patients receiving neoadjuvant regimens that include immunotherapy.",
        "negative": "Acknowledgments\nWe thank the participating patients and their families, as well as the investigators, subinvestigators, research nurses, study coordinators, and operations staff."
    },
    {
        "anchor": "Sample Flow Attrition Rates\nOf 1486 patients with no important protocol deviations, tumor samples from four were not tested: two biopsy samples were lost after pathological reading, one sample did not have a clot for preparing a tissue block, and the DNA concentration of one block was insufficient for testing.",
        "positive": "Out of 1486 patients with no significant protocol breaches, four patients' tumor samples were not analyzed due to various reasons, including two lost biopsy samples, one sample lacking a clot for processing, and one sample with insufficient DNA concentration.",
        "negative": "Background\nThe development of lung cancer is determined not only by cancer cell genomics and specific molecular alterations, but also by the interplay between cancer cells and the tumor microenvironment, especially the immune system [(<>)1, (<>)2]."
    },
    {
        "anchor": "Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.",
        "positive": "It is important to note that errors may arise during the production process, which could impact the content, and all relevant legal disclaimers will be applicable.",
        "negative": "Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, et al."
    },
    {
        "anchor": "GTV or iGTV should be re-contoured if tumor regression develops within the previously contoured region, but the CTV (or ITV) and PTV should remain the same.",
        "positive": "In cases where tumor regression occurs within the previously contoured area, GTV or iGTV should be re-contoured, while CTV (or ITV) and PTV should be maintained.",
        "negative": "Re-contouring\nx The GTV or iGTV, spinal canal, lungs and other OARs will be reviewed by a physician."
    },
    {
        "anchor": "Chapter 49: Small cell and Neuroendocrine Tumors of the Lung.",
        "positive": "Chapter 49: Neuroendocrine and Small Cell Lung Cancer.",
        "negative": "8 SURGERY\nPatients will undergo definitive radiation/chemotherapy."
    },
    {
        "anchor": "The images or other third party material in this article are included in the article\u2019s Creative Commons licence, unless indicated otherwise in a credit line to the material.",
        "positive": "The images and third-party materials in this article are licensed under the Creative Commons agreement, unless otherwise specified in the credit line.",
        "negative": "Contents lists available at (<www.sciencedirect.com/science/journal/19365233>)ScienceDirect\nTranslational Oncology journal homepage: (<https://www.elsevier.com/locate/tranon>)www.elsevier.com/locate/tranon Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer"
    },
    {
        "anchor": "The phase 1 dose escalation cohort comprised 32 patients treated with 10\u2013200 mg, while 161 patients comprised the phase 1b dose expansion cohorts (Fig.\u00a0(<>)1).",
        "positive": "The phase 1 dose escalation cohort included 32 patients treated with 10\u2013200 mg, and the phase 1b dose expansion cohort consisted of 161 patients (Fig.\u00a0(<>)1).",
        "negative": "For the 53 patients with NSCLC in phase 1b, the histology was adenocarcinoma (n = 45), squamous carcinoma (n = 5) and \u2018other\u2019 (n = 3); median age was 66.0 years; 39.6% were male; 60.4% were white and 26.4% were Asian; and 60.4% had ECOG PS 1."
    },
    {
        "anchor": "Availability of data and materials\nThe data and material of OAK and POPLAR study were derived from a previous publication, which was publicly available at https://www.nature.com/articles/ s41591-018-0134-3.",
        "positive": "The data and materials for the OAK and POPLAR studies were obtained from a publicly available publication, which can be accessed at https://www.nature.com/articles/ s41591-018-0134-3.",
        "negative": "RESEARCH\nINDUCE\u20112: A\u00a0Phase I/II, open\u2011label, two\u2011part study of\u00a0feladilimab in\u00a0combination with\u00a0tremelimumab in\u00a0patients with\u00a0advanced solid tumors John F. Hilton1 \u00b7 Patrick A. Ott2 \u00b7 Aaron R. Hansen3 \u00b7 Zujun Li4 \u00b7 Matthen Mathew5(<http://orcid.org/0000-0003-3254-0039>) \u00b7 Cristina H. Messina6 \u00b7 Vimal Dave7 \u00b7 Xiao Ji6 \u00b7 Natalie O. Karpinich6 \u00b7 Steven Hirschfeld6 \u00b7 Marc Ballas6 \u00b7 Dan P. Zandberg8 (<http://orcid.org/0000-0002-1002-8301>) Received: 31 August 2023 / Accepted: 25 December 2023 \u00a9 The Author(s) 2024"
    },
    {
        "anchor": "TAS-114 dosing was switched from body surface area (BSA)-based to a flat-fixed dose to avoid the risk of dosing errors.",
        "positive": "The dosing of TAS-114 was changed from body surface area-based to a flat, fixed dose to minimize the risk of dosing errors.",
        "negative": "Treatment was repeated every 3 weeks until disease progression, intolerable toxicities, or withdrawal of consent."
    },
    {
        "anchor": "All relationships are considered compensated unless otherwise noted.",
        "positive": "All relationships are considered compensated, unless otherwise disclosed.",
        "negative": "Declaration of interests\n\u2610 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."
    },
    {
        "anchor": "Accountability logs related to study drug will be maintained by each clinical centre.",
        "positive": "Each clinical centre will maintain accountability logs for study drug-related activities.",
        "negative": "ethics statement\nThe study was approved by the Tianjin Medical University Cancer Institute and Hospital ethics committee."
    },
    {
        "anchor": "AXL has emerged as a major therapeutic target and a potential biomarker in several cancer types, and future investigations are warranted to develop novel and effective treatment and diagnostic tools based on this target.",
        "positive": "AXL has been identified as a promising therapeutic target and biomarker in various cancer types, and future research is necessary to develop innovative treatment and diagnostic strategies.",
        "negative": "Online content\nAny methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at (<https://doi.org/10.1038/s41591-023-02593-0>)https://doi.org/10.1038/s41591-023-02593-0."
    },
    {
        "anchor": "Relative killing was calculated by comparing the luciferase intensity of no target control wells (100% killed) and no effector control wells (0% killed).",
        "positive": "The relative killing rate was determined by comparing the luciferase activity in wells with no target (100% killing) to those with no effector (0% killing).",
        "negative": "Human in\u00a0vitro T\u2009cell repetitive stimulation assay\nPrimary healthy human donor T cells were isolated from a fresh Leukopak (StemCell Technologies) using a EasySep Human T cell isolation kit (StemCell Technologies, 17951) and frozen."
    },
    {
        "anchor": "We are grateful to Anthony Secreto and Gwenn Danet for their technical assistance with mouse studies.",
        "positive": "We would like to express our appreciation to Anthony Secreto and Gwenn Danet for their technical support in conducting mouse studies.",
        "negative": "Acknowledgments\nThis work was supported by a research agreement with Novartis."
    },
    {
        "anchor": "(Figure 1)\n\nSafetyThe most common CNCT19-related adverse events (AEs) were CRS and NT and there were 3 cases of Grade \u2265 3 CRS (n=3, 8.3%) and 3 cases of Grade \u2265 3 NT (n=3, 8.3%).",
        "positive": "(Figure 1) Safety The most frequent adverse events associated with CNCT19 were CRS and NT, with 3 cases of Grade \u2265 3 CRS (8.3%) and 3 cases of Grade \u2265 3 NT (8.3%) reported.",
        "negative": "Title: Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China\n\nAbstract: Background:Only 18-44% of adult patients with R/R B-Cell ALL achieve remission with median overall survival (OS) of 2 to 6 months after salvage chemotherapy."
    },
    {
        "anchor": "Source documents include but are not limited to hospital records, clinical and office charts, laboratory notes, memoranda, subjects\u2019 diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial.",
        "positive": "The source documents used in this study include, but are not limited to, hospital records, clinical charts, laboratory notes, and other relevant documentation, such as patient diaries, evaluation checklists, and pharmacy records.",
        "negative": "10.6.1 Study Documentation\nStudy documentation includes but is not limited to source documents, case report forms, monitoring logs, appointment schedules, study team correspondence with Sponsor or regulatory bodies/committees, and regulatory documents that can be found in the DCI-mandated \u201cRegulatory Binder\u201d, which includes but is not limited to signed protocol and amendments, approved and signed informed consent forms, FDA Form 1572, CAP and CLIA laboratory certifications, and clinical supplies receipts and distribution records."
    },
    {
        "anchor": "Severe NT also positively correlated with classically activated macrophages (M1) and alternatively activated macrophages (M2; Fig.",
        "positive": "Severe NT was linked to the presence of both classically activated macrophages (M1) and alternatively activated macrophages (M2), as depicted in Figure.",
        "negative": "Description\nCreatethedefinitionofthearcsinhTransformationthatwillbeappliedonsomeparameterviathe transform method.Thedefinitionofthisfunctioniscurrentlyx<-asinh(a+b*x)+c).Thetrans-formationwouldnormallybeusedtoconverttoalinearvaluedparametertothenaturallogarithm scale.Bydefaultaandbarebothequalto1andcto0."
    },
    {
        "anchor": "The latter criterion to reduce suction was introduced after study initiation to prevent non-protocolled suction regulation after randomization.",
        "positive": "The study introduced a new criterion to prevent non-protocol deviations in suction regulation after randomization.",
        "negative": "Postoperative management\nAll the participants had their chest drain connected to a digital drainage device (Thopaz+, Medela AG, Switzerland) directly after surgery until drain removal."
    },
    {
        "anchor": "All patients developing neurologic symptoms were evaluated by the neurology consult service and followed with daily neurologic assessments until neurologic symptom resolution.",
        "positive": "Patients with neurologic symptoms were assessed by the neurology consult service and received daily evaluations until their symptoms improved.",
        "negative": "Toxicity assessment:\nCRS was graded according to the MSKCC CRS grading system (Supplementary Table S4)."
    },
    {
        "anchor": "Conclusions\nAs the population of cancer survivors grows, ONE TEAM will contribute to closing the CVD outcomes gap among cancer survivors by optimizing and integrating cancer care and primary care teams.",
        "positive": "As the cancer survivor population grows, ONE TEAM will work to address the CVD outcomes gap by optimizing and integrating cancer care and primary care services.",
        "negative": "ONE TEAM is designed so that it will be possible for others to emulate and implement at scale."
    },
    {
        "anchor": "The overall rates of toxicities related or possibly related to radiation were slightly higher among patients treated with adaptive plans than for those treated with non-adaptive plans, but the overall number of events was low.",
        "positive": "Radiation-related toxicities were more common among patients treated with adaptive plans compared to those treated with non-adaptive plans, although the overall number of events was low.",
        "negative": "Toxicities\nToxicity rates for the entire group are published elsewhere (2)."
    },
    {
        "anchor": "Secondary Endpoints:\n1.",
        "positive": "Secondary outcome measures: 1.",
        "negative": "Toxicity o Assessed by the NCI-CTC v.4 4."
    },
    {
        "anchor": "We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-free survival (PFS) in patients with treatment-naive EGFR-mutant non\u2013small-cell lung cancer (NSCLC) by preventing or delaying resistance.abstract",
        "positive": "The research examined whether the combination of afatinib and cetuximab could improve progression-free survival in treatment-naive patients with EGFR-mutant non-small-cell lung cancer, compared to afatinib alone, by reducing or delaying the development of resistance.",
        "negative": "3.2 | Pro completion rates\nFigure 1 (CONSORT) shows the number of assessments completed at each time point and reasons for non-completion."
    },
    {
        "anchor": "In the bevacizumab-EU group, the median number of cycles of bevacizumab-EU treatment was 11.0 (range 1\u201338), with 6.0 cycles (range 1\u20136 cycles) of paclitaxel treatment and 6.0 cycles (range 1\u20136 cycles) of carboplatin treatment.",
        "positive": "The median number of treatment cycles in the bevacizumab-EU group was 11, with a range of 1-38 cycles, and patients received 6 cycles of paclitaxel and 6 cycles of carboplatin.",
        "negative": "Patients and Treatment\nFrom November 2015 to February 2019, 682 eligible patients were randomly assigned: 339 to receive osi-mertinib and 343 to receive placebo (Data Supplement)."
    },
    {
        "anchor": "One patient died of infection while on ibrutinib and with ongoing hypogammaglobulinemia in CR at 31 months, considered possibly related to treatment.",
        "positive": "A patient died from an infection while on ibrutinib treatment and had ongoing hypogammaglobulinemia in complete remission at 31 months, and the cause of death was possibly related to the treatment.",
        "negative": "Safety\n20 Safety analysis was performed on all 19 patients who received an infusion of huCART-19."
    },
    {
        "anchor": "All TransCon IL-2 \u03b2/\u03b3 dose levels are expressed in IL-2 equivalents, and all dose levels of TransCon TLR7/8 Agonist correspond to the amount of resiquimod.",
        "positive": "The doses of TransCon IL-2 \u03b2/\u03b3 are measured in IL-2 equivalents, and the doses of TransCon TLR7/8 Agonist are equivalent to the amount of resiquimod.",
        "negative": "Discussion\nThis is the first report of a planned prospective study combining discretionary neoadjuvant chemotherapy, followed by limited surgery (VATS and TEMLA) followed by SBRT ultimately followed by adjuvant chemotherapy in locally advanced NSCLC."
    },
    {
        "anchor": "FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.",
        "positive": "Figure 1: CONSORT diagram.",
        "negative": "Human research participants\nPolicy information about studies involving human research participants and Sex and Gender in Research."
    },
    {
        "anchor": "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.",
        "positive": "The anti-tumor activity of crizotinib in lung cancers with a MET exon 14 mutation.",
        "negative": "Cortot AB, Kherrouche Z, Descarpentries C, et al.Exon 14 deleted MET receptor as a new biomarker and target in cancers."
    },
    {
        "anchor": "TH reports grants from Astellas during the conduct of the study, grants and personal fees from Chu-gai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Novartis Pharma, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Clovis Oncology, and grants from Eisai, Takeda Bio, Dainippon Sumitomo Pharma, Abbvie, Merck Ser-ono, MSD, Kyowa Hakko Kirin, and Daiichi Sankyo outside the submitted work.",
        "positive": "The author received research funding from Astellas during the study, and also received grants and personal fees from multiple pharmaceutical companies, including Chu-gai Pharmaceutical, Eli Lilly, and others, outside the scope of the submitted work.",
        "negative": "Exercise training\nResearch has shown that exercise training (e.g."
    },
    {
        "anchor": "Boxplots showing percentage changes of blood flow (A), blood volume (B), and permeability (C) at day +7, and day +42 after treatment initiation compared to basal values in the entire population.",
        "positive": "The boxplots show the percentage changes in blood flow, blood volume, and permeability at day +7 and day +42 after treatment initiation, compared to baseline values in the entire population.",
        "negative": "\ue014\ue017\ue003 '$7$\ue003$1'\ue0036$)(7<\ue003021,725,1*\ue003\n14.1 The Radiation Oncology Department will ensure the integrity of systems for monitoring trial data and participant safety."
    },
    {
        "anchor": "In this example, 20\ue003PP\ue003 VKRXOG\ue003 EH\ue003 UHFRUGHG\ue003 DV\ue003 WKH\ue003 QRGH\ue003 PHDVXUHPHQW\ue011\ue003 $OO\ue003 RWKHU\ue003 SDWKRORJLFDO\ue003 QRGHV\ue003 \ue00bWKRVH\ue003 ZLWK\ue003 VKRUW\ue003 D[LV\ue003 t\ue003\ue014\ue013\ue003PP\ue003 EXW\ue003 \ue01f\ue003\ue014\ue018\ue003PP\ue00c\ue003 VKRXOG\ue003 EH\ue003 FRQVLGHUHG\ue003 QRQ\ue010WDUJHW\ue003 OHVLRQV\ue011\ue003 1RGHV\ue003 WKDW\ue003 KDYH\ue003 D\ue003 VKRUW\ue003 D[LV\ue003 \ue01f\ue003\ue014\ue013\ue003PP\ue003 DUH\ue003 FRQVLGHUHG\ue003 QRQ\ue010SDWKRORJLFDO\ue003 DQG\ue003 VKRXOG\ue003QRW\ue003EH\ue003UHFRUGHG\ue003RU\ue003IROORZHG\ue011\ue003\ue003 $\ue003 sum of the diameters\ue003 ORQJHVW\ue003 IRU\ue003 QRQ\ue010QRGDO\ue003 OHVLRQV\ue00f\ue003 VKRUW\ue003 D[LV\ue003 IRU\ue003 QRGDO\ue003 OHVLRQV\ue00c\ue003IRU\ue003DOO\ue003WDUJHW\ue003OHVLRQV\ue003ZLOO\ue003EH\ue003FDOFXODWHG\ue003DQG\ue003UHSRUWHG\ue003DV\ue003WKH\ue003 baseline sum diameters\ue011\ue003 ,I\ue003 O\\PSK\ue003 QRGHV\ue003 DUH\ue003 WR\ue003 EH\ue003 LQFOXGHG\ue003 LQ\ue003 WKH\ue003 VXP\ue00f\ue003 WKHQ\ue003 DV\ue003 QRWHG\ue003 DERYH\ue00f\ue003 RQO\\\ue003 WKH\ue003 VKRUW\ue003 D[LV\ue003 LV\ue003 DGGHG\ue003 LQWR\ue003 WKH\ue003 VXP\ue011\ue003 7KH\ue003 EDVHOLQH\ue003 VXP\ue003 GLDPHWHUV\ue003 ZLOO\ue003 EH\ue003 XVHG\ue003 DV\ue003 UHIHUHQFH\ue003 WR\ue003 IXUWKHU\ue003 FKDUDFWHUL]H\ue003 DQ\\\ue003 REMHFWLYH\ue003 WXPRU\ue003 UHJUHVVLRQ\ue003 LQ\ue003 WKH\ue003 PHDVXUDEOH\ue003GLPHQVLRQ\ue003RI\ue003WKH\ue003GLVHDVH\ue011\ue003\ue003 $OO\ue003 RWKHU\ue003 OHVLRQV\ue003 \ue00bRU\ue003 VLWHV\ue003RI\ue003 GLVHDVH \ue00c\ue003LQFOXGLQJ\ue003SDWKRORJLFDO\ue003 O\\PSK\ue003 QRGHV\ue003 should be identi\u00bfed as non\ue010WDUJHW\ue003OHVLRQV\ue003DQG\ue003VKRXOG\ue003 DOVR\ue003EH\ue003 UHFRUGHG\ue003DW\ue003 EDVHOLQH\ue011\ue003 0HDVXUHPHQWV\ue003 DUH\ue003 QRW\ue003 UHTXLUHG\ue003 DQG\ue003 WKHVH\ue003 OHVLRQV\ue003 VKRXOG\ue003 EH\ue003 followed as \u2018present\u2019, \u2018absent\u2019, or in rare cases \u2018unequivocal progression\u2019 (see also \u201cSpecial notes on assessment of progression of non\ue010WDUJHW\ue003 disease\u201d).\ue003 ,Q\ue003DGGLWLRQ\ue00f\ue003LW\ue003LV\ue003SRVVLEOH\ue003WR\ue003UHFRUG\ue003PXOWLSOH\ue003QRQ\ue010WDUJHW\ue003OHVLRQV\ue003LQYROYLQJ\ue003WKH\ue003VDPH\ue003 organ as a single item on the case report form (e.g.",
        "positive": "In this example, 20% of patients with non-small-cell lung cancer (NSCLC) should be identified as non-progressive disease (NP) and followed as such. The remaining patients with NSCLC should be identified as progressive disease (PD) and followed as such.",
        "negative": "Treatment\nChemotherapy consisted of three cycles of 100 mg/m2 cisplatin and 85 mg/m2 docetaxel given once every 3 weeks, with mandatory granulocyte colony-stimulating factor."
    },
    {
        "anchor": "Tumor-bearing mice were treated with four intratumoral injections of mRNA c-Met-CAR T cells at weeks 6, 7, 9, and 11 (Fig.",
        "positive": "Mice with tumors received four injections of mRNA c-Met-CAR T cells at weeks 6, 7, 9, and 11, as depicted in Figure.",
        "negative": "Antitumor effects of mRNA c-Met-CAR T cells in a xenograft model\nWe have previously demonstrated the effectiveness of stably transduced c-Met-CAR T cells in shrinking preestablished c-Met-expressing tumors in NSG mouse tumor models (16)."
    },
    {
        "anchor": "ORR ratios were within the predefined equivalence margins in most subgroups, including patients aged <65 years, male patients, patients with adenocarcinoma, patients with different EGFR mutation status (mutated or wild type), smoking status (yes or no), number of metastases (<3or \u22653) and brain metastasis status (present or absent) (Figure (<>)2).",
        "positive": "In most patient subgroups, the ORR ratios fell within the predetermined equivalence margins, including those with age <65 years, male patients, patients with adenocarcinoma, and those with different EGFR mutation status, smoking habits, and metastasis counts.",
        "negative": "ER\u03b2 inhibits AR-mediated TNBC progression and function\n19 1 19 20 2 ER\u03b1 and ER\u03b2 are two subtypes of estrogen receptors with heterogeneous expression and various biological functions in breast cancers."
    },
    {
        "anchor": "'DLO\\\ue0037UHDWPHQW\ue003/RFDOL]DWLRQ\ue012,*57\ue003\nImage-guided radiation therapy (IGRT) is radiation therapy using imaging to facilitate accuracy and precision throughout its entire process from target and normal tissue delineation, to radiation delivery, to adaptation of therapy to anatomic and biological changes over time in individual patients.",
        "positive": "Image-guided radiation therapy (IGRT) is a type of radiation treatment that utilizes imaging to ensure accurate and precise delivery of radiation to the target area, taking into account normal tissue and anatomic changes over time.",
        "negative": "In this section we use the terminology IGRT to focus on image-guidance at the time of radiation delivery to ensure its adherence to the planned treatment."
    },
    {
        "anchor": "Percent of CD3+CD4+ lymphocytes stained with commercial anti-PD-1 mAb before and after MGD019 administration was recorded for each patient.",
        "positive": "The proportion of CD3+CD4+ lymphocytes stained with commercial anti-PD-1 antibody was recorded for each patient at baseline and after MGD019 administration.",
        "negative": "In vivo PD-1 Blockade Studies\nPatients whole blood samples (per time point/per patient) were incubated with commercial, APC-labeled, MGD019-competing anti-PD-1 mAb (clone J105, eBioscience, San Diego, USA)."
    },
    {
        "anchor": "In its systematic review, the Cochrane Collaboration found that these interventions improved knowledge and encouraged more appropriate use of surgical interventions.",
        "positive": "The Cochrane Collaboration's review found that these interventions improved knowledge and led to more appropriate surgical practices.",
        "negative": "1.1 Background on Intervention\nMany physicians are reluctant to disclose specific details to cancer patients, such as risks of treatment, prognosis and treatment alternatives.1-4 Communication is complicated by the stigma and fear associated with cancer, 5 the complexity of the information, and uncertainty about the course of the disease and benefits of treatment."
    },
    {
        "anchor": "Subject populations\nBlood samples were obtained from patients enrolled in institutional review board\u2013approved clinical trials of CTL019 or ibrutinib, and written informed consent was provided in accordance with the Declaration of Helsinki.",
        "positive": "Blood samples were collected from patients participating in institutional review board-approved clinical trials of CTL019 or ibrutinib, with written informed consent obtained in compliance with the Declaration of Helsinki.",
        "negative": "For additional information, see supplemental Methods, available on the Blood Web site."
    },
    {
        "anchor": "Methods\n\nUntransduced T-cells (UTD) and CAR T-cells targeting CD33 (CART33) were manufactured using paired steady state (ss) cells and cells collected after rhG-CSF treatment (mob).",
        "positive": "The methods used to manufacture T-cells included the production of untransduced T-cells (UTD) and CAR T-cells targeting CD33 (CART33), using paired steady-state cells and cells collected after rhG-CSF treatment.",
        "negative": "Anti-CD19-CAR T Cell Preparation\n36 10 PBMCs obtained from each patient by apheresis were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 IU/mL IL-2 (Novartis)."
    },
    {
        "anchor": "11 6 No patient in part B had an OR; 10 (63 %) achieved disease control.",
        "positive": "In part B, none of the patients achieved an objective response, but 10 (63%) patients achieved disease control.",
        "negative": "Tumor IL13R\u03b12 expression for each patient\nA, Immunohistochemical staining of IL13R\u03b12 on paraffin-embedded primary patient derived brain tissues."
    },
    {
        "anchor": "Primary outcome\nProgression-free survival (PFS) The primary outcome is PFS, which will be measured every 41\u201356 days (2 cycles) from the randomization to the onset of disease progression or death, whichever comes first.",
        "positive": "The primary endpoint is progression-free survival (PFS), which will be assessed every 41-56 days (2 cycles) from randomization to disease progression or death, whichever occurs first.",
        "negative": "Patients without progression at the cutoff date will be censored on the date of the last contact."
    },
    {
        "anchor": "lung Function\nA total of 34 patients had baseline spirometry measurements (FEV1, FVC, FEV1/FVC ratio, PEF).",
        "positive": "Baseline spirometry measurements were obtained for 34 patients, including FEV1, FVC, FEV1/FVC ratio, and PEF.",
        "negative": "In general, spirometry results indicated that pulmonary function remained stable over the course of treatment."
    },
    {
        "anchor": "Coexisting gene alterations at baseline bTMB was not significantly different between patients with PSC and other NSCLC subtypes (3.70 versus 3.17; p= 0.995).",
        "positive": "The baseline TMB levels did not show a statistically significant difference between patients with PSC and other NSCLC subtypes, with values of 3.70 and 3.17, respectively.",
        "negative": "Association of baseline and post-treatment METex14 status with clinical outcomes by NSCLC subtypes\nOf the 66 patients in this post hoc analysis cohort, 22 (33.3%) had PSC, while the others had other NSCLC subtypes (mainly LUAD)."
    },
    {
        "anchor": "The recommended dose was defined as the highest dose at which not more than 2 out of 6 patients had DLT during the first two cycles after ipilimumab treatment (i.e., from Day 1 at Cycle 3 to Day 21 at Cycle 4).",
        "positive": "The maximum tolerated dose was determined as the highest dose at which no more than two out of six patients experienced DLT during the initial two treatment cycles following ipilimumab administration.",
        "negative": "Patient Disposition, Demographics, and Disease Characteristics\nBetween February 2, 2021, and February 18, 2022, 277 patients were enrolled (full analysis set; (<>)Fig 1)."
    },
    {
        "anchor": "Two patients completed at least four cycles before stopping without evidence of progression.",
        "positive": "Two patients completed four or more treatment cycles without exhibiting disease progression.",
        "negative": "Safety and Toxicity\nFor the phase I portion, 12 patients were enrolled at the dose levels shown in table 1."
    },
    {
        "anchor": "Neurotoxicity following CTL019 infusion was common in this pediatric and young adult sample, occurring in 23/51 (45%; 95% CI, 31\u201360%) subjects, 21/23 of these cases were classified into the a priori \u201ccommon neurotoxicities\u201d panel (Table 2).",
        "positive": "Neurotoxicity was a frequent adverse effect in this pediatric and young adult population, affecting 45% of subjects (23/51), with 21 of these cases classified as common neurotoxicities.",
        "negative": "PD-L1, LAG-3 and LAG-3/PD-1 expression on tissue tumor samples\nPD-L1 expression was determined per Agilent PD-L1 IHC 22C3 pharmDx Kit (SK00621-5) on the Agilent Link 48 autostainer."
    },
    {
        "anchor": "Among patients with colon cancer who were treated with cetuximab (n = 43), RR was significantly higher in arm 3 than that in arm 1 (76.9% vs. 40.0%; p = .049).",
        "positive": "In the group of patients with colon cancer treated with cetuximab (n = 43), the response rate was significantly higher in arm 3 compared to arm 1, with rates of 76.9% and 40.0%, respectively.",
        "negative": "Efficacy of EGF Ointment\nBaseline ERSEs of patients were evaluated."
    },
    {
        "anchor": "Patients with brain metastasis were eligible if they were asymptomatic, neurologically stable, and off corticosteroids.",
        "positive": "Patients with brain metastases were eligible for the study if they were asymptomatic, had stable neurological function, and were not taking corticosteroids.",
        "negative": "\u03b1CD47/PD-L1 BisAb treatment increases the frequency of stem-like progenitor and effector CD8+ T cell subsets in the tumor and promotes the differentiation of progenitor CD8+ T cells to an effector-like state\n26\u201328 29 30 Consistent with our flow cytometry data, we observed significant increases in intratumoral CD8+ T cell populations upon mBisAb treatment by scRNA-seq ((<https://dx.doi.org/10.1136/jitc-2021-003464>)online (<https://dx.doi.org/10.1136/jitc-2021-003464>)supplemental figure 4D)."
    },
    {
        "anchor": "Processing was done in a reference laboratory by one of two investigators.",
        "positive": "Samples were processed in a reference laboratory by either of two investigators.",
        "negative": "LC-MS measurement of glutamate and quinolinic acid in CSF:\nLC-MS grade solvents were purchased from Fisher Scientific, quinolinic acid (QA), glutamate (Glut) and 13C5,15N-Glut (internal standard, ISTD) were purchased from Sigma, and D3-QA acid (ISTD) was purchased from Buchem BV."
    },
    {
        "anchor": "Efficacy data for the first 25 pediatric subjects treated in the CTL019 trial have been previously published (8), although details regarding time course, organ dysfunction severity, and response to critical care interventions have not been reported.",
        "positive": "The efficacy data for the initial 25 pediatric patients treated in the CTL019 trial have been published, but the specifics regarding the progression of disease, organ dysfunction severity, and response to critical care interventions have not been reported.",
        "negative": "Patients\nBetween March 2018 and January 2019, a total of 17 patients were enrolled, and 15 were treated with a total of 25 infusions of MPTK-CAR-T cells at an escalating dose (0.18\u201311 \u00d7 106 CAR-T cells/kg) (Supplementary Fig."
    },
    {
        "anchor": "Any changes in study conduct must be reported to the IRB.",
        "positive": "Any modifications to the study protocol must be communicated to the Institutional Review Board (IRB).",
        "negative": "Hematological and non-hematological side effects according to severity of CRS\nThe absolute neutrophil count (mCRS vs. sCRS: 0.48 \u00b1 0.55 \u00d7 109/L vs. 0.22 \u00b1 0.32 \u00d7 109/L, p=0.08, (<>)Figure 5A)between the patients with mCRS and sCRS was similar while the hemoglobin (Hb, mCRS vs. sCRS: 69.30 \u00b1 20.54 g/L vs. 53.41 \u00b1 8.05 g/L, p<0.01, (<>)Figure 5B) and platelet (PLT, mCRS vs. sCRS: 77.48 \u00b1 80.53 \u00d7 109/L vs. 17.88 \u00b1 20.45 \u00d7 109/L, p<0.01, (<>)Figure 5B) were lower in patients with sCRS."
    },
    {
        "anchor": "Ethical Considerations\nTIGER-3 was conducted in compliance with Good Clinical Practices, including the International Conference on Harmonization\u2019s Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines, the U.S. Food and Drug Administration regulatory requirements, and the ethical principles of the Declaration of Helsinki.",
        "positive": "The TIGER-3 study was conducted in compliance with Good Clinical Practices, following the guidelines of the International Conference on Harmonization, U.S. Food and Drug Administration regulations, and the ethical principles of the Declaration of Helsinki.",
        "negative": "(T)\nTX Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy."
    },
    {
        "anchor": "\u2020Investigator assessment based on RECIST version 1.1.",
        "positive": "\u2020Assessment of patients will be conducted according to the RECIST 1.1 criteria.",
        "negative": "A waterfall plot of the maximum change in target lesions following treatment with larotrectinib in patients with advanced TRK fusion-positive thyroid carcinoma."
    },
    {
        "anchor": "Higher peak of IL-15 is associated with a higher CD19 CAR T cell AUC0-90 in humans.",
        "positive": "A correlation has been found between higher IL-15 levels and higher CD19 CAR T cell activity in humans.",
        "negative": "Disclosure\nDr Xing-Sheng Hu, Dr Sheng Yang, Dr Ning Li, Dr Lin Wang, Dr Yuan-Yuan Song and Dr Yuan-Kai Shi report non-financial support from Jiangsu Simcere Pharmaceutical Co. Ltd and grants from the Chinese National Major Project for New Drug Innovation during the conduct of the study."
    },
    {
        "anchor": "Investigators\nPatients will be recruited by the Department of Radiation Oncology at the University of Heidelberg and by the Department of Medical Oncology of the Thoraxklinik Heidelberg.",
        "positive": "Recruitment will take place at the University of Heidelberg's Department of Radiation Oncology and the Thoraxklinik Heidelberg's Department of Medical Oncology.",
        "negative": "Due to the multi-modal nature of the trial, all investigators are experienced oncologists from the fields of radiation oncology and medical oncology."
    },
    {
        "anchor": "Our results provide evidence against the use of melatonin in the prevention of recurrence and mortality in patients with early stage resected NSCLC, and potential evidence supporting its use in patients with late stage resected NSCLC.",
        "positive": "Our findings suggest that melatonin may not be effective in preventing recurrence and mortality in early-stage NSCLC patients, but may have a role in late-stage patients.",
        "negative": "Added value of this study\nThis is the first randomized, placebo-controlled, blinded phase III clinical trial evaluating the effect of melatonin on recurrence and mortality in patients with resected NSCLC."
    },
    {
        "anchor": "However, there were no significant differences in QOL scores between the usual care group and intervention group for FCGs (Table 3).",
        "positive": "Despite this, there were no notable differences in quality of life scores between the control group and intervention group for FCGs, as shown in Table 3.",
        "negative": "Intervention\nThe interdisciplinary palliative care intervention appeared to have a greater impact on patients than FCGs."
    },
    {
        "anchor": "Following the initial 24 h, a combination of ibuprofen 400 mg and codeine phosphate 25 mg sustained release tablets was prescribed according to the patient\u2019s needs.",
        "positive": "A combination of ibuprofen 400 mg and codeine phosphate 25 mg sustained release tablets was prescribed to patients after the initial 24 hours, tailored to their specific requirements.",
        "negative": "Anaesthetic and pain control management\nAll patients were subjected to the same anaesthetic and pain control protocol."
    },
    {
        "anchor": "The GARNET study involves human participants and the ethics committee at each investigational site approved the protocol.",
        "positive": "The GARNET study involves human subjects, and the ethics committee at each investigational site has reviewed and approved the study protocol.",
        "negative": "What this study adds\n\u2022 Dostarlimab PK was well described by a 2-compartment model with time-dependent linear elimination, like other anti-PD-1 monoclonal antibodies."
    },
    {
        "anchor": "Candidate mutation-associated neoantigens were computationally predicted from somatic variants in pretreatment tumors and therefore were proportional to the mutational burden.",
        "positive": "Using computational methods, neoantigens associated with mutations in pretreatment tumors were predicted and found to be proportional to the mutational load.",
        "negative": "GENOMIC ANALYSES\nTo examine the landscape of genomic alterations, predicted neoantigens, and their potential association with pathological response, we performed whole-exome sequencing of pretreatment tumors obtained from 12 patients who had adequate available tissue (Tables S4 through S7 in Supplementary Appendix 2).17 A median of 92 somatic mutations (range, 5 to 366) per tumor were noted and specific driver mutations identified, including in TP53, KRAS, CDKN2A, ARID1A, NOTCH1, and RB1, findings that were consistent with previous observations in patients with NSCLC (Tables S8, S9, and S10 in Supplementary Appendix 2 and Fig."
    },
    {
        "anchor": "Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.1.",
        "positive": "An event is classified as serious if it meets the criteria outlined in Section 8.1 for a serious adverse event (SAE).",
        "negative": "Recording of Adverse Events\nAt each contact with the subject, the investigator must seek information on adverse events by non-directive questioning and, as appropriate, by examination."
    },
    {
        "anchor": "The interdependence of distress observed in these patient-caregiver dyads is best understood within theories surrounding interpersonal emotion dynamics, which assume that partners\u2019 emotions become interconnected and influence each other via emotional contagion [(<>)62] when they experience a shared stimulus (e.g., cancer diagnosis).",
        "positive": "In the context of patient-caregiver relationships, the interdependence of distress can be understood through theories of interpersonal emotion dynamics, which propose that partners' emotions become intertwined and influence each other through emotional contagion when they share a common experience, such as a cancer diagnosis.",
        "negative": "Correlation of ctDNA molecular response with secondary endpoints\n3 6 14 18 19 Patients with mR attained longer PFS than patients with mPD (median PFS 5.03 months versus 2.6 months for patients with ctDNA mR and mPD, respectively) (Fig."
    },
    {
        "anchor": "Details of the planned eprenetapopt dose deescalation (if required) for the dose-\ufb01nding portion are provided in the following section.",
        "positive": "The protocol outlines the planned adjustments to eprenetapopt dosing, if necessary, for the dose-finding phase.",
        "negative": "Study design\nERICA is a prospective, monocentric, randomised controlled, open-label feasibility study, conducted at the Centre L\u00e9on B\u00e9rard Comprehensive Cancer Centre (Lyon, France)."
    },
    {
        "anchor": "(<http://dx.doi.org/10.1038/nm.4086>)Nat Med 2016;22:679\u201384.",
        "positive": "The reference cited is a 2016 publication in Nature Medicine (Volume 22, pages 679-84).",
        "negative": "22) Interpretation consistent with results, balancing beneUts and harms, and considering other relevant evidence\nNPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group"
    },
    {
        "anchor": "Taking drop-out rate into account, the total sample size was set at 160 (80 for each treatment arm).",
        "positive": "With the dropout rate in mind, the total sample size was set at 160, with 80 participants in each treatment arm.",
        "negative": "Results\nFrom June 2016 to June 2017, a total of 18 patients with advanced tumors [lung (n=9), colon (n=8), and cervical (n=1)] pretreated with at least two lines of chemotherapy were treated with nintedanib combined with bevacizumab at 15mg/kg in 2 dose escalation groups (dose levels 1 and 2): 150mg x 2 (n=3) and 200mg x 2 (n=3), respectively."
    },
    {
        "anchor": "Results were also similar in samples from patients with different tumor types.",
        "positive": "The findings were consistent across patient populations with various tumor types.",
        "negative": "Detection of enadenotucirev DNA in blood\nEnadenotucirev DNA levels in blood samples following IT injection in patients with CRC (cohort A) were below the quantification limit of the qPCR assay (data not shown)."
    },
    {
        "anchor": "Validation considerations for kit assays include, but are not limited to, the following examples: - Site-specific validation should be performed.",
        "positive": "Validation of kit assays includes, but is not limited to, site-specific validation procedures.",
        "negative": "C. Diagnostic Kits\nDiagnostic kits are sometimes co-developed with new drug or therapeutic biological products as analytical methods that are used during the development of new drugs and therapeutic biologics."
    },
    {
        "anchor": "Selumetinib and erlotinib were supplied by CTEP.",
        "positive": "CTEP provided selumetinib and erlotinib for use in the study.",
        "negative": "patient population and study design\nThis was a randomized phase II trial in five US institutions sponsored by the Cancer Therapy Evaluation Program (CTEP), National Cancer Institute (NCI), reviewed and approved by each institutional review board (IRB)."
    },
    {
        "anchor": "There were no clear trends in levels of serum cytokines, except for slight increases in levels of serum IL-1b, MMP-9, and possibly IL-10 at the analysis on cycle 3 day 15 (ie, after administration of nivolumab; (<>)Supplementary (<>)Figure 3).",
        "positive": "Serum cytokine levels did not show any distinct patterns, except for minor increases in IL-1b, MMP-9, and possibly IL-10 at cycle 3 day 15, following nivolumab administration.",
        "negative": "Pharmacodynamics\nAlthough ACY-241 is a potent inhibitor of HDAC6 (a class IIb HDAC), it does retain its inhibitory activity against class I HDACs(ie,HDAC1, HDAC2,HDAC3,and HDAC8)."
    },
    {
        "anchor": "Usage: transform(flowSet, ...) filter Apply a filter object on a flowSet object.",
        "positive": "The transform function can be used to apply a filter to a flowSet object.",
        "negative": "show display object summary."
    },
    {
        "anchor": "Forty-four (43.6%) and 42 (47.2%) patients in the placebo and the Vx-001 arm, respectively, experienced disease control after 3 treatment cycles (2 or 3 months).",
        "positive": "In the placebo and Vx-001 groups, 44.4% and 47.2% of patients, respectively, achieved disease control after 2-3 months of treatment.",
        "negative": "Response to treatment\nThere was no documented objective CR or PR according to the RESIST criteria."
    },
    {
        "anchor": "Clinical supplies may not be used for any purpose other than that stated in the protocol.",
        "positive": "Clinical supplies can only be used for the purposes outlined in the protocol.",
        "negative": "9.4 Storage and Handling Requirements\nClinical supplies must be stored in a secure, limited-access location under the storage conditions specified on the label."
    },
    {
        "anchor": "\ue014\ue019\ue011\ue003 &21),'(17,$/,7<\ue0032)\ue00375,$/\ue003'2&80(176\ue003$1'\ue0033$7,(17\ue003 5(&25'6\ue003\nThe investigator must assure that patients\u2019 anonymity will be maintained and that WKHLU\ue003 LGHQWLWLHV\ue003 DUH\ue003 SURWHFWHG\ue003 IURP\ue003 XQDXWKRUL]HG\ue003 SDUWLHV\ue011\ue003 2Q\ue003 H&5)V\ue003 RU\ue003 RWKHU\ue003 GRFXPHQWV\ue003 VXEPLWWHG\ue003 WR\ue003 WKH\ue003 6SRQVRU\ue00f\ue003 SDWLHQWV\ue003 VKRXOG\ue003 QRW\ue003 EH\ue003 LGHQWLILHG\ue003 E\\\ue003 WKHLU\ue003 QDPHV\ue00f\ue003 EXW\ue003 E\\\ue003 DQ\ue003 LGHQWLILFDWLRQ\ue003 FRGH\ue011\ue003 7KH\ue003 LQYHVWLJDWRU\ue003 VKRXOG\ue003 NHHS\ue003 D\ue003 SDWLHQW\ue003 HQUROOPHQW\ue003 ORJ\ue003 VKRZLQJ\ue003 FRGHV\ue00f\ue003 QDPHV\ue003 DQG\ue003 DGGUHVVHV\ue011\ue003 7KH\ue003 LQYHVWLJDWRU\ue003 VKRXOG\ue003 maintain documents not for submission to Roche, e.g., patients\u2019 written consent IRUPV\ue00f\ue003LQ\ue003VWULFW\ue003FRQILGHQFH\ue011\ue003\ue003 *LYHQ\ue003WKH\ue003VHQVLWLYH\ue003QDWXUH\ue003RI\ue003JHQHWLF\ue003GDWD\ue00f\ue0035RFKH\ue003KDV\ue003LPSOHPHQWHG\ue003D\ue003QXPEHU\ue003RI\ue003 DGGLWLRQDO\ue003 SURFHVVHV\ue003 WR\ue003 DVVXUH\ue003 SDWLHQW\ue003 FRQILGHQWLDOLW\\\ue011\ue003 \ue003 $OO\ue003 VSHFLPHQV\ue003 WDNHQ\ue003 IRU\ue003 LQKHULWHG\ue003 JHQHWLF\ue003 UHVHDUFK\ue003 WKDW\ue003 ZLOO\ue003 EH\ue003 VWRUHG\ue003 LQ\ue003 WKH\ue003 5&5\ue003 \ue00bVHH\ue003 6HFWLRQ\ue003 \ue018\ue011\ue017\ue011\ue015 \ue00c\ue003 XQGHUJo a second level of \u201ccoding\u201d.",
        "positive": "Patients' confidentiality must be protected, and all personal data must be kept confidential. The investigator must also ensure that patients' data are not shared with Roche or any other third party, except for the purpose of the study.",
        "negative": "2.1 Clinical Studies\nFive clinical studies of lucitanib in patients with advanced cancers were included in the PopPK analysis (Table (<>)1)."
    },
    {
        "anchor": "Study inclusion criteria included histologically or cytologically confirmed advanced malignant solid tumor.",
        "positive": "The study included patients with advanced solid tumors that had been diagnosed through histological or cytological testing.",
        "negative": "*CORRESPONDENCE\nChangju Qu qcj310@163.com Depei Wu wudepei18@163.com Zhengming Jin jinzhengming519519@163.com equally to this work"
    },
    {
        "anchor": "The monoclonal antibody zolbetuximab is the first CLDN18.2-targeted treatment under clinical development.",
        "positive": "Zolbetuximab is the first monoclonal antibody to target the CLDN18.2 protein, a new target in cancer treatment.",
        "negative": "Changsong Qi1,5, Jifang Gong1,5, Jian Li1,5, Dan Liu2, Yanru Qin3, Sai Ge1, Miao Zhang2, Zhi Peng1 , Jun Zhou1, Yanshuo Cao1, Xiaotian Zhang1, Zhihao Lu1, Ming Lu1, Jiajia Yuan1, Zhenghang Wang1 , Yakun Wang2, Xiaohui Peng4, Huiping Gao4, Zhen Liu4, Huamao Wang4, Daijing Yuan4, Jun Xiao4 , Hong Ma4, Wei Wang4, Zonghai Li4 and Lin Shen\u200a(<http://orcid.org/0000-0003-1134-2922>)1\u2009\u2709\nDespite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited."
    },
    {
        "anchor": "Eur J Cardiothorac Surg.",
        "positive": "European Journal of Cardiothoracic Surgery.",
        "negative": "Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer."
    },
    {
        "anchor": "The first three authors and the last author vouch for the accuracy and completeness of the data.",
        "positive": "The first three authors and the last author verify the accuracy and completeness of the data.",
        "negative": "Funding\nThese studies were funded by Bayer Healthcare and Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company."
    },
    {
        "anchor": "Results\u2014We demonstrate the feasibility of manufacturing sufficient numbers of autologous CTL clones expressing an IL13(E13Y)-zetakine CAR for redirected HLA-independent IL13R\u03b12specific effector function for a cohort of patients diagnosed with GBM.",
        "positive": "We demonstrate the ability to produce sufficient numbers of autologous CTL clones expressing an IL13(E13Y)-zetakine CAR for redirected HLA-independent IL13R\u03b12-specific effector function in patients with GBM.",
        "negative": "AZD9291\nAbout 50%\u201360% of patients with EGFR mutation-positive tumours progressing after first-line treatment on an EGFR TKI become resistant via the acquisition of the secondary gatekeeper mutation T790M."
    },
    {
        "anchor": "Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3)[J].",
        "positive": "Initial results from a multicenter study (LCMC3) on the use of neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC).",
        "negative": "Copy and paste relevant sections from the manuscript or cite the Ugure number if applicable (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briepy explain why the item is not applicable/relevant for your study \"The attrition rate in this study (33.6%, 36/107) in the CHESS-Only group and 38.1% (42/110) in the CHESS+CR group) is comparable with other clinical trials of patients with advanced cancer."
    },
    {
        "anchor": "WX-0593 was generally well tolerated, and most AEs were grade 1\u20132.",
        "positive": "WX-0593 was generally well tolerated, with most adverse events being mild to moderate.",
        "negative": "Additional information and management recommendations can also be found in the IB regarding\nimportant potential risks associated with axicabtagene ciloleucel, as well as possible\ncomplications associated with malignancy and cancer treatment."
    },
    {
        "anchor": "Analysis and interpretation of data: E. Tan, W. Lim, M. Ahn, Q. Ng, J. Ahn, M. Han, W. Yin, J. Jac, K. Park.",
        "positive": "The analysis and interpretation of the data were performed by E. Tan, W. Lim, M. Ahn, Q. Ng, J. Ahn, M. Han, W. Yin, J. Jac, and K. Park.",
        "negative": "Author\ue020Contributions\ue020\nConception and design: E. Tan, M. Han, F. Payumo, J. Jac, K. Park."
    },
    {
        "anchor": "Caregivers who agreed to participate also provided written informed consent.",
        "positive": "Caregivers who agreed to participate in the study gave written informed consent.",
        "negative": "International Journal of Clinical Oncology (2022) 27:1828\u20131838 https://doi.org/10.1007/s10147-022-02232-7\nORIGINAL ARTICLE Brigatinib in\u00a0Japanese patients with\u00a0tyrosine kinase inhibitor\u2011naive ALK\u2011positive non\u2011small cell lung cancer: first results from\u00a0the\u00a0phase 2\u00a0J\u2011ALTA study Shunichi Sugawara1 \u00b7 Masashi Kondo2 \u00b7 Toshihide Yokoyama3 \u00b7 Toru Kumagai4 \u00b7 Makoto Nishio5 \u00b7 Koichi Goto6 \u00b7 Kazuhiko Nakagawa7 \u00b7 Takashi Seto8 \u00b7 Nobuyuki Yamamoto9 \u00b7 Kentarou Kudou10 \u00b7 Takayuki Asato11 \u00b7 Pingkuan Zhang12 \u00b7 Yuichiro Ohe13 (<http://orcid.org/0000-0002-6137-073X>) Received: 13 May 2022 / Accepted: 3 August 2022 / Published online: 29 August 2022 \u00a9 The Author(s) 2022, corrected publication 2022"
    },
    {
        "anchor": "Moreover, some studies have demonstrated that KLTi had antitumor and immunostimulatory activities in C57BL/6 mice with Lewis lung carcinoma [(<>)29].",
        "positive": "Research has shown that KLTi exhibited antitumor and immunostimulatory properties in C57BL/6 mice with Lewis lung carcinoma.",
        "negative": "Pharmacokinetics\nSerum samples for assessment of circulating CDX-1401 were obtained before vaccination and at 2, 4, and 24 hours after the first vaccination, and before vaccination for all other vaccinations in the first cycle."
    },
    {
        "anchor": "A total of 15 patients received one or more infusions of MPTK-CAR-T cells without prior lymphodepletion.",
        "positive": "A total of 15 patients received multiple infusions of MPTK-CAR-T cells without prior lymphodepletion.",
        "negative": "Circulating MPTK-CAR-T cells peaked at days 7\u201314 and became undetectable beyond 1 month."
    },
    {
        "anchor": "5.2 Mutation type: Exon 19 vs. Exon 21 L858R.",
        "positive": "Mutation type: Exon 19 versus Exon 21 L858R.",
        "negative": "Patient population\nPatients meeting the following key inclusion criteria were enrolled into phase I: (1) aged \u226518\u00a0years; (2) pathologically confirmed diagnosis of advanced solid tumor with failed on or with no standard antitumor therapy; (3) at least one measurable lesion according to RECIST v1.1; (4) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy of greater than 3\u00a0months."
    },
    {
        "anchor": "81873434) and Major Technological Innovation Special Project of Hubei Province of China (No.",
        "positive": "This project was supported by the 81873434 grant and the Major Technological Innovation Special Project of Hubei Province of China.",
        "negative": "sUPPleMenTarY MaTerial\nThe Supplementary Material for this article can be found online at (<https://www.frontiersin.org/articles/10.3389/fonc.2018.00253/full#supplementary-material>)https://www.frontiersin.org/articles/10.3389/fonc.2018.00253/ (<https://www.frontiersin.org/articles/10.3389/fonc.2018.00253/full#supplementary-material>)full#supplementary-material."
    },
    {
        "anchor": "Tocilizumab and corticosteroid use was 28.8% and 15.2%, respectively, for relma-cel compared to these other CAR-T trials reporting 19%\u201345% and 15%\u201327%, respectively.",
        "positive": "The use of tocilizumab and corticosteroids was 28.8% and 15.2%, respectively, for relma-cel, compared to 19%\u201345% and 15%\u201327% in other CAR-T trials.",
        "negative": "4 | DISCUSSION\nThis is the first prospective, single-arm, multicenter, pivotal study of a CD19-specific CAR-T conducted under Chinese IND to support an NMPA-accepted BLA submission in patients with r/r LBCL."
    },
    {
        "anchor": "The non-responders included the subject who had grade 5 cerebral edema, a subject with engraftment of CAR T cells without tumor clearance, and a subject with a necrotic marrow that was not evaluable for disease response assessment and who ultimately presented with CD19-negative leukemia documented 63 days post CAR T\u2013cell infusion.",
        "positive": "The non-responders consisted of a patient with grade 5 cerebral edema, a patient with CAR T cell engraftment without tumor clearance, and a patient with a necrotic marrow that was not evaluable for disease response assessment, who ultimately developed CD19-negative leukemia 63 days after CAR T cell infusion.",
        "negative": "Study endpoints\nThe primary endpoint was ORR assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ((<>)24)."
    },
    {
        "anchor": "Three patients in the NSCLC cohort and 2 patients in the UC cohort were still receiving avelumab and axitinib at data cut-off.",
        "positive": "At the data cut-off, three patients in the NSCLC cohort and two patients in the UC cohort were still receiving avelumab and axitinib.",
        "negative": "Patients and treatment\nBetween 24 May 2018, and 29 July 2019, 61 patients from 19 sites in 7 countries were enrolled and treated."
    },
    {
        "anchor": "RNA-seq analysis showed an elevated proportion of activated CD4 memory cell population among CD7-/-CAR-T cells, with gene enrichment on cytokine signaling pathway and T cells co-stimulatory pathways on CD7-/-T and CAR-T cells, respectively.",
        "positive": "The RNA sequencing analysis showed an elevated proportion of activated CD4 memory cells in CD7-/-CAR-T cells, with gene enrichment in cytokine signaling and T cell co-stimulatory pathways.",
        "negative": "Title: Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells\n\nAbstract: BackgroundPatients with relapsed/refractory acute T lymphoblastic leukemia (T-ALL) suffer from unsatisfactory prognosis and limited treatment options."
    },
    {
        "anchor": "Additional end points were radiologic response and safety.",
        "positive": "Radiologic response and safety were secondary endpoints.",
        "negative": "Correlative translational studies\nCorrelative translational analyses performed as exploratory study endpoints included correlation between plasma levels of INCAGN01949 and receptor occupancy (using an OX40-expressing cell model), and effects of INCAGN01949 on biomarkers in peripheral blood and tumor tissue (collected by biopsy at cycles 3\u20134) and compared with baseline."
    },
    {
        "anchor": "The median age was 63 years.",
        "positive": "The median age of the patients was 63 years.",
        "negative": "Acknowledgements\nThe authors would like to thank Mr. Ivan Vasilievich Besprozvannykh for his help with graphs/figures."
    },
    {
        "anchor": "If PET CT is performed > 28 days prior to the initiation of conditioning chemotherapy or if\nsubject receives any anti-cancer therapy between screening and conditioning chemotherapy,\nthe scans must be repeated to establish a new baseline.",
        "positive": "In cases where PET CT scans are conducted more than 28 days before chemotherapy begins or where the subject receives anti-cancer treatment between screening and chemotherapy, the scans must be updated to establish a new baseline.",
        "negative": "2.3 Statistical analysis\nStatistical analyses including descriptive analysis, Student\u2019st-tests, Chi-squared tests, Fisher\u2019s exact tests, Wilcoxon signed rank tests and Mann Whitney u tests were used when appropriate and multivariate analysis with logistical regression was also performed."
    },
    {
        "anchor": "CI confidence interval; HR hazard ratio; NA not available; PD-L1 programmed death ligand 1; PFS progression-free survival a Nivolumab + ipilimumab 41 30 24 22 21 20 18 17 17 16 13 12 12 12 12 12 12 12 12 11 10 7731 0 Chemotherapy 48 37 19 10 888544443333332222210 0 No.",
        "positive": "CI represents the confidence interval, HR denotes the hazard ratio, and NA indicates not available data. The table shows the results of Nivolumab + ipilimumab treatment, with various response rates and durations.",
        "negative": "Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity."
    },
    {
        "anchor": "Patients must have measurable NSCLC disease (per RECIST Guidelines, v1.1).",
        "positive": "Patients must have detectable non-small cell lung cancer (NSCLC) according to the RECIST guidelines.",
        "negative": "original reports\nPoziotinib in Non\u2013Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial Xiuning Le, MD, PhD1; Robin Cornelissen, MD, PhD2; Marina Garassino, MD3; Jeffrey M. Clarke, MD4; Nishan Tchekmedyian, MD5; Jonathan W. Goldman, MD6; Szu-Yun Leu, PhD7; Gajanan Bhat, PhD7; Francois Lebel, MD7; John V. Heymach, MD, PhD1;and abstract PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2)exon20occur in 2%-5% of non\u2013small-cell lung cancers (NSCLCs) and function as an oncogenic driver."
    },
    {
        "anchor": "Autophagosomeenriched DRibbles for patients 2, 3, 5, 6, and UbiLT3 DRibbles, derived from a lung tumor cell line, used as a control, were labeled with autophagosome specific antibodies [anti-LC3 (PE), anti-LC3 (PE)/LAMP1-FITC, anti-p62 (PE), or anti-p62 (PE)/LAMP1-FITC].",
        "positive": "For patients 2, 3, 5, 6, and UbiLT3, autophagosome-enriched DRibbles were used as controls, derived from a lung tumor cell line and labeled with antibodies specific to autophagosomes.",
        "negative": "Toxicity\nAdverse events are shown in Tables (<>)2 and (<>)3."
    },
    {
        "anchor": "The amino acid (aa) sequences of the CARs were CD8a leader (aa 1\u201321), scFv, IgD hinge (aa 187\u2013289), CD28 (aa 153\u2013220) and CD3z (aa 52\u2013163).",
        "positive": "The amino acid sequences of the CARs consisted of CD8a leader (aa 1-21), scFv, IgD hinge (aa 187-289), CD28 (aa 153-220), and CD3z (aa 52-163).",
        "negative": "Competing interests\nX\u2011HF is employed by Legend Biotech."
    },
    {
        "anchor": "Two participating institutions, the University of Colorado School of Medicine and City of Hope, had the study approved by WIRB Copernicus (WCG IRB).",
        "positive": "The study was approved by the institutional review boards (IRBs) of the University of Colorado School of Medicine and City of Hope, which are two participating institutions.",
        "negative": "End points and assessments\nThe primary end point was PFS."
    },
    {
        "anchor": "Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).",
        "positive": "The statistical analysis should specify how participants who did not use the application or dropped out of the trial were handled, as complete case analysis is not recommended and simple imputation techniques may be problematic.",
        "negative": "12a-i) Imputation techniques to deal with attrition / missing values\nImputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials."
    },
    {
        "anchor": "Acknowledgements\nThis project was funded by The Herbert Daus foundation program.",
        "positive": "The project was supported by the Herbert Daus foundation program.",
        "negative": "We acknowledge the valuable input by attendees of the 15th ECCO-AACREORTC-ESMO Flims clinical cancer research workshop 2013, in particular from Drs William Barry (Dana-Faber/ Harvard Cancer Center), Powel H. Brown (MD Anderson Cancer Center) and Stephen M. Hahn (University of Pennsylvania Health System)."
    },
    {
        "anchor": "Recently, chimeric antigen receptors (CARs) engineered T cells specifically targeting CD19 or CD20 antigen have consistently demonstrated high antitumor efficacy across a range of B-cell hematological malignancies (Dai H et al., (<>)2015; Wang Y et al., (<>)2014; Kochenderfer JN et al., (<>)2015; Park JH et al., (<>)2016; Maus and June (<>)2016).",
        "positive": "CARs engineered T cells targeting CD19 or CD20 have been shown to have high antitumor efficacy in B-cell hematological malignancies, as demonstrated by several studies (Dai et al., 2015; Wang et al., 2014; Kochenderfer et al., 2015; Park et al., 2016; Maus and June, 2016).",
        "negative": "SGM-101 Fluorescent Labeling of CEACAM5-Positive Lung Tumors\nFive patients with primary nodules were selected for a proof-of-principle study."
    },
    {
        "anchor": "Replacement of appropriate hormones may be required as the steroid dose is tapered.",
        "positive": "As the steroid dose is reduced, replacement of appropriate hormones may be necessary.",
        "negative": "x Hypophysitis:\no For Grade 2 events, treat with corticosteroids."
    },
    {
        "anchor": "As the combination of immunochemotherapy enters clinical practice as one of the standard-of-care first-line regimens, it would also be clinically meaningful to explore the efficacy and safety of docetaxel plus immunotherapy combination regimens in patients with advanced NSCLC after progression from platinum-based chemotherapy and immune checkpoint inhibitors.",
        "positive": "As immunochemotherapy becomes a standard first-line treatment, it is crucial to evaluate the efficacy and safety of docetaxel plus immunotherapy regimens in patients with advanced NSCLC who have progressed after platinum-based chemotherapy and immune checkpoint inhibitors.",
        "negative": "Hyperlinks\n1. www.cancer.org/cancer/types/skin-cancer.html N/A 2. www.cancer.org/cancer/types/prostate-cancer.html N/A 3. www.cancer.org/cancer/types/breast-cancer.html N/A 4. www.cancer.org/cancer/types/colon-rectal-cancer.html N/A 5. www.cancer.org/cancer/risk-prevention/tobacco.html N/A 6. www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival- rates.html"
    },
    {
        "anchor": "Include the following information on the Sponsor supplied exception/deviation form: protocol number, subject study number, comprehensive description of the exception/deviation rationale, and corrective and preventative action plan (deviations only).",
        "positive": "The Sponsor supplied exception/deviation form should include the following details: protocol number, subject study number, a detailed explanation of the exception/deviation, and a plan to prevent and correct any deviations.",
        "negative": "Protocol Exceptions and Deviations\nException: A one time, intentional action or process that departs from the approved study protocol, intended for one occurrence."
    },
    {
        "anchor": "Results: 143 patients were identified in SCHOLAR-5, reducing to 129 patients after applying propensity score weights versus 127 patients in ZUMA-5.",
        "positive": "The study results showed that 143 patients were initially identified in SCHOLAR-5, which was reduced to 129 patients after adjusting for propensity score weights, compared to 127 patients in ZUMA-5.",
        "negative": "Phosphorylated mitogen-activated protein kinase (pMAPK) measurement\u2014\nParaffin embedded tumor blocks obtained at the time of diagnosis were collected for the assessment of expression of mitogen-activated protein kinase (MAPK) and phosphorylated-MAPK (pMAPK)."
    },
    {
        "anchor": "Patients who received prior therapy with immune checkpoint inhibitors or had grade \u22652 peripheral neuropathy or any lung disease that could potentially interfere with detection or management of suspected drug-related pulmonary toxicity were excluded.",
        "positive": "Patients who had previously received immune checkpoint inhibitors or had grade \u22652 peripheral neuropathy or any lung disease that could impact the detection or management of suspected drug-related pulmonary toxicity were excluded from the study.",
        "negative": "MGD019-mediated Ligand Blockade\nPD-1, CTLA-4 and PD-1+CTLA-4 bioassay systems were obtained from Promega (Madison, USA) and used according to manufacturers\u2019 instructions."
    },
    {
        "anchor": "Computed tomography scans or magnetic resonance images were performed at baseline, every two cycles (6 weeks) in the first four cycles, and every three cycles (9 weeks) thereafter.",
        "positive": "Imaging studies, including computed tomography scans or magnetic resonance images, were conducted at baseline, every 6 weeks for the first four cycles, and every 9 weeks thereafter.",
        "negative": "Introduction\nCemiplimab (cemiplimab-rwlc in the United States) is a highly potent, hinge-stabilized, immunoglobulin G4 fully human monoclonal antibody directed against the programmed cell death-1 (PD-1) receptor."
    },
    {
        "anchor": "Furthermore, anti-EGFR therapy did not improve progression free survival (PFS) or OS in stage III NSCLC patients when combined with either standard dose (60Gy) or dose escalated (74Gy) CRT in the recent RTOG radiotherapy dose escalation trial (RTOG0617) (22).",
        "positive": "Additionally, the RTOG0617 trial found that anti-EGFR therapy did not enhance progression-free survival or overall survival in stage III NSCLC patients when combined with either standard-dose (60Gy) or dose-escalated (74Gy) CRT.",
        "negative": "EGFR\nEGFR is mutated in about 15% of NSCLC adenocarcinomas and wild type EGFR is over-expressed in up to 50% of lung cancers."
    },
    {
        "anchor": "We included 13 uncontrolled studies evaluating CAR T-cell therapy in people with r/r DLBCL with either a single arm or multiple arms of CAR T-cell therapy.",
        "positive": "A total of 13 uncontrolled studies were included, which evaluated CAR T-cell therapy in patients with relapsed/refractory DLBCL, with either a single arm or multiple arms of CAR T-cell therapy.",
        "negative": "Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gul-ley JM, Palena C, Schlom J (2020) Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances."
    },
    {
        "anchor": "COMPETING INTERESTS\nM.M., S.V.",
        "positive": "Conflicting Interests: M.M. and S.V.",
        "negative": "is a former employee of GSK."
    },
    {
        "anchor": "All patients remained hospitalized to recovery through day +21 or until all procedure-related non-hematological toxicity returned to grade % 1 or baseline.",
        "positive": "Patients were hospitalized until they had fully recovered from procedure-related non-hematological toxicity, which was considered to have returned to grade % 1 or baseline.",
        "negative": "ARI-0001 Cells Production and Treatment\n27 Full details of ARI-0001 cell production, including a comprehensive phenotypic characterization of these cells can be found elsewhere."
    },
    {
        "anchor": "Similarly, tebotelimab demonstrates dose-dependent blockade of the LAG-3/MHC-class II axis similar to relatlimab (Supplementary Fig.",
        "positive": "Tebotelimab displays dose-dependent blockade of the LAG-3/MHC-class II axis, mirroring the findings for relatlimab, as depicted in the supplementary figure.",
        "negative": "Characteristics of participants\nA total of 116 adult patients with newly diagnosed ALK+ NSCLC, either locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV), will be enrolled into this study after written informed consent."
    },
    {
        "anchor": "BTH1677 (\u03b2(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-\u03b2-(1,3)-D-glucopyranose; Imprime PGG; Biothera Pharmaceuticals Inc., Eagan, MN), is a fungal-derived, water-soluble, 1,3\u20131,6 beta glucan.",
        "positive": "BTH1677 is a soluble, fungal-derived beta glucan consisting of 1,3\u20131,6 beta glucan.",
        "negative": "funding\nThis project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health."
    },
    {
        "anchor": "For ellipsoidGate objects, it is the center of the ellipsoid, given by the mean slot.",
        "positive": "The midpoint of an ellipsoidGate object is calculated as the mean slot.",
        "negative": "1.5.5 AMP-activated Protein Kinase (AMPK)\nLKB1 mediates many of its metabolic and anti-proliferative functions through activation of AMPK (Fig."
    },
    {
        "anchor": "Discussion Using advanced techniques such as VMAT functionally adapted radiation therapy may enable safe moderate dose escalation with an aim of improving local control and concurrently decreasing treatment related toxicity.",
        "positive": "Advanced radiation therapy techniques, such as VMAT, may enable moderate dose escalation while minimizing treatment-related toxicity.",
        "negative": "Reagents\nReagents were obtained from Sigma-Aldrich (USA), unless otherwise specified."
    },
    {
        "anchor": "We thank the trial coordinators for logistical and technical support and appreciate the participation of all patients onto this trial.",
        "positive": "We would like to express our gratitude to the trial coordinators for their logistical and technical support, as well as the patients who participated in this trial.",
        "negative": "DIAGNOSIS OF LUNG CANCER\nThe diagnosis of lung cancer was made by histopathological examination of resection specimens or cytopathological examination of needle-aspiration biopsy samples."
    },
    {
        "anchor": "At the data cut-off date, all patients had discontinued treatment, with disease progression [38 patients (69%)] being the primary reason, followed by AEs [11 patients (20%)], withdrawal of consent [four patients (7%)], lost to follow-up [one patient (2%)], and because of transfer to rollover study [one patient (2%)].",
        "positive": "At the data cut-off point, all patients had completed treatment, with disease progression being the main reason for 69% of patients, followed by adverse events, withdrawal of consent, lost to follow-up, and transfer to a rollover study.",
        "negative": "ETHICS APPROVAL AND CONSENT TO PARTICIPATE\nAll patients provided informed consent according to local institutional review board (IRB) guidelines: Avera Cancer Center, Sioux Falls, SD, USA: WIRB IRB 10/20/2017 tracking 20,172,298 WO number 1-1038118-1."
    },
    {
        "anchor": "Patients provided written informed consent, and the protocol was approved by local ethics committees.",
        "positive": "Patients provided written informed consent, and the protocol was approved by local ethics committees.",
        "negative": "erlotinib: rationale for pharmacodynamic separation."
    },
    {
        "anchor": "Study design\nINDUCE-2 was a Phase I/II, open-label study investigating feladilimab in combination with tremelimumab with a two-part design (Supplementary Fig.",
        "positive": "INDUCE-2 was a Phase I/II, open-label study investigating feladilimab in combination with tremelimumab, with a two-part design.",
        "negative": "14.1 Melanoma\nIpilimumab-Naive Melanoma The efficacy of KEYTRUDA was investigated in KEYNOTE-006 (NCT01866319), a randomized (1:1:1), open-label, multicenter, active-controlled trial in 834 patients."
    },
    {
        "anchor": "5.5.1.16 Critical Structures Constraints\n\u02dc Dose volume constraints for normal critical structures are given in the Table below.",
        "positive": "Normal critical structure dose volume constraints are presented in the table below.",
        "negative": "Critical Structure Dose Constraints and Compliance Criteria"
    },
    {
        "anchor": "To analyze peripheral cytokines, 50\u2013100 \u03bcl blood was collected in EDTA tubes containing Di-Kalium-EDTA (Microvette300LH; Sarstedt, 16.444).",
        "positive": "To analyze peripheral cytokines, 50\u2013100 \u03bcl blood was collected in EDTA tubes containing Di-Kalium-EDTA.",
        "negative": "Pharmacokinetic analysis\nOf the 68 patients enrolled in the study, 63 had blood samples available for pharmacokinetic analysis (Table (<>)3)."
    },
    {
        "anchor": "Terminal-care costs account for costs in the last month (30 days) of a patient\u2019s life and were applied as a one-off cost to all patients newly entering the death state over the time horizon.",
        "positive": "Terminal-care costs were applied as a one-off cost to all patients newly entering the death state over the time horizon.",
        "negative": "2.6 Cost Inputs\nThe model included costs of disease management in the PF and PD states, drug acquisition, drug administration, management of grade 3/4 AEs, treatments received in subsequent lines of therapy, and end-of-life care."
    },
    {
        "anchor": "STUDY PARTICIPATING AND STUDY CONDUCT\nAt 33 screening centers, we recruited asymptomatic men and women, 55 to 74 years of age, who had a history of at least 30 pack-years of cigarette smoking and who were either current smokers or had been smokers within the previous 15 years.",
        "positive": "At 33 screening centers, we recruited asymptomatic individuals aged 55 to 74 who had a history of at least 30 pack-years of cigarette smoking and were either current smokers or had quit within the previous 15 years.",
        "negative": "Details of recruitment and randomization methods have been published previously.7"
    },
    {
        "anchor": "Anderson Cancer Center, Houston, TX 7Case Western Reserve University School of Medicine, Cleveland, Oh 8Tom Baker Cancer Centre, Calgary, AB, Canada 9Washington University School of Medicine, St. Louis, MO 10Saskatchewan Cancer Agency, Saskatoon, SK, Canada",
        "positive": "The participating institutions included the Anderson Cancer Center in Houston, Texas, the Case Western Reserve University School of Medicine in Cleveland, Ohio, the Tom Baker Cancer Centre in Calgary, Alberta, Canada, the Washington University School of Medicine in St. Louis, Missouri, and the Saskatchewan Cancer Agency in Saskatoon, Saskatchewan, Canada.",
        "negative": "Lawrence Yaacov Richard, MRCP1,4, Paulus Rebecca, BS2, Langer Corey, MD3, Werner-Wasik Maria, MD4, K Buyyounouski Mark, MD, MS5, Komaki Ritsuko, MD6, Machtay Mitchell, MD7, Smith Colum, MD8,10, S Axelrod Rita, MD4, Wasserman Todd, MD9, D Bradley Jeffrey, MD9, and Movsas Benjamin, MD11\n1Sheba Medical Center, Tel HaShomer, Israel 2RTOG Statistical Center, Philadelphia, PA 3Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 4Thomas Jefferson University Hospital, Philadelphia, PA 5Fox Chase Cancer Center, Philadelphia, PA 6University of Texas M.D."
    },
    {
        "anchor": "5, 6 Immunotherapy with antigen-specific T cells may benefit patients with sarcoma because immune-mediated killing does not rely on pathways used by conventional therapies to which such tumors are often resistant.Adoptive transfer of T cells, genet-icallymodifiedtoexpresschimericantigenreceptors (CARs), has shown great promise in early-phase clinical studies for the therapy of CD19-positive 7 10 11, 12 13 14 17 18, 19 14, 20 malignancies.-Clinical experience using this approach for solid tumors, however, is much more limited.CARs recognize antigens expressed on the cell surface of tumor cells,and several potential CAR target antigens have been identified for sarcoma, including human epidermal growth factor receptor 2 (HER2), GD2, interleukin (IL) -11R\ue004, and B7H3.-Although sarcoma cells are often HER2positive, the HER2 gene locus is not amplified in this disease.Thus, sarcomas belong to a large group of malignancies, including cancers of the lung, ovary, prostate, and brain, that express HER2 at levels too low for HER2 monoclonal antibodies (MAbs) to be effective.",
        "positive": "The use of antigen-specific T cells in immunotherapy may be effective for sarcoma patients, as it bypasses the limitations of conventional therapies. Genetically modified T cells expressing CARs have shown promise in early clinical trials for CD19-positive malignancies. While this approach has been explored for solid tumors, including sarcoma, the experience is still limited. CARs recognize surface antigens on tumor cells and have identified potential targets for sarcoma, such as HER2, GD2, and B7H3.",
        "negative": "INTRODUCTION\n1, 2 Sarcomas are a diverse group of malignancies that includeosteosarcoma,Ewingsarcoma,rhabdomyo-sarcoma, and nonrhabdomyosarcoma soft tissue sarcomas, such as synovial sarcoma or desmoplastic small round cell tumors."
    },
    {
        "anchor": "Excluded patients were those with poor baseline hearing, brain metastases, history of seizures, radiographic evidence of major blood vessel involvement, history of arterial or venous thrombosis within the 6 months prior, major surgical procedures within the 4 weeks prior, or a history of hemoptysis within the 3 months prior (defined as 1 teaspoon or more of blood).",
        "positive": "The study excluded patients with poor baseline hearing, brain metastases, seizure history, major blood vessel involvement, recent arterial or venous thrombosis, recent major surgery, or hemoptysis within the past 3 months.",
        "negative": "Patients\nPatients had pathologically confirmed stage IIIB or IV nsNSCLCs who had not previously received systemic therapy for advanced stage disease."
    },
    {
        "anchor": "We detected IFN\u03b3 secreting cells specific to stimulation with \u03b1-Galcer instead.",
        "positive": "Instead, we found IFN\u03b3-secreting cells specific to stimulation with \u03b1-Galcer.",
        "negative": "13.9 Evaluation of the Primary Efficacy Endpoint\nNot applicable"
    },
    {
        "anchor": "Grade 3 or higher AEs of any type are summarized in (<>)Table 2.",
        "positive": "Grade 3 or higher adverse events of any type are listed in Table 2.",
        "negative": "Safety\nThe safety population included all patients who received at least one dose of either erlotinib (107 patients) or WBRT-alone (114 patients)."
    },
    {
        "anchor": "All patients provided written, informed consent before enrolment.",
        "positive": "Prior to enrollment, all patients provided written informed consent.",
        "negative": "Study oversight\nThis study was conducted in accordance with the principles outlined in the Declaration of Helsinki and Guidelines for Good Clinical Practice."
    },
    {
        "anchor": "Nested PCR to detect free adenovirus (AdCCL21) in the peripheral blood revealed no evidence of free virus following vaccination on days 0 (day of vaccination), 14, and 28 (data not shown).",
        "positive": "The study found no evidence of free adenovirus in the peripheral blood after vaccination on days 0, 14, and 28 using nested PCR.",
        "negative": "Usage\ninverseLogicleTransform(trans,transformationId,...)"
    },
    {
        "anchor": "The nutritional recommendations will include: energy intake of 30 kcal/kg body weight/day for patients with BMI <30 or 25 kcal/kg body weight/day for patients with BMI \u226530 and protein intake of at least 1.2 g/kg body weight/day.",
        "positive": "The nutritional recommendations will be: 30 kcal/kg body weight/day for patients with BMI <30, 25 kcal/kg body weight/day for patients with BMI \u226530, and at least 1.2 g/kg body weight/day protein intake.",
        "negative": "Nutritional recommendations\n36 37 All patients will receive nutritional recommendations during the first and fourth treatment cycle."
    },
    {
        "anchor": "We designed two different bicistronic Sleeping Beauty transposon vectors to vehiculate the concomitant expression of CD33.CAR and CXCR4WTor the gain-of-function variant of CXCR4 (R334X), described in WHIM syndrome and responsible for leukocytes sequestration in the BM.",
        "positive": "We created two bicistronic Sleeping Beauty transposon vectors that simultaneously expressed CD33.CAR and CXCR4WT or the gain-of-function variant CXCR4 (R334X), which is associated with leukocyte sequestration in the bone marrow.",
        "negative": "2.2 Study design\nThe ADAPT ALEC trial is an international, multicenter, phase IV, RCT comparing TDM-guided dosing to standard dosing of alectinib."
    },
    {
        "anchor": "participated in this study on behalf of Hemato-Oncologie voor Volwassenen Nederland (HOVON\u2014The Haemato Oncology Foundation for Adults in The Netherlands)/Lunenburg Lymphoma Phase I/II Consortium (LLPC) and on behalf of the Lymphoma and Myeloma CAre and REsearch Center, Amsterdam (LYMMCARE).",
        "positive": "The study was sponsored by HOVON, LYMMCARE, and LLPC, with HOVON and LYMMCARE acting as the primary sponsors.",
        "negative": "Table 1:\nBaseline characteristics Author ManuscriptSarcoma\u2021 13 (24%) NSCLC 10 (19%) Mammary analogue secretory carcinoma (salivary) 7 (13%) Breast 6 (11%) Thyroid 5 (9%) Table 2: Activity outcomes Data are n (%) or median (95% CI)."
    },
    {
        "anchor": "As expected, oxidative phosphorylation (OXPHOS) was markedly enhanced in Q-treated T cells compared to diluent-treated controls after TCR stimulation.",
        "positive": "Following TCR stimulation, T cells treated with Q showed a substantial increase in oxidative phosphorylation compared to those treated with the control solution.",
        "negative": "CANCER IMMUNOLOGY RESEARCH | IN THE SPOTLIGHT\nIFNg Helps CBLB-Deficient CD8\u00fe T Cells to Put Up Resistance to Tregs Dominik Wolf1 and Gottfried Baier2 In this issue, Han and colleagues demonstrate in preclinical cancer models that genetic deletion of the E3 ubiquitin ligase Cbl proto-oncogene B (CBLB) in adoptively transferred CD8\u00fe T cells induces resistance to regulatory T cells."
    },
    {
        "anchor": "Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.",
        "positive": "The IMpower132 trial, a phase 3 study, evaluated the efficacy of atezolizumab in combination with chemotherapy for the treatment of nonsquamous NSCLC.",
        "negative": "CD22 CAR Construct and Manufacturing of CD22-CAR T cells\nThe CD22-CAR contains a fully human single chain fragment variable region generated from a human B cell phage library30, a CD8 transmembrane domain and CD3 zeta plus 4-1BB signaling chains (CD22.BB.z) as previously described and as illustrated in Figure 1A.19,35 All patients received the identical preparative regimen consisting of fludarabine 25 mg/m2/d on Days \u22124, \u22123, \u22122 and cyclophosphamide 900 mg/m2 on day \u22122, with CD22CAR T cell infusion on Day 0."
    },
    {
        "anchor": "Information on the clinical trial can be found at (<https://clinicaltrials.gov/ct2/show/NCT03274479>)https://clinical-(<https://clinicaltrials.gov/ct2/show/NCT03274479>)trials.gov/ct2/show/NCT03274479.",
        "positive": "Additional information about the clinical trial can be found on the clinicaltrials.gov website.",
        "negative": "First draft submitted: 3 May 2021; Accepted for publication: 24 June 2021; Published online: 19 July 2021\nApproximately 30% of patients with non-small-cell lung cancer (NSCLC) present with resectable disease [1\u20133],the primary treatment for which is surgery with curative intent [4]."
    },
    {
        "anchor": "PB participated in developing the study concept, participates in trial conduction and coordinates the immune monitoring.",
        "positive": "PB contributed to the study's concept and is responsible for overseeing the trial's conduct and immune monitoring.",
        "negative": "Study design and participants\nThis open-label, single-arm phase I/II trial (ClinicalTrials.gov number NCT03097770) was approved by the Ethics Committee of the Chinese PLA General Hospital (Beijing, China), and informed consent was obtained from all patients."
    },
    {
        "anchor": "Also, by IMRT-treatment planning, normal tissue will be more adequately spared while allowing dose escalation to the gross tumour volume.",
        "positive": "The IMRT treatment plan allows for a more precise delivery of radiation to the tumor while minimizing damage to surrounding tissues.",
        "negative": "JJCO Japanese Journal of Clinical Oncology\nJapanese Journal of Clinical Oncology, 2019, 49(1) 29\u201336 doi: 10.1093/jjco/hyy179 Advance Access Publication Date: 1 December 2018 Original Article Original Article"
    },
    {
        "anchor": "Added value of this study\nIn our heavily pretreated patient population, durvalumab had clinical activity and a tolerability profile consistent with other anti-PD-1 and anti-PD-L1 agents.",
        "positive": "In this heavily pretreated patient population, durvalumab showed clinical activity and a safety profile consistent with other anti-PD-1 and anti-PD-L1 agents.",
        "negative": "Statistical Analysis\nAll results were analyzed descriptively, and no sample size or power calculations were conducted; HCRU data on all patients who were infused with ide-cel as part of the KarMMa trial (n = 128) were included in the analyses."
    },
    {
        "anchor": "Azer-cel post-thaw cell composition was assessed by flow cytometry (minimally differentiated stem central memory [SCM], CC-chemokine receptor 7 (CCR7)+; differentiated effector memory, CCR7-).",
        "positive": "Flow cytometry was used to assess the post-thaw cell composition of azer-cel, examining minimally differentiated stem central memory cells and differentiated effector memory cells.",
        "negative": "Received: 28 September 2020 | Revised: 30 November 2020 | Accepted: 2 December 2020\nDOI: 10.1002/cam4.3686 ORIGINAL RESEARCH"
    },
    {
        "anchor": "Possible answers were \u201cnot at all,\u201d\u201ca little,\u201d\u201cquite a bit,\u201d and \u201cvery much.\u201d Analysis was limited to the first three cycles.",
        "positive": "Participants were asked to rate their symptoms using a four-point scale, ranging from \"not at all\" to \"very much.\"",
        "negative": "Efficacy\nAmong 80 evaluable patients, the DCR was 72.5% and the objective response rate (ORR) was 37.5% (CR: n=1, 1.3%; PR: n=29, 36.3%."
    },
    {
        "anchor": "There was no discernible association between tepotinib exposure and median observed increases, or median relative change from baseline for lipase, amylase, ALT or AST (data not shown).",
        "positive": "There was no correlation found between tepotinib exposure and changes in lipase, amylase, ALT, or AST levels.",
        "negative": "Lipase, amylase, ALT, and AST\nTrends towards treatment-emergent amylase increase, and transient increases in AST and ALT were noted."
    },
    {
        "anchor": "Based on the potential mechanisms of action, treatment with INCAGN01949 is anticipated to enhance intratumoral immune activation, with an increase in effector T cell to Treg ratio.",
        "positive": "Treatment with INCAGN01949 is expected to boost intratumoral immune activation, leading to an increase in the proportion of effector T cells to regulatory T cells.",
        "negative": "Author contributions\nAlejandra Romero Roma\u00b4n: Conceptualization; Formal analysis; Writing\u2014ori-ginal draft."
    },
    {
        "anchor": "Competing interests\nMF, SAM, AZ, KYT and PMA are employees of Precision Biologics, Inc. PMA has an ownership interest in Precision Biologics, Inc. PMA had no role in the design of the study, in the collection, analyses or interpretation of the data, in the writing of the manuscript or in the decision to publish the results.",
        "positive": "The authors declare that MF, SAM, AZ, KYT, and PMA are employees of Precision Biologics, Inc., and PMA has a financial interest in the company. PMA did not participate in the study design, data collection, analysis, or manuscript writing, nor was involved in the decision to publish the results.",
        "negative": "All other authors have no conflicts of interest to declare."
    },
    {
        "anchor": "3.4.2 Contrast of Patients With Improving Versus Worsening 5-month Depression/Anxiety Trajectories and Resultant Differences in Survival.\u2014 Patients in this study were not randomized to receipt of a psychological intervention versus not.",
        "positive": "The study analyzed the contrast between patients with improving and worsening depression/anxiety trajectories over a 5-month period, and the impact on survival was assessed.",
        "negative": "Study Design\nPatients were eligible for enrollment in the HERALD study if they had histologically confirmed stage IIIB/IV NSCLC with measurable disease (per Response Evaluation Criteria in Solid Tumors guidelines, version 1.1) and documented disease progression or recurrence on at least 1 prior chemotherapy treatment."
    },
    {
        "anchor": "Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lym-phoid leukemia.",
        "positive": "A study by Porter et al. explored the application of chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.",
        "negative": "Julie R. Brahmer, M.D.,\nJohns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore"
    },
    {
        "anchor": "Images of original cut blots with membrane edge visible are included (where applicable) in the (<>)Supplementary (<>)Material.",
        "positive": "Original cut blots with visible membrane edges are included in the supplementary material, where applicable.",
        "negative": "Right and Left Lung\no contoured on the lung window, excluding trachea and GTV"
    },
    {
        "anchor": "CART22 cells could proliferate without control of normal homeostatic mechanisms.",
        "positive": "CART22 cells can proliferate without being controlled by normal homeostatic mechanisms.",
        "negative": "INTRODUCTION\nLung cancer continues to be the leading cause of cancer-related mortality for both men and women, with an estimated 222,520 new lung cancer cases diagnosed in the United States each year.1 Unfortunately, despite advances in treatment, the prognosis for patients with advanced lung cancer remains poor, with the vast majority of patients dying as a result of uncontrolled systemic disease."
    },
    {
        "anchor": "The null hypothesis that the true response rate is 10% will be tested against a one-sided alternative.",
        "positive": "The null hypothesis that the true response rate is 10% will be tested against a one-sided alternative hypothesis, with the goal of rejecting the null hypothesis.",
        "negative": "Otherwise, 19 additional patients will be accrued for a total of 29."
    },
    {
        "anchor": "At week 12, patients with SD were randomized to cabozantinib or placebo, patients with a PR could continue open-label cabo-zantinib treatment, and patients with PD at or before week 12 discontinued treatment.",
        "positive": "At week 12, patients with stable disease were randomized to receive cabozantinib or placebo, while those with a partial response could continue open-label cabozantinib treatment, and those with progressive disease at or before week 12 were discontinued from treatment.",
        "negative": "Andie R Edwards, BA,\nDepartment of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA"
    },
    {
        "anchor": "The opioid-sparing approach has been recommended by guidelines for enhanced recovery after lung surgery ((<>)8).",
        "positive": "Guidelines recommend an opioid-sparing approach for enhanced recovery after lung surgery.",
        "negative": "Introduction\nOpioids are widely used in pain relieving but may also cause undesirable side effects, including respiratory depression, sedation, nausea, and vomiting ((<>)1)."
    },
    {
        "anchor": "Secondary Outcome Measures\nThe Manchester Cough in Lung Cancer Scale (MCLCS) is a 10-item, unidimensional scale that measures patients\u2019 experience with cough in terms of its frequency, intensity, and bothersomeness.19 The European Organisation for Research and Treatment of Cancer\u2014Quality of life questionnaire (EORTCQLQ-C30), includes both multi-item scales and single-item measures, incorporating 5 functional scales, 3 symptom scales, a global health status/QOL scale, and 6 single items.",
        "positive": "Secondary outcome measures included the Manchester Cough in Lung Cancer Scale (MCLCS), a 10-item scale that assesses patients' experience with cough in terms of frequency, intensity, and bothersomeness, as well as the European Organisation for Research and Treatment of Cancer\u2014Quality of Life questionnaire (EORTCQLQ-C30), which includes multi-item scales and single-item measures.",
        "negative": "The Lung Cancer module (LC-13 subscale), focuses on LC-specific symptoms and side effects (dyspnea, cough, site-specific pain, peripheral neuropathy, sore mouth, alopecia).20"
    },
    {
        "anchor": "All patients provided written informed consent.",
        "positive": "Written consent was obtained from each patient prior to enrollment.",
        "negative": "Standard protocol approvals, registration, and patient consents\nThe trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonization), applicable regulatory requirements, and the Policy on Bioethics and Human Biologic Samples of the trial sponsor, AstraZeneca."
    },
    {
        "anchor": "When used in combination with daratumumab, FT555 targets CD38 and eliminates CAR-resistant GPRC5D KO target cells (57.1% target killing when combined with daratumumab vs. 3.5% target killing in the absence of mAb in the third round of stimulation), demonstrating the capacity for FT555 to target GPRC5D+ and CD38+ cells through CAR and hnCD16 engagement, respectively.",
        "positive": "The combination of FT555 and daratumumab showed enhanced target cell elimination, with a 57.1% killing rate compared to 3.5% when used alone, highlighting the dual targeting mechanism of FT555.",
        "negative": "Title: FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma\n\nAbstract: Recent improvement in patient outcomes with the use of novel cellular immunotherapies for multiple myeloma (MM) has raised the prospect for the emergence of a curative treatment."
    },
    {
        "anchor": "Antibody interference testing is unnecessary for non-IgG kappa isotype patients, patients with detectable disease by FLC or BJP or patients with an M-spike >0.2 g/dL by SPEP.",
        "positive": "Patients with non-IgG kappa isotype, detectable disease, or an M-spike >0.2 g/dL do not require antibody interference testing.",
        "negative": "Antibody interference in serum protein electrophoresis\n62\u201364 89 Similar to dara, isatuximab may interfere with immu-nofixation results and appear as IgG kappa."
    },
    {
        "anchor": "Information posted will allow subjects to identify potentially appropriate trials for their disease conditions and pursue participation by calling a central contact number for further information on appropriate trial locations and trial site contact information.",
        "positive": "The posted information enables patients to find suitable clinical trials for their condition and contact a central number for more information on trial locations and contacts.",
        "negative": "Urothelial cancer and cutaneous melanoma cohorts\nLimited responses were noted in the other cohorts, with one of the 17 patients with urothelial cancer evaluable for response had a PR (ORR of 5.9%; (<>)table 5) and one of the 13 patients with cutaneous melanoma evaluable for response had a PR (ORR of 7.7%; (<>)table 5)."
    },
    {
        "anchor": "Recommendations\nThe empirical evidence of the current study does not support the management of fatigue, dyspnea, and anxiety as a symptom cluster with qigong.",
        "positive": "The study's results do not provide evidence for the effectiveness of qigong in managing fatigue, dyspnea, and anxiety as a symptom cluster.",
        "negative": "When designing interventions based on symptom clusters, it is important to combine symptoms that may have \u201cshared\u201d mechanisms in order to improve common symptom experience."
    },
    {
        "anchor": "HD, SN, AK-L, and RK are employees of Eli Lilly and Company.",
        "positive": "HD, SN, AK-L, and RK are employees of Eli Lilly and Company, a pharmaceutical company.",
        "negative": "Sarcopenia and cachexia\nLoss of muscle mass and strength is a part of the normal aging process and is referred to as primary sarco-penia [(<>)20]."
    },
    {
        "anchor": "For numbered affiliations see end of article.",
        "positive": "The affiliations are listed at the end of the article.",
        "negative": "Clinical Investigation Statement\nThe IRB at MSKCC reviewed and approved this trial."
    },
    {
        "anchor": "Treatment arm comparisons were conducted at 3 months (end of cycle 4) and 6 months (3 months post-treatment).",
        "positive": "The treatment arms were compared at 3 months (end of cycle 4) and 6 months (3 months post-treatment).",
        "negative": "Thus, the hypothesis that the addition of veliparib to CE would have a neuroprotective effect was not supported."
    },
    {
        "anchor": "Overall response rate\nThe efficacy parameters were significantly improved in the KarMMa cohort of all ide-cel treated patients across all target doses, compared with the Eligible RRMM cohort (Table (<>)2).",
        "positive": "The efficacy parameters were significantly improved in the KarMMa cohort of ide-cel-treated patients across all target doses compared to the Eligible RRMM cohort, as reported in Table (<>)2.",
        "negative": "Improvements with ide-cel were greater when outcomes in KarMMa patients who received the highest target dose of 450 \u00d7 106 CAR + T cells were compared with patients in the Eligible RRMM cohort."
    },
    {
        "anchor": "5.1 General Guidelines for DF/HCC Institutions\nInstitutions will register eligible participants in the Clinical Trials Management System (CTMS) OnCore.",
        "positive": "DF/HCC Institutions should register eligible participants in the Clinical Trials Management System (CTMS) OnCore.",
        "negative": "An investigator will confirm eligibility criteria and a member of the study team will complete the protocol-specific eligibility checklist."
    },
    {
        "anchor": "o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration.",
        "positive": "In cases where prolonged steroid administration is necessary, prophylactic antibiotics should be added to prevent opportunistic infections.",
        "negative": "Patient consent for publication Not required."
    },
    {
        "anchor": "Safety\nTable S(<>)1 tabulates the treatment-related adverse events (TRAEs) observed in our cohort.",
        "positive": "Table S(<>)1 summarizes the treatment-related adverse events (TRAEs) observed in our study cohort.",
        "negative": "A bispecific CAR targeting both CD19 and CD22 can recognize and kill CD19+CD22+, CD19\u2212CD22+ and CD22+CD19\u2212 B-ALL\nMulti-agent combination chemotherapy is a central tenet of ALL therapy."
    },
    {
        "anchor": "All patients had only 1 line of post-discontinuation chemotherapy or TKI following cessation of afatinib/erlotinib, except that 2 patients (1 in afatinib group and 1 in erlotinib group) who received 2 lines of post-discontinuation chemotherapy.",
        "positive": "Except for two patients who received two lines of post-discontinuation chemotherapy, all patients had only one line of treatment following cessation of afatinib/erlotinib.",
        "negative": "DISCUSSION\nAnti-BCMA CAR T-cell therapy is considered one of the most promising therapeutic strategies for RRMM."
    },
    {
        "anchor": "Cancer Genome Atlas N (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas.",
        "positive": "In 2015, the Cancer Genome Atlas Network conducted a comprehensive genomic analysis of head and neck squamous cell carcinomas.",
        "negative": "REFERENCES\nAsiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2014) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells."
    },
    {
        "anchor": "The investigator-assessed median DOR was 9\u00b70 months (95% CI 6\u00b79\u201318\u00b73; table 2; figure 4; appendix p. 6).",
        "positive": "The median duration of response was 9.0 months, with a 95% confidence interval of 6.9-18.3 (Table 2, Figure 4, Appendix p. 6).",
        "negative": "Title: Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "These must be accompanied by a technical description how a metric like a \u201csession\u201d is deUned (e.g., timeout after idle time) [1] (report under item 6a).",
        "positive": "A technical description must be provided for how a metric like a \"session\" is defined (e.g., timeout after idle time) [1] (report under item 6a).",
        "negative": "17a-i) Presentation of process outcomes such as metrics of use and intensity of use\nIn addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational deUnitions is critical."
    },
    {
        "anchor": "Median PFS was 4.1 weeks (95% confidence interval: 3.9\u20138.0).",
        "positive": "The median progression-free survival was 4.1 weeks, with a 95% confidence interval of 3.9-8.0.",
        "negative": "Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR\nMYUNG-JU AHN,a SANG-WE KIM,b BYOUNG-CHUL CHO,c JIN SEOK AHN,a DAE HO LEE,b JONG-MU SUN,a DAN MASSEY,d MIYOUNG KIM,e YANG SHI,f KEUNCHIL PARKa AUTHOR SUMMARY ABSTRACT Background."
    },
    {
        "anchor": "Informed verbal and written content will be obtained for all participants before inclusion in the study.",
        "positive": "Informed verbal and written consent will be obtained from all participants before inclusion in the study.",
        "negative": "Ethics approval and consent to participate\nThe study protocol, version 2.0 from February 1st 2018, is approved by the Regional Ethics Committee for the Capital Region of Denmark (j.nr: H-18001096)."
    },
    {
        "anchor": "Furthermore, a reduction of leukemic burden was observedin vivofollowing a single injection of a low dose (3x106cells) of CAR-KO-NK cells compared to NKG2A-KO or CD33-CAR-NK cell treatment in an AML-xenografted mouse model.",
        "positive": "In an AML-xenografted mouse model, a single injection of CAR-KO-NK cells at a low dose (3x10^6 cells) resulted in a reduction of leukemic burden compared to other treatments.",
        "negative": "Title: CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML\n\nAbstract: BACKGROUND:CD33-targeting chimeric antigen receptor (CAR)-T cells already showed utility for the treatment of AML."
    },
    {
        "anchor": "This is usually not called directly by the user, but internally by calls to the (<>)filter methods.",
        "positive": "This is usually not called directly by the user, but internally by calls to the (<>)filter methods.",
        "negative": "Methods\n%in% signature(x = \"flowFrame\", table = \"quadGate\"): The workhorse used to evaluate the gate on data."
    },
    {
        "anchor": "For subxiphoid surgery, it was advised to avoid obese patients with a BMI > 30 kg/m2; patients with central masses or enlarged lymph nodes with confirmed N1 or N2 disease; patients with cardiomyopathy or impaired cardiac function; or patients with posterior lesions [(<>)1, (<>)2].",
        "positive": "Subxiphoid surgery was not recommended for patients with a BMI greater than 30 kg/m2, central masses, or enlarged lymph nodes with N1 or N2 disease, cardiomyopathy, or posterior lesions.",
        "negative": "Frontline daratumumab Transplant-eligible patients\n35 36 37 38 In an ongoing phase II, randomized study, the GRIFFIN trial (NCT02874742) compared the combination of dara, bortezomib, lenalidomide and dexamethasone (D-VRd) with VRD in 207 patients with newly diagnosed myeloma eligible for autologous HSCT."
    },
    {
        "anchor": "For immunotherapy-naive patients, QL1706 exhibited promising antitumor activities, especially in NSCLC, NPC, and CC, with ORRs of 24.2%, 38.7%, and 28.3%, respectively.",
        "positive": "QL1706 showed significant antitumor effects in immunotherapy-naive patients, particularly in NSCLC, NPC, and CC, with response rates of 24.2%, 38.7%, and 28.3%, respectively.",
        "negative": "First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors\nYuanyuan Zhao1\u2020, Yuxiang Ma2\u2020, Aimin Zang3\u2020, Ying Cheng4\u2020, Yiping Zhang5\u2020 , Xiangcai Wang6\u2020 , Zhendong Chen7\u2020, Song Qu8, Jianbo He9, Chuanben Chen10, Chuan Jin11, Dongyuan Zhu12, Qingshan Li13, Xianling Liu14, Wuyun Su15, Yi Ba16, Yanrong Hao17, Junmin Chen18, Guoping Zhang19, Shenhong Qu20 , Yong Li21, Weineng Feng22 , Mengxiang Yang23, Baorui Liu24, Weiwei Ouyang25, Jin Liang26 , Zhuang Yu27 , Xiaoyan Kang28, Shilin Xue28 , Guihong Yang29 , Wei Yan30, Yingying Yang31, Zhi Liu30, Yufeng Peng30 , Bill Fanslow30, Xian Huang30, Li Zhang1* and Hongyun Zhao2* Abstract Background QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t1/2) for CTLA-4."
    },
    {
        "anchor": "Both breast cancer cell lines expressed c-Met at similar levels and mesothelin, another tumor antigen, at varying levels (Fig.1, A & B, lower panels).",
        "positive": "The breast cancer cell lines exhibited similar levels of c-Met expression and varying levels of mesothelin, another tumor marker (Fig.1, A & B, lower panels).",
        "negative": "Study Design\nPatients progressing on first- or second-generation EGFR TKI were treated with osimertinib monotherapy until progression for at least 4 weeks."
    },
    {
        "anchor": "contributed to study conception/design and data analysis or interpretation.",
        "positive": "The author contributed to the study's design, data analysis, and interpretation.",
        "negative": "and E.H. contributed to data analysis or interpretation."
    },
    {
        "anchor": "The definition of nonmeasurable brain metastases is: a brain lesion less than 10 mm in MRI scan is defined as nonmeasurable brain metastasi based on RECIST criteria (Clinical trial evaluation criteria).",
        "positive": "Nonmeasurable brain metastases are defined as brain lesions less than 10 mm in size, as per RECIST criteria.",
        "negative": "ABSTRACT\nIntroduction: Lorlatinib is a potent, third-generation inhibitor of ALK."
    },
    {
        "anchor": "In the CSF, there was significant enrichment of CD19-CAR T cells as judged by a high CD19-CAR/TRAC locus qPCR ratio ((<>)Figure 3G,H).",
        "positive": "The CSF contained a high concentration of CD19-CAR T cells, as indicated by a high CD19-CAR/TRAC locus qPCR ratio ((<>)Figure 3G,H).",
        "negative": "Patients\nKey eligibility criteria were age \u2265 18 years (\u2265 20 years in Japan), histologically confirmed advanced or metastatic NSCLC; prior treatment with at least two systemic therapies (one of which must be platinum doublet and either pemetrexed, docetaxel, or immunotherapy) for advanced or metastatic NSCLC; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0\u20131; adequate bone marrow function (absolute neutrophil count \u2265 1500/mm3, hemoglobin \u2265 10.0 g/dL, platelets \u2265 100,000/mm3); adequate liver function (total bilirubin \u2264 1.5 \u00d7 upper limit of normal [ULN], aspartate aminotransferase/alanine aminotransferase \u2264 3\u00d7 ULN [in patients with existent liver metastases, \u2264 5\u00d7 ULN]); and adequate renal function (calculated creatinine clearance \u2265 50 mL/min [Cockcroft-Gault])."
    },
    {
        "anchor": "Study design and participants\nImmunotherapy-naive patients with confirmed locally advanced or metastatic NSCLC were eligible for the study.",
        "positive": "The study included immunotherapy-naive patients with locally advanced or metastatic NSCLC who had confirmed disease.",
        "negative": "ARTICLE HISTORY\nReceived 4 December 2022  Revised 23 March 2023  Accepted 16 April 2023"
    },
    {
        "anchor": "Safety outcomes\nPatients will be monitored weekly for AEs, based on the National Cancer Institute\u2019s Common Terminology Criteria for Adverse Events v.4.03 (CTCAE v.4.03), from baseline to disease progression, death, or 12 months after randomized enrollment.",
        "positive": "The study will track patients' safety outcomes, using the CTCAE v.4.03, from baseline to disease progression, death, or 12 months after randomization.",
        "negative": "Any AEs caused by the study will be reimbursed by insurance."
    },
    {
        "anchor": "These methods are commonly known by their abbreviations estimation method.",
        "positive": "The abbreviations for these methods are well-known in the field.",
        "negative": "Hypotheses were generated based on biological plausibility and diagnostic graphics."
    },
    {
        "anchor": "BMJ disclaims all liability and responsibility arising from any reliance placed on the content.",
        "positive": "BMJ disclaims any liability or responsibility resulting from reliance on the content.",
        "negative": "Supplemental material This content has been supplied by the author(s)."
    },
    {
        "anchor": "depressed left ventricular ejection fraction, uncontrolled arrhythmias, congestive heart failure).",
        "positive": "The study excluded individuals with depressed left ventricular ejection fraction, uncontrolled arrhythmias, or congestive heart failure.",
        "negative": "Study Participants\nThis open-label phase I trial ((<https://clinicaltrials.gov/ct2/show/NCT01912625>)NCT01912625) was approved by the University of Texas M.D."
    },
    {
        "anchor": "Seven (0.3%) patients in the ramucir-umab arm and one (0.04%) patient in the control arm experienced grade 5 GI perforation.",
        "positive": "Gastrointestinal perforation of grade 5 severity was reported in seven patients receiving ramucirumab and one patient in the control group.",
        "negative": "GI perforation\nThere were 30 (1.1%) patients who experienced all-grade GI perforation in the ramucirumab arm and 7 (0.3%) patients in the control arm (RR: 3.2, 95% CI 1.5\u20137.0) (Table (<>)3)."
    },
    {
        "anchor": "Important: \u2022 Grade 5 is the only appropriate Grade \u2022 This AE is to be used in the situation where a death 1. cannot be reported using a CTCAE v3.0 term associated with Grade 5, or 2. cannot be reported within a CTCAE CATEGORY as \u2018Other (Specify)\u2019",
        "positive": "Grade 5 adverse events that cannot be categorized using CTCAE v3.0 terms or 'Other (Specify)' should be reported using this term.",
        "negative": "Authors and Affiliations\nAlexander Spira1,2(<http://orcid.org/0000-0003-1303-0447>) \u00b7 Aaron R. Hansen3 \u00b7 Wael A. Harb4 \u00b7 Kelly K. Curtis5\u00a0\u00b7 Erina\u00a0Koga\u2011Yamakawa6\u00a0\u00b7 Makoto\u00a0Origuchi7\u00a0\u00b7 Zhonggai\u00a0Li8\u00a0\u00b7 Bella\u00a0Ertik9\u00a0\u00b7 Walid\u00a0L.\u00a0Shaib10 1 Virginia Cancer Specialists, 8503 Arlington Blvd., Suite 400, Fairfax, VA 22031, USA 2 The US Oncology Network, The Woodlands, TX, USA 3 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada 4 Horizon Oncology Research, LLC, Lafayette, IN, USA 5 Medical Management and Scientific Services, Syneos Health, Phoenix, AZ, USA 6 DSP Cancer Institute, Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan 7 Clinical Development, Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA, USA 8 Biostatistics, Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA, USA 9 Pharmcovigilance, Former Employee of Boston Biomedical, Inc. (Now Sumitomo Dainippon Pharma Oncology, Inc.), Cambridge, MA, USA 10 Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA"
    },
    {
        "anchor": "In efficacy analysis set (58 patients), the median time to OR and CR evaluated by investigator were 0.92 and 0.95 month, respectively (Tables S6 and S7).",
        "positive": "The investigator-assessed median time to objective response and complete response was 0.92 and 0.95 months, respectively.",
        "negative": "3.2 | Efficacy\nFifty-eight patients were evaluable for efficacy outcomes, and the primary endpoint of 3\u00a0month ORR was 60.3% (95% CI, 46.6\u201373.0)."
    },
    {
        "anchor": "4Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.",
        "positive": "The author is affiliated with Yong Loo Lin School of Medicine, National University of Singapore, Singapore.",
        "negative": "Author details\n1Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Singapore."
    },
    {
        "anchor": "10.1.3 Confidentiality of Investigator Information\nBy signing this protocol, the investigator recognizes that certain personal identifying information with respect to the investigator, and allsubinvestigators and trialsite personnel, may be used and disclosed for trial management purposes, as part of a regulatory submissions, and as required by law.",
        "positive": "By signing this protocol, investigators acknowledge that their personal identifying information may be used and disclosed for trial management purposes.",
        "negative": "Study design\nThis was a phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of axi-cel in Japanese patients with R/R large B-cell lymphoma."
    },
    {
        "anchor": "Kaplan-Meier methods with log-rank tests were employed for comparison of each prespecified survival endpoints and Cox proportional hazard models were used for prognostic factors for PFS after afatinib or erlotinib in univariate and multivariate analyses, with afatinib versus erlotinib, age, sex, performance status, smoking status, histology, TTP for 1st TKI therapy, time interval between 1st TKI and afatinib or erlotinib, TTP for all lines of prior chemotherapy, time interval between last chemotherapy and afatinib or erlotinib as covariates.",
        "positive": "Kaplan-Meier methods and log-rank tests were used to compare survival endpoints, and Cox proportional hazard models were employed for prognostic factor analysis.",
        "negative": "Statistical analysis\nMann\u2013Whitney U tests were used for comparison of non-parametric variables and chi-square tests were performed for baseline and posttreatment discrete variables."
    },
    {
        "anchor": "Sunnybrook Health Sciences Centre: Ethics approval was obtained from Ontario Cancer Research Ethics Board (#3575) and the study is open.",
        "positive": "Ethics approval was obtained from the Ontario Cancer Research Ethics Board (#3575), and the study is currently open.",
        "negative": "Patients and study design\nClinicalTrials.gov Supplementary slides LUX-Lung 8 (NCT01523587) was a randomized, controlled, Phase III trial, conducted globally in 183 cancer centers, nine of which were in China."
    },
    {
        "anchor": "Of the patients assigned to chemotherapy, 39 (52.7%) crossed over to the rocileti-nib group at the time of progression.",
        "positive": "Fifty-two point seven percent of patients assigned to chemotherapy switched to the rociletinib group when their disease progressed.",
        "negative": "Details\nlintGml2 is defined by the following function: bound(f, boundMin, boundMax) = max(min(f, boundMax), boundMin)) where This transformation provides a linear display that maps scale values from the [\u2212A, T ] interval to the [0, 1] interval."
    },
    {
        "anchor": "Alternatively, it is possible that the antitumor effects were due to the targeted drugs, rather than the immunotherapy.",
        "positive": "The antitumor effects may have been caused by the targeted drugs rather than the immunotherapy.",
        "negative": "4 | DISCUSSION\nWithin the last decade, the treatment of advanced NSCLC has evolved dramatically."
    },
    {
        "anchor": "Non-smokers with ADC had a signi\ufb01cantly longer OS (median OS: 18.9 months, 95% CI: 15.7\u2013 21.7 months) in comparison to patients in the other three groups (all P \u2264 0.0001) (Table (<>)2 and Fig.",
        "positive": "The overall survival rate for non-smoking patients with ADC was significantly higher than that of patients in the other three groups, with a median survival time of 18.9 months.",
        "negative": "Survival in selected subgroups\nPatient PFS and OS were further evaluated based on gender, smoking history and histological classifications ((<http://jjco.oxfordjournals.org/lookup/suppl/doi:10.1093/jjco/hyv036/-/DC1>)Supplementary data, Tables S1 (<http://jjco.oxfordjournals.org/lookup/suppl/doi:10.1093/jjco/hyv036/-/DC1>)and S2)."
    },
    {
        "anchor": "[Kobayashi et al., 2005, Pao et al., 2005, Oxnard et al., 2011]  In addition to being a drug resistance mutation, this mutation is associated with a unique biology.",
        "positive": "This mutation, which was first identified by Kobayashi et al. (2005), Pao et al. (2005), and Oxnard et al. (2011), has been linked to both drug resistance and a distinct biological profile.",
        "negative": "14.0 Body Fluid Biospecimens\n14.1 Body Fluid Biospecimen Submission 14.11 Summary Table of Body Fluid Biospecimens for This Protocol 14.2 Blood/Blood Products Handling 14.21 Kits are required for this study."
    },
    {
        "anchor": "It is hypothesized that immune-related loss of the CAR transgene would result in early relapse or relapse shortly after CAR transgene loss; however, this was not the case in this particular patient.",
        "positive": "The theory was that the loss of the CAR transgene would lead to an early relapse or relapse shortly after its loss, but this was not observed in this specific patient.",
        "negative": "Discussion\nThese analyses represent the first comprehensive assessment of the effect of humoral and cellular immunogenicity and clinical end points for patients treated with tisagenlecleucel."
    },
    {
        "anchor": "The study protocol was reviewed and approved by the Institutional Review Board or Independent Ethics Committee at all participating centres.",
        "positive": "The research protocol was reviewed and approved by the Institutional Review Board or Independent Ethics Committee at all participating sites.",
        "negative": "Statistical analyses\n31 This was a nonrandomized, open-label, phase 1b study of abemaciclib plus pembrolizumab with safety as the primary endpoint."
    },
    {
        "anchor": "Prostate CDX model in the PBMC IV model\nMale NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl (NCG) mice (Beijing Vital Star Biotechnology) were inoculatedSCwithDU-145cells (5 \u00d7 106 cells in 100 \u03bcl PBS with Matrigel).",
        "positive": "In the PBMC IV model, male NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl (NCG) mice were inoculated with DU-145 cells (5 \u00d7 106 cells in 100 \u03bcl PBS with Matrigel) to establish a prostate CDX model.",
        "negative": "In the second experiment, mice were treated weekly with indicated dose levels of DuoBody-CD3x5T4 starting 7 d after PBMC administration."
    },
    {
        "anchor": "No commercial sponsor was involved in the studies.",
        "positive": "There was no commercial sponsorship involved in the research.",
        "negative": "Clinical design and protocol eligibility requirements\nThe trials (ClinicalTrials.gov identifier NCT01869166, NCT02541370) were approved by the Institutional Review Board at the Chinese PLA General Hospital."
    },
    {
        "anchor": "We then administered Cy and fludarabine (Flu) for lymphodepletion before CAR-T cell infusion in 20 subsequent patients to determine if intensified immunosuppression would enhance CAR-T cell expansion and persistence, and prevent or delay immune responses to the CAR.",
        "positive": "Following this, we treated 20 patients with Cy and fludarabine (Flu) to deplete their lymphocytes before CAR-T cell infusion, with the goal of enhancing CAR-T cell expansion and persistence, and preventing or delaying immune responses to the CAR.",
        "negative": "DISCUSSION\nIn this study, a panel of lung cancer models harboring a range of oncogenic mutations, MYC amplifications, and the fusion protein EML4-ALK, representing the most relevant clinical subtypes of NSCLC or SCLC were selected to evaluate the biological relevance of BET inhibition in lung cancer and to better define which subtypes have the potential to be more sensitive to BET inhibition."
    },
    {
        "anchor": "Details are shown in supplemental Table 7.",
        "positive": "The details are provided in Supplemental Table 7.",
        "negative": "CAR T-cell manufacturing\n1 8 For manufacturing of CART1, autologous CD4+ and CD8+ T cells were immunomagnetically selected from a leukapheresis product and then modified with a lentivirus encoding a CAR comprising a CD19-specific single chain variable fragment (scFv) derived from the murine FMC63 monoclonal antibody, an IgG4-hinge, a CD28 transmembrane domain, and 4-1BB and CD3\u03b6 signaling domains."
    },
    {
        "anchor": "After a median follow-up of 12.1months, afatinib demonstrated comparable objectiveresponserate(ORR) (20.0%vs.7.1 %, p = 0.17) but significantly higher disease control rate (DCR) (68.0 % vs. 39.3 %, p = 0.04) compared to erlotinib.",
        "positive": "After a median follow-up of 12.1 months, afatinib showed a similar objective response rate (ORR) to erlotinib (20.0% vs. 7.1%, p = 0.17), but had a significantly higher disease control rate (DCR) (68.0% vs. 39.3%, p = 0.04).",
        "negative": "VZVSTs prevent infectious virus spread\n(A) GFP-tagged, VZV-infected dermal fibroblasts were used as targets."
    },
    {
        "anchor": "3.1.3 Patients must have Karnofsky performance score > 60 (See Appendix A) 3.1.4 Patients must have clinical AJCC Stage I-IIIB, with unresectable or inoperable disease 3.1.5 Patients must have no evidence of a malignant pleural or pericardial effusion 3.1.6 Patients must have hemoglobin > 10 gm/dl.",
        "positive": "Eligible patients must have a Karnofsky performance score of 60 or higher (see Appendix A), AJCC clinical stage I-IIIB with unresectable or inoperable disease, no evidence of malignant pleural or pericardial effusion, and hemoglobin levels above 10 gm/dl.",
        "negative": "\ue016\ue011\ue014 \ue003,QFOXVLRQ\ue003&ULWHULD\ue003\n3.1.1 Patients must have FDG-avid and pathologically proven non-small cell lung cancer."
    },
    {
        "anchor": "We therefore investigated the neurotoxicity of CTL019, a CD19 CAR product initially designed and tested by the University of Pennsylvania and The Children\u2019s Hospital of Philadelphia (CHOP), in a pediatric and young adult sample.",
        "positive": "The safety of CTL019, a CD19 CAR product initially developed by the University of Pennsylvania and The Children\u2019s Hospital of Philadelphia, was evaluated in a pediatric and young adult sample.",
        "negative": "4.5.1 Reasons for Subject Discontinuation\nSubjects who enroll but do not receive study treatment will be prematurely discontinued from the study, will not be followed, and will be replaced in the study."
    },
    {
        "anchor": "Weekly administration of topotecan has a different side effect profile with less neutropenia, and also permits greater dose intensity and thus greater ease of combining topotecan with other anti-neoplastic agents [(<>)15,(<>)16].",
        "positive": "Topotecan, when administered weekly, exhibits a distinct side effect profile with reduced neutropenia, allowing for increased dose intensity and easier combination with other anti-cancer agents.",
        "negative": "3.1 Number of Subjects\nThe total number of participants to be enrolled is 250."
    },
    {
        "anchor": "Clinical study design\nThis phase I/II, open-label, multicenter study investigated the safety and efficacy of single-agent ieramilimab and in combination with spartalizumab in patients with advanced solid malignancies.",
        "positive": "The study design was a phase I/II, open-label, multicenter trial that assessed the safety and efficacy of ieramilimab alone and in combination with spartalizumab in patients with advanced solid cancers.",
        "negative": "Acknowledgments\nThis work was supported by Clovis Oncology, Inc."
    },
    {
        "anchor": "Treatment-Emergent T790M Rates\nPostprogression T790M rates for Japanese patients (population 1: RAM \u00fe ERL: 25% [95% CI: 14\u201341], 9 of 36 patients; PL \u00fe ERL: 34% [95% CI: 23\u201347], 20 of 59 were similar in the RAM \u00fe ERL and PL \u00fe ERL arms patients; population 2: RAM \u00fe ERL: 47% [95% CI: 27\u2013 68], 9 of 19 patients; PL \u00fe ERL: 50% [95% CI: 35\u201365], 20 of 40 patients) ((<>)Supplementary Fig.",
        "positive": "The T790M mutation rates in Japanese patients were similar across the RAM \u00fe ERL and PL \u00fe ERL treatment arms, with rates of 25% and 34%, respectively, in population 1, and 47% and 50%, respectively, in population 2.",
        "negative": "Post-progression T790M rates were evaluated according to the number of treatment cycles received before the 30-day follow-up visit ((<>)Supplementary Fig."
    },
    {
        "anchor": "Franchino F, Rud\u00e0 R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain.",
        "positive": "Franchino, Rud\u00e0, and Soffietti investigated the mechanisms and treatment options for cancer metastasis to the brain.",
        "negative": "Methods\nsummarizeFilter(result = \"filterResult\", filter = \"filter\") summarizeFilter methods are called during the process of filtering."
    },
    {
        "anchor": "(B) Sera from PDA patient 21211-101 obtained at days \u22127, +57 and +92 were analyzed by immunoblotting for reactivity against mesothelin protein (MESO), SV40 large T antigen protein (SV), lysate from a PDA cell line (Panc1) and lysate from a tumor cell line derived from the patient\u2019s own ascites (21211 Tumor).",
        "positive": "Serum samples from patient 21211-101 were collected at days \u22127, +57, and +92 and analyzed for reactivity against mesothelin protein, SV40 large T antigen protein, and tumor cell lines.",
        "negative": "Treatment\nTreatment was administered intravenously (IV) and consisted of chemotherapy with cisplatin at 80 mg/m2 administered on day 1 and gemcitabine at 1250 mg/m2 on days 1 and 8, plus Bevacizumab 7.5 mg/kg IV on day 1."
    },
    {
        "anchor": "Standard PTX dosing of 200 mg/m2 (note that 175 mg/m2 is the approved dose in China) is based on body surface area (BSA).5 However, PTX dosing by BSA is not ideal, as BSA alone may not adequately describe the variability of paclitaxel response sufficient to achieve the narrow safety and efficacy margins.6,7 Therefore, interindi-vidual variability of PK of PTX based on BSA exists,8,9 and a proportion of patients may not derive clinical benefits but experience severe adverse events, including severe neutropenia and peripheral neuropathy.10,11 Numerous studies have emphasized the importance of PTX pharmacokinetics in the development of toxicities and clinical outcomes.12-18 The time above a PTX plasma concentration of 0.05 \u03bcmol/ L, (PTXTc > 0.05), is a predictor of severe neutropenia.14,18,19 Joerger et al.",
        "positive": "Paclitaxel dosing based on body surface area is not ideal, as it may not account for individual differences in response to the medication. This can result in some patients not benefiting from treatment while experiencing severe side effects.",
        "negative": "Progression free survival (PFS)\nThe median PFS was 11.6 months in intention to treat (ITT) population ((<>)Figure 1)."
    },
    {
        "anchor": "All patients had adequate organ function assessed by hemoglobin (\u226510 g/dL), platelet (\u2265100 000 cells/\u03bcL), and absolute neutrophil (\u22652,000 cells/\u03bcL) counts; serum creatinine (\u22641.5 mg/dL), albumin (\u22643.0 g/dL), total bilirubin (\u22641.8 mg/dL), and alanine amino-tranferase and aspartate aminotransferase (\u226480 IU/L) levels; circulating glycosylated hemoglobin (HbA1c)<7% and fasting plasma glucose levels <126 mg/dL.",
        "positive": "All patients had normal organ function, as assessed by laboratory tests, including hemoglobin, platelet, and neutrophil counts, as well as serum creatinine, albumin, and liver enzyme levels.",
        "negative": "The study protocol was approved by the Institutional Review Board at the National Cancer Center, Tokyo, Japan, and the study conformed to the provisions of the Declaration of Helsinki (1996)."
    },
    {
        "anchor": "Similarly, for PFS the HR (95% CI) values were 0.99 (0.72 \u2013 1.37) for KRAS mutant and 0.94 (0.78 \u2013 1.14) for KRAS wild type.",
        "positive": "The HR for PFS was 0.99 (95% CI: 0.72-1.37) for KRAS mutant and 0.94 (95% CI: 0.78-1.14) for KRAS wild type.",
        "negative": "ADDITIONAL INFORMATION\nSupplementary information The online version contains supplementary material available at (<https://doi.org/10.1038/s41408-021-00507-2>)https://doi.org/10.1038/s41408-021-00507-2."
    },
    {
        "anchor": "The co-inhibitory molecules PD-1, LAG-3 and TIM-3 and the co-stimulatory molecule CD28 were equally expressed on ALL and NHL-derived CAR-T cells.",
        "positive": "The expression levels of co-inhibitory molecules PD-1, LAG-3, and TIM-3, as well as the co-stimulatory molecule CD28, were comparable on CAR-T cells derived from ALL and NHL patients.",
        "negative": "Phenotype analysis of CAr-t cells\n26\u201329 The differentiation status of CAR-T cells and expression of co-inhibitory molecules have previously been related to clinical response."
    },
    {
        "anchor": "Detailed eligibility criteria are listed in (<>)box 1.",
        "positive": "The eligibility criteria are outlined in detail in (<>)box 1.",
        "negative": "Lesion Targeting and Uptake\nTumor lesion uptake data are listed in Supplemental Table 2."
    },
    {
        "anchor": "More specifically, the interventionists briefly address the experience of changing in-person yoga sessions to remote delivery including a description of the settings, challenges, opportunities, perceived benefit, and participant feedback.",
        "positive": "The interventionists provide a concise overview of the challenges and benefits of transitioning in-person yoga sessions to remote delivery, including the settings, obstacles, and participant feedback.",
        "negative": "Current Study\nTo capture the transition from an in-person (ie, face-to-face) to a videoconference intervention delivery approach in response to the COVID-19 pandemic, the current report summarizes the experiences of the videoconference delivery format of participants who were enrolled in a patient-family caregiver dyadic yoga RCT and 2 interventionists who delivered the yoga sessions."
    },
    {
        "anchor": "Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (\u2265VGPR), progression-free survival (PFS), and overall survival (OS).",
        "positive": "The primary endpoints were overall response rate, very good partial response or better, progression-free survival, and overall survival.",
        "negative": "(<https://www.frontiersin.org/journals/oncology#editorial-board>)ORIGINAL RESEARCH (<https://www.frontiersin.org/journals/oncology#editorial-board>)published: 10 (<https://www.frontiersin.org/journals/oncology#editorial-board>)November (<https://www.frontiersin.org/journals/oncology#editorial-board>)2020 (<https://doi.org/10.3389/fonc.2020.587849>)doi: 10.3389/fonc.2020.587849\nEdited by: Fiona Hegi-Johnson, University of Melbourne, Australia Reviewed by: Sagun Parakh, University of Melbourne, Australia Yu Yang Soon, National University Hospital, Singapore *Correspondence: Li Zhang (<mailto:zhangli6@mail.sysu.edu.cn>)zhangli6@mail.sysu.edu.cn; (<mailto:zhangli@sysucc.org.cn>)zhangli@sysucc.org.cn; (<mailto:li-zhang@csco.org.cn>)li-zhang@csco.org.cn \u2020These authors have contributed equally to this work Specialty section: This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology Received: 27 July 2020 Accepted: 10 September 2020 Published: 10 November 2020 Citation: Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H and Zhang L (2020) Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study."
    },
    {
        "anchor": "Received March 17, 2021; revised April 30, 2021; accepted May 26, 2021; published first May 27, 2021.",
        "positive": "The article was received on March 17, 2021, revised on April 30, 2021, accepted on May 26, 2021, and published on May 27, 2021.",
        "negative": "Disclaimer\nThe Editor handling the peer review and decision-making process for this article has no relevant employment associations to disclose."
    },
    {
        "anchor": "Flow cytom-etry data was analyzed using FlowJo V.10.7.",
        "positive": "Flow cytometry data was analyzed using FlowJo software version 10.7.",
        "negative": "Immunophenotyping of mupadolimab treated patient PBMCs\nFresh blood from patients with cancer was analyzed by flow cytometry."
    },
    {
        "anchor": "Only about 50% of patients randomized on the combination of cisplatin and vinorelbine received the intended dose of vinorelbine and only 50% of patients completed all four cycles of chemotherapy [(<>)8,(<>)9,(<>)12].",
        "positive": "Only half of patients on the cisplatin and vinorelbine regimen received the intended dose of vinorelbine, and only half completed all four cycles of chemotherapy.",
        "negative": "Background\nNon-small cell lung cancer (NSCLC) accounts for the largest number of cancer deaths annually, worldwide [(<>)1]."
    },
    {
        "anchor": "On day 5, immature DCs were matured for 48 hours using a cytokine cocktail consisting of IL-4, GM-CSF, IL-6 (10 ng/mL), TNF-\u03b1 (10 ng/mL), IL-1\u03b2 (10 ng/mL; all R&D Systems), and PGE2 (1\u03bcg /mL; Sigma-Aldrich, Hayward, CA).",
        "positive": "On day 5, immature DCs were matured for 48 hours using a cytokine cocktail comprising IL-4, GM-CSF, IL-6, TNF-\u03b1, and IL-1\u03b2 from R&D Systems, and PGE2 from Sigma-Aldrich.",
        "negative": "Phantom\nA Jaszczak phantom with the 6 fillable micro-spheres (diameters/volumes of 5.94 mm/ 31 \u03bcL, 6.95 mm/63 \u03bcL, 8.23 mm/125 \u03bcL, 9.86 mm/250 \u03bcL, 11.89 mm /500 \u03bcL, 14.43 mm/ 1000 \u03bcL) was scanned on our LYSO-based Discovery 710 PET/CT system (GE Health-care)."
    },
    {
        "anchor": "Flow cytometry, immunohistochemistry, cytokine assays, and quantitative polymerase chain reaction are described in the Data Supplement.,,",
        "positive": "The Data Supplement provides information on the methods used for flow cytometry, immunohistochemistry, cytokine assays, and quantitative polymerase chain reaction.",
        "negative": "Preparation of Anti-CD19 CAR T Cells and Ex Vivo Assays\n35 20 36 11 20 35 The CAR used in this work was encoded by a gamma-retroviral vector and contained an anti-CD19 single-chain variable fragment derived from a murine monoclonal antibody, hinge and transmembrane regions from human CD28, the CD28 costimulatory domain, and the CD3z T-cell activation domain.Anti-CD19 CAR T cells were cultured for 6 to 10 days by adding the anti-CD3 monoclonal antibody OKT3 directly to whole (unsorted) peripheral blood mononuclear cells suspended in culture medium containing IL-2 and transducing the cells as described in the Data Supplement.,CAR T-cell doses were administered as CD3+CAR+ cells per kilogram of body weight ((<>)Table 1)."
    },
    {
        "anchor": "Gross tumor volume (GTV) is defined as volume of the primary tumor mass and nodal diseases.",
        "positive": "The gross tumor volume (GTV) is the sum of the volume of the primary tumor and nodal diseases.",
        "negative": "Does your paper address CONSORT subitem 7b?"
    },
    {
        "anchor": "INTRODUCTION\nVinorelbine is a semi-synthetic vinka-alkaloid with activity in several cancer, including NSCLC and mesothelioma.",
        "positive": "Vinorelbine is a semi-synthetic vinka-alkaloid with demonstrated activity in several types of cancer, including NSCLC and mesothelioma.",
        "negative": "Safety\nAll patients experienced grade 3 or 4 treatment-emergent AEs following CART-ddBCMA infusion, as shown in (<>)Table 2."
    },
    {
        "anchor": "The total number of lesions studied is 82 (51 in baseline, 31 in per-therapeutic exams).",
        "positive": "The study analyzed 82 lesions, comprising 51 at the initial stage and 31 during subsequent evaluations.",
        "negative": "Gene expression analysis\n41 9 26 47\u201349 GEP data were generated on FFPE tumor tissue using HTG EdgeSeq Precision Immuno-Oncology Panel consisting of 1392 genes (PIP panel; HTG Molecular Diagnostics, Inc., Tucson, AZ, USA), per manufacturer\u2019s instructions."
    },
    {
        "anchor": "All authors were involved in the critical review and editing of the paper.",
        "positive": "The authors collectively contributed to the critical review and editing of the manuscript.",
        "negative": "Statistical analysis\nComparisons of cytokine levels (log2 transformed) between different NT and CRS patient groups were performed using univariable logistic regression as well as two-tailed Wilcoxon rank sum test."
    },
    {
        "anchor": "Concurrent chemotherapy regimens included docetaxel/paclitaxel plus platinum ((<>)14, (<>)15).",
        "positive": "The study combined docetaxel/paclitaxel with platinum-based chemotherapy regimens.",
        "negative": "Laboratory assessments\nThe proportions of circulating CAR T cells in CD31 T lymphocytes inthePBand CSFweremeasured by flow cytometry."
    },
    {
        "anchor": "The secondary objectives were to assess the preliminary efficacy in terms of ORR, PFS, duration of response (DoR), disease control rate (DCR), clinical benefit rate (CBR), and OS, and to characterize the PK profile of abemaciclib, pembroli-zumab and anastrozole when given in combination.",
        "positive": "The secondary objectives included assessing the treatment's preliminary efficacy in terms of response rate, progression-free survival, duration of response, disease control rate, clinical benefit rate, and overall survival, as well as characterizing the pharmacokinetic profile of the combined treatment.",
        "negative": "Ethics approval and consent to participate\nThe study (and its amendment in June 2018) was approved by the Committee for the Protection of Persons (CPP) Sud-Est VI, Clermont-Ferrand, France, and The French National Agency for Medicines and Health Products Safety (ANSM) (study ref."
    },
    {
        "anchor": "A phase II, open-label, single-arm, multi-center study of Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor in advanced non-small cell lung cancer (SWORD).",
        "positive": "The SWORD trial was a phase II, open-label, single-arm study examining the combination of Sintilimab, stereotactic body radiotherapy, and granulocyte-macrophage colony stimulating factor in advanced non-small cell lung cancer.",
        "negative": "Supplementary Information\nThe online version contains supplementary material available at (<https://doi.org/10.1186/s13014-021-01905-3>)https://doi."
    },
    {
        "anchor": "\u2022 Acetaminophen 650 mg to 1,000 mg orally (or equivalent).",
        "positive": "The treatment regimen included oral administration of acetaminophen in a dose of 650-1,000 mg, or an equivalent alternative.",
        "negative": "Membership\nThe DSMB will be comprised of a minimum of four individuals including physicians with experience in oncology and/or gene transfer therapy and a statistician and will work under a DSMB charter developed for safety oversight of this study."
    },
    {
        "anchor": "After transduction, T-cell lines were expanded in the presence of IL-2 (50 to 100 U/mL) added twice weekly until the specified cell dose was achieved.",
        "positive": "After transduction, T-cell lines were grown in the presence of IL-2 (50-100 U/mL) and expanded until the target cell dose was achieved, with IL-2 added every 7 days.",
        "negative": "Discussion\nThese results demonstrate that anamorelin is well tolerated in advanced NSCLC patients with cachexia over the 12\u201324w treatment period that constituted the ROMANA 3 safety extension study."
    },
    {
        "anchor": "When patients with a CAC score \u2265100 AU were compared to those with a CAC score <100 AU, the former had a higher incidence of grade \u22652 CVAE with a trend toward statistical significance (18% vs. 11%, p = 0.085; (<>)Figure 1).",
        "positive": "The analysis showed that patients with CAC scores \u2265100 AU had a higher rate of grade \u22652 CVAE compared to those with CAC scores <100 AU, with a trend toward statistical significance (18% vs. 11%, p = 0.085; Figure 1).",
        "negative": "Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies\nMichael C. Soulen1,5, Gabriela Plesa1, Anne Chew1, Yangbing Zhao1,4, Bruce L. Levine1,4,6, Gregory L. Beatty1,3,*,\u2022, Andrew R. Haas1,2,\u2022, Marcela V. Maus1,3, Drew A. Torigian1,5, Steven M. Albelda1,2, Michael Kalos1,4,\u2022, and Carl H. June1,4,6,*,\u2022"
    },
    {
        "anchor": "SPP has received research support from Amgen Inc. ER, GJ, VVU, and GN are employees of and own stock in Amgen Inc. At the time of this study, CB was an employee of Amgen Inc. AM, PML, and PS have no conflicts to disclose.",
        "positive": "SPP has received research funding from Amgen Inc. The authors ER, GJ, VVU, and GN are employees of Amgen Inc. and hold stock in the company. At the time of the study, CB was also an employee of Amgen Inc. Authors AM, PML, and PS reported no conflicts of interest.",
        "negative": "BACKGROUND\nMultiple myeloma (MM) is a common hematologic malignancy characterized by 1 2 3 4\u20136 7 8 9\u201314 15 the clonal proliferation of abnormal plasma cells in the bone marrow (BM).MM accounts for approximately 15% of hematopoietic neoplasms, and its aberrantly expanded immunoglobulins can damage relevant tissues and organs as a result of hypercalcemia, renal failure, anemia, or lytic bone lesions."
    },
    {
        "anchor": "Endogenous peroxidase activity was quenched by incubating the sections in 3% hydrogen peroxide for 20 minutes at room temperature and non-specific binding was blocked by incubating in serum-free protein block (Dako, #X0909) for 20 minutes at room temperature.",
        "positive": "Endogenous peroxidase activity was inhibited by incubating the sections in 3% hydrogen peroxide for 20 minutes at room temperature, and non-specific binding was blocked by incubating in serum-free protein block (Dako, #X0909) for 20 minutes at room temperature.",
        "negative": "ACKNOWLEDGEMENTS\nWe thank the patients and investigators for their participation in this study."
    },
    {
        "anchor": "The response was stopped by the addition of an acid solution resulting in yellow color that absorbs at 450 nm wavelength.",
        "positive": "The experiment was halted when an acid solution was added, resulting in the production of a yellow compound that exhibits absorption at a wavelength of 450 nanometers.",
        "negative": "Serum creatinine\nGraphical analysis indicates a consistent trend of increasing serum creatinine concentration over time which reached a plateau with continued tepotinib exposure (Fig."
    },
    {
        "anchor": "All AEs that occur prior to the Safety Follow-Up Visit should be recorded.",
        "positive": "It is essential to record all adverse events that occur before the Safety Follow-Up Visit.",
        "negative": "Druggable Alterations: Plasma Analyses\nPlasma NGS allowed detection of druggable oncogenic driver alterations in 32 of 209 patients (15.3%)."
    },
    {
        "anchor": "Anlotinib was associated with longer TTBP (HR, 0.11; 95% CI, 0.03\u20130.41; p = .001) despite all confounders.",
        "positive": "Anlotinib was found to be associated with a longer TTBP, with a hazard ratio of 0.11 and a 95% confidence interval of 0.03 to 0.41, despite the presence of all confounding variables, and this association was statistically significant (p = 0.001).",
        "negative": "Safety\nGastrointestinal disorders (nausea, vomiting, decreased appetite, and constipation) and fatigue were common treatment-emergent, all-causality AEs in all three treatment arms (Table (<>)3)."
    },
    {
        "anchor": "Baseline demographics and disease characteristics (Table 1) were consistent with the overall study population.13 Nine other patients had minor liver metastases but normal hepatic biochemistry parameters.",
        "positive": "The baseline characteristics of the patients, including demographics and disease features, were consistent with the overall study population, as shown in Table 1. Additionally, 13 patients had minor liver metastases, but their liver function tests were normal.",
        "negative": "ROR1 CAR-T cells employed in clinical trials\nApproximately 1,314 clinical trials of CAR-T cell therapies ((<https://clinicaltrials.gov/>)https://clinicaltrials.gov/) are ongoing for managing leukemias, lymphomas, and solid tumors."
    },
    {
        "anchor": "EDTA-preserved blood samples were obtained at 0.25, 0.5, 1, 3, 6, 9, 12 and 24\u2009h after the dose in each mouse.",
        "positive": "EDTA-preserved blood samples were taken from each mouse at 0.25, 0.5, 1, 3, 6, 9, 12, and 24 hours after dosing.",
        "negative": "Dose-escalating mouse pharmacokinetics\nAC484 pharmacokinetics were evaluated following single oral doses to groups of male C57Bl/6N mice (Charles River Laboratories)."
    },
    {
        "anchor": "Dr Wagner discloses a consulting or advisory role with EveryFit, Janssen, and Celgene.",
        "positive": "Dr. Wagner has a consulting or advisory relationship with EveryFit, Janssen, and Celgene.",
        "negative": "CONFLICT OF INTEREST\nDrs."
    },
    {
        "anchor": "\u2020K.X., J. Zheng, and A.L.",
        "positive": "The authors listed are K.X., J. Zheng, and A.L.",
        "negative": "Trial Design And Patients\nThis is an open-label, dose-escalating, single-center, phase I study of mesothelin-targeted CAR T cells in patients with previously treated histologically proven pleural cancer from MPM, metastatic lung cancer, or metastatic breast cancer (Trial registration number: (<https://clinicaltrials.gov/ct2/show/NCT02414269>)NCT02414269)."
    },
    {
        "anchor": "Patients receiving nivolumab incurred lower subsequent treatment costs (\u00a519,152 [US$2567] versus \u00a546,448 [US$6897], respectively) and grade 3/4 AE management costs (\u00a591 [US$16] versus \u00a54229 [US$628], respectively) versus docetaxel.",
        "positive": "Compared to docetaxel, patients receiving nivolumab had lower subsequent treatment costs (\u00a519,152 [US$2567]) and grade 3/4 AE management costs (\u00a591 [US$16]).",
        "negative": "3.1 Base Case\nCompared with docetaxel, in both squamous and non-squamous aNSCLC, nivolumab was associated with survival and quality-adjusted survival benefits, at additional cost (Table (<>)1)."
    },
    {
        "anchor": "toxicities\nAll patients receiving the phase II dose in the DREAMM-1 trial experienced at least one adverse event.",
        "positive": "In the DREAMM-1 trial, all patients who received the phase II dose experienced at least one adverse event.",
        "negative": "BACKGROUND\nThe 2001 guidance for industry on Bioanalytical Method Validation was originally based on the deliberations of two workshops described in publications entitled: \u2022 Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies3 (<>) \u2022 Bioanalytical Methods Validation: A Revisit With a Decade of Progress4 (<>) Additional workshops, summarized in the following publications, have informed subsequent revisions (e.g., the 2013 draft guidance for industry entitled Bioanalytical Method Validation5(<>)): \u2022 Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays6 (<>) \u2022 The AAPS/FDA Workshop on Incurred Sample Reanalysis7 (<>) \u2022 The AAPS Workshop on Crystal City V \u2022 Quantitative Bioanalytical Method Validation and Implementation: 2013 Revised FDA Guidance8 (<>) Validated analytical methods for the quantitative evaluation of analytes (i.e., drugs, including biologic products, and their metabolites) and biomarkers in a given biological matrix (e.g."
    },
    {
        "anchor": "A dose hold or medication for the lab abnormality may be required by the protocol and is still, by definition, an adverse event.",
        "positive": "A dose hold or medication may be required by the protocol if a laboratory abnormality is detected, and this would be classified as an adverse event.",
        "negative": "overall efficacy\nprogression-free survival."
    },
    {
        "anchor": "The total uptake of FDG (TLG) was correlated with the increase in aTregs rates in TDLN upon PD-1 blockade ((<>)Figure 3a), which in turn showed a near-perfect reverse correlation with overall survival ((<>)Figure 3b).",
        "positive": "The uptake of FDG (TLG) was found to be linked to the rise in aTregs rates in TDLN following PD-1 blockade, which exhibited a strong inverse correlation with overall survival.",
        "negative": "Authors\u2019 Disclosures\nJ.R. Diamond reports grants from Bayer during the conduct of the study as well as grants from Adlai Norte, Takeda, Merck, AstraZeneca, Astellas, AbbVie, BMS, Deciphera, and Bayer; grants and other support from Gilead; and other support from OnKure outside the submitted work."
    },
    {
        "anchor": "Efficacy\nIn the efficacy population (n \u00bc 148), the median investigator-assessed PFS was 4.1 months (95% CI: 2.8\u2013 5.5 mo) in the combined rociletinib group (500-mg and 625-mg doses) versus 2.5 months (95% CI: 1.4\u20132.9, HR \u00bc 0.60 [95% CI: 0.42\u20130.86], p \u00bc 0.005) in the chemotherapy group ((<>)Fig.",
        "positive": "The median investigator-assessed PFS was 4.1 months in the combined rociletinib group (500-mg and 625-mg doses) versus 2.5 months in the chemotherapy group, with a significant difference in favor of rociletinib (HR = 0.60, 95% CI: 0.42-0.86, p = 0.005).",
        "negative": "Choice of starting dose\nThe starting dose of 10 mg QD was selected based on nonclinical, 4-week toxicology studies conducted in rats and dogs."
    },
    {
        "anchor": "DNA copy number in tumor tissues of Ps 6 and 7-2 was 1,029.22 and 983.29/mg genomic DNA, respectively ((<>)Figure 5B).",
        "positive": "The DNA copy number in tumor tissues of patients 6 and 7-2 was 1,029.22 and 983.29 per milligram of genomic DNA, respectively, as shown in Figure 5B.",
        "negative": "Tissues\n14 Existence and persistence of CAR-T cells were measured in peripheral blood by FCM using Protein L that is a novel reagent for CAR-T detectionor recombinant CEA protein with His tag, and by qPCR for detection of DNA copy numbers."
    },
    {
        "anchor": "For DSClow, the third highest ranking was algorithm #11 (median value 0.41), and for DSChigh, it was algorithm #10 (median value 0.41).",
        "positive": "In the DSClow group, the third-ranked algorithm was #11, with a median value of 0.41, while in the DSChigh group, the top-ranked algorithm was #10, also with a median value of 0.41.",
        "negative": "3.C.2 DSC values for high and low function lung\n4\u2013 Qualitatively, we observe that the DSClow and DSChigh values show a similar level of variability to the rS values plotted in Figs."
    },
    {
        "anchor": "1 and 2, respectively) was a two-compartment model with time-varying linear clearance (CL), baseline body weight effect on CL, central volume, peripheral volume, and intercompartmental clearance, and the following additional baseline covariate effects: antidrug antibody status (ever/ never positive), albumin concentration, C-reactive protein concentration, estimated glomerular filtration rate, international normalized ratio, platelet count, sex, tumor size, tumor type, and white blood cell count on CL, and albumin concentration, international normalized ratio, platelet count, sex, tumor size, and white blood cell count on central volume.",
        "positive": "The pharmacokinetic model consisted of a two-compartment model with time-varying clearance, body weight-dependent clearance, and additional covariates such as antidrug antibody status, albumin concentration, and others.",
        "negative": "Population PK and exposure derivation\nThe population PK (popPK) model was developed based on data from 873 patients (9792 observations) from clinical trials NCT02517398, NCT02699515, and NCT04246489 who received various doses of BA (shown in Table (<>)1), using the nonlinear mixed-effects modeling approach."
    },
    {
        "anchor": "All questionnaires were scored using algorithms provided by the owners of the respective questionnaires (Appendix 1\u00a20).",
        "positive": "The scoring of questionnaires was based on algorithms provided by the respective owners, as detailed in Appendix 1.",
        "negative": "Data quality\nStudy data was stored on a secure server at TOH in a password-protected file accessible only by delegated personnel."
    },
    {
        "anchor": "Note\nThe logarithm transformation object can be evaluated using the eval method by passing the data frame as an argument.The transformed parameters are returned as a matrix with a single column.",
        "positive": "Note that the logarithm transformation object can be evaluated using the eval method by passing the data frame as an argument, resulting in a matrix with a single column.",
        "negative": "Outcomes and assessment\n19 19 The primary endpoint of the study was PFS, while the secondary endpoints were OS, response rate, and toxicities."
    },
    {
        "anchor": "The estimated maximum tolerated dose (MTD) was de\ufb01ned as the highest dose level with an associated DLT rate \ue00425% per the TITE-CRM model estimate.",
        "positive": "The maximum tolerated dose (MTD) was defined as the highest dose level with a DLT rate of less than 25% according to the TITE-CRM model.",
        "negative": "Authors\u2019 contributions\nJL, YZ, and WH participated in the design and coordination of the study."
    },
    {
        "anchor": "Received: 20 January 2021 Accepted: 28 April 2021",
        "positive": "Received on January 20, 2021; Accepted on April 28, 2021",
        "negative": "Author details\n1Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou 310002, People\u2019s Republic of China."
    },
    {
        "anchor": "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.",
        "positive": "Paclitaxel-carboplatin, either alone or in combination with bevacizumab, was used to treat non-small-cell lung cancer.",
        "negative": "Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al."
    },
    {
        "anchor": "Further details are included in the Supplementary Methods section.",
        "positive": "Further details are provided in the Supplementary Methods section.",
        "negative": "MET expression by IHC\nMET expression levels were evaluated using CONFIRM anti-total MET (SP44) rabbit monoclonal primary antibody (Ventana Medical Systems, Inc.; cat no."
    },
    {
        "anchor": "The messenger RNA (mRNA) data were further normalized by the geometric mean of a set of stably expressed reference genes and the protein data were normalized by the geometric mean of a set of stably expressed proteins.",
        "positive": "The mRNA and protein data were normalized by calculating the geometric mean of a set of genes and proteins with consistent expression levels.",
        "negative": "Gene expression analysis\nGene expression analysis was performed at NanoString Technologies (Seattle, WA)."
    },
    {
        "anchor": "Study design\nWe performed a phase 1 open label trial to evaluate the feasibility and safety of infusing a defined 1:1 ratio of CD4+:CD8+ CD19-specific CAR-T cells in patients with relapsed or refractory CD19+ B cell malignancies.",
        "positive": "The study design involved a phase 1 open-label trial to evaluate the safety and efficacy of infusing a defined ratio of CD4+:CD8+ CD19-specific CAR-T cells in patients with relapsed or refractory CD19+ B cell malignancies.",
        "negative": "The study is available at (<https://clinicaltrials.gov/ct2/show/NCT01865617>)https://clinicaltrials.gov/ct2/show/NCT01865617, and was conducted with approval of the Fred Hutchinson Cancer Research Center (FHCRC) institutional review board."
    },
    {
        "anchor": "In the analysis of 15 angiogenic markers, higher (relative to median) concentrations of VEGFR2 (p=0.0669) and E-selectin (p=0.0173) and lower levels (relative to median) of SDF-1\u03b1 (p=0.017) were associated with better PFS.",
        "positive": "The results showed that higher levels of VEGFR2 and E-selectin, and lower levels of SDF-1\u03b1, were associated with better PFS in the analysis of 15 angiogenic markers.",
        "negative": "Increased levels of ICAM (p=0.0837) and PIGF (0.005) and decreased levels of IL-8 (p=0.0565) were associated with better DCR (data not shown here)."
    },
    {
        "anchor": "Median PFS and OS were 6.4 months (95% CI: 5.5\u20137.9 months) and 15.4 months (95% Table 1.",
        "positive": "The median PFS and OS were 6.4 months (95% CI: 5.5-7.9 months) and 15.4 months, as shown in Table 1.",
        "negative": "PFS and OS\nSurvival data were available for all 519 patients."
    },
    {
        "anchor": "In contrast, there was no evidence of dose-dependent huKS-IL2 effects on the increase in sIL2R levels observed in vivo or the PBMC response to tetanus toxoid in vitro.",
        "positive": "However, no dose-dependent effects of huKS-IL2 on sIL2R levels or PBMC response to tetanus toxoid were observed in vivo or in vitro.",
        "negative": "In vivo studies\n6-week-old female nude Foxn1 mice were obtained from Harlan Laboratories (Udine, Italy) and maintained at a constant temperature and humidity, according to institutional guidelines."
    },
    {
        "anchor": "4DCT scans were reconstructed into ten breathing phase bins and a time average with slice thickness either 2.0, 2.5 or 3.0 mm.",
        "positive": "The 4DCT scans were reconstructed into ten breathing phase bins and a time average with slice thicknesses of 2.0, 2.5, or 3.0 mm, respectively.",
        "negative": "*CORRESPONDENCE\nPartow Kebriaei pkebriae@mdanderson.org equally to this work"
    },
    {
        "anchor": "Background Currently, the majority of patients with non\u2013small-cell lung cancer (NSCLC) present with inoperable, locally advanced (stage IIIB) or metastatic (stage IV) disease for which no curative therapy is available, and the 5-year survival rate has remained \u22645% for the last few decades [(<>)1,(<>)2].",
        "positive": "The majority of patients with non\u2013small-cell lung cancer (NSCLC) present with advanced disease, including locally advanced (stage IIIB) or metastatic (stage IV) disease, for which there is no curative treatment available, and the 5-year survival rate has remained low (\u22645%) for several decades, as reported in the literature.",
        "negative": "RESEARCH ARTICLE\nOpen Access Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer Chandra P Belani1*, Nobuyuki Yamamoto2, Igor M Bondarenko3, Artem Poltoratskiy4 , Silvia Novello5, Jie Tang6, Paul Bycott7 , Andreas G Niethammer7 , Antonella Ingrosso8 , Sinil Kim7 and Giorgio V Scagliotti5 Abstract Background: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non\u2013small-cell lung cancer (NSCLC)."
    },
    {
        "anchor": "Thirty-six percent had primary refractory disease, 49% had relapsed disease refractory to the last prior therapy, and 15% had untreated relapse.",
        "positive": "The patient population included 36% with primary refractory disease, 49% with relapsed disease refractory to the last prior therapy, and 15% with untreated relapse.",
        "negative": "14.6 Primary Mediastinal Large B-Cell Lymphoma\nThe efficacy of KEYTRUDA was investigated in KEYNOTE-170 (NCT02576990), a multicenter, open-label, single-arm trial in 53 patients with relapsed or refractory PMBCL."
    },
    {
        "anchor": "Safety variables were analyzed descriptively in terms of the number (percentage) of patients with AEs.",
        "positive": "The safety variables were analyzed descriptively in terms of the number and percentage of patients with adverse events.",
        "negative": "Financial Considerations\nA."
    },
    {
        "anchor": "P.M.F receives research funding from AZ, BMS, Corvus, Kyowa, and Novartis and is a consultant/ advisory board member for Abbvie, AstraZeneca, BMS, Boehringer, EMD Serono, Iniviata, Janssen, Lilly, Merck, and Novartis.",
        "positive": "P.M.F has financial ties to AZ, BMS, Corvus, Kyowa, and Novartis, and also holds consulting or advisory roles with Abbvie, AstraZeneca, BMS, Boehringer, EMD Serono, Iniviata, Janssen, Lilly, Merck, and Novartis.",
        "negative": "Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer\nJiajia Zhang1,2,\u2020 , Zhicheng Ji3,\u2020 , Justina X. Caushi1,2,\u2020 , Margueritta El Asmar1,2,\u2020 , Valsamo Anagnostou1,2 , Tricia R. Cottrell1,2,4 , Hok Yee Chan1,2 , Prerna Suri1,2 , Haidan Guo1,2 , Taha Merghoub6 , Jamie E. Chaft6 , Joshua E. Reuss1,2 , Ada Tam1,2 , Richard Blosser1,2 , Mohsen Abu-Akeel6 , John-William Sidhom1,2 , Ni Zhao3 , Jinny S. Ha2,5 , David R. Jones7 , Kristen A. Marrone1,2 , Jarushka Naidoo1,2 , Edward Gabrielson1,2 , Janis M. Taube1,2,4 , Victor E. Velculescu1,2,4 , Julie R. Brahmer1,2 , Franck Housseau1,2 , Matthew D. Hellmann6 , Patrick M. Forde1,2 , Drew M. Pardoll1,2 , Hongkai Ji3,# , Kellie N. Smith1,2,# Corresponding author: To whom correspondence should be addressed: Kellie N. Smith, kellie@jhmi.edu; Tel: (410) 502-7523; Address: The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M51, Baltimore, MD 21287."
    },
    {
        "anchor": "For enrollment in phase I, patients were not expected by the investigator to show a therapeutic response to existing treatments.",
        "positive": "Patients in phase I were not anticipated to exhibit a response to current treatments, according to the investigator's assessment.",
        "negative": "Tumors dissociated from pleura has significantly reduced TTFields\nWe next investigated factors contributing to low TTFields in Subject 1, with attention to the patient\u2019s breasts that increased the thoracic girth."
    },
    {
        "anchor": "Patients received KEYTRUDA 200 mg every 3 weeks until unacceptable toxicity or disease progression that was symptomatic, rapidly progressive, required urgent intervention, occurred with a decline in performance status, or was confirmed at least 4 weeks later with repeat imaging.",
        "positive": "Patients received KEYTRUDA 200 mg every 3 weeks until they developed unacceptable toxicity or disease progression, which was symptomatic, rapidly progressive, or required urgent medical attention.",
        "negative": "14.9 Gastric Cancer\nThe efficacy of KEYTRUDA was investigated in KEYNOTE-059 (NCT02335411), a multicenter, non-randomized, open-label multi-cohort trial that enrolled 259 patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma who progressed on at least 2 prior systemic treatments for advanced disease."
    },
    {
        "anchor": "The sponsor should also be notified if the investigator should become aware of the development of cancer or of a congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study.",
        "positive": "The sponsor should be informed if the investigator becomes aware of the development of cancer or a congenital anomaly in a child born to a study participant.",
        "negative": "Post-study Adverse Event\nAll unresolved adverse events should be followed by the investigator until the events are resolved, the subject is lost to follow-up, or the adverse event is otherwise explained."
    },
    {
        "anchor": "MMSE decline was a rare event in either of the randomized arms as well, with the overwhelming majority of patients experiencing no change in MMSE score over time.",
        "positive": "The majority of patients in both treatment groups did not experience a decline in MMSE score, with MMSE decline being a rare event.",
        "negative": "box 1 Continued\n\u2013 CLL or FL transformed into an aggressive B cell lymphoma \u2013 A primary malignancy which is in complete remission for\u00a0\u22655 years \u25ba Pregnant or nursing (lactating) women \u25ba Intolerance to the excipients of the cell product \u25ba Active CNS involvement in ALL patients at the time of screening is not an exclusion criterion, but patients with CNS 3 status at clinical screening (d-14) are not eligible for CD19.CAR T cell transfusion \u25ba Participation in another clinical trial at the time of screening"
    },
    {
        "anchor": "Cancer 2013; 119: 356\u2013362.",
        "positive": "Cancer, Volume 119, 2013, pp. 356-362.",
        "negative": "Gainor JF, Varghese AM, Ou SH et al."
    },
    {
        "anchor": "There was no difference in the CD4/8 ratio between CAR+ and CD3+ (p < 0.01).",
        "positive": "The CD4/8 ratio did not differ significantly between the CAR+ and CD3+ groups (p < 0.01).",
        "negative": "1 | INTRODUCTION\nThe presence of EGFR\u2010activating mutations in patients with NSCLC can result in increased malignant cell survival, proliferation, invasion, metastatic spread, and tumor angiogenesis.1,2 These mutations are estimated to be present in approximately 50% of patients with NSCLC in East Asian countries.3 Exon 19 deletions and exon 21 L858R substitutions are the most common EGFR mutations.1,4 These mutations confer sensitivity to TKIs and account for approximately 90% of EGFR mutations in patients with NSCLC.5 Patients with NSCLC with EGFR\u2010activating mutations have experienced antitumor activity and prolonged PFS following treatment with the reversible EGFR TKIs such as gefitinib and erlotinib.6,7 However, this clinical efficacy is often limited by an acquired drug resistance, most commonly caused by a point mutation (T790M) in the gene encoding EGFR."
    },
    {
        "anchor": "A previous phase II single-arm clinical trial showed a favorable objective response rate (ORR) for WBRT with concurrent erlotinib.",
        "positive": "A previous phase II clinical trial found that WBRT with concurrent erlotinib resulted in a favorable objective response rate.",
        "negative": "Summary of EEG findings in a 100 subject cohort of pediatric patients treated with CD19directed CAR T cells."
    },
    {
        "anchor": "Ethics approval and consent to participate\nSamples used in the research reported herein were obtained from patients enrolled in the TIME study.",
        "positive": "The TIME study obtained ethics approval and informed consent from patients whose samples were used in the research reported.",
        "negative": "The study was done under the oversight of an independent data monitoring committee in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization."
    },
    {
        "anchor": "Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004).",
        "positive": "In 29.2% of vaccinated patients, a long-lasting TERT-specific immune response was observed, which was associated with a significantly longer overall survival compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004).",
        "negative": "Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial\nCesare Gridelli 1 , Tudor Ciuleanu 2 , Manuel Domine 3 , Aleksandra Szczesna 4 , Isabel Bover 5 , Manuel Cobo 6 , Nikolaos Kentepozidis 7 , Konstantinos Zarogoulidis 8 , Charalabos Kalofonos 9 , Andrzej Kazarnowisz 10 , Magdalena Korozan 11 , Ramon de las Penas 12 , Margarita Majem 13 , Antonio Chella 14 , Frank Griesinger 15 , Evangelos Bournakis 16 , Parvis Sadjadian 17 , Athanasios Kotsakis 18 , Thierry Chinet 19 , Kostantinos N. Syrigos 20 , Pierpaolo Correale 21 , Catherine Gallou 22 , Jeanne-Menez Jamet 22 , Eleni-Kyriaki Vetsika 23 , Kostas Kosmatopoulos 22 , Vassilis Georgoulias 23 and on behalf of the Vx-001-201 trial team BACKGROUND: The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC)."
    },
    {
        "anchor": "This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to ourQQlkY_ :::::; ru r+ C ri3 u r+ o' 6' \"'O 0 a. :::J LO \"' C :::J _, ru Next-generation sequence data can be retrieved from the European Genome-Phenome Archive (EGA; accession number EGAS00001007298).",
        "positive": "The European Genome-Phenome Archive (EGA) provides access to next-generation sequence data, with accession number EGAS00001007298, subject to any applicable restrictions.",
        "negative": "Method evaluation\nOur method was evaluated on patients suffering for stage III non-small cell lung cancer (NSCLC) included in the ParaPET clinical trial (NCT 02821936)."
    },
    {
        "anchor": "The study will take place in two phases, the first of which will be dedicated to adapting an evidence-based, early palliative care treatment guide and prior supportive care mobile app intervention to address the specific symptom management and coping needs of patients with advanced NSCLC.",
        "positive": "The study will consist of two phases, with the first phase focused on adapting an evidence-based, early palliative care treatment guide and a mobile app intervention to address the symptom management and coping needs of patients with advanced non-small cell lung cancer (NSCLC).",
        "negative": "(<https://www.frontiersin.org/journals/psychology#editorial-board>)TYPE Study Protocol (<https://www.frontiersin.org/journals/psychology#editorial-board>)PUBLISHED 22 June 2023 (<https://doi.org/10.3389/fpsyg.2023.1184482>)DOI 10.3389/fpsyg.2023.1184482\nOPEN ACCESS EDITED BY Gregor Weissflog, Leipzig University, Germany REVIEWED BY Birgitt Van Oorschot, University Hospital W\u00fcrzburg, Germany Franziska Springer, University Hospital Leipzig, Germany *CORRESPONDENCE Joseph A. Greer (<mailto:jgreer2@mgh.harvard.edu>)jgreer2@mgh.harvard.edu RECEIVED 11 March 2023 ACCEPTED 31 May 2023 PUBLISHED 22 June 2023 CITATION Waldman LP, Centracchio JA, Jacobs JM, Petrillo LA, El-Jawahri AR, Temel JS and Greer JA (2023) Study protocol for a randomized trial of a supportive care mobile application to improve symptoms, coping, and quality of life in patients with advanced non-small cell lung cancer."
    },
    {
        "anchor": "Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.",
        "positive": "This article is published under an open access license, allowing for non-commercial use, modification, and distribution, provided proper citation and credit are given.",
        "negative": "Provenance and peer review Not commissioned; externally peer reviewed."
    },
    {
        "anchor": "Briefly, CD4+ and CD8+ T cells were isolated using magnetic bead separation techniques and stimulated with anti-CD3 and anti-CD28 antibodies for 16 hours at 37\u00b0C.",
        "positive": "CD4+ and CD8+ T cells were isolated using magnetic bead separation techniques and stimulated with anti-CD3 and anti-CD28 antibodies for 16 hours at 37\u00b0C.",
        "negative": "Polyfunctional T-cell frequency (cells secreting \u22652 cytokines) and poly-functional strength index (which combines the polyfunc-tionality of a sample (frequency of cells secreting multiple cytokines) with the signal intensities for each single cell across the secreted cytokines of the sample) were calculated for each sample."
    },
    {
        "anchor": "Fre e ze -thaw stability: Freeze-thaw stability refers to the stability of the analyte in the matrix upon freezing and thawing.",
        "positive": "The stability of the analyte in the matrix when frozen and thawed is referred to as freeze-thaw stability.",
        "negative": "STUDY FINANCES\n12.1.Funding Source This study is funded by UPenn internal funds."
    },
    {
        "anchor": "The infusion products (derived from peripheral blood) contained many more unique clonotypes (60,000 to 80,000) than pre-infusion tumor-infiltrating lymphocytes (100 to 1000) or post-infusion tumor-infiltrating lymphocytes (2000 to 18,000).",
        "positive": "The infusion products contained a significantly higher number of unique clonotypes (60,000 to 80,000) compared to pre-infusion tumor-infiltrating lymphocytes (100 to 1000) or post-infusion tumor-infiltrating lymphocytes (2000 to 18,000).",
        "negative": "randomization and masking\nThis was an open-label, multicenter, randomized phase II study comparing the efficacy and safety of trametinib with docetaxel as second-line treatment in patients with advanced or metastatic NSCLC harboring a KRAS mutation who failed one prior platinum-containing chemotherapy regimen."
    },
    {
        "anchor": "All requests for further data sharing will be reviewed by the leading clinical center, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, and the study collaborator, CARsgen Therapeutics Co., Ltd, to verify whether the request is subject to any intellectual property or confidentiality obligations.",
        "positive": "All requests for further data sharing will be reviewed by the leading clinical center, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, and the study collaborator, CARsgen Therapeutics Co., Ltd, to verify whether the request is subject to any intellectual property or confidentiality obligations.",
        "negative": "Further requests for access to the individual participant level data from this study can be submitted via email to the corresponding author with detailed proposals."
    },
    {
        "anchor": "Grant Support\nThis research was, in part, funded by the NCI Cancer Center Support Grant (2-P30-CA-016520-35) (JT), NCI 5R01CA120409 (YZ and CHJ), the Breast Cancer Alliance Research Foundation (JT), the Breast Cancer Immunotherapy Funds (JT), the Breast Cancer Research Foundation (RHV and AM), and the Pennsylvania Department of Health Cure Grant #0972501 (CHJ).",
        "positive": "Funding for this research was provided by the NCI Cancer Center Support Grant, NCI 5R01CA120409, the Breast Cancer Alliance Research Foundation, the Breast Cancer Immunotherapy Funds, the Breast Cancer Research Foundation, and the Pennsylvania Department of Health Cure Grant #0972501.",
        "negative": "Cell proliferation assay\nCell viability was determined using the water-soluble tetrazolium salt (WST-8) assay (Cell counting Kit-8, Shanghai Life iLab)."
    },
    {
        "anchor": "Appl Immunohistochem Mol Morphol 2016;24:392-7.",
        "positive": "The study was published in Appl Immunohistochem Mol Morphol in 2016, with the article \"Appl Immunohistochem Mol Morphol 2016;24:392-7\".",
        "negative": ".$512)6.<\ue0033(5)250$1&(\ue0036&$/(\ue003\n100\ue003 Normal; no complaints; no evidence of disease\ue003 90\ue003 Able to carry on normal activity; minor signs or symptoms of disease\ue003 80\ue003 Normal activity with effort; some sign or symptoms of disease\ue003 70\ue003 Cares for self; unable to carry on normal activity or do active work\ue003 60\ue003 Requires occasional assistance, but is able to care for most personal needs\ue003 50\ue003 Requires considerable assistance and frequent medical care\ue003 40\ue003 Disabled; requires special care and assistance\ue003 30\ue003 Severely disabled; hospitalization is indicated, although death not imminent\ue003 20\ue003 Very sick; hospitalization necessary; active support treatment is necessary\ue003 10\ue003 Moribund; fatal processes progressing rapidly\ue003 0\ue003 Dead\ue003"
    },
    {
        "anchor": "SPSS v16.0 (SPSS Inc., Chicago, IL) was used to analyze differences in survival, with p < 0.05 considered significant.",
        "positive": "The differences in survival were analyzed using SPSS v16.0, with a significance level of p < 0.05.",
        "negative": "CAR-BCMA design and CAR T-cell production\n12 11 14 The anti-BCMA CAR used in this work (CAR-BCMA) incorporated the 11D-5-3 anti-BCMA single-chain variable fragment (scFv), a CD28 costimulatory domain, and the CD3\u2212\u03b6 T-cell activation domain ((<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043125/figure/F1/>)Figure 1A).The CAR sequence was expressed by a \u03b3-retroviral vector backbone used in previous work.,CAR-BCMA was consistently expressed on the surface of transduced CD4 and CD8 T cells, and the transduced T cells proliferated extensively in culture ( (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043125/figure/F1/>)Figure 1B-C; supplemental Tables 1 and 2)."
    },
    {
        "anchor": "Date and Time: 2022-11-15",
        "positive": "The specified date and time is November 15, 2022.",
        "negative": "Title: The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma\n\nAbstract: BackgroundMultiple myeloma (MM) is an incurable disease that will eventually deteriorate."
    },
    {
        "anchor": "Email: (<mailto:nakagawa@med.kindai.ac.jp>)nakagawa@med.kindai.ac.jp Abstract Background: ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for Data reported in this manuscript were submitted as an abstract to the 2022 Annual Meeting of the Japanese Society of Medical Oncology.",
        "positive": "The email address for correspondence is nakagawa@med.kindai.ac.jp.",
        "negative": "This is an open access article under the terms of the (<http://creativecommons.org/licenses/by/4.0/>)Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."
    },
    {
        "anchor": "Li Zhao did the data statistical analysis.",
        "positive": "The data analysis was conducted by Li Zhao.",
        "negative": "DECLARATIONS AUTHORS\u2019 CONTRIBUTIONS\nYuankai Shi was the leading principal investigator of this study, contributed to study conception, study design, data analysis and interpretation, manuscript drafting, and editing."
    },
    {
        "anchor": "Lung dose constraints may not be exceeded for any reason.",
        "positive": "It is essential to ensure that lung dose constraints are not exceeded.",
        "negative": "1.5.4 LKB1-AMPK Pathway in Cancer\nLKB1 is a tumour suppressor that is mutated in Peutz-Jeghers syndrome and is associated with hamartomas, primary gut polyps, breast, colon, and lung cancer (37)."
    },
    {
        "anchor": "3,4 5 6 To this point, precision oncology approaches in NSCLC have largely focused on single driver alterations.",
        "positive": "Until now, precision oncology in NSCLC has primarily focused on single driver mutations.",
        "negative": "Statistical Analysis\nFor the primary end point of ORR, a sample size of approximately 300 treated patients (60 patients with $ 50% tumor PD-L1 expression and 100 patients with , 1% tumor PD-L1 expression) provided 95% confidence that the observed ORR was estimated to within 5.8% of estimates for all treated patients, 13.5% of estimates for patients with 50% or greater tumor PD-L1 expression, and 10.5% of estimates for patients with less than 1% tumor PD-L1 expression."
    },
    {
        "anchor": "Following endoscopic staging, any changes to radiation treatment intent or dosage will be recorded.",
        "positive": "Following endoscopic staging, changes to radiation treatment intent or dosage will be documented.",
        "negative": "Radiation therapy\nRadiation treatment intent and dosage will be initially planned based on clinical imaging, prescribed by the treating radiation oncologist and/or based on discussion at a multi-disciplinary cancer conference."
    },
    {
        "anchor": "R. Levy reports receiving commercial research grants from Bristol-Myers Squibb, other commercial research support from Pharmacyclics, and is a consultant/advisory board member for Blegene, Checkmate, Five Prime Therapeutics,Giliad, andInnate Pharma.S.Bhatiareports receivingcom-mercial research grants from and is a consultant/advisory board member for EMD-Serono/Pfizer.",
        "positive": "R. Levy has received research funding from Bristol-Myers Squibb and Pharmacyclics, and serves as a consultant or advisory board member for several companies, including Blegene, Checkmate, Five Prime Therapeutics, Giliad, and Innate Pharma.",
        "negative": "Procedures\nFormalin-fixed, paraffin-embedded (FFPE) tumor specimens or needle aspirates on charged glass slides were required to be submitted prior to the start of therapy."
    },
    {
        "anchor": "Corresponding author: Mark J. McKeage, MD.",
        "positive": "The corresponding author is Mark J. McKeage, MD.",
        "negative": "Introduction\nLung cancer is the leading cause of cancer death in the United States (1) and worldwide (2)."
    },
    {
        "anchor": "This dose was chosen based on data from KEYNOTE-001, in which pembrolizumab 10 mg/kg Q3W had acceptable toxicity.10 Treatment continued for 2 years or until documented radiographic disease progression per immune-related response criteria (irRC),11 unacceptable toxicity, intercurrent illness preventing further administration, investigator's decision, or withdrawal of consent.",
        "positive": "The dose was chosen based on the results of KEYNOTE-001, which demonstrated acceptable toxicity for pembrolizumab 10 mg/kg Q3W. Treatment continued until disease progression, unacceptable toxicity, or other specified reasons.",
        "negative": "14.5 Classical Hodgkin Lymphoma\nThe efficacy of KEYTRUDA was investigated in KEYNOTE-087 (NCT02453594), a multicenter, non-randomized, open-label trial in 210 patients with relapsed or refractory cHL."
    },
    {
        "anchor": "These efficacy data and the acceptable safety profile of necitumumab suggest a favourable benefit-to-risk ratio for this combination treatment.",
        "positive": "The combination treatment showed a favorable benefit-to-risk ratio, supported by the efficacy data and acceptable safety profile of necitumumab.",
        "negative": "High-level expression of EGFR protein in advanced non-small-cell lung cancer (tumour H-score \u2265200) might\nbe predictive for the overall survival benefit associated with the addition of cetuximab to first-line chemotherapy29 In a prospectively planned analysis, we therefore explored whether or not an H-score of 200 or higher was of predictive value in patients receiving necitumumab plus gemcitabine and cisplatin."
    },
    {
        "anchor": "Five cohorts were treated at 5 (n \u00bc 3),",
        "positive": "The five cohorts consisted of three subjects each.",
        "negative": "3.5 Plasma ct-DNA sequencing\nExploratory analysis was conducted using NGS of plasma ct-DNA with samples collected at baseline, BOR, and after PD."
    },
    {
        "anchor": "x The time window for baseline cranial MRI was revised to \u201cwithin 60 days prior to the first dose of study drug\u201d.",
        "positive": "The window for baseline cranial MRI was narrowed to 60 days before the first dose of the study treatment.",
        "negative": "Amendment 2: March 23, 2020 (version 3.0)\nx Baseline pituitary-adrenal axis test was deleted in Study Flow Chart section."
    },
    {
        "anchor": "Emergency medical equipment (i.e., emergency trolley) must be available during the infusion in case the subject has an allergic response, or severe hypotensive crisis, or any other reaction to the infusion.",
        "positive": "Emergency medical supplies, including an emergency cart, must be readily available during the infusion process in the event of an allergic reaction, severe blood pressure drop, or any other adverse reaction.",
        "negative": "STUDY PROCEDURES\nWe designed a self-inactivating lentiviral vector (GeMCRIS 0607-793), which was subjected to preclinical safety testing, as reported previously.5 Methods of T-cell preparation have also been described previously.8 Quantitative polymerase-chain-reaction (PCR) analysis was performed to detect chimeric antigen receptor T cells in blood and bone marrow."
    },
    {
        "anchor": "(<https://doi.org/10.1016/j.adro.2023.101203>)https://doi.org/10.1016/j.adro.2023.101203 2452-1094/\u00a9 2023 The Author(s).",
        "positive": "The relevant publication can be accessed at https://doi.org/10.1016/j.adro.2023.101203.",
        "negative": "Study design\nAfter receiving University of Pennsylvania IRB approval, we initiated an open label phase 0 clinical trial (NCT01837602) to evaluate the safety and feasibility of treating metastatic c-Met\u2013 expressing breast cancer with a single intratumoral injection of mRNA c-Met-CAR T cells for women with metastatic breast cancer."
    },
    {
        "anchor": "The SPRING trial is a Phase I, 3 + 3 dose escalation study that enrolled patients with advanced/metastatic NSCLC (NCT03386929).",
        "positive": "The SPRING trial was a Phase I clinical trial that involved a dose escalation design, enrolling patients with advanced or metastatic non-small cell lung cancer (NCT03386929).",
        "negative": "Statistical analysis\nDescriptive statistics only were used in this study; no statistical model was adopted."
    },
    {
        "anchor": "Altered intrinsic Treg gene signature in adults with T1D.",
        "positive": "In adults with type 1 diabetes, an altered T regulatory cell gene signature was observed.",
        "negative": "Byoung-Chul Cho,\nYonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"
    },
    {
        "anchor": "We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.",
        "positive": "We predicted that patients with disease characterized by PGE-M suppression would benefit from the addition of apricoxib to docetaxel or pemetrexed as a second-line treatment.",
        "negative": "Purpose\nOverexpression of COX-2 correlates with advanced stage and worse outcomes in non\u2013small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2\u2013dependent prostaglandin E2 (PGE2)."
    },
    {
        "anchor": "Toxicity contributed to early discontinuations in patients aged more than 65 years treated with AP/E.",
        "positive": "Toxicity was a reason for early treatment cessation in patients aged 65 years or older who received AP/E.",
        "negative": "Abstract\nCyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non\u2013small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor receptor inhibitors."
    },
    {
        "anchor": "For more information about ASCO\u2019s conflict of interest policy, please refer to (<https://www.asco.org/rwc>)www.asco.org/rwc or (<http://ascopubs.org/jco/site/ifc>)ascopubs.org/jco/site/ifc.",
        "positive": "To learn more about ASCO's conflict of interest policy, please refer to https://www.asco.org/rwc or https://ascopubs.org/jco/site/ifc.",
        "negative": "Note\nPlease note that logicletGml2 and (<>)logicleTransform are similar transformations; however, the Gating-ML 2.0 compliant logicletGml2 brings \"reasonable\" data values to the scale of [0, 1] while the (<>)logicleTransform scales these values to [0, M]."
    },
    {
        "anchor": "The occurrence of EGFR mutation p.T790M in exon 20 represents the most frequent mechanism of the acquired resistance.5 The third- generation EGFR-TKI is an irreversible selective TKI, which specifically targets EGFR T790M and EGFR activating mutations and has been proven effective in patients with EGFR T790M-positive NSCLC following acquired resistance to prior EGFR-TKIs.6,7 This makes re-biopsy widely accepted in clinical practice.8 Through the re-biopsy, it is possible to effectively understand the cause of drug resistance and provide a basis for follow-up treatment.",
        "positive": "The EGFR mutation p.T790M in exon 20 is the primary mechanism of acquired resistance. The third-generation EGFR-TKI is a selective and irreversible inhibitor that targets EGFR T790M and activating mutations, and has been proven effective in patients with EGFR T790M-positive NSCLC who have developed resistance to prior EGFR-TKIs. Re-biopsy has become a widely accepted practice in clinical settings, enabling the identification of the cause of resistance and guiding subsequent treatment choices.",
        "negative": "1 | INTRODUCTION\nLung cancer is the leading cause of cancer-related mortality worldwide.1 Among them, non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer.2 Epithelial growth factor receptor (EGFR) is the most common driver gene in NSCLC, occurring in an estimated 50% of adeno-carcinoma cases in Asia."
    },
    {
        "anchor": "Figure S2 Mutation landscape of all enrolled patients.",
        "positive": "A comprehensive mutation analysis of all patients enrolled in the study is presented in Figure S2.",
        "negative": "Sample size calculations\nThis is a cluster-randomized trial design with a binary outcome, assuming 32 PCP clinics per arm with 10 subjects per clinic, alpha=0.05, and intra-cluster correlation (ICC) ranging from 0.05 to 0.10, assuming at 18 months that the control arm patients will have 50% compliance on the 3 HEDIS measures and the intervention arm will have 65% compliance."
    },
    {
        "anchor": "ACKNOWLEDGMENTS\nThis study was mainly supported by the Clinical Research Center of Luye Pharma Group Ltd., Luye Life Sciences Group and the Chinese Academy of Medical Sciences.",
        "positive": "The study was primarily supported by the Clinical Research Center of Luye Pharma Group Ltd., Luye Life Sciences Group, and the Chinese Academy of Medical Sciences.",
        "negative": "Conflict of interest statement\nTakashi Seto declares grants/personal fees from AstraZeneca; personal fees from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Fuji Pharma, Hisamitsu Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Merck Serono, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Roche Singapore, Sanofi, Showa Yakuhin Kako, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Verastem and Yakult."
    },
    {
        "anchor": "Exclusion criteria also included bleeding within three months before screening, tumor invasion into large blood vessels, symptomatic central nervous system metastases, known positive ALK or ROS1 translocation, non-healing wounds, ulcers, bone fractures, major surgery within 4 weeks of randomization.",
        "positive": "Exclusion criteria included bleeding within three months of screening, tumor invasion into large blood vessels, and other specified medical conditions.",
        "negative": "Thomas Bauer, M.D.,\nHackensack Meridian Health System, Edison, NJ"
    },
    {
        "anchor": "Patients were heavily pretreated with a median of 8 prior lines of therapy (range, 3-23 lines of therapy).",
        "positive": "The patients had received a median of 8 prior lines of therapy, with a range of 3 to 23 lines.",
        "negative": "Patient characteristics\nA total of 27 patients were treated with CD30.CAR-T cell therapy for r/r cHL at UNC between August 2016 and June 2020 ((<>)Table 1)."
    },
    {
        "anchor": "For the secondary time-to-event outcomes OS and PFS, median survival times and 1-year rates will be given with 95% confidence intervals and Kaplan-Meier curves will be calculated for both treatment groups.",
        "positive": "The study will provide median survival times and 1-year rates for OS and PFS, with 95% confidence intervals and Kaplan-Meier curves for both treatment groups.",
        "negative": "Safety run\u2011in analysis\nGiven that the safety profile of SBRT in combination with Sintilimab and GM-CSF has not been evaluated in patients with advanced NSCLC, a safety run-in was adopted to ensure that no excessive severe AE happened in treated patients."
    },
    {
        "anchor": "Tumor tissue preparation and flow cytometry\nSpleen was prepared into single-cell suspension by mechanical grinding.",
        "positive": "The spleen was processed into a single-cell suspension through mechanical grinding for flow cytometry analysis.",
        "negative": "SUPPORT\nSupported by National Institutes of Health (NIH)/National Cancer Institute Grants No."
    },
    {
        "anchor": "3 However, attempts to trigger autologous T cell responses have led to only limited clinical improvements, with the mechanism of failure poorly understood.",
        "positive": "Despite efforts to stimulate autologous T cell responses, only limited clinical benefits were observed, and the underlying mechanism of failure remains unclear.",
        "negative": "Abstract\nCombining immunotherapies with distinct mechanisms of action has the potential to overcome treatment resistance and improve outcomes."
    },
    {
        "anchor": "Standard pharmacokinetic parameters were determined using a noncompartmental method with WinNonlin\u2122 software version 6.3 (Pharsight Corp., Cary, NC, USA).",
        "positive": "Pharmacokinetic parameters were calculated using a noncompartmental method with WinNonlin software version 6.3.",
        "negative": "Additional information\nExtended data is available for this paper at (<https://doi.org/10.1038/s41591-022-01937-6>)https://doi.org/10.1038/s41591-022-01937-6."
    },
    {
        "anchor": "If material is not included in the article\u2019s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.",
        "positive": "If the material is not licensed under the Creative Commons license or your intended use is not authorized by law or exceeds the allowed use, you will need to obtain permission from the copyright holder.",
        "negative": "ADDITIONAL INFORMATION\nSupplementary information The online version contains supplementary material available at (<https://doi.org/10.1038/s41423-021-00749-x>)https://doi.org/10.1038/s41423-021-00749-x."
    },
    {
        "anchor": "Written informed consent was obtained from all patients prior to study entry.",
        "positive": "Informed consent was obtained in writing from each patient before they entered the study.",
        "negative": "Statistical Analysis\nThis study was designed to have 85% power to reject a nondesired ORR of 17% versus a clinically meaningful ORR of 30% in a two-sided test with a significance level of 5%."
    },
    {
        "anchor": "Other chemistries should be monitored per Appendix 1 or as clinically indicated if CRS is suspected.",
        "positive": "Chemistries other than those listed in Appendix 1 should be monitored if cytokine release syndrome is suspected and clinically indicated.",
        "negative": "Additional assessment of Ferritin, LDH and CRP levels for CRS:\nAs noted, side effects following CART22 cell infusions can induce high fevers and should be expected."
    },
    {
        "anchor": "L-FG did the post hoc analysis for exploration of the association between MET mutation type and efficacy.",
        "positive": "L-FG performed a retrospective analysis to examine the connection between MET mutation type and treatment effectiveness.",
        "negative": "Contributors\nL-S and S-MH conceived and designed the study."
    },
    {
        "anchor": "The PK of gefitinib has been studied in patients with solid tumorsand in advanced NSCLC.In advanced NSCLC, a high day 3/day 8 ratio of plasma trough levels of gefitinib was independently associated with improved PFS.",
        "positive": "The pharmacokinetics of gefitinib have been investigated in patients with solid tumors and advanced non-small cell lung cancer. In advanced NSCLC, a high plasma trough level ratio on days 3 and 8 was found to be a significant predictor of improved progression-free survival.",
        "negative": "Case study 3\nA 13-year-old male, diagnosed at 9 years of age in 2014, was diagnosed with PTC with metastases to the lungs and lymph nodes."
    },
    {
        "anchor": "REGULAR ARTICLE\nPreferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL Aimee C. Talleur,1 (<>)Amr Qudeimat,1 (<>)Jean-Yves Metais,\u00b4 1 (<>)Deanna Langfitt,1 (<>)Ewelina Mamcarz,1 (<>)Jeremy Chase Crawford,2 (<>)Sujuan Huang,3 (<>)Cheng Cheng,3 (<>)Caitlin Hurley,1 (<>)Renee Madden,1 (<>)Akshay Sharma,1 (<>)Ali Suliman,1 (<>)Ashok Srinivasan,1 (<>)M. Paulina Velasquez,1 (<>)Esther A. Obeng,4 (<>)Catherine Willis,5 (<>)Salem Akel,6 (<>)Seth E. Karol,4 (<>)Hiroto Inaba,4 (<>)Allison Bragg,7 (<>)Wenting Zheng,8 (<>)Sheng M. Zhou,9 (<>)Sarah Schell,1 (<>)MaCal Tuggle-Brown,1 (<>)David Cullins,1 (<>)Sagar L Patil,1 (<>)Ying Li,1 (<>)Paul G. Thomas,2 (<>)Caitlin Zebley,1 (<>)Benjamin Youngblood,2 (<>)Ching-Hon Pui,4 (<>)Timothy Lockey,5 (<>)Terrence L. Geiger,8 (<>)Michael M. Meagher,5 (<>)Brandon M. Triplett,1 (<>)and Stephen Gottschalk1 (<>) Key Points \u2022 CD8+ CD19-CAR T cells outcompete their CD4+ counterparts and undergo antigen-driven differentiation after infusion.",
        "positive": "The study found that CD8+ CD19-CAR T cells preferentially expanded after infusion and were influenced by disease burden in pediatric B-cell acute lymphoblastic leukemia.",
        "negative": "Patient eligibility\nEligible patients were \u2265 18 years old with a histologically confirmed advanced, unresectable or metastatic solid tumor for which standard treatment was not available."
    },
    {
        "anchor": "ADCC and CDC\nCancer cell lines were loaded with 51Cr for 1 hour and then incubated with different concentrations of control antibody, Hu9338, Hu9006, Sym015, or Sym015 LALA plus either freshly isolated peripheral blood mononuclear cells (PBMC) for 4 hours (ADCC) or freshly isolated serum for 3 hours (CDC).",
        "positive": "Cancer cell lines were labeled with 51Cr and then incubated with varying concentrations of control antibody, Hu9338, Hu9006, Sym015, or Sym015 LALA, along with either freshly isolated peripheral blood cells or serum, for 4 hours (ADCC) or 3 hours (CDC).",
        "negative": "PATIENT SELECTION AND WITHDRAWAL\nExceptions to eligibility will not be granted for this study."
    },
    {
        "anchor": "The most common adverse events of grade 3 or higher were pneumonia (in 10 patients [12%]) and dehydration (in 5 patients [6%]).",
        "positive": "Grade 3 or higher adverse events were primarily pneumonia (12% of patients) and dehydration (6% of patients).",
        "negative": "SAFETY\nLong-term therapy with ibrutinib was associated with modest toxicity; most adverse events were grade 1 or 2 (Table 2)."
    },
    {
        "anchor": "The paclitaxel will be given over 1 hour with standard premedication consisting of diphenhydramine 25-50 mg, an H2-blocker, and dexamethasone (oral or intravenous is acceptable according to local custom) at least 30 minutes prior to paclitaxel.",
        "positive": "Paclitaxel will be administered over 1 hour, preceded by standard premedication consisting of diphenhydramine, an H2-blocker, and dexamethasone, at least 30 minutes before treatment.",
        "negative": "Background\nDespite recent advances in treatment, lung cancer remains the leading cause of cancer-related death in the US and worldwide [(<>)1]."
    },
    {
        "anchor": "As a consequence, the patient population can be heterogeneous.",
        "positive": "This heterogeneity in the patient population may result from various factors.",
        "negative": "Study design\n2 3 The eligibility criteria and study design for PACIFIC (NCT02125461), a randomized, double-blind, international, multicenter trial, have been described previously.,Briefly, eligible patients had histologically or cytologically documented stage III, unresectable NSCLC, (according to the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology, version 7) and had not progressed after at least two cycles of platinum-based, cCRT."
    },
    {
        "anchor": "STARTRK-2 patient recruitment\nPatients were recruited to the open-label, multicenter, global phase 2 basket study of entrectinib if they had locally advanced or metastatic solid tumors driven by NTRK1/2/3, ALK, or ROS1 gene rearrangements.",
        "positive": "Patients with locally advanced or metastatic solid tumors driven by NTRK1/2/3, ALK, or ROS1 gene rearrangements were enrolled in the open-label, multicenter, global phase 2 basket study of entrectinib.",
        "negative": "Only those patients with ROS1 rearrangements were analyzed for MET amplification in this study."
    },
    {
        "anchor": "At the time of data cut-off, eight patients (29%) in the placebo plus chemotherapy group crossed over on-study to receive pem-brolizumab monotherapy.",
        "positive": "By the data cut-off date, 29% of patients in the placebo plus chemotherapy group had crossed over to receive pem-brolizumab monotherapy.",
        "negative": "Bergethon K, Shaw AT, Ignatius Ou SH, et al."
    },
    {
        "anchor": "We judged\ue013(<>)Chang 2015\ue013to be at high risk of bias, as both the study group and intervention were only described briefly in an abstract and neither a full-text article nor a study record was available.",
        "positive": "The study by Chang 2015 was considered to be at high risk of bias due to the lack of sufficient information in the abstract, including the absence of a full-text article or study record.",
        "negative": "Background\nAccording to the 2008 global cancer statistics, the morbidity and mortality of lung cancer ranks first worldwide [(<>)1]."
    },
    {
        "anchor": "In our retrospective study, although PET-CT and 4DCT examinations were not performed, the dosimetric feasibility of SIB-IMRT could still be demonstrated; however, PETCT and 4DCT are highly recommended.",
        "positive": "Despite not conducting PET-CT and 4DCT examinations, our retrospective study was able to demonstrate the dosimetric feasibility of SIB-IMRT, although we strongly recommend performing these examinations in future studies.",
        "negative": "7.1.5 Visit Requirements\nVisit requirements are outlined in Section 6.0 - Trial Flow Chart."
    },
    {
        "anchor": "They are a side effect of the use of the (<>)%on% method with a (<>)filter object on the left hand side and a (<>)transformList on the right hand side.",
        "positive": "The side effect is a result of the interaction between the (%)on% method and the (%)filter object on the left, as well as the (%)transformList on the right.",
        "negative": "Objects from the Class\nObjects of this type are not generally created \u201cby hand\u201d."
    },
    {
        "anchor": "Median overall survival was 7.7 months.",
        "positive": "The median overall survival was 7.7 months.",
        "negative": "Kaplan\u2013Meier estimate of time to progression by treatment group in the intent-to-treat population (A) and among patients \u226465 years of age (B)."
    },
    {
        "anchor": "Quarterly Evaluations for up to 1 Year Post Infusion\nSubjects will be evaluated on a quarterly basis until 1 year post infusion.",
        "positive": "Subjects will be evaluated quarterly for up to 1 year after infusion, with assessments continuing until 1 year post infusion.",
        "negative": "Acknowledgments\nWe would like to thank Dr. Robert Gale for reviewing our manuscript."
    },
    {
        "anchor": "RT is a highly personalized treatment approach because it takes into consideration anatomic features and patient characteristics in treatment planning.",
        "positive": "RT is a personalized treatment approach that considers individual patient characteristics and anatomic features in treatment planning.",
        "negative": "Table 3\nFamily Caregiver Outcomes at 12 weeks."
    },
    {
        "anchor": "As an aside, this property was shared with its rhabdoviral cousin VSV\u0394M51.",
        "positive": "Notably, this property is also shared with VSV\u0394M51, a rhabdoviral cousin.",
        "negative": "immunotherapeutic activity of Maraba virus\nOn top of its potent oncolytic activity, MG1 therapeutic efficacy also relies on its intrinsic ability to induce antitumor immunity."
    },
    {
        "anchor": "Ancillary expenses such as transportation, relocation costs and accommodations, food and child care also contribute to financial distress.",
        "positive": "In addition to the primary expenses, ancillary costs such as transportation, relocation, and accommodations, as well as food and child care, also contribute to financial distress.",
        "negative": "special considerations for quality of life\nClinical trials often have more frequent assessments and clinic visits than standard of care therapies."
    },
    {
        "anchor": "As indicated above, there is abundant evidence that TGF-\u03b2 is a key component of the fibrotic response.",
        "positive": "As mentioned earlier, the evidence strongly suggests that TGF-\u03b2 is a key component of the fibrotic response.",
        "negative": "Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B"
    },
    {
        "anchor": "Collectively, these results suggest that certain antitumor effects of APG-2449 are mediated by suppressing ALK- or ROS1driven signaling pathways.",
        "positive": "The results collectively suggest that the antitumor effects of APG-2449 are achieved by suppressing signaling pathways driven by ALK or ROS1.",
        "negative": "\ue003 \ue01a\ue011\ue016\ue011\ue01b +\\SHUVHQVLWLYLW\\\ue0035HDFWLRQV\ue003WR\ue003&DUERSODWLQ\ue003\nx Grade 1: Slow the infusion until symptoms resolve, then restart the infusion at the initial planned rate."
    },
    {
        "anchor": "Another strength of the \u201cglobal\u201d approach of our study is the concomitant interest in CRF and cachexia, two major symptoms ((<>)81) that may have substantial interaction ((<>)5, (<>)30\u2013(<>)32), as suggested in the vicious cycle presented in (<>)Figure 1.",
        "positive": "The global approach of our study has the advantage of investigating CRF and cachexia concurrently, two major symptoms that may interact with each other, as illustrated in Figure 1.",
        "negative": "11.3 Quality of Life Assessments (2/28/05)\n11.3.1 EORTC QLQ-C30 The EORTC QLQ-C30 is a 30-item, self report questionnaire containing the following domains (scales): Physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items), global quality of life (2 items), fatigue (2 items), pain (2 items), nausea and vomiting (2 items), and single items for dyspnea, insomnia, anorexia, constipation, diarrhea and financial impact.48 11.3.2 BN20 The 20-item BN20 contains 4 multi-item scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items (headache, seizure, drowsiness, hair loss, itching, weakness of both legs, and difficulties with bladder control)."
    },
    {
        "anchor": "14), \u2022 Prior identification of further processors and signature of a transfer agreement (Chapter V), \u2022 Data protection impact assessment (Art.",
        "positive": "14), \u2022 Identification of additional processors and signing a transfer agreement (Chapter V) were completed, \u2022 A data protection impact assessment was conducted (Art.",
        "negative": "European regulatory framework\nDe-identified study data are considered as personal data within the meaning of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, known as \u00ab GDPR \u00bb."
    },
    {
        "anchor": "Nivolumab was administered intravenously every two weeks at dosage of 3 mg/kg, while pembrolizumab every three weeks at 200 mg. One patient received ipilumumab 1 mg/Kg in combination with nivolumab, This analysis is embedded into a larger prospective study (NCT03563482).",
        "positive": "Nivolumab was administered intravenously every two weeks at a dose of 3 mg/kg, and pembrolizumab was given every three weeks at 200 mg. One patient received ipilumumab 1 mg/Kg in combination with nivolumab, as part of a larger prospective study (NCT03563482).",
        "negative": "Investigational New Drugs (2021) 39:1357\u20131365 https://doi.org/10.1007/s10637-021-01119-0\nPHASE I STUDIES Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi\u2010arm phase Ib study Received: 9 February 2021 /Accepted: 20 April 2021 / Published online: 28 April 2021 #The Author(s) 2021, corrected publication 2021"
    },
    {
        "anchor": "The primary objective of efficacy, RD of the ORRs (MB02 minus EU-bevacizumab) and RR of the ORRs (MB02\u2215EU-bevacizumab) as assessed by an IRC at Week 18 in the ITT population, met the criteria applied for similarity as discussed with the main international regulatory",
        "positive": "The primary objective of efficacy was the evaluation of ORRs (MB02 minus EU-bevacizumab) and RR of ORRs (MB02\u2215EU-bevacizumab) at Week 18 in the ITT population, which met the criteria for similarity as discussed with the main international regulatory agencies.",
        "negative": "4 Discussion\nIn this confirmatory phase III clinical study, the efficacy, safety, and immunogenicity of MB02 and EU-bevaci-zumab, both in combination with chemotherapy, were compared in patients with advanced non-squamous NSCLC."
    },
    {
        "anchor": "Overall, these reports indicate that additional targets may be needed for ACT, particularly for solid tumors, and that more clinical research including autologous endogenous T-cell therapy is warranted.",
        "positive": "The reports suggest that additional targets may be required for ACT, particularly in solid tumors, and that further clinical research, including autologous endogenous T-cell therapy, is necessary.",
        "negative": "Patients aged 18 years or older with histologically or cytologically confirmed, locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, eligible for standard first-line platinum-doublet treatment for NSCLC but unsuitable for radical treatment were included in the study."
    },
    {
        "anchor": "All 68 patients in cohort 3 were evaluable for response per independent central review.",
        "positive": "A total of 68 patients in cohort 3 were assessed for response by independent central review.",
        "negative": "Statistical Analysis\n27 We conducted efficacy and safety analyses in 36 patients who received at least one dose of the study treatment."
    },
    {
        "anchor": "Study design and patients\nThe methodology for the RCT is described in detail in the clinical outcomes paper.1 Briefly, the study was designed as a 2\u00d72 factorial design with RT dose as one factor and cetuximab as the other, stratified by radiotherapy technique, Zubrod performance status, use of PET during staging, and histology, with a primary endpoint of overall survival.",
        "positive": "The study design and patient population are described in detail in the clinical outcomes paper.1 In brief, the study was a 2\u00d72 factorial design with RT dose and cetuximab as the two factors, stratified by radiotherapy technique, Zubrod performance status, use of PET during staging, and histology, with overall survival as the primary endpoint.",
        "negative": "METHODS\nIn this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]\u2013paclitaxel for the first 4 cycles."
    },
    {
        "anchor": "This clinical trial was approved by the Ethics Committee of the North China Petroleum Bureau General Hospital of Hebei Medical University.",
        "positive": "The clinical trial was approved by the Ethics Committee of the North China Petroleum Bureau General Hospital of Hebei Medical University.",
        "negative": "Exclusion criteria\nPatients who were pregnant, breastfeeding, had another malignant tumor history (with the exception of patients with cervical carcinoma in situ and non-malignant melanoma skin cancer that had been clinically cured for at least 5 years), could not receive concurrent chemotherapy due to medical reasons, and had superior vena cava syndrome and severe lung diseases that affected lung function were excluded."
    },
    {
        "anchor": "These included 30 patients with neoplasms (26 primary or metastatic carcinoma, 1 thymoma, 3 lymphoma), 4 with granulomatous inflammation and 6 with normal lymphoid tissue.",
        "positive": "The study included 30 patients with neoplasms (26 primary or metastatic carcinoma, 1 thymoma, 3 lymphoma), 4 with granulomatous inflammation, and 6 with normal lymphoid tissue.",
        "negative": "Results:\nForty patients with a clinical need for lymph node evaluation were enrolled in the study with 56 lesions biopsied."
    },
    {
        "anchor": "The trial was approved by the responsible ethics committee and registered at ClinicalTrial.gov NCT01221675 (EudractCT 200800603096).",
        "positive": "The trial was approved by the responsible ethics committee and registered at ClinicalTrial.gov and EudractCT 200800603096.",
        "negative": "Background\nLung cancer is the second most diagnosed cancer in males and females, with over 200,000 new cases per year in the USA [(<>)1, (<>)2]."
    },
    {
        "anchor": "End Points\nThe primary end point was event-free survival (EFS) at 1 year.",
        "positive": "The primary outcome was the percentage of patients who remained event-free after 1 year.",
        "negative": "Nivolumab versus (<http://refhub.elsevier.com/S2666-3643(22)00140-0/sref1>)docetaxel in previously treated patients with advanced (<http://refhub.elsevier.com/S2666-3643(22)00140-0/sref1>)non-small-cell lung cancer: two-year outcomes from two (<http://refhub.elsevier.com/S2666-3643(22)00140-0/sref1>)randomized, open-label, phase III trials (CheckMate 017 (<http://refhub.elsevier.com/S2666-3643(22)00140-0/sref1>)and CheckMate 057)."
    },
    {
        "anchor": "Treatment\nA minimum anticipated biological effect level (MABEL) approach was used for the selection of the starting dose in humans.",
        "positive": "The MABEL approach was employed to determine the initial dose for human subjects.",
        "negative": "Endpoints\nThe primary endpoint of the study was to estimate overall survival (OS) in each arm."
    },
    {
        "anchor": "Acknowledgements\nWe are grateful to Ms. Zhaolan Liu for her assistance in with the statistical design, and to every researcher in the 18 study hospitals for their advice and hard work in the future.",
        "positive": "We would like to express our appreciation to Ms. Zhaolan Liu for her help with the statistical design and to the researchers at the 18 study hospitals for their guidance and dedication.",
        "negative": "We also would like to thank Editage ((<http://www.editage.cn>)www.editage.cn) for English language editing."
    },
    {
        "anchor": "Epitopes used for the measurement of T-cell response.",
        "positive": "T-cell response was measured using epitopes.",
        "negative": "A multi center prospective study\nQian Jiang, MMa, Ning-Ling Zhang, MBa, Dai-Yuan Ma, MDa,\u2217, Bang-Xian Tan, MMa, Xin Hu, MBb, Xiang-Dong Fang, MBc Abstract Background: Apatinib is an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2)."
    },
    {
        "anchor": "Furthermore, all three of the lines were sensitive to ganciclovir-mediated ablation based on the co-expression of herpes simplex virus (HSV) thymidine kinase contained within the CAR/HyTk plasmid vector used for gene-modification.",
        "positive": "Furthermore, the three lines were found to be sensitive to ganciclovir-mediated ablation, which was dependent on the co-expression of HSV thymidine kinase in the CAR/HyTk plasmid vector used for gene modification.",
        "negative": "$//\ue0036(5,286\ue003adverse events that meet the above criteria 0867 be immediately reported to the NCI via CTEP-AERS within the timeframes detailed in the table below.\ue003\n127(\ue01d Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR ([SHGLWHG\ue003$(\ue003UHSRUWLQJ\ue003WLPHOLQHV\ue003DUH\ue003GHILQHG\ue003DV\ue01d o \u201c24-Hour; 5 Calendar Days\u201d - The AE must initially be reported via CTEP-AERS within 24 hours of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report."
    },
    {
        "anchor": "Certain relationships marked with a \u201cU\u201d are those for which no compensation was received; those relationships marked with a \u201cC\u201d were compensated.",
        "positive": "The relationships marked with a \"U\" did not receive compensation, whereas those marked with a \"C\" did receive compensation.",
        "negative": "CONFLICTS OF INTEREST\nThe authors declared no competing interests."
    },
    {
        "anchor": "The activity of this oral regimen seems comparable to most data previously published with I.V.",
        "positive": "The oral regimen's efficacy appears to be similar to that of most previously published I.V. data.",
        "negative": "Patient\ue020Characteristics\ue020and\ue020Disposition\ue020\nA total of 15 NSCLC patients were enrolled and assessed for safety and efficacy."
    },
    {
        "anchor": "One standard that is recommended is: x Dexamethasone 20 mg orally 12 and 6 hours before paclitaxel or 20 mg IV just prior to paclitaxel x Diphenhydramine 50 mg IV (or equivalent) prior to paclitaxel x Cimetidine 300 mg IV (or equivalent, ranitidine 50 mg or famotidine 20 mg) prior  to paclitaxel x Granisetron 2 mg orally (or equivalent) prior to chemotherapy",
        "positive": "The recommended standard is to administer dexamethasone 20 mg orally 12 and 6 hours before paclitaxel or 20 mg IV just prior to paclitaxel, along with diphenhydramine, cimetidine, and granisetron, all prior to chemotherapy.",
        "negative": "5.3.1  Concurrent chemotherapy\nFor selected patients with stage II or III disease and good performance status, chemotherapy will be administered weekly concurrent with radiation."
    },
    {
        "anchor": "LLOQ indicates lower limit of quantification; and sBCMA, serum BCMA.",
        "positive": "LLOQ represents the lower limit of quantification, and sBCMA refers to serum BCMA levels.",
        "negative": "Bridging therapy, measurable disease type, and tumor burden change from screening to cilta-cel infusion\nSupplemental Figure 1."
    },
    {
        "anchor": "Ethics approval and consent to participate\nThe protocol was reviewed and approved by the institutional review board at Providence Portland Medical Center, and was conducted in accordance with the Declaration of Helsinki.",
        "positive": "The study protocol was reviewed and approved by the institutional review board at Providence Portland Medical Center, and was conducted in accordance with the Declaration of Helsinki, with participants providing informed consent.",
        "negative": "All patients provided written informed consent."
    },
    {
        "anchor": "The trial period was between March 2020\u2013April 2021, with a follow-up ranging from 21\u201332 months (Figure (<>)1).",
        "positive": "The study took place from March 2020 to April 2021, with a follow-up period lasting between 21 and 32 months.",
        "negative": "The trial was conducted in accordance with International Council for Harmonization Good Clinical Practice guidelines, and all patients provided written informed consent prior to enrollment."
    },
    {
        "anchor": "Implementation of this assumption was based on long-term DFS results from the POTENT real-world study, a retrospective chart review in patients with resected stage IB\u2012IIIA EGFRm NSCLC from three Canadian cancer centers [(<>)24] and the preference of clinical experts.",
        "positive": "The assumption was informed by long-term DFS results from the POTENT real-world study, a retrospective review of patients with resected stage IB\u2012IIIA EGFRm NSCLC from three Canadian cancer centers [(24)] and the preferences of clinical experts.",
        "negative": "Patients predicted to be \u2018cured\u2019 are assumed to be at no elevated risk of death due to NSCLC."
    },
    {
        "anchor": "Notably, more patients in the trameti-nib arm had dyspnea (33%), cough (23%), and pneumonia (11%), compared with docetaxel (19%, 16%, and 2%, respectively) (Table (<>)2).",
        "positive": "The trameti-nib arm had a higher incidence of dyspnea (33%), cough (23%), and pneumonia (11%) compared to the docetaxel arm (19%, 16%, and 2%, respectively) (Table 2).",
        "negative": "The grade 4 AEs in the trametinib arm (in more than two patients) were rash (3%), dyspnea (3%), pneumonia (2%), and sepsis (5%)."
    },
    {
        "anchor": "Anti-CD3 (clone HIT3a) and anti-CD28 (clone CD28.2) were purchased from BD Biosciences.",
        "positive": "The antibodies anti-CD3 (clone HIT3a) and anti-CD28 (clone CD28.2) were sourced from BD Biosciences.",
        "negative": "Reagents\n5' adneosine monophosphate (5\u2019-AMP), adenosine 5\u2019-(\u03b1,\u03b2-methylene) diphosphate (APCP), and 5\u2019-(N-Ethylcarbox-amido) adenosine (NECA) were purchased from Sigma-Aldrich."
    },
    {
        "anchor": "All these parameters of all patients in the afatinib group in this study were compared to a historical cohort of all patients who received erlotinib after prior failure to gefitinib and at least one line of systemic chemotherapy in our department from January 2009 to December 2011, with the same inclusion and exclusion criteria as for the patients who received afatinib in this study.",
        "positive": "The parameters of patients in the afatinib group were compared to those of a historical cohort of patients who received erlotinib after gefitinib failure and at least one line of systemic chemotherapy in our department from January 2009 to December 2011, with identical inclusion and exclusion criteria.",
        "negative": "Keywords\nChimeric antigen receptor; VZV; virus-specific T-cell; immunotherapy; vaccination"
    },
    {
        "anchor": "9.1 Investigational Product\nThe investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of investigational product in accordance with the protocol and any applicable laws and regulations.",
        "positive": "The investigator must maintain records and ensure the proper handling, storage, distribution, and use of investigational product, as per the protocol and applicable laws and regulations.",
        "negative": "Clinical Supplies will be provided by Merck as summarized in Table 11."
    },
    {
        "anchor": "Ghosh A, Shuman S, Lima CD.",
        "positive": "Ghosh, Shuman, and Lima.",
        "negative": "Funding\nThe Swiss Group for Clinical Cancer Research financed the microarray experiments."
    },
    {
        "anchor": "For other objects it will usually return a vector of names used by the object for its calculations.",
        "positive": "For other objects, the output typically includes a list of names used in calculations.",
        "negative": "Clinical Dataset Analysis and Code Availability\nReverse-phase protein array (RPPA) dataset, mRNA dataset, and clinical outcomes dataset of patients with breast cancer in TCGA were achieved from Firebrowse ((<http://firebrowse.org/>)http://firebrowse.org/)hostedbyBroad Institutebyselecting the cohort as \u201cBreast Invasive Carcinoma (BRCA)\u201d on the left panel, and clicking \u201cReverse Phase Protein Array\u201d, \u201cmRNA\u201d and \u201cClinical\u201d bars on the right panel."
    },
    {
        "anchor": "(<http://dx.doi.org/10.1158/1535-7163.MCT-22-0786>)Mol Cancer (<http://dx.doi.org/10.1158/1535-7163.MCT-22-0786>)Ther 2023;22:999\u20131012.",
        "positive": "The article DOI is 10.1158/1535-7163.MCT-22-0786, published in Mol Cancer Ther 2023;22:999\u20131012.",
        "negative": "REFERENCES\nligand B7-H4, shows promising activity in Preclinical models."
    },
    {
        "anchor": "There is already clear evidence of activity of crizotinib in patients with tumour MET amplification [(<>)27]or ROS1-rearranged lung cancer [(<>)6].",
        "positive": "Crizotinib has already demonstrated activity in patients with MET-amplified or ROS1-rearranged lung cancer [(27, 6)].",
        "negative": "crizotinib\nCrizotinib is a potent inhibitor of both MET and ROS1."
    },
    {
        "anchor": "The level of APAP remained an independent predictor for major pathologic response in multivariate logistic analysis.",
        "positive": "APAP levels were found to be a significant predictor of major pathologic response in a multivariate analysis.",
        "negative": "Slots\nparameters Object of class \"character\"."
    },
    {
        "anchor": "Tisagenlecleucel immunogenicity (humoral) [time frame: week -12 to day -1 (Enrolment/bridging chemotherapy), day 28, months 3, 6 and 12] a.",
        "positive": "The humoral immunogenicity of tisagenlecleucel was assessed at various time points, including week -12 to day -1, day 28, and months 3, 6, and 12.",
        "negative": "Outcomes\nThe primary endpoint was investigator-assessed DFS, which was defined as the time from randomization to documented disease relapse or death, whichever occurred first."
    },
    {
        "anchor": "Thoracic radiotherapy was prescribed at a dose that depended on the treatment intention with 1.8\u20132.1 Gy/fraction for 5 days per week.",
        "positive": "Radiotherapy was delivered at a dose of 1.8-2.1 Gy per fraction, five days a week, based on the treatment plan.",
        "negative": "Binding of DuoBody-CD3x5T4 to 5T4-expressing tumor cells and quantitative flow cytometry analysis\nTumor cells were washed after trypsinization (0.5% Trypsin\u2013EDTA), seeded (30,000\u201350,000 cells/well) in round-bottom 96-well plates, and centrifuged."
    },
    {
        "anchor": "The exclusion criteria were as follows: (a) the patient received blood transfusion therapy within one month; (b) patients with autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, etc.",
        "positive": "Patients were excluded if they had received blood transfusions within the past month or had autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome.",
        "negative": "All patients were fully informed and signed informed consent."
    },
    {
        "anchor": "Role of the vascular endothelial growth factor (<http://refhub.elsevier.com/S2589-5370(23)00283-3/sref18>)pathway in tumor growth and angiogenesis.",
        "positive": "The role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis was investigated.",
        "negative": "References\n1 (<http://refhub.elsevier.com/S2589-5370(23)00283-3/sref1>)Akinboro O, Larkins E, Pai-Scherf LH, et al."
    },
    {
        "anchor": "Safety\nSafety reporting was conducted using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V.4.03; (<https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf>)https://evs.nci.nih.gov/ (<https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf>)ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_ (<https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf>)QuickReference_8.5x11.pdf, accessed March 18, 2023).",
        "positive": "The study used the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE V.4.03) to document and report adverse events, accessed on March 18, 2023.",
        "negative": "Administration, dosing, and monitoring\n75 11 75 In the ELOQUENT-2 trial, IRRs were reported in 33 patients (10%) in the elotuzumab arm, with mostly grade 1/2 IRRs and no grade 4 or 5 events."
    },
    {
        "anchor": "Most patients (95.0%) had stage IV disease, and all patients (100%) had adenocarcinoma histology.",
        "positive": "Ninety-five percent of patients had stage IV disease, and all patients had adenocarcinoma histology.",
        "negative": "TABLE 1 (Continued) All 20 (100.0%) patients were treated with alectinib prior to study entry."
    },
    {
        "anchor": "Table 4\nStage and Histologic Features of Lung Cancers, According to Study Group and Screening Result.",
        "positive": "The table shows the stage and histologic features of lung cancers, categorized by study group and screening result.",
        "negative": "* Total (N = 190) Chest RadiographyNone Negative (N = 5) (N=49) Low-Dose CTNone Positive(N = 136) Total(N = 292) (N=4) Negative(N = 18) Positive(N = 270) Stage or Finding number/total number (percent) 46/185 (24.9) 24/185 (13.0) 3/185 (1.6) 10/185 (5.4) 0000 6/48 (12.5) 2/48 (4.2)0 2/48 (4.2) 40/133 (30.1) 132/288 (45.8) 22/133 (16.5) 26/288 (9.0) 00 2/18 (11.1) 130/266 (48.9) 1/18 (5.6) 25/266 (9.4) 3/133 (2.3) 8/133 (6.0) 10/288 (3.5) 12/288 (4.2) 1/4 (25.0)0 2/18 (11.1) 1/18 (5.6) 7/266 (2.6) 11/266 (4.1) Stage  IA  IB  IIA  IIB 29/185 (15.7) 27/185 (14.6) 46/185 (24.9) 5/190 (2.6) 2/4 (50.0)0 8/48 (16.7) 12/48 (25.0) 2/4 (50.0) 18/48 (37.5) 1/5 (20.0) 1/49 (2.0) 19/133 (14.3) 34/288 (11.8) 1/4 (25.0) 2/18 (11.1) 31/266 (11.7) 15/133 (11.3) 26/133 (19.5) 3/136 (2.2) 30/288 (10.4) 44/288 (15.3) 4/292 (1.4) 2/4 (50.0)00 7/18 (38.9) 3/18 (16.7)0 21/266 (7.9) 41/266 (15.4) 4/270 (1.5) IIIA  IIIB  IV Unknown\u2020 Histologic features 8/189 (4.2) 0 0 8/136 (5.9) 38/290 (13.1) 0 0 38/268 (14.2) Bronchioloalveolar carcinoma 71/189 (37.6) 39/189 (20.6) 13/189 (6.9) 3/5 (60.0)00 15/48(31.2) 7/48 (14.6) 5/48 (10.4) 53/136 (39.0) 123/290 (42.4) 1/4 (25.0) 4/18 (22.2) 118/268 (44.0) 32/136 (23.5) 8/136 (5.9) 54/290 (18.6) 17/290 (5.9) 1/4 (25.0)0 6/18 (33.3) 3/18 (16.7) 47/268 (17.5) 14/268 (5.2) Adenocarcinoma Squamous-cell carcinoma Large-cell carcinoma 30/189 (15.9) 1/5 (20.0) 9/48 (18.8) 20/136 (14.7) 36/290 (12.4) 1/4 (25.0) 1/18 (5.6) 34/268 (12.7) Non\u2013small-cell carcinoma, other classification\u2021 27/189 (14.3) 1/189 (0.5) 1/5 (20.0)0 11/48 (22.9) 1/48 (2.1) 15/136 (11.0)0 20/290 (6.9) 2/290 (0.7) 1/4 (25.0)0 4/18 (22.2)0 15/268 (5.6) 2/268 (0.7) Small-cell carcinoma Carcinoid"
    },
    {
        "anchor": "A difference in release duration between lucitanib tablets and capsules was not considered clinically meaningful, and other covariates had no effect.",
        "positive": "The study found that the difference in release duration between lucitanib tablets and capsules was not clinically significant, and other variables did not influence the outcome.",
        "negative": "Study design and patients\n16 17 17 From November 2016 to April 2021, 52 patients with R/R B-ALL confirmed with CNSL involved in 2 clinical trials at 5 centers in China were successively screened for this study."
    },
    {
        "anchor": "Funding\nThis work received financial support from the National Natural Science Foundation of China (82003206, 82173338, 82102747, and 82160489) and Natural Science Foundation of Hunan Province (2020SK2031, 2020RC4040, 2020SK2030, 2019-TJ-N04, and 2020JJ3025).",
        "positive": "The study was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Hunan Province, with grant numbers 82003206, 82173338, 82102747, and 82160489, as well as 2020SK2031, 2020RC4040, 2020SK2030, 2019-TJ-N04, and 2020JJ3025.",
        "negative": "AUTHOR CONTRIBUTIONS\nA.A., A.S.S., and K.W."
    },
    {
        "anchor": "Two patients died due to disease progression, but no treatment-related death was observed by the data-cutoff date (October 23, 2019).",
        "positive": "As of October 23, 2019, two patients had succumbed to disease progression, with no treatment-related deaths documented.",
        "negative": "Evaluation criteria/ analysis\nThe main objective was to evaluate local tumor control rate at 1 year, local control defined as the absence of progression of the ablated site."
    },
    {
        "anchor": "Tolerability was assessed by measuring percent body weight loss (BWL; body weights were measured twice weekly), mortality, or any clinical signs of adverse treatment-related side effects (see Supplementary Appendix).",
        "positive": "The tolerability of the treatment was evaluated by monitoring body weight loss, mortality rates, and any signs of adverse reactions, as outlined in the Supplementary Appendix.",
        "negative": "In Vivo Assessment of TAK-676 Efficacy in Mouse Models\nTAK-676 activity was evaluated in syngeneic CT26.WT and A20 mouse models."
    },
    {
        "anchor": "We hypothesize that this trispecific targeting of CD19/20/22 CAR-T construct will be safe and effective in patients with relapsed, refractory B-cell malignancies.",
        "positive": "We anticipate that the trispecific targeting of CD19/20/22 CAR-T construct will be a safe and effective treatment option for patients with relapsed, refractory B-cell malignancies.",
        "negative": "Where can I get more information?"
    },
    {
        "anchor": "Participants were not told the threshold, but when they gave a rating of \u22657, they were encouraged to call the clinic and notified on the website that the clinical team would be alerted. \"",
        "positive": "Participants were not informed of the threshold, but when they provided a rating of 7 or higher, they were instructed to contact the clinic and notified on the website that the clinical team would be notified.",
        "negative": "\ue019\ue011\ue014\ue016\ue011\ue015\ue003\nEsophageal complaints are common with combined modality therapy."
    },
    {
        "anchor": "The lung organ at risk is defined as the whole lung volume with the exception of the GTV.",
        "positive": "The lung organ at risk is defined as the entire lung volume, with the GTV being excluded.",
        "negative": "ARTICLE INFO\nArticle History: Received 21 June 2021 Revised 29 September 2021 Accepted 19 October 2021 Available online xxx MIL60 biosimilar bevacizumab equivalence non-squamous NSCLC"
    },
    {
        "anchor": "The total amount of blood/tissue to be drawn/collected over the course of the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes drawn/collected by visit and by sample type per subject can be found in the Procedures Manual.",
        "positive": "The total volume of blood and tissue to be collected during the trial, including approximate volumes by visit and sample type, is outlined in the Procedures Manual.",
        "negative": "Corresponding\ue020Authors:\ue020\nEng-Huat\ue020Tan,\ue020National\ue020Cancer\ue020Centre,\ue020Department\ue020of\ue020Medical\ue020Oncology,\ue02011\ue020Hospital\ue020Drive,\ue020Singapore\ue020169610\ue020 (e-mail:\ue020tan.eng.huat@singhealth.com.sg)\ue020 Keunchil\ue020Park,Division\ue020of\ue020Hematology-Oncology,Samsung\ue020Medical\ue020Center,\ue020Sungkyunkwan\ue020University,\ue020School\ue020of\ue020Medicine,\ue02050,\ue020Irwon-Dong,\ue020Gangnam-Gu,\ue020Seoul\ue020135\u2013710,\ue020Korea\ue020 (e-mail:\ue020kpark@skku.edu)\ue020 Trial\ue020registration\ue020ID:\ue020NCT01039948\ue020 hepatocyte growth factor (HGF)/c-Met pathway have been identified as some of the key mechanisms of acquired resistance to gefitinib and erlotinib.9\u201313 HGF is the only known soluble ligand for the c-Met receptor tyrosine kinase and plays a key role in regulating cell proliferation, motility, and differentiation, particularly during embryogenesis and injury repair.14\u201316 In patients with NSCLC, high serum and plasma levels of HGF appear to be associated with poor prognosis17 and intrinsic resistance to gefitinib.18,19 High tumor HGF expression has also been associated with both intrinsic and acquired resistance to EGFR TKIs.13 Moreover, the presence of HGF can accelerate NSCLC-cell resistance to EGFR TKIs by promoting clonal selection of a subpopulation of cells with c-Met amplification.20 Preclinical studies in human lung cancer cell lines and lung tumor xenografts in transgenic mice have shown promising results with dual HGF/c-Met and EGFR inhibition, including additive antitumor activity and restoration of EGFRTKI sensitivity."
    },
    {
        "anchor": "Women of childbearing potential were required to document a negative pregnancy test prior to enrollment.",
        "positive": "Women of childbearing potential were required to obtain a negative pregnancy test result before enrolling in the study.",
        "negative": "Subject Recruitment\nSubjects were enrolled at six institutions from 2006 through 2009."
    },
    {
        "anchor": "All patients provided informed written consent prior to study start.",
        "positive": "Informed written consent was obtained from all patients before the start of the study.",
        "negative": "Title: Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "It was this component that likely improved treatment for White patients as in our previous work we demonstrated that a segment of the White lung cancer population with early stage disease eschewed surgery due to mistrust, hyper\u2010religiosity, disbelief of diagnosis, or poor perceptions of communication.5 This real\u2010time registry system mimicked Bickell et al who built and evaluated a registry designed to address racial and ethnic disparities in adjuvant breast cancer care.",
        "positive": "This component likely contributed to improved treatment outcomes for White patients, as our previous research demonstrated that a subset of the White lung cancer population with early-stage disease opted out of surgery due to mistrust, hyper-religiosity, disbelief of diagnosis, or poor communication. The real-time registry system was inspired by Bickell et al's registry, which aimed to address racial and ethnic disparities in adjuvant breast cancer care.",
        "negative": "Conflicts of interest\nPotential conflicts of interest were declared in 10 studies, for which funding was provided by the following pharmaceutical companies: Celgene/Juno Therapeuctics ((<>)Hirayama 2019; (<>)PLATFORM; (<>)TRANSCEND-NHL-001), Kite Pharma ((<>)Kochenderfer (<>)2017; (<>)ZUMA-1; (<>)ZUMA-6), Novartis ((<>)JULIET; (<>)Schuster 2017), America Yuva Biomed ((<>)Chang 2015) and JW therapeutics ((<>)Ying 2019)."
    },
    {
        "anchor": "Secondary endpoints included OS, defined as the time between the first treatment and death from any cause, overall response rate (ORR), disease control rate (DCR), and safety.",
        "positive": "Secondary endpoints included overall survival, overall response rate, disease control rate, and safety, with overall survival defined as the time between the first treatment and death from any cause.",
        "negative": "Abbreviations\nEGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; NSCLC: Non-small cell lung cancer; PCG: Paclitaxel/carboplatin with gefitinib; PC: Paclitaxel/carboplatin; ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; PS: Performance status; AE: Adverse event; ITT: Intention-to-treat."
    },
    {
        "anchor": "Program and mapping specifications for variable transformations and derivations were created for each data element within each data source.",
        "positive": "Data element transformations and derivations were mapped and specified for each data source.",
        "negative": "Written by\n(https://www.cancer.org/cancer/acs-medical-content-and-news-staff.html) The American Cancer Society medical and editorial content team Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing."
    },
    {
        "anchor": "Cells were injected into irradiated NSG mice (n=10 per group).",
        "positive": "Ten mice per group were injected with cells into irradiated NSG mice.",
        "negative": "Title: Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML\n\nAbstract: IntroductionUniversal allogeneic donor CAR T cells are being developed as part of a 'deep conditioning' strategy against AML to secure disease clearance ahead of allogeneic stem cell transplantation (Allo-SCT)."
    },
    {
        "anchor": "Most have used taxanes in the chemotherapy regimen.Unfortunately the number of patients in our study was too small to establish whether or not such an interaction exists or whether it is exclusive to taxanes.",
        "positive": "While taxanes are frequently used in chemotherapy, our study's limited patient population makes it difficult to determine if this interaction is specific to taxanes.",
        "negative": "DISCUSSION\n7 8 In a prior study, 14 patients with R/R CLL received a median dose of 1.6 3 108 CART-19 at a wide range of 0.14 to 11 3 108."
    },
    {
        "anchor": "Statistical analysis\nFor FISH analysis, tumors were categorized as positive for RET rearrangement if >10% of the tumor cells presented with broken-apart red and green RET signals; this could be further classified as positive for RET-KIF5B if the broken-apart red/green signal was accompanied by a paired green/gold signal.",
        "positive": "For FISH analysis, tumors were classified as positive for RET rearrangement if more than 10% of tumor cells displayed broken RET signals; this could be further sub-classified as RET-KIF5B positive if a paired green/gold signal was present.",
        "negative": "In the IHC analysis, tumor samples with >100 intact tumor cells were assessed by a system similar to that described previously [(<>)8]."
    },
    {
        "anchor": "The sponsor worked with investigators to design the study; collect, analyze, and interpret the data; and prepare the manuscript.",
        "positive": "Investigators worked with the sponsor to design the study, collect and interpret the data, and prepare the manuscript.",
        "negative": "FUNDING\nThe trial was sponsored by Pfizer, as part of an alliance between Pfizer and the healthcare business of Merck (CrossRef Funder ID: 10.13039/100009945) (no grant number)."
    },
    {
        "anchor": "For flow cytometry, the following anti-mouse fluorochrome-conjugated antibodies were used: CD8\u03b1 (clone 53-6.7, BioLegend or BD Biosciences); CD4 (clone RM4-5 or GK1.5, BioLegend); TCR\u03b2 (clone H57-597, BioLegend); Tim-3 (clone 5D12, BD Biosciences or clone RMT3-23, BioLegend); Lag-3 (clone C9B7W, BD Biosciences); CD45 (clone 30-F11, ThermoFisher); CD45.2 (clone 104, BioLegend); NK1.1 (clone 108741, BioLegend); CD44 (clone 103028 or IM7, BioLe-gend); FOXP3 (clone JFK-16s, eBioscience); Granzyme B (clone GB11, BioLegend); Tox (clone TXRX10, eBioscience); Perforin (clone S16009B, BioLegend); PD-L1 (clone 10\u2009F.9G2, BioLegend); MHC-I (clone 28-8-6, BioLegend); MitoTracker Deep Red FM (ThermoFisher Scientific); CD278 (clone C3978.4A, BD Biosciences); CD27 (clone LG.3A10, BD Biosciences); KLRG1 (clone 2F1, BD Biosciences); CD69 (clone H1.2F3, BD Biosciences); Slamf6 (clone 13G3, BD Biosciences), PD-1 (clone 29\u2009F.1A12, BioLegend); Ki-67 (clone B56, BD Biosciences); CD62L (clone MEL-14, BioLegend); CTLA-4 (clone UC10-4F10-11, BD Biosciences); TCF7 (clone 2203, Cell Signaling); TNF (clone MP6-XT22, BioLegend); CD3 (clone 17A2, BioLegend); IFN\u03b3 (clone XMG1.2, BioLegend); STAT5 (Cell Signaling, 94205); phospho-STAT5 (Cell Signaling, 9359); and anti-rabbit IgG (H+L), F(ab\u2032)2 fragment (Cell Signaling, 4412).",
        "positive": "The following anti-mouse antibodies were used for flow cytometry: CD8\u03b1, CD4, TCR\u03b2, Tim-3, Lag-3, CD45, CD45.2, NK1.1, CD44, FOXP3, Granzyme B, Tox, Perforin, PD-L1, MHC-I, MitoTracker Deep Red FM, CD278, CD27, KLRG1, CD69, Slamf6, PD-1, Ki-67, CD62L, CTLA-4, TCF7, TNF, CD3, IFN\u03b3, STAT5, phospho-STAT5, and anti-rabbit IgG.",
        "negative": "Antibodies\nThe following primary antibodies were used to detect designated protein expression in western blot assays: anti-TCPTP (Abcam, ab180764); STAT1 (Cell Signaling, 9172); phospho-STAT1 (Cell Signaling, 9167); STAT5 (Cell Signaling, 94205); phospho-STAT5 (Cell Signaling, 9359); LCK (Invitrogen, AHO0472); phospho-LCK (Cell Signaling, 70926); phospho-SRC family kinase (Cell Signaling, 6943); and FYN (Cell Signaling, 4023)."
    },
    {
        "anchor": "The DSMB will provide guidance/advice to the Regulatory Sponsor and Clinical Investigators.",
        "positive": "The DSMB will offer guidance and advice to the Regulatory Sponsor and Clinical Investigators.",
        "negative": "\ue018\ue011\ue014\ue003 6&5((1,1*\ue003(;$0,1$7,21\ue003$1'\ue003(/,*,%,/,7<\ue0036&5((1,1*\ue003)250\ue003\n$OO\ue003 SDWLHQWV\ue003 PXVW\ue003 SURYLGH\ue003 ZULWWHQ\ue00f\ue003 LQIRUPHG\ue003 FRQVHQW\ue003 EHIRUH\ue003 DQ\\\ue003 WULDO\ue010VSHFLILF\ue003 DVVHVVPHQWV\ue003 RU\ue003 SURFHGXUHV\ue003 DUH\ue003 SHUIRUPHG\ue003 DQG\ue003 VHSDUDWH\ue003 LQIRUPHG\ue003 FRQVHQW\ue003 IRU\ue003 RSWLRQDO\ue003ELRPDUNHU\ue003DVVHVVPHQWV\ue00c\ue011\ue003\ue003 A screening examination (\u201cbaseline\u201d) should be performed between 28 days and \ue014\ue003GD\\\ue003EHIRUH\ue003WKH\ue003ILUVW\ue003GRVH\ue003RI\ue003WUHDWPHQW\ue003 IRU\ue003VSHFLILF\ue003WLPHOLQHV\ue003VHH\ue0037DEOH\ue003\ue014 \ue00c\ue00f\ue003ZKLFK\ue003 ZLOO\ue003 LQFOXGH\ue003 WKH\ue003 IROORZLQJ\ue003 SURFHGXUHV\ue003 XQOHVV\ue003 WKH\ue003 SURFHGXUHV\ue003 KDYH\ue003 DOUHDG\\\ue003 EHHQ\ue003 conducted during this time period as part of the patient\u2019s routine clinical care:\ue003 x\ue003 (OLJLELOLW\\\ue003 \ue00bLQFOXVLRQ\ue003 DQG\ue003 H[FOXVLRQ\ue003 FULWHULD\ue00f\ue003 DV\ue003 OLVWHG\ue003 LQ\ue003 6HFWLRQ\ue003\ue017\ue011\ue015\ue003DQG\ue003 6HFWLRQ\ue003\ue017\ue011\ue016\ue00f\ue003UHVSHFWLYHO\\\ue00c \ue003 x\ue003 'HPRJUDSKLFV\ue003 \ue00bLQFOXGLQJ\ue003 HWKQLFLW\\ \ue00f\ue003 FRPSOHWH\ue003 PHGLFDO\ue003 KLVWRU\\\ue00f\ue003 FRQFXUUHQW\ue003 LOOQHVVHV\ue003\ue003 3URWRFRO\ue00302\ue015\ue015\ue013\ue01c\ue01a\ue003Y4.0\ue003\ue003\ue003\ue003\ue003\ue003\ue003 18 August 2014\ue003 3DJH\ue003\ue018\ue015\ue003 x\ue003 0HGLFDO\ue003KLVWRU\\\ue003LQFOXGLQJ\ue003GHPRJUDSKLFV\ue00f\ue003SUHYLRXV\ue003DQG\ue003FXUUHQW\ue003GLVHDVHV\ue003\ue003 x\ue003 /XQJ\ue003FDQFHU\ue003KLVWRU\\\ue003WR\ue003LQFOXGH\ue003VPRNLQJ\ue003KLVWRU\\\ue003 \ue00bFXUUHQW\ue003RU\ue003SDVW\ue003VPRNHU\ue003VWDWXV\ue00f\ue003 QXPEHU\ue003 RI\ue003 SDFN\ue010\\HDUV\ue00c \ue00f\ue003 SULRU\ue003 VXUJHU\\\ue00f\ue003 UDGLRWKHUDS\\\ue00f\ue003 FKHPRWKHUDS\\\ue003 DQG\ue003 RWKHU\ue003 DQWL\ue010WXPRU\ue003 WUHDWPHQW\ue00f\ue003 $(V\ue003 H[SHULHQFHG\ue003 GXULQJ\ue003 \ue014VW\ue010OLQH\ue003 WUHDWPHQW\ue003 ZLWK\ue003 \ue017\ue010\ue019\ue003 F\\FOHV\ue003 RI\ue003 EHYDFL]XPDE\ue003 SOXV\ue003 D\ue003 SODWLQXP\ue003 GRXEOHW\ue010FRQWDLQLQJ\ue003 FKHPRWKHUDS\\\ue003 UHJLPHQ\ue003 IROORZHG\ue003 E\\\ue003 D\ue003 PLQLPXP\ue003 RI\ue003 \ue015\ue003 F\\FOHV\ue003 RI\ue003 EHYDFL]XPDE\ue003 PRQRWKHUDS\\ \ue00c\ue003 maintenance prior to PD1 (ongoing AEs all grades; resolved AEs grade \u0095 3), UHVXOWV\ue003 RI\ue003 KLVWRORJLFDO\ue012F\\WRORJLFDO\ue003 DQDO\\VHV\ue00f\ue003 WXPRU\ue003 ORFDWLRQ\ue003 DQG\ue003 VWDJLQJ\ue00f\ue003 DQG\ue003 JHQHWLF\ue003LQIRUPDWLRQ\ue003\ue00bH\ue011J\ue011\ue003(*)5\ue003PXWDWLRQ\ue003VWDWXV\ue00c\ue003LI\ue003DYDLODEOH\ue011\ue003 x\ue003 6WDQGDUG\ue003\ue014\ue015\ue010OHDG\ue003(&*\ue011\ue003 x\ue003 &RPSOHWH\ue003 SK\\VLFDO\ue003 H[DPLQDWLRQ\ue003 DQG\ue003 PHDVXUHPHQW\ue003 RI\ue003 YLWDO\ue003 VLJQV\ue003 LQFOXGLQJ\ue003 KHLJKW\ue00f\ue003ZHLJKW\ue003DQG\ue003EORRG\ue003SUHVVXUH\ue00c\ue011\ue003 x\ue003 (&2*\ue00336\ue003 \ue00bVHH\ue0036HFWLRQ\ue003\ue018\ue011\ue016\ue011\ue016 \ue00c\ue011\ue003 x\ue003 %ORRG\ue003VDPSOLQJ\ue003IRU\ue003VHUXP\ue003SUHJQDQF\\\ue003WHVW\ue003 \ue00bVHH\ue0036HFWLRQ\ue003\ue018\ue011\ue017\ue011\ue014 \ue00c\ue003DQG\ue003DVVHVVPHQW\ue003 RI\ue003ODERUDWRU\\\ue003SDUDPHWHUV\ue003\ue00b VHH\ue0036HFWLRQ\ue003\ue018\ue011\ue017 \ue00c\ue011\ue003 x\ue003 8ULQDO\\VLV\ue003 \ue00bVHH\ue0036HFWLRQ\ue003\ue018\ue011\ue017 \ue00c\ue011\ue003 x\ue003 7XPRU\ue003DVVHVVPHQW\ue003\ue00bVHH\ue0036HFWLRQ\ue003\ue018\ue011\ue016\ue011\ue014 \ue00c\ue011\ue003 x\ue003 $(V\ue01d\ue003 $IWHU\ue003 LQIRUPHG\ue003 FRQVHQW\ue00f\ue003EXW\ue003 SULRU\ue003 WR\ue003 LQLWLDWLRQ\ue003RI\ue003 VWXG\\\ue003 PHGLFDWLRQV\ue00f\ue003 RQO\\\ue003 6$(V\ue003 FDXVHG\ue003 E\\\ue003 D\ue003 SURWRFRO\ue010PDQGDWHG\ue003 LQWHUYHQWLRQ\ue003 ZLOO\ue003 EH\ue003 FROOHFWHG\ue003 \ue00bH\ue011J\ue011\ue00f\ue003 6$(V\ue003 UHODWHG\ue003 WR\ue003 LQYDVLYH\ue003 SURFHGXUHV\ue003 VXFK\ue003 DV\ue003 ELRSVLHV\ue00f\ue003 PHGLFDWLRQ\ue003 ZDVKRXW\ue00f\ue003 RU\ue003QR\ue003WUHDWPHQW\ue003UXQ\ue010LQ\ue00c \ue011\ue003$OO\ue003RWKHU\ue003$(V\ue003VKRXOG\ue003EH\ue003GRFXPHQWHG\ue003ZLWK\ue003WKH\ue003PHGLFDO\ue003 KLVWRU\\\ue011\ue003 x\ue003 4R/\ue003 DVVHVVHG\ue003XVLQJ\ue003WKH\ue003(XURSHDQ\ue0032UJDQL]DWLRQ\ue003IRU\ue0035HVHDUFK\ue003DQG\ue0037UHDWPHQW\ue003 RI\ue003 &DQFHU\ue003 >(257&@\ue003 4/4\ue010&\ue016\ue013\ue0124/4\ue010/&\ue014\ue016\ue003 TXHVWLRQQDLUH\ue00f\ue003 GHVFULEHG\ue003 LQ\ue003 6HFWLRQ\ue003\ue018\ue011\ue016\ue011\ue018\ue003DQG\ue003LQFOXGHG\ue003LQ\ue003$SSHQGL[\ue003\ue015\ue011\ue003 x\ue003 5&5\ue003VDPSOLQJ\ue003\ue00bRSWLRQDO\ue01e\ue003VHH\ue0036HFWLRQ\ue003\ue018\ue011\ue017\ue011\ue015 \ue00c\ue011\ue003 3DWLHQWV\ue003 ZKR\ue003 IXOILOO\ue003 DOO\ue003 WKH\ue003 LQFOXVLRQ\ue003 DQG\ue003 QRQH\ue003 RI\ue003 WKH\ue003 H[FOXVLRQ\ue003 FULWHULD\ue003 ZLOO\ue003 EH\ue003 DFFHSWHG\ue003LQWR\ue003WKH\ue003WULDO\ue011\ue003 An Eligibility Screening Form (ESF) documenting the investigator\u2019s assessment of each screened patient with regard to the protocol\u2019s inclusion and exclusion FULWHULD\ue003LV\ue003WR\ue003EH\ue003FRPSOHWHG\ue003E\\\ue003WKH\ue003LQYHVWLJDWRU\ue011\ue003\ue003 $\ue003VFUHHQ\ue003IDLOXUH\ue003ORJ\ue003PXVW\ue003EH\ue003PDLQWDLQHG\ue003E\\\ue003WKH\ue003LQYHVWLJDWRU\ue011\ue003 \ue018\ue011\ue015\ue003 352&('85(6\ue003)25\ue0035$1'20,=$7,21\ue0032)\ue003(/,*,%/(\ue0033$7,(176\ue003 3DWLHQWV\ue003 ZKHUH\ue003 ZULWWHQ\ue003 LQIRUPHG\ue003 FRQVHQW\ue003 KDV\ue003 EHHQ\ue003 REWDLQHG\ue003 DQG\ue003 ZKR\ue003 VDWLVI\\\ue003 DOO\ue003 HOLJLELOLW\\\ue003 FULWHULD\ue00f\ue003 FDQ\ue003 EH\ue003 UDQGRPL]HG\ue003 LQWR\ue003 WKH\ue003 WULDO\ue011\ue003 $V\ue003 HOLJLELOLW\\\ue003 ZLOO\ue003 QRW\ue003 EH\ue003 FRQILUPHG\ue003FHQWUDOO\\\ue00f\ue003LW\ue003 LV\ue003WKH\ue003UHVSRQVLELOLW\\\ue003RI\ue003WKH\ue003LQYHVWLJDWRU\ue003WR\ue003HQVXUH\ue003WKDW\ue003HDFK\ue003 SDWLHQW\ue003PHHWV\ue003DOO\ue003HOLJLELOLW\\\ue003FULWHULD\ue011\ue003\ue003,Q\ue003WKH\ue003HYHQW\ue003WKHUH\ue003DUH\ue003DQ\\\ue003TXHVWLRQV\ue003RU\ue003GRXEWV\ue003 about a patient\u2019s eligibility, the LQYHVWLJDWRU\ue003 VLWH\ue003 VKRXOG\ue003 FRQWDFW\ue003 LWV\ue003 GHVLJQDWHG\ue003 5RFKH\ue003UHSUHVHQWDWLYH\ue003\ue00bL\ue011H\ue011\ue003VWXG\\\ue003PRQLWRU\ue00c \ue003EHIRUH\ue003HQUROOLQJ\ue003WKH\ue003SDWLHQW\ue011\ue003 3URWRFRO\ue00302\ue015\ue015\ue013\ue01c\ue01a\ue003Y4.0\ue003\ue003\ue003\ue003\ue003\ue003\ue003 18 August 2014\ue003 3DJH\ue003\ue018\ue016\ue003 7KH\ue003 LQYHVWLJDWRU\ue003 VLWH\ue003 ZLOO\ue003 EH\ue003 SURYLGHG\ue003 ZLWK\ue003 D\ue003 XQLTXH\ue003 WULDO\ue003 SDWLHQW\ue003 LGHQWLILFDWLRQ\ue003 QXPEHU\ue003 YLD\ue003 WKH\ue003 H&5)\ue00f\ue003 DW\ue003 WKH\ue003 WLPH\ue003 RI\ue003 LQGLYLGXDO\ue003 SDWLHQW\ue003 HQUROPHQW\ue011\ue003 7KH\ue003 SDWLHQW\ue003 QXPEHUV\ue003 ZLOO\ue003 EH\ue003 DOORFDWHG\ue003 VHTXHQWLDOO\\\ue003 LQ\ue003 WKH\ue003 RUGHU\ue003 LQ\ue003 ZKLFK\ue003 WKH\ue003 SDWLHQWV\ue003 DUH\ue003 HQUROOHG\ue011\ue003 7KH\ue003 LQYHVWLJDWRU\ue003 RU\ue003 GHVLJQHH\ue003 ZLOO\ue003 XVH\ue003 WKH\ue003 ,:56\ue012,956\ue003 WR\ue003 UDQGRPL]H\ue003 WKH\ue003 SDWLHQW\ue003 LQWR\ue003WKH\ue003WULDO\ue003DQG\ue003ZLOO\ue003HQWHU\ue003HQUROOPHQW\ue003GDWD\ue003LQWR\ue003WKH\ue003H&5)\ue011\ue003 $\ue003 3DWLHQW\ue003 (QUROOPHQW\ue003 DQG\ue003 ,GHQWLILFDWLRQ\ue003 &RGH\ue003 /LVW\ue003 PXVW\ue003 EH\ue003 PDLQWDLQHG\ue003 E\\\ue003 WKH\ue003 LQYHVWLJDWRU\ue011\ue003 (OLJLEOH\ue003SDWLHQWV\ue003 ZLOO\ue003EH\ue003 UDQGRPO\\\ue003 DVVLJQHG\ue003 WR\ue003WUHDWPHQW\ue003 JURXSV\ue011\ue003 \ue0035DQGRPL]DWLRQ\ue003 ZLOO\ue003 EH\ue003 SHUIRUPHG\ue003 WKURXJK\ue003 D\ue003 FHQWUDO\ue003 VWUDWLILHG\ue003 EORFN\ue003 UDQGRPL]DWLRQ\ue003SURFHVV\ue003 XVLQJ\ue003 WKH\ue003IROORZLQJ\ue003VWUDWLILFDWLRQ\ue003IDFWRUV\ue01d\ue003\ue003 x\ue003 7\\SH\ue003RI\ue003SODQQHG\ue003\ue015QG\ue010OLQH\ue003WUHDWPHQW\ue003\ue00bHUORWLQLE\ue003YV\ue011\ue003GRFHWD[HO\ue003YV\ue011\ue003SHPHWUH[HG\ue00c \ue003 x\ue003 1XPEHU\ue003RI\ue003F\\FOHV\ue003RI\ue003EHYDFL]XPDE\ue003PDLQWHQDQFH\ue003WUHDWPHQW\ue003SULRU\ue003WR\ue0033'\ue014\ue003 \u0094\ue003\ue019\ue003YV\ue011\ue003 !\ue003\ue019 \ue003 x\ue003 6PRNLQJ\ue003VWDWXV\ue003 \ue00bQHYHU\ue003YV\ue011\ue003IRUPHU\ue003YV\ue011\ue003FXUUHQW\ue00c \ue003"
    },
    {
        "anchor": "Experiments were performed in duplicate.",
        "positive": "The experiments were replicated twice.",
        "negative": "In vitro proliferation assays\nFor single-agent experiments evaluating DCA, cisplatin, and docetaxel, cells were seeded in duplicate at 5,000 to 10,000 cells per well in a 24-well plate."
    },
    {
        "anchor": "The results of this trial could demonstrate a beneficial immune related effect and suggest low dose radiation to be a complementary neoadjuvant component of immunotherapy prior to surgery in operable NSCLC with only mild side effects in future.",
        "positive": "This trial may show a beneficial immune-related effect and suggest that low-dose radiation could be a useful addition to immunotherapy before surgery in operable NSCLC, with minimal side effects.",
        "negative": "Discussion\nNon-small cell lung cancer (NSCLC) has still a poor prognosis."
    },
    {
        "anchor": "Supplementary data\nSupplementary data related to this article can be found at (<https://doi.org/10.1016/j.eclinm.2023.102106>)https://doi.",
        "positive": "The supplementary data for this article can be found at <https://doi.org/10.1016/j.eclinm.2023.102106>https://doi.",
        "negative": "Efficacy\nAll treated patients were evaluable for efficacy."
    },
    {
        "anchor": "3Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.",
        "positive": "Department of Geriatric Hematology at the Chinese PLA General Hospital in Beijing, China.",
        "negative": "Author details\n1Department of Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, No."
    },
    {
        "anchor": "However, if local policies did not permit submission of a tissue block, 10 serial unstained sections could be submitted.",
        "positive": "In cases where local policies prohibit the submission of a tissue block, 10 unstained sections can be submitted as an alternative.",
        "negative": "Sections measuring 5 lm in thickness were placed on frosted glass slides, and in situ quantification was performed by the automated quantitative analysis method (PM-2000 [version 1]; HistoRx Inc, New Haven, CT) as previously described.9,16,18 The primary antibody for the detection of ERCC1 was clone 8F1 (product code NB500-704, lots G412 and H347 from Novus Biologicals [Littleton, Colo]), and the antiserum for RRM1 was R1AS-6 (generated in a rabbit in 2003 against a keyhole limpet hemocyanin [KLH]-conjugated 21-aminoacid peptide specific to the N-terminal of RRM1, column purification lot 09-2008)."
    },
    {
        "anchor": "Detectable METex14 is defined by a minimum variant supporting read value of 3.",
        "positive": "A minimum variant supporting read value of 3 or higher is required to detect METex14.",
        "negative": "Procedures\nPlasma samples were prospectively collected at baseline and at each tumour evaluation visit (every 6 weeks within 1 year of the first dose, and every 12 weeks thereafter) until end of treatment."
    },
    {
        "anchor": "Cox proportional hazard multivariate analysis based on progression-free survival (A) and overall survival (B).",
        "positive": "A Cox proportional hazard multivariate analysis was conducted to examine the relationship between progression-free survival and overall survival.",
        "negative": "Table 2 Hematologic and Nonhematologic Toxicity Note: There were three grade 5 events in patients receiving sunitinib (one pulmonary hemorrhage, one other pulmonary event, and one death not associated with a Common Terminology Criteria for Adverse Events term)."
    },
    {
        "anchor": "AUTHOR CONTRIBUTIONS\nXQ, HX, and LJ contributed to the conception and design of the study.",
        "positive": "XQ, HX, and LJ contributed to the design and conception of the study.",
        "negative": "Safety\nMedian duration of treatment was 13.8 months (range, 0.4\u201319.3 months) in the TKI-naive cohort."
    },
    {
        "anchor": "systemic infections), subjects may be given intravenous immunoglobulin (IVIG) by established clinical dosing guidelines to restore normal levels of serum immunoglobulin levels.",
        "positive": "If patients develop systemic infections, they may receive IVIG according to established clinical guidelines to restore normal serum immunoglobulin levels.",
        "negative": "Study Design\nThis was a phase III, multicenter, randomized, open-label trial undertaken in 10 centers in China (ClinicalTrials.gov identifier: NCT01887795)."
    },
    {
        "anchor": "Correspondence\nKailin Xu, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, 99th West Huaihai Road, Xuzhou, Jiangsu 221002, China.",
        "positive": "Correspondence can be directed to Kailin Xu at the Department of Hematology at the Affiliated Hospital of Xuzhou Medical University.",
        "negative": "Construction of tebotelimab\nTebotelimab is a cynomolgus monkey, cross-reactive, Fc-bearing (IgG4) DART molecule comprising bispecificity for two checkpoint molecules, PD-1 (CD279) and LAG-3 (CD223)."
    },
    {
        "anchor": "Consent to participate Written informed consent was obtained from each patient in all studies included in this manuscript prior to participation.",
        "positive": "Informed consent was obtained from each patient before participating in all studies included in this manuscript.",
        "negative": "Declarations\nFunding This analysis was funded by Clovis Oncology, Inc."
    },
    {
        "anchor": "(Continued) Patient-reported outcome analyses included all randomized patients who received at least 1 dose of study drug and completed at least 1 HRQoL assessment.",
        "positive": "Patient-reported outcome analyses were conducted for all randomized patients who received at least one dose of study medication and completed at least one HRQoL assessment.",
        "negative": "Statistical Analyses\nFor the study primary endpoint analyses, the study had 85% power to detect an HR of 0.65 for disease progression or death, with a 1-sided \u03b1 of 0.025 (based on 215 PFS events)."
    },
    {
        "anchor": "If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.",
        "positive": "If the material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.",
        "negative": "Title: Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience\n\nAbstract: \n\nDate and Time: 2020-11-05"
    },
    {
        "anchor": "The two definitions coincide when the efficacy curve is monotone or has an umbrella shape, while multiple optimal doses may satisfy the second definition for a dose\u2013efficacy curve with a plateau.",
        "positive": "The definitions converge when the efficacy curve is either monotonic or has a plateau, allowing for multiple optimal doses in the latter case.",
        "negative": "Probability model\nConsider a phase I/II trial with J dose levels, let pTj and pEj denote the toxicity and efficacy probabilities at dose level j respectively, for j = 1, ..., J ."
    },
    {
        "anchor": "2School of Life Science, East China Normal University, Shanghai, China.",
        "positive": "School of Life Sciences, East China Normal University, Shanghai, China.",
        "negative": "5 Department of Emergency Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."
    },
    {
        "anchor": "BCMA expression did not appear to correlate with clinical response.",
        "positive": "There was no apparent correlation between BCMA expression and clinical response.",
        "negative": "BCMA expression and clinical response\nFig."
    },
    {
        "anchor": "B) Peak concentrations (median and interquartile range) of serum IL-6, IFN-\u03b3, ferritin, and CRP after CAR-T cell infusion in patients with sCRS, with mild CRS (signs and symptoms of CRS, but not requiring ICU admission), and without CRS.",
        "positive": "B) Peak serum levels (median and interquartile range) of IL-6, IFN-\u03b3, ferritin, and CRP in patients with sCRS, mild CRS, and no CRS after CAR-T cell infusion.",
        "negative": "P values are shown in Table S6."
    },
    {
        "anchor": "When an eligible patient is successfully recruited, an investigator will log onto the randomisation system and enter the detailed information of the patient.",
        "positive": "Following patient enrollment, the investigator will access the randomization system and enter the patient's detailed information.",
        "negative": "Clinicians and patients are blinded to treatment allocation."
    },
    {
        "anchor": "28 of 27 March, 1997 and/ or The Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics No.",
        "positive": "28th March 1997, and/or the Act on Ensuring the Quality, Efficacy, and Safety of Pharmaceuticals, Medical Devices, and Regenerative and Cellular Therapy Products.",
        "negative": "Supplementary Information\nThe online version contains supplementary material available at (<https://doi.org/10.1186/s12885-023-11534-6>)https://doi."
    },
    {
        "anchor": "Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).",
        "positive": "Eligible researchers can submit a request outlining the research goals, relevant Amgen products and studies, desired endpoints, statistical analysis plan, data requirements, publication plan, and researcher qualifications.",
        "negative": "Amgen Data Sharing Statement\nThere is a plan to share data."
    },
    {
        "anchor": "11 Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China 12 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, P. R. China 13 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China 14 Department of Medical Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, The Third Clinical Medical College, Fujian Medical University, Xiamen, Fujian, P. R. China 15 Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China 16 Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, P. R. China 17 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China 18 Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China 19 Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China 20 Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China 21 Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China 22 Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China 23 Department of Respiratory Medicine, Shanghai Fifth\u2019 People\u2019s Hospital, Fudan University, Shanghai, P. R. China 24 Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China 25Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China 26 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China 27 Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, P. R. China 28 Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, P. R. China 29 Department of Respiratory and Critical Care Medicine, The General Hospital of the Eastern Theater Command of PLA, Nanjing, Jiangsu, P. R. China 30 Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, P. R. China 31 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China 32Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, P. R. China 33 Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, P. R. China 34 Department of Oncology, The First People\u2019s Hospital of Changzhou, Changzhou, Jiangsu, P. R. China 35 Department of Tumor Radiotherapy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, P. R. China 36 Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P. R. China 37 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, P. R. China 38 Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin, P. R. China 39 Department of Oncology, Jiangsu Taizhou People\u2019s Hospital, Taizhou, Jiangsu, P. R. China 40New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, Jiangsu, P. R. China 41Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, Jiangsu, P. R. China",
        "positive": "The participating institutions included Xuzhou Central Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University Cancer Institute and Hospital, and other institutions.",
        "negative": "Institutional review board (IRB) / research ethics board (REB)\nThe protocol (and any amendments), the informed consent form, and any other written information to be given to subjects has been reviewed and approved by the Ontario Cancer Research Ethics Board, operating in accordance with the current federal regulations."
    },
    {
        "anchor": "Competing interests\nRC and EC has served in advisory boards for Nestl\u00e8 Health Science.",
        "positive": "RC and EC have served on advisory boards for Nestl\u00e8 Health Science.",
        "negative": "Other Authors declare that they have no competing interests."
    },
    {
        "anchor": "The transformed parameters are returned as matrix with one column.",
        "positive": "The transformed parameters are returned as a single-column matrix.",
        "negative": "Note\nThe ratiotGml2 transformation object can be evaluated using the eval method by passing the data frame as an argument."
    },
    {
        "anchor": "Twelve patients (92%) died, among which 10 (83%) died from cancer progression including 9 (75%) with LM and CNS involvement progression and one (8%) with systemic disease progression.",
        "positive": "A total of 92% of patients passed away, with 83% of those deaths attributed to cancer progression, including 75% with both LM and CNS involvement and 8% with systemic disease progression.",
        "negative": "Neuro-Oncology\n23(1), 169\u2013171, 2021 | doi:10.1093/neuonc/noaa236 | Advance Access date 19 October 2020 Letter to the Editor The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy 1 2 3 4 It has been suggested that high-dose glucocorticoids might impair the efficacy of anti\u2013programmed cell death 1 (PD1)/PD ligand 1 (PDL-1) immunotherapies., However, glucocorticoid treatment is also considered one of the main treatment options for edema caused by brain metastases in non-small-cell lung cancer (NSCLC) patients.Therefore, it is important to explore new strategies for edema treatment that does not negatively impact immunotherapy efficacy in patients with edema while on treatment with immunotherapy."
    },
    {
        "anchor": "Table (<>)1 shows baseline characteristics of eligible patients who performed mediastinal sampling.",
        "positive": "The baseline characteristics of patients who underwent mediastinal sampling are displayed in Table 1.",
        "negative": "Does your paper address CONSORT subitem 6b?"
    },
    {
        "anchor": "Altogether, 47% of participants experienced an irAE; the most common were liver function test (LFT) abnormalities, adrenal insufficiency, and rash.",
        "positive": "Forty-seven percent of participants developed an immune-related adverse event, with the most frequent being liver function test abnormalities, adrenal insufficiency, and rash.",
        "negative": "2.2 Secondary Objectives\n2.2.1 Determine the neuropsychologic impact of PCI 2.2.2 Determine the impact of PCI on QOL 2.2.3 Determine the impact of PCI on the incidence of CNS metastases"
    },
    {
        "anchor": "Seventy-three patients (14%) had at least one SAE, most of which were caused by the disease progression, respiratory, thoracic and mediastinal disorders, infections or other complications.",
        "positive": "A total of 14% of patients suffered at least one severe adverse event, primarily caused by disease progression, respiratory, thoracic, and mediastinal disorders, infections, or other complications.",
        "negative": "Safety and tolerability\nSafety and tolerability data were available for 519 patients."
    },
    {
        "anchor": "All patients underwent bone marrow (BM) evaluation prior to STAR-OX40 T-cell infusion.",
        "positive": "Bone marrow evaluation was performed on all patients before STAR-OX40 T-cell infusion.",
        "negative": "2.1 | Trial design\nIn the phase I trial, 18 CD19+ R/R B-ALL patients were enrolled between December 2019 and June 2020 ((<https://clinicaltrials.gov>)https://clinicaltrials.gov, NCT03953599)."
    },
    {
        "anchor": "Body weight is shown in (C) and images of this BLI assessment are shown to demonstrate location and burden of tumors (D).",
        "positive": "The body weight is displayed in (C), and images of the BLI assessment are shown to demonstrate the location and burden of tumors (D).",
        "negative": "Vector Design\nmRNA was isolated using the RNEasy Plus Mini Kit (QIAGEN) from human peripheral blood mononuclear cells (PBMCs) to produce Figure 6."
    },
    {
        "anchor": "conducted the clinical study and provided the data.",
        "positive": "The clinical study was carried out by and the data was supplied by.",
        "negative": "Please read the following statements and mark your choice:\nI permit ACCRU to give my sample(s) to outside researchers: Yes No Please initial here: Date:"
    },
    {
        "anchor": "& Cartee, T. V. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.",
        "positive": "According to a study by & Cartee, T. V., epidermal growth factor receptor inhibition increases the expression of MHC class I and II genes.",
        "negative": "Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H. et al."
    },
    {
        "anchor": "The mean dose was from 263 Gy to 4,282 Gy, and the maximum dose was from 2,832 Gy to 7,222 Gy.",
        "positive": "The dose range was 263 Gy to 4,282 Gy, with a maximum dose of 2,832 Gy to 7,222 Gy.",
        "negative": "The dose increments of 5 Gy was used until V69 (the percentage of the esophageal volume that received a 69 Gy or greater radiation dose); a total of 14 dosimetric-volumetric parameters ranging from V5 to V69 were defined."
    },
    {
        "anchor": "There were no grade 4 or 5 TRAEs ((<>)Supplementary 4).",
        "positive": "No severe treatment-related adverse events (grade 4 or 5) were observed ((<>)Supplementary 4).",
        "negative": "Safety: Tolerability and AEs Profile\nIn 92% of the patients, an AE was reported, of which 11 grade greater than or equal to 3 AEs in five patients."
    },
    {
        "anchor": "However, in a subset of patients with fibrotic interstitial lung disease (ILD), elevated rates of SABR-related toxicity and mortality have been described.",
        "positive": "Elevated rates of SABR-related toxicity and mortality have been reported in a subset of patients with fibrotic ILD.",
        "negative": "The accrual target is 39 adult patients with T1\u2013 2N0M0 non-small cell lung cancer with co-existing ILD who are not candidates for surgical excision."
    },
    {
        "anchor": "Thus, the second of the two goals of this study was to demonstrate how we quantitatively assessed the robustness of our findings to potential sources of bias in a comprehensive and systematic fashion to act as a guide for future SCA studies using RWD,.",
        "positive": "This study aimed to demonstrate a comprehensive and systematic method for assessing the robustness of our findings to potential sources of bias, which can inform future SCA studies using real-world data.",
        "negative": "ARTICLE\nhttps://doi.org/10.1038/s41467-022-30908-1 OPEN Addressingchallengeswithreal-worldsyntheticcontrolarmstodemonstratethecomparativeeffectivenessofPralsetinibinnon-smallcelllungcancer SanjayPopat(<http://orcid.org/0000-0003-2087-4963>)(<http://orcid.org/0000-0003-2087-4963>)1,StephenV.Liu2,NicolasScheuer3,GraceG.Hsu(<http://orcid.org/0000-0001-7191-6612>)(<http://orcid.org/0000-0001-7191-6612>)4,AlexandreLockhart4,SreeramV.Ramagopalan(<http://orcid.org/0000-0002-5038-0916>)(<http://orcid.org/0000-0002-5038-0916>)5\u2709,FrankGriesinger6&VivekSubbiah(<http://orcid.org/0000-0002-6064-6837>)(<http://orcid.org/0000-0002-6064-6837>)7\u2709 Asadvancednon-smallcelllungcancer(aNSCLC)isbeingincreasinglydividedintorareoncogene-drivensubsets,conductingrandomisedtrialsbecomeschallenging.Usingreal-worlddata(RWD)toconstructcontrolarmsforsingle-armtrialsprovidesanoptionforcomparativedata.However,non-randomisedtreatmentcomparisonshavethepotentialtobebiasedandcauseconcernfordecision-makers.UsingtheexampleofpralsetinibfromaRETfusion-positiveaNSCLCsingle-armtrial(NCT03037385),wedemonstratearelativesurvivalbenefitwhencomparedtopembrolizumabmonotherapyandpembrolizumabwithchemotherapyRWDcohorts.QuantitativebiasanalysesshowthatresultsfortheRWD-trialcomparisonsarerobusttodatamissingness,potentialpooreroutcomesinRWDandresidualconfounding.Overall,thestudyprovidesevidenceinfavourofpralsetinibasafirst-linetreatmentforRETfusion-positiveaNSCLC.Thequantificationofpotentialbiasperformedinthisstudycanbeusedasatemplateforfuturestudiesofthisnature."
    },
    {
        "anchor": "Table 1 Patient and product characteristics.",
        "positive": "Table 1: Patient and product characteristics.",
        "negative": "Immunohistochemical colocalization of CD3/FoxP3 and CD8/Ki67\n(A and B) Analysis of brain tumor samples performed pre\u2013 and post\u2013CART-EGFRvIII infusion."
    },
    {
        "anchor": "The follow-up range includes all follow-up times.",
        "positive": "The study's follow-up period covers all scheduled follow-up visits.",
        "negative": "Population\nA total of 225 patients were enrolled across both studies and received alectinib 600 mg BID [(<>)13]."
    },
    {
        "anchor": "This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets the following conditions: \u2022 Either o Stopped initial treatment with pembrolizumab after attaining an investigator-determined confirmed CR according to RECIST 1.1, and \u2022 Was treated for at least 24 weeks with pembrolizumab before discontinuing therapy \u2022 Received at least two treatments with pembrolizumab beyond the date when the initial CR was declared",
        "positive": "This study offers a second course of treatment, contingent upon the study remaining open and the subject meeting specific conditions, including stopping initial treatment after achieving a confirmed CR and receiving at least 24 weeks of treatment.",
        "negative": "7.1.5.5 Second Course Phase (Retreatment Period)\nSubjects who stop pembrolizumab with SD or better may be eligible for up to one year of additional pembrolizumab therapy if they progress after stopping study treatment."
    },
    {
        "anchor": "The calibration range was 2.00\u2012500\u00a0ng/mL [lower limit of quantification (LLOQ), 2.00\u00a0ng/mL].",
        "positive": "The calibration range was 2.00 to 500\u00a0ng/mL, with a lower limit of detection of 2.00\u00a0ng/mL.",
        "negative": "Abstract\nBackground Bevacizumab is an antiangiogenic recombinant humanized monoclonal antibody that inhibits tumor growth."
    },
    {
        "anchor": "In arm 2, daily CBCT is preferred.",
        "positive": "Arm 2 prioritizes daily CBCT imaging.",
        "negative": "Panel recommendations\n\u25ba The panel did not make any recommendations regarding the use of vaccines in myeloma."
    },
    {
        "anchor": "CD169-Cre mice were a gift from Paul Frenette.",
        "positive": "Paul Frenette generously donated CD169-Cre mice for this study.",
        "negative": "EFFICACY\nThe overall response rate based on the standard criteria30,33 was 71% (2 complete responses and 34 partial responses) in the 420-mg cohort and 71% (24 partial responses) in the 840-mg cohort."
    },
    {
        "anchor": "Additional Treatment Infusions:\n1.",
        "positive": "One additional treatment infusion is available.",
        "negative": "\ue019\ue011\ue014\ue011\ue014\ue011\ue015\ue003 +\\SHUWHQVLRQ\ue003\n3DWLHQWV\ue003PXVW\ue003EH\ue003 FORVHO\\\ue003 PRQLWRUHG\ue003RQ\ue003 WULDO\ue003IRU\ue003WKH\ue003GHYHORSPHQW\ue003RU\ue003 ZRUVHQLQJ\ue003 RI\ue003 K\\SHUWHQVLRQ\ue011\ue003 %ORRG\ue003 SUHVVXUH\ue003 PHDVXUHPHQWV\ue003 VKRXOG\ue003 RFFXU\ue003 DIWHU\ue003 WKH\ue003 SDWLHQW\ue003 KDV\ue003 been in a resting position for \u0095\ue003\ue018\ue003minutes."
    },
    {
        "anchor": "Furthermore, improved and uniform definitions of patients who may or may not be suitable for surgery will be essential in this setting.",
        "positive": "Defining patients who are or are not suitable for surgery will be crucial in this context.",
        "negative": "Conclusions\nIn the PACIFIC trial, treatment benefit was observed with durvalumab versus placebo in patients with stage IIIA-N2, unresectable NSCLC."
    },
    {
        "anchor": "End Points and Assessments\nThe primary efficacy end point was OS in current smokers.",
        "positive": "Overall survival was the primary outcome measure for smokers who were still smoking.",
        "negative": "Clinical assessments including radiographic tumor assessments were conducted at baseline, before treatment on cycle 3 day 1 and cycle 5 day 1, every 6 weeks until 1 year after beginning treatment, and then every 12 weeks until radiographic progression, additional cancer treatment, or death."
    },
    {
        "anchor": "HHS Public Access\nAuthor manuscript JAMA Oncol.",
        "positive": "A study published in the Journal of the American Medical Association's Oncology section.",
        "negative": "Patients and Treatment\nOverall, 427 patients were enrolled from February 2016 through November 2016, and 288 patients (67%) were treated."
    },
    {
        "anchor": "Overall, we found that the safety profile of necitumumab plus gemcitabine and cisplatin was acceptable and in line with expectations.",
        "positive": "The safety profile of necitumumab plus gemcitabine and cisplatin was found to be acceptable and consistent with expectations.",
        "negative": "Study assessments\nTumor assessments were performed before treatment with sintilimab and docetaxel."
    },
    {
        "anchor": "In this 3 + 3 study design, assessment of safety was conducted by a safety review committee (SRC) after the first 3 patients in a cohort completed 1 cycle of therapy.",
        "positive": "A safety review committee assessed the safety of patients after the first three patients in each cohort completed one cycle of treatment.",
        "negative": "If 1 of 3 patients experienced a DLT, \u2265 3 additional patients could be added to the dose level."
    },
    {
        "anchor": "Resected tissues were CHCP treated ex vivo.",
        "positive": "Tissues resected during surgery underwent a chemical treatment process outside the body.",
        "negative": "efficacy\nIn all treated patients, 24 died or had disease progression."
    },
    {
        "anchor": "Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor\u2010resistant disease.",
        "positive": "Research on epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease was conducted by Ohashi et al.",
        "negative": "3.2.3 | \u201cOther tumors\u201d group\nAll patients in the \u201cother tumors\u201d group were evaluable for response (Table 2), and the ORR was 11.8% (95% CI, 1.5\u201336.4)."
    },
    {
        "anchor": "We will collect pilot data related to the collaborative, patient-oriented approach facilitated by this decision aid.",
        "positive": "We will collect data on the patient-centered approach facilitated by this decision-making tool.",
        "negative": "Discussion\nTo our knowledge, the phase II BRAIN study represents the first prospective study of bevacizumab in patients with nonsquamous NSCLC and untreated brain metastases."
    },
    {
        "anchor": "Mutational analysis of the MET SEMA domain identified residues 89\u2013162 in blade 2 as the epitope for Hu9338 and residues 171\u2013233 in blade 3 as the epitope for Hu9006.",
        "positive": "The MET SEMA domain was analyzed for mutations, identifying specific residues as the epitope for Hu9338 and Hu9006.",
        "negative": "Data availability statement\nThe original contributions presented in the study are included in the article/supplementary material."
    },
    {
        "anchor": "The IPCW estimate of the OS HR was 0.571 (95% CI: 0.413, 0.802).",
        "positive": "The estimated hazard ratio for overall survival was 0.571, with a 95% confidence interval of 0.413 to 0.802.",
        "negative": "Statistical analysis\nBased on the Cox proportional hazards model and taking into account the influence of sex (male or female), Eastern Cooperative Oncology Group (ECOG) performance status score, hazard ratio, and 95% confidence interval (CI) were calculated in the full analysis population."
    },
    {
        "anchor": "White blood cell count reduction (16.7%, n = 2) and neutrophil count reduction (10.0%, n = 4) were the most frequent grade \u2265 3 immune-related adverse events among the 12 patients receiving N and the 40 patients receiving N/C, respectively.",
        "positive": "The most common grade 3 or higher immune-related adverse events were white blood cell count reduction and neutrophil count reduction.",
        "negative": "Safety\nOverall, adverse events were manageable, without new concerns of safety in comparison to the known safety profiles for neoadjuvant nivolumab monotherapy and nivolumab plus chemotherapy."
    },
    {
        "anchor": "Correspondence\nCaicun Zhou, Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No.",
        "positive": "Correspondence details for Caicun Zhou can be found at the Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine.",
        "negative": "Email: (<mailto:caicunzhou_dr@163.com>)caicunzhou_dr@163.com #These authors contributed equally to this work."
    },
    {
        "anchor": "Fourteen patients received 3 infusions, and 5 patients received 2 infusions of huCART-19 ((<>)Table 2).",
        "positive": "A total of 19 patients received either 2 or 3 infusions of huCART-19, as outlined in Table 2.",
        "negative": "Background\nLung cancer is the leading cause of cancer-related death in the UK with a five-year overall survival rate only in the region of 16% [(<>)1]."
    },
    {
        "anchor": "PK analyses were performed on all patients in the safety population who had $ 1PK concentration.",
        "positive": "PK assessments were carried out on all patients in the safety population who had measurable PK levels.",
        "negative": "Heather A. Wakelee, MD [co-chair],\nStanford Cancer Institute, Stanford, California, USA, CA180816"
    },
    {
        "anchor": "Axitinib dose could be increased step-wise to 7 mg bid, and then to a maximum of 10 mg bid, in patients who tolerated axitinib with no treatment-related CTCAE Grade \u22653AEs for \u22652 weeks, unless BP was greater than 150/90 mmHg or patient was taking antihypertensive medication.",
        "positive": "Patients who tolerated axitinib without severe side effects could have their dose increased to 7 mg twice daily, and then to a maximum of 10 mg twice daily, unless they had hypertension or were taking antihypertensive medication.",
        "negative": "Introduction\nMultiple myeloma is a hematologic malignancy of bone marrow plasma cells, which are immunoglobulin-secreting B-lineage cells."
    },
    {
        "anchor": "CRS grade and use of anticytokine therapy or corticosteroids were also obtained.",
        "positive": "The study collected data on CRS grade and the use of anticytokine therapy or corticosteroids.",
        "negative": "Data source\nFor the present retrospective analysis, NT patient-level data from case report forms were collected for the JULIET trial for the 9-month data cutoff of December 2017."
    },
    {
        "anchor": "\u2022 Concomitant administration (schema 2): SBRT (3 fractions of 8 Gy in 5 days) starting on week 1, with the first injection of atezolizumab + tiragolumab concomitant to the first radiotherapy fraction, then every 21 days.",
        "positive": "Schema 2 involved administering SBRT in three fractions over 5 days, starting on week 1, with the first injection of atezolizumab and tiragolumab given concurrently with the first radiotherapy fraction, and then every 21 days.",
        "negative": "This dose regimen was used in the CITYSCAPE trial that assessed the atezolizumab and tiragolumab combination in metastatic NSCLC [(<>)14, (<>)15]."
    },
    {
        "anchor": "This work was also supported by the National Cancer Institute of the NIH under award numbers R01CA170820, R01EB017206, P01CA132681, and F31CA200242 and the National Nature Science Foundation of China under award number 81620108023.",
        "positive": "This research was also funded by the National Cancer Institute of the NIH, with grant numbers R01CA170820, R01EB017206, P01CA132681, and F31CA200242, as well as the National Nature Science Foundation of China, with grant number 81620108023.",
        "negative": "ACKNOWLEDGMENTS\nWe thank the patients who participated in this study and their families, as well as the study staff and health care providers at The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine."
    },
    {
        "anchor": "(C) B-cell depletion and rapid recovery in peripheral blood in responding patients (n=14).",
        "positive": "Responding patients showed a marked decrease in B-cell levels in the peripheral blood, followed by a rapid increase in B-cell counts (n=14).",
        "negative": "Data Collection\nEthical approval from the 2 hospitals involved in the study and The Hong Kong Polytechnic University\u2019s ethics committee was obtained before data collection."
    },
    {
        "anchor": "See rights and permissions.",
        "positive": "Please refer to the relevant documentation for information on rights and permissions.",
        "negative": "Background\nThe evidence base regarding the most effective approach and model for providing community-based palliative care (PC) for patients with advanced, serious illnesses continues to evolve."
    },
    {
        "anchor": "Nine rociletinib-treated patients (12.0%) experienced a QTc prolongation of greater than or equal to 501 msec using the Fridericia correction method.",
        "positive": "A total of 12.0% of patients treated with rociletinib experienced a QTc prolongation of 501 msec or more, as measured using the Fridericia correction method.",
        "negative": "Title: A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "I also agree to handle all clinical supplies provided by the Sponsor and collect and handle all clinical specimens in accordance with the protocol.",
        "positive": "I consent to manage all clinical supplies provided by the Sponsor and handle clinical specimens in accordance with the study protocol.",
        "negative": "13.2 Investigator\nI agree to conduct this clinical trial in accordance with the design outlined in this protocol and to abide by all provisions of this protocol (including other manuals and documents referenced from this protocol)."
    },
    {
        "anchor": "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.",
        "positive": "The CheckMate 067 trial: a four-year analysis of the effectiveness of nivolumab and ipilimumab, either separately or together, in treating advanced melanoma patients.",
        "negative": "Combination of CTLA-4 and PD-1 blockers for treatment of cancer."
    },
    {
        "anchor": "As a negative control, DCs were loaded with human IgG (Endobulin, Baxter, Unterschleissheim, Germany), which was considered as nonspecific background.",
        "positive": "DCs were loaded with human IgG from Endobulin, Germany, to serve as a control group with no specific biological activity.",
        "negative": "IFN-g ELISPOT assay\n11 ELISPOT assays were performed as described previouslywith a few modifications."
    },
    {
        "anchor": "This dose maximises free sPD-L1 inhibition, has a manageable safety profile, and incorporates a biologically active dose of tremelimumab that is associated with antitumour activity, including in patients with PD-L1\u2212 tumours.",
        "positive": "This dose of treatment optimizes the inhibition of sPD-L1, has a tolerable safety profile, and includes a biologically effective dose of tremelimumab, which has been shown to be effective in patients with PD-L1-negative tumours.",
        "negative": "Discussion\nIn this study, the MTD was exceeded at D20 q4w/T3."
    },
    {
        "anchor": "The 4-1BB CAR consisted of anti-CD19 scFv FMC63, a CD8a hinge, a TM domain, and 4-1BB and CD3z cytoplasmic domains.",
        "positive": "The 4-1BB CAR consisted of FMC63 anti-CD19 scFv, a CD8a hinge, a transmembrane domain, and 4-1BB and CD3z cytoplasmic domains.",
        "negative": "Anti-CD19 CAR T-cell manufacture\nCAR T cells were manufactured by using peripheral blood mononuclear cells (PBMCs) collected by leukapheresis."
    },
    {
        "anchor": "The CT elements of SPECT/CT pre-and post-treatment images were rigidly co-registered to planning 4DCT average intensity projection images in MIM 6.8\u2122 (MIM Software Inc., Cleveland, OH) using mutual information.",
        "positive": "Pre- and post-treatment SPECT/CT images were precisely aligned with planning 4DCT images using MIM 6.8 software, based on mutual information.",
        "negative": "2.2 Image acquisition and processing\nPatients underwent pre-treatment [99mTc] MAA perfusion SPECT/CT on a Precedence (Philips Healthcare, Cleveland, OH) 16-slice CT scanner with a dual-head gamma camera to extract candidate radiomic predictors of pneumonitis."
    },
    {
        "anchor": "Medical writing support was funded by Amgen Inc.",
        "positive": "Medical writing assistance was sponsored by Amgen Inc.",
        "negative": "Supplementary Data\nNote: To access the supplementary material accompanying this article, visit the online version of the JTO Clinical and Research Reports at (<http://www.jtocrr.org>)www.jtocrr.org and at (<https://doi.org/10.1016/j.jtocrr.2022.100461>)10.1016/j.jtocrr.2022.100461."
    },
    {
        "anchor": "Activation by the ligand, hepatocyte growth factor (HGF), induces MET receptor dimerization and phosphorylation of tyrosine residues in the cytoplasmic tail of the receptor that engages with intracellular signaling pathways [(<>)3, (<>)4].",
        "positive": "HGF binding to the MET receptor causes receptor dimerization and phosphorylation, leading to the activation of downstream signaling pathways.",
        "negative": "2.1 Primary Objective\nTo evaluate the pathological complete response (pCR) rate of neoadjuvant camrelizumab in combination with chemotherapy (nab-paclitaxel plus cisplatin/carboplatin/nedaplatin) in resectable NSCLC."
    },
    {
        "anchor": "This consensus statement is intended to provide guidance and is not a substitute for the professional judgment of individual treating physicians.",
        "positive": "This consensus statement aims to offer guidance, but it is not intended to replace the professional expertise of individual treating physicians.",
        "negative": "Stability\nDuring method development, the sponsor should determine the chemical stability of the analyte in a given matrix, including the effects of sample collection, handling, and storage of the analyte."
    },
    {
        "anchor": "Durham AL, Adcock IM.",
        "positive": "Durham and Adcock.",
        "negative": "Received: 13 August 2020 Accepted: 9 November 2020\nReferences 1."
    },
    {
        "anchor": "Patients in the chemotherapy group received up to four cycles of gemcitabine plus carboplatin (gemcit-abine 1000mg/m\u00b2 intravenous on days 1 and 8, carbo-platin (area under the curve=5) intravenous on day 1 of a 3-week cycle) and cisplatin (gemcitabine 1250mg/m\u00b2 intravenous on days 1 and 8, cisplatin 75 mg/m\u00b2 intravenous on day 1 of a 3-week cycle) in the OPTIMAL trial and ENSURE trial, respectively.",
        "positive": "Patients in the chemotherapy group received a regimen of gemcitabine, carboplatin, and cisplatin, with a maximum of four cycles.",
        "negative": "the treatments\nPatients in the erlotinib group received oral erlotinib (150 mg/day) until disease progression or unacceptable toxicity."
    },
    {
        "anchor": "[PubMed: 20367572] 70.",
        "positive": "[Reference: 20367572, page 70]",
        "negative": "Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al."
    },
    {
        "anchor": "Motion management\nMotion assessment is mandatory.",
        "positive": "Motion assessment is a compulsory component of motion management.",
        "negative": "Dose Rationale\nBased on the clinical experience with adult ALL patients treated with CART19 as part of the UPenn protocol UPCC21413 and UPCC04409, subjects will receive 1-5x108 CART22 cells as a 10%, 30% and 60% fraction administered over 3 days."
    },
    {
        "anchor": "Quality of life (QoL) also needs to be assessed in these trials, especially in patients who demonstrate a response on the physical function assessment.",
        "positive": "Quality of life assessment is necessary in these trials, especially for patients who exhibit a physical function response.",
        "negative": "Crystal L. Mackall\nStock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Apricity Health Consulting or Advisory Role: Bryology, Vor Biopharma, Apricity Health, TPG, Alimera Sciences, PACT Pharma, Nektar, Lyell Immunopharma, NeoImmuneTech Patents, Royalties, Other Intellectual Property: I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics."
    },
    {
        "anchor": "x Optional FLT-PET Scan (Refer to Section 9) o A pregnancy test will be conducted before the scan for women of child-bearing potential.",
        "positive": "An optional FLT-PET scan is available, and a pregnancy test will be performed before the scan for women of child-bearing age.",
        "negative": "PRETREATMENT EVALUATIONS/MANAGEMENT\nBaseline studies include the following minimum diagnostic workup, which is standard-of-care: x History/physical examination, including vital signs with weight, blood pressure, heart rate, oxygen saturation, documentation of smoking history, alcohol use, acid reflux, and pre-chemotherapy laboratory tests as per standard-of-care within 30 days prior to registration; x FDG-PET scan for staging within 90 days prior to registration."
    },
    {
        "anchor": "Data regarding the influence of alectinib on body composition will also be collected as exploratory objective, as weight gain is a known but not well understood side-effect.",
        "positive": "The impact of alectinib on body composition will be investigated as an exploratory objective, as weight gain is a recognized but poorly understood side effect.",
        "negative": "2.1 Aim and objectives\nThe aim of this RCT is to investigate the effect of TDM-guided dosing of alectinib on treatment outcomes of patients with ALK+ NSCLC."
    },
    {
        "anchor": "The peak levels of interleukin-6 increased with severity of CRS (Additional file (<>)6).",
        "positive": "Interleukin-6 levels peaked with increasing severity of CRS, as shown in Additional file 6.",
        "negative": "Ethics statement\nThe studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Soochow University."
    },
    {
        "anchor": "Adverse events (AEs) should be treated with the appropriate maximum supportive care and dose reductions will be documented.",
        "positive": "Adverse events will be treated with optimal supportive care, and dose reductions will be documented.",
        "negative": "A number of studies compared Metformin to placebo."
    },
    {
        "anchor": "Percent survival post-treatment was determined using the Kaplan-Meier survival curve in GraphPad Prism.",
        "positive": "Post-treatment survival rates were calculated using the Kaplan-Meier survival curve in GraphPad Prism.",
        "negative": "In vivo mouse models\nCT26 cells in serum-free phosphate-buffered saline (PBS) were inoculated in the right flank at 2.5\u00d7105 cells per implant and allowed to grow for 14 days."
    },
    {
        "anchor": "Expression of surface markers was evaluated by percentage of positive cells and median fluorescence intensity (MFI) using fluorescence minus one (FMO) controls.",
        "positive": "Surface marker expression was evaluated by analyzing the percentage of positive cells and median fluorescence intensity, with FMO controls used as a reference.",
        "negative": "2.3 Immunophenotyping of PBMCs\nCryopreserved pretreatment and posttreatment PBMCs were thawed in parallel, washed with 5% FBS in 1\u00d7 PBS, and surface stained with CD3-PerCP (clone BW264/56), CD4-Viogreen (clone REA623), CD8-APCVio770 (clone BW135/80), CD14-APC (clone T\u00fck4), CD16-Viogreen (clone REA423), CD19-FITC (clone LT19), CD56APCVio770 (clone REA196), CD69-FITC (clone REA824), CD107a-FITC (clone H4A3), CTLA4-PE (clone BNI3), PD1-PEVio770 (clone PD1.3.1.3), NKG2D-PE (clone REA797), NKp44-PEVio770 (clone 2.29) from Miltenyi 28 Biotec (Germany) and CD25-PeCy7 (clone M-A251) from BD Bioscience (NJ, USA)."
    },
    {
        "anchor": "Elevated levels of CD11b+ MDSCs or CD163+ TAMs in the TME are associated with poor prognosis in patients with prostate cancer.",
        "positive": "In patients with prostate cancer, high levels of CD11b+ MDSCs or CD163+ TAMs in the tumor microenvironment are linked to a poor outcome.",
        "negative": "Prostate, colorectal, gastric, and esophageal cancers\n3 13 3 16 77 88 16 Although GB1275 has not been assessed to date in animal models of prostate, colorectal, gastric, or esophageal cancers, there is a strong rationale for its investigation in these tumor types."
    },
    {
        "anchor": "Cells were counted every 24 h over the 72-h period of OTX015 exposure as well as during the 72 h after drug washout.",
        "positive": "Cell counts were taken every 24 hours during the 72-hour period of OTX015 treatment and continued for 72 hours after treatment ended.",
        "negative": "OTX015 antiproliferative activity in TNBC cell lines\nThree TNBC-derived cell lines were selected: HCC1937, MDA-MB-231 and MDA-MB-468, which present different alterations in the PTEN, BRCA1 and TP53 genes [24] (Table 1)."
    },
    {
        "anchor": "All entries will be entered into an electronic data capture system (EDC).",
        "positive": "The data will be captured electronically and stored in a centralized system.",
        "negative": "Case Report Forms\nThe study case report form (CRF) is the primary data collection instrument for the study."
    },
    {
        "anchor": "[PubMed: 24055823] 12.",
        "positive": "A study published in PubMed (reference number 24055823) found that...",
        "negative": "Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children\u2019s oncology group."
    },
    {
        "anchor": "Seven (5.8%) patients experienced a fatal SAE, none of which were treatment related.",
        "positive": "Seven patients (5.8%) suffered a fatal adverse event, and none of these events were treatment-related.",
        "negative": "Safety\nAEs, regardless of study drug relationship, were observed in 132 (98.5%) and 120 (99.2%) patients in the single- agent and combination groups, respectively, and were comparable between treatment arms."
    },
    {
        "anchor": "7.1 General Design\nThis is an open label, phase 1 study to evaluate the safety and tolerability, and persistence and engraftment of autologous T cells engineered to express a chimeric antigen receptor targeting EGFRvIII, that is linked to the CD3\u03b6-4-1BB signaling chains in patients with newly diagnosed EGFRvIII+ GBM.",
        "positive": "The study design is an open-label, phase 1 trial aimed at assessing the safety, tolerability, persistence, and engraftment of autologous T cells engineered to target EGFRvIII in patients with newly diagnosed EGFRvIII-positive glioblastoma.",
        "negative": "DISCUSSION\nWe previously investigated the therapeutic effect of FAP-specific, redirected T cells as an option for treatment of MPM (9,11)."
    },
    {
        "anchor": "Radiographic assessments were done to evaluate tumor response every two cycles according to RECIST criteria.",
        "positive": "Radiological assessments were performed every two cycles to assess tumor response according to RECIST guidelines.",
        "negative": "Patients evaluation\nThis was a multi-center, prospective, noncomparative study to determine whether apatinib administered in combination with docetaxel played a vital in patients with advanced NSCLC after first- or second-line chemotherapy failure."
    },
    {
        "anchor": "Shipment labels will be provided within 5 business days.",
        "positive": "Labels for shipping will be available within five business days.",
        "negative": "Group C.\nIn this observational group, patients will not be allocated to a treatment and will be managed by the investigator or healthcare professional responsible for their care, in accordance with local practice guidelines."
    },
    {
        "anchor": "Statistical Analysis\nA minimum of 75 PFS events was required to provide adequate precision in the hazard ratio (HR) estimate.",
        "positive": "A minimum of 75 patient follow-up events was needed to ensure accurate estimation of the hazard ratio.",
        "negative": "OS was analyzed using the date of the 90th survival event as the cutoff to better estimate the effect of adding linifanib to carboplatin-paclitaxel."
    },
    {
        "anchor": "High incidence of false-positive PET scans in patients with aggressive non-Hodgkin\u2019s lymphoma treated with rituximab-containing regimens.",
        "positive": "A high proportion of patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens experienced false-positive PET scans.",
        "negative": "Background\nMolecular targeted therapies (e.g., tyrosine kinase inhibitors [TKIs]), have achieved clinical successes when directed against strong oncogenic drivers, such as ana-plastic lymphoma kinase (ALK) rearrangement and epidermal growth factor receptor (EGFR) mutation."
    },
    {
        "anchor": "chemotherapy, targeted therapy, immunotherapy) is at the discretion of the treating oncologists.",
        "positive": "Oncologists have the autonomy to decide on the use of chemotherapy, targeted therapy, or immunotherapy.",
        "negative": "9.0 FOLLOW-UP EVALUATION AND ASSESSMENT OF EFFICACY\nPatients will be seen at 2 weeks post radiotherapy."
    },
    {
        "anchor": "However, their possible contribution and a way of monitoring their biological effects have yet to be revealed.",
        "positive": "The impact and monitoring of their biological effects are yet to be explored.",
        "negative": "CLInICaL Case RepoRT\nCancer Biology & Therapy 15:3, 266\u2013270; March 2014; \u00a9 2014 Landes Bioscience Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy Gabriele Gamerith1,*, Thomas auer2 , arno amann1 , Daniel putzer2 , Bettina schenk3, Brigitte Kircher1, Wolfgang Hilbe1 ,  Heinz Zwierzina1, and Judith Loeffler-Ragg4 Abbreviations: IMiDs, immunomodulatory drugs; NK cells, natural killer cells; FDG-PET, [F-18]2-deoxy-2-fluoro-d-glucose positron emission tomography; ADCC, antibody-dependent cellular cytotoxicity The failure of eGFR inhibitors in colorectal tumors with KRas mutations requires the development of alternative treatment strategies for this patient subgroup."
    },
    {
        "anchor": "Pollak M: Targeting insulin and insulin-like growth factor signalling in oncology.",
        "positive": "Pollak M's work explores the concept of targeting insulin and insulin-like growth factor signaling in oncology.",
        "negative": "KEY POINTS\nQUESTION: Is it feasible to image CD81 leukocytes in patients with cancer using 89Zr-IAB22M2C PET/CT?"
    },
    {
        "anchor": "Safety evaluation\nTEAEs were recorded and graded using the CTCAE 5.0 criteria.",
        "positive": "Adverse events were documented and assessed according to the CTCAE 5.0 guidelines.",
        "negative": "Title: Overcoming Barriers to T Cell Therapy Against AML with Dual Costimulatory Receptors\n\nAbstract: Acute myeloid leukemia (AML) is a rapidly progressing and highly fatal disease, with only 27% of patients surviving 5 years after diagnosis."
    },
    {
        "anchor": "At the time of written informed consent, patients identified a caregiver; only one caregiver was enrolled per study patient.",
        "positive": "When patients provided written informed consent, they designated a caregiver, with only one caregiver per patient participating in the study.",
        "negative": "Participants\nPatients were eligible to participate if they were within 8 weeks of being informed of their diagnosis of incurable lung (nonsmall cell, small cell, or mesothelioma) or gastrointestinal (hepatobiliary, esophageal, gastric) cancer being treated with noncurative intent at the institution."
    },
    {
        "anchor": "We thank Raj Bhardwaj (Certara Strategic Consulting, Parsippany, New Jersey) for assistance with PK data analysis.",
        "positive": "We acknowledge the support of Raj Bhardwaj from Certara Strategic Consulting in New Jersey for his help with PK data analysis.",
        "negative": "Acknowledgements\nWe thank the patients and their families and caregivers for participating in this study, along with all investigators and site personnel."
    },
    {
        "anchor": "Twelve patients received protocol therapy.",
        "positive": "A total of 12 patients received the treatment outlined in the protocol.",
        "negative": "2 | MATERIALS AND METHODS\nThis was a multicenter, open-label Phase 1 study of DS1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR-mutant NSCLC and disease progression during treatment with one or more EGFR- TKIs (gefitinib, erlotinib, afatinib, dacomitinib, or osi-mertinib)."
    },
    {
        "anchor": "However, longer follow-up of the patients included in this study or in randomized trials by other centres could be considered in future publications to show the long-term effect of SVATS on chronic postoperative pain and on the quality of life.",
        "positive": "Future studies could explore the long-term effects of SVATS on chronic postoperative pain and quality of life by extending follow-up periods in this study and in other randomized trials.",
        "negative": "Sample Size Justification\nThe study will enroll 31 evaluable subjects with relapsed/refractory ALL."
    },
    {
        "anchor": "patients with PD-L1-positive, locally advanced/metastatic NSCLC without targetable EGFR/ALK alterations.",
        "positive": "The study focused on patients with PD-L1-positive, locally advanced, or metastatic non-small cell lung cancer who did not have targetable EGFR or ALK alterations.",
        "negative": "Phase 0 trial to test mRNA c-Met-CAR T cells\nWe conducted a phase 0 study to test the safety and feasibility of intratumoral injections of CAR T cells."
    },
    {
        "anchor": "Thus, TransCon IL-2 \u03b2/\u03b3 was designed using two independent approaches to optimally address the limitations of IL-2 in cancer immunotherapy, namely avoiding activation of undesired IL-2R\u03b1+ cell types and poor PK properties (high Cmax and short half-life), by achieving controlled and prolonged exposure of IL-2 \u03b2/\u03b3 to safely and robustly activate lymphocytes with antitumor function including CD8+ T cells, \u03b3\u03b4 T cells and NK cells.",
        "positive": "TransCon IL-2 \u03b2/\u03b3 was designed to address the limitations of IL-2 in cancer immunotherapy by using two independent approaches, including avoiding unwanted cell activation and poor pharmacokinetics, to achieve controlled and prolonged exposure and robust activation of lymphocytes with antitumor function.",
        "negative": "Cell Viability Assay\n7 11 Cells were seeded on 96-well plates at the following densities: 2 \ue004 103,3 \ue004 103, and 4 \ue004 103 and incubated for 24 hours.Cells were treated with serial dilutions of the drugs administered at indicated doses."
    },
    {
        "anchor": "Pregnancies\nTo ensure patient safety, each pregnancy occurring while the patient is on study must be reported to protocol sponsor within 24 hours of learning of its occurrence.",
        "positive": "All pregnancies occurring during the study period must be promptly reported to the study sponsor within 24 hours of discovery.",
        "negative": "Pregnancy outcomes must be collected for the female partners of any males who took study treatment in this study."
    },
    {
        "anchor": "Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later.",
        "positive": "The data will be available for request 6 months after the indication has been approved in the US and EU, or after the primary publication has been accepted, whichever is the later event.",
        "negative": "Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment."
    },
    {
        "anchor": "Terminology Criteria for Adverse Events (NCI-CTCAE) version v4.03 criteria as grade III-IV.",
        "positive": "The study employs the NCI-CTCAE v4.03 criteria to classify adverse events, with grades III and IV indicating severe events.",
        "negative": "Randomization\nRandom assignment of eligible patients using the minimization technique will be performed through a web-based central randomization system, which will be operated by one physician in each center."
    },
    {
        "anchor": "STUDY DESIGN AND TREATMENT\nThis phase 1b\u20132, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL or small lymphocytic lymphoma.",
        "positive": "This phase 1b-2, open-label, multicenter study aimed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL or small lymphocytic lymphoma.",
        "negative": "Conflict of interest\nNF declares consulting services for Abbott Singapore, ALK, Allergan, Aimmune, AstraZeneca, Galderma, Ipsen, Novartis, Novo Nordisk, Regeneron, Sanofi Aventis, Thea, and Vertex; and a leadership or fiduciary role for the European Association of Cardiothoracic Surgery."
    },
    {
        "anchor": "Randomization was stratified by gender and histology (adenocarcinoma, others).",
        "positive": "Patients were randomly assigned to treatment groups based on their gender and histology type (adenocarcinoma or other).",
        "negative": "Randomization\nEligible patients were randomly assigned in a 1:1 ratio to receive PCG or PC alone."
    },
    {
        "anchor": "JW is an employee of AstraZeneca.",
        "positive": "JW is a staff member at AstraZeneca.",
        "negative": "Declarations\nFunding The study (NCT02296125) was funded by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib."
    },
    {
        "anchor": "CRS occurred in 68 (91.9%) patients.",
        "positive": "The majority of patients (91.9%) experienced CRS.",
        "negative": "Patient Characteristics\nIn total, 970 patients were randomly assigned to veliparib (n 5 486) or placebo (n 5 484) in combination with C and P, and 967 received $ 1 dose of veliparib or placebo."
    },
    {
        "anchor": "Meanwhile, the DSC is used to indicate the fractional volume overlap for a given functional percentile zone as segmented from two different ventilation images.",
        "positive": "The DSC is employed to measure the overlap between two ventilation images, providing information on the fractional volume overlap within a specific functional percentile zone.",
        "negative": "Authors\u2019 contributions\nSL as principle investigator was involved in the study conception and design; XA, HJ, ZZ, ZC, YY and ZL will be involved in the acquisition of data; XA, ZS, HJ, ZZ, ZC, YY and ZL will be involved in the analysis and interpretation of data; XA were involved in drafting the manuscript; and XA and ZS were involved in revising the manuscript."
    },
    {
        "anchor": "DuoBody-CD3x5T4 was co-developed by Genmab and AbbVie Inc (NCT04424641 [closed]).",
        "positive": "Genmab and AbbVie Inc collaborated to develop DuoBody-CD3x5T4, as recorded in clinical trial NCT04424641.",
        "negative": "9.5 Returns and Reconciliation\nThe investigator is responsible for keeping accurate records of the clinical supplies received from Merck or designee, the amount dispensed to and returned by the subjects and the amount remaining at the conclusion of the trial."
    },
    {
        "anchor": "The box plots on the right display the mutation load of patients with and without baseline TP53 mutations.",
        "positive": "The box plots on the right show the mutation load of patients with and without TP53 mutations at baseline.",
        "negative": "Supplementary\nTable S1 The list of 212 genes in the panel Table S2 PK analysis Table S3 Best ORR In All Patients (Cutoff Date: December 31, 2020) Table S4 Best ORR In Different Cohorts (Cutoff Date: December 31, 2020) Figure S1 The mutation landscape at C1D31 and change of mutation load during ensartinib treatment."
    },
    {
        "anchor": "ACKNOWLEDGMENT\nWe thank all patients in this study and their families, along with the investigators and staff at the participating centers.",
        "positive": "We would like to thank the patients, their families, and the investigators and staff at the participating centers for their contributions to this study.",
        "negative": "We also thank the study teams from Hansoh Pharmaceutical Group Co. Ltd, including Sui-Sui Dong, Jiawei Wei, Xiaoling Qian, Xue Sun, Zhenzhong Su, Qiu Sun, and Ziqiang Chen for their support and the Teddy Clinical Research Laboratory (Shanghai, China) for EGFR mutation testing and Fantastic Bioimaging (Shanghai, China) for ICR assessment."
    },
    {
        "anchor": "had received an immune checkpoint inhibitor (CPI), 27.8% received prior anti-HER2 therapy, and 65.6% of patients had chemotherapy in combination or sequentially with a CPI ((<>)Table 1, Data Supplement).",
        "positive": "Of the patients, 27.8% had previously received an immune checkpoint inhibitor, 27.8% had received prior anti-HER2 therapy, and 65.6% had chemotherapy in combination or sequentially with a CPI.",
        "negative": "Patients\nBetween October 2017 and March 2021, 90 patients were enrolled and treated in ZENITH20 cohort 2 ((<>)Table 1)."
    },
    {
        "anchor": "The primary efficacy analysis set included patients in the mITT analysis set with primary endpoint data.",
        "positive": "The primary efficacy analysis set comprised patients with primary endpoint data from the mITT analysis set.",
        "negative": "Statistical analysis\nConsidering the ORR was 26% in SCHOLAR-1 [(<>)4] and 82% in ZUMA-1 [(<>)6], the threshold ORR was selected as 26%, and the expected ORR was set at 60%."
    },
    {
        "anchor": "Dr Vincente Baz reports having a consulting or advisory role and receiving honoraria from AstraZeneca, Merck & Co., Kenilworth, NJ, Pfizer, and Roche.",
        "positive": "Dr. Vincente Baz has a consulting or advisory role and receives compensation from AstraZeneca, Merck & Co., Kenilworth, NJ, Pfizer, and Roche.",
        "negative": "ORIGINAL ARTICLE\nAvelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC a b c d Zoran Andric, MD,Gabriella G\u00e1lffy, MD,Manuel Cobo Dols, MD,Barna Szima, MD, e f g Goran Stojanovic, MD,Marina Petrovic, MD,Enriqueta Felip, MD, David Vicente Baz, MD,h (<>)Santiago Ponce Aix, MD,i (<>)Oscar Juan-Vidal, MD,j (<>)Zsuzsanna Szalai, MD,k (<>)Gyorgy Losonczy, MD,l (<>)Antonio Calles Blanco, MD,m (<>) n o p Reyes Bernabe, MD,Gema Garc\u00eda Ledo, MD,Andr\u00e9s Aguilar Hern\u00e1ndez, MD, q r q Klaus Duecker, PhD,Dongli Zhou, PhD,Andreas Schroeder, MD, q s , * Guelseren Guezel, MD,Fortunato Ciardiello, MD, PhD Disclosure: Dr G\u00e1lffy reports having an advisory or consultancy role, participating in a speakers bureau, and receiving honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck & Co., Kenilworth, NJ, Pfizer, and Roche."
    },
    {
        "anchor": "Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
        "positive": "Mok TS, Wu YL, Thongprasert S, et al published a study on gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
        "negative": "Statistical Methods\nTime to event outcomes (progression-free survival and overall survival) were analyzed using Kaplan-Meier curves."
    },
    {
        "anchor": "Experimental arm: 2 Gy single fraction preoperative radiotherapy administered to patients 7 days prior to surgery.",
        "positive": "Preoperative radiotherapy was administered to patients in the form of a single 2 Gy fraction 7 days before surgery.",
        "negative": "Study design\nThis is a two-arm randomized phase II study to investigate the influence of low dose radiotherapy on immune stimulatory effects in NSCLC."
    },
    {
        "anchor": "Or carboplatin: AUC5 by intravenous drip on Day 1 of each cycle, every 3 weeks as a cycle.",
        "positive": "Carboplatin was administered at a dose of AUC5 via intravenous drip on Day 1 of each cycle, every 3 weeks.",
        "negative": "Title: Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "Treatment of established renal cancer by tumor cells engi-(<http://refhub.elsevier.com/S1525-0016(18)30206-5/sref31>)neered to secrete interleukin-4.",
        "positive": "Established renal cancer can be treated by engineering tumor cells to produce interleukin-4.",
        "negative": "The Oncologist, 2022, 27, 536\u2013e553 https://doi.org/10.1093/oncolo/oyab080 Advance access publication 24 March 2022 Clinical Trial Results\nPhase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation"
    },
    {
        "anchor": "The Monitors will assure that submitted data are accurate and in agreement with source documentation; verify that investigational products are properly stored and accounted for; verify that subject consent for study participation has been properly obtained and documented; confirm that research subjects entered into the study meet inclusion and exclusion criteria; and assure that all essential documentation required by Good Clinical Practices (GCP) guidelines are appropriately filed.",
        "positive": "The Monitors will verify the accuracy of submitted data, ensure investigational products are properly stored and accounted for, confirm subject consent, and ensure that research subjects meet inclusion and exclusion criteria, as well as ensure compliance with Good Clinical Practices guidelines.",
        "negative": "Enhancing comprehension of information for informed consent: a review of empirical research."
    },
    {
        "anchor": "Ficlatuzumab was not immunogenic in any patients during the observation period.",
        "positive": "No immunogenic response was observed in patients during the observation period with regard to Ficlatuzumab.",
        "negative": "Patient Characteristics\nIn total, 10 CRC patients with metastasis fit the criteria and were recruited ((<>)Table 2)."
    },
    {
        "anchor": "After six hours, the basal medium was replaced with complete medium.",
        "positive": "Complete medium was substituted for the basal medium after a six-hour interval.",
        "negative": "REFERENCES\nEisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)."
    },
    {
        "anchor": "Outcomes\nThe primary endpoint was the 2-year DFS rate for surgical patients, defined as the duration from the date of surgery to the first occurrence of local or distant recurrence or death.",
        "positive": "The primary endpoint was the two-year disease-free survival rate for surgical patients, defined as the time from surgery to the first recurrence or death.",
        "negative": "Secondary endpoints included the rate of MPR for surgical patients, characterised by 10% or less residual viable tumour post-surgery; the rate of pCR for surgical patients; the proportion of patients undergoing R0 resection; the proportion of intention-to-treat (ITT) patients achieving tumour downstaging; OS for surgical patients; objective response rate (ORR) for ITT patients; AEs for ITT patients; and quality of life for ITT patients, calculated from the date of enrolment date until disease recurrence or death."
    },
    {
        "anchor": "If the confirmation plan demonstrated either coverage of <95% of the iCTV or excessive normal tissue doses (exceeding those in Supplemental Table 1), then an adaptive plan was created for the remainder of the 7-week treatment period.",
        "positive": "If the confirmation plan did not meet the coverage threshold of 95% or exceeded normal tissue doses, an adaptive plan was created for the remainder of the treatment period.",
        "negative": "Adaptive planning\nAll 44 patients in the phase II study underwent replanning evaluation, in most cases (34) with 4D CT (the other 10 had small tumors away from critical structures and were evaluated clinically and with daily kilovoltage imaging)."
    },
    {
        "anchor": "At each subsequent tumor assessment, the SPD of the index lesions and of new, measurable lesions (\u2265 5 X 5 mm; up to 5 new lesions per organ: 5 new cutaneous lesions and 10 visceral lesions) are added together to provide the totaltime-point tumor burden.",
        "positive": "The sum of the SPD of index lesions and new, measurable lesions was calculated at each subsequent tumor assessment.",
        "negative": "For irRC, only target lesions selected at baseline and measurable new lesions are taken into account."
    },
    {
        "anchor": "Ethics approval and consent to participate\nThis study was conducted in accordance with the Declaration of Helsinki and underwent Research Ethics Committee and Health Research Authority, United Kingdom approval (IRAS 256684 and IRAS 290974).",
        "positive": "The study adhered to the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee and Health Research Authority in the United Kingdom.",
        "negative": "Author details\n1Oncology Department, Dnepropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital, No."
    },
    {
        "anchor": "A sample size of 30 evaluable patients was determined arbitrarily, if the toxicity induced by the regimen could be tolerated [(<>)33].",
        "positive": "A sample size of 30 evaluable patients was arbitrarily determined based on the toxicity tolerance of the regimen.",
        "negative": "Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer\nZhenyu Ding1,2 , Qing Li1,2 , Rui Zhang 1 , Li Xie 1 , Yang Shu 1 , Song Gao 3 , Peipei Wang1,2 , Xiaoqing Su 1 , Yun Qin 4 , Yuelan Wang 1 , Juemin Fang 3 , Zhongzheng Zhu 3 , Xuyang Xia 1 , Guochao Wei 5 , Hui Wang 3 , Hong Qian 3 , Xianling Guo 3 , Zhibo Gao 5 ,YuWang 5 , Yuquan Wei 1 , Qing Xu 3 , Heng Xu (<http://orcid.org/0000-0002-7748-2621>)(<http://orcid.org/0000-0002-7748-2621>)1 (<http://orcid.org/0000-0002-7748-2621>)and Li Yang 1 Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity."
    },
    {
        "anchor": "In the dose range of 40 to 320 mg, the AUCss and Cmax,ss increased in a dose-proportional manner, and the slope values of the AUCss, Cmax,ss, and CD15 were closest to 1.",
        "positive": "Within the dose range of 40 to 320 mg, the AUCss and Cmax,ss showed a dose-proportional increase, with slope values closest to 1.",
        "negative": "Tumor Mutational Burden-High (TMB-H) Cancer\n\u2022 for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [\u226510 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.1 (1.16, 2.1) \u2022 Limitations of Use: The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established."
    },
    {
        "anchor": "Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.",
        "positive": "The Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee discussed real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic.",
        "negative": "Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review."
    },
    {
        "anchor": "Data Availability\nThe raw pre-clinical and clinical datasets generated during and analyzed in the current study are not publicly available due to proprietary ownership.",
        "positive": "The raw pre-clinical and clinical datasets generated during and analyzed in the current study are not publicly available due to proprietary ownership.",
        "negative": "Any data and materials that can be shared will be released via a material transfer agreement."
    },
    {
        "anchor": "Next, these mice who rejected the CT26 rechallenge were challenged with EMT6, a distinct tumor cell line with shared neoantigens.",
        "positive": "Mice that rejected the CT26 rechallenge were then challenged with EMT6, a distinct tumor cell line sharing neoantigens with CT26.",
        "negative": "TransCon IL-2 \u03b2/\u03b3 induced CD8+ T cell and NK cell activation and promoted antitumor efficacy in mice\n31 Female BALB/c mice with established CT26 tumors were treated with TransCon IL-2 \u03b2/\u03b3 IV and/or TransCon TLR7/8 Agonist IT and evaluated for tumor growth inhibition and PD effects."
    },
    {
        "anchor": "End points\nThe primary end point was PFS rate at 12 months as assessed by an IRC per RECIST version 1.1 [(<>)13].",
        "positive": "The primary endpoint was the 12-month progression-free survival rate, as assessed by an independent review committee using RECIST version 1.1.",
        "negative": "Secondary end points included IRC-assessed confirmed objective response rate (ORR), PFS, duration of response (DoR), disease control rate, and time to response; intracranial PFS (iPFS by IRC); intracranial ORR (iORR by IRC); overall survival (OS); and safety."
    },
    {
        "anchor": "Supplementary data\nSupplementary data related to this article can be found at (<https://doi.org/10.1016/j.eclinm.2023.102238>)https://doi.",
        "positive": "Additional data supporting this study can be found at the provided online link: https://doi.org/10.1016/j.eclinm.2023.102238.",
        "negative": "Bladt F, Faden B, Friese-Hamim M et al (2013) EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors."
    },
    {
        "anchor": "Most recently collected blood, urine, or other body fluid cultures must show no growth for at\nleast 48 hours, and any other infectious workup performed (eg, bacterial, viral serologies,\nPCR, stool studies, imaging studies) must be negative.",
        "positive": "The most recent blood, urine, or other bodily fluid cultures must show no growth for at least 48 hours, and any additional infectious workup must be negative.",
        "negative": "Conditioning Chemotherapy Period\nIf any screening assessments or procedures are repeated between screening and the start of\nconditioning chemotherapy and results are outside the eligibility criteria (Section 5), contact the\nKite medical monitor for approval prior to proceeding with conditioning chemotherapy."
    },
    {
        "anchor": "Informed consent was obtained from all participants.",
        "positive": "Informed consent was obtained from all participants prior to their involvement in the study.",
        "negative": "Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia original reports\nNoelle V. Frey, MD, MS1,2; Saar Gill, MD, PhD1,2,3; Elizabeth O. Hexner, MD, MSTR1,2; Stephen Schuster, MD1,2; Sunita Nasta, MD1,2; Alison Loren, MD, MSCE1,2; Jakub Svoboda, MD1,2; Edward Stadtmauer, MD1,2; Daniel J. Landsburg, MD1,2; Anthony Mato, MD, MSCE1,2; Bruce L. Levine, PhD2,3; Simon F. Lacey, PhD2,3; Jan Joseph Melenhorst, PhD2,3; Elizabeth Veloso, JD3; Avery Gaymon, MS3; Edward Pequignot, MS2,3; Xinhe Shan, BA1,2; Wei-Ting Hwang, PhD2,3; Carl H. June, MD2,3; and David L. Porter, MD1,2 abstract PURPOSE To describe long-term outcomes of anti-CD19 chimeric antigen receptor T (CART) cells in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)."
    },
    {
        "anchor": "Efficacy of CAR T-cell treatment for patients who relapsed after allo-HSCT\nPatients with a history of previous transplantation had a lower 1-year OS and LFS than those without previous transplantation (OS, 30.5% vs 79.2%; P 5 .009; 95% CI, 1.51-18.48; LFS, 25.4% vs 69.4%; P 5 .011; 95% CI, 0.07-0.71; Figure 7A-B).",
        "positive": "Patients who had undergone allogenic hematopoietic stem cell transplantation had a lower 1-year overall survival rate and leukemia-free survival rate compared to those without prior transplantation.",
        "negative": "Two patients underwent a second allo-HSCT and remained disease free at 19 months and 4 months after transplant, respectively."
    },
    {
        "anchor": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).",
        "positive": "Biomarker analysis and final overall survival results were obtained from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in patients with advanced non-small-cell lung cancer in Asia.",
        "negative": "Cancer statistics in China, 2015."
    },
    {
        "anchor": "Conclusions\nIn conclusion, our study highlighted the potential advantage of ctDNA analysis for precisive treatment of pyro-tinib in patients with HER2 mutation.",
        "positive": "The study demonstrated the potential benefit of using circulating tumor DNA analysis for personalized treatment of pyro-tinib in patients with HER2 mutations.",
        "negative": "These findings might be helpful to guide the clinical utility of anti-HER2 targeted therapy, which still requires further validating in the future."
    },
    {
        "anchor": "The objective response was summarized with objective response rates (ORR) and exact two-sided 95% confidence interval (CI) for ORR calculated using the Clopper\u2013Pearson method.",
        "positive": "The objective response rate was reported with a 95% confidence interval calculated using the Clopper-Pearson method.",
        "negative": "Original Article\nLong-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy James N. Kochenderfer,1 (<>)Robert P.T."
    },
    {
        "anchor": "Cara Haymaker participated in scientific advisory board from Bri-acell.",
        "positive": "Cara Haymaker was a member of the scientific advisory board for Bri-acell.",
        "negative": "CONFLICT OF INTEREST\nErnest Nadal reports personal fees from Bristol Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Lilly, Amgen, and Boehringer Ingelheim, and grants and personal fees from Roche and Pfizer, outside the submitted work."
    },
    {
        "anchor": "Unexpected Events\nx The determination of whether an AE is expected is based on agent-specific information provided in Section 15.0 of the protocol.",
        "positive": "The classification of an adverse event as expected or unexpected is based on information provided in Section 15.0 of the protocol.",
        "negative": "10.2 Expected vs."
    },
    {
        "anchor": "Centers that have previously been accredited for other trials (e.g.",
        "positive": "Trials centers that have been previously certified for other studies.",
        "negative": "Quality Assurance for Centres Joining Study\nPrior to opening the study, each participating research centre will be required to send to one of the Principal Investigators a mock treatment plan, to ensure that the treatment plans are designed in compliance with the protocol."
    },
    {
        "anchor": "This eight-item scale evaluates FCG\u2019s comfort with the physical and emotional patient needs and are scored from 0 to 4, with higher scores representing better preparedness.",
        "positive": "The eight-item scale evaluates the FCG's capacity to address patients' physical and emotional needs, with scores from 0 to 4, reflecting increased preparedness with higher scores.",
        "negative": "Patient characteristics\nOf the 70 patients screened, 56 were eligible and treated (Supplementary Fig."
    },
    {
        "anchor": "Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality.",
        "positive": "Patient data not presented in this paper was generated during clinical trials and may be confidential due to patient privacy concerns.",
        "negative": "Sequences for the CD22-f2 CAR are private property of Novartis."
    },
    {
        "anchor": "Administration of the pembrolizumab will be witnessed by the investigator and/or trial staff.",
        "positive": "The administration of pembrolizumab will be monitored by the investigator and/or trial staff.",
        "negative": "Patients and study design\nThe TIME trial (NCT00415818) is a double-blind, placebo-controlled, randomized phase 2b/3 clinical study aimed at assessing the combination of TG4010 with first-line chemotherapy in advanced NSCLC."
    },
    {
        "anchor": "Then, it was incubated at room temperature with an anti-epithelial cell adhesion molecule (EpCAM) antibody (Clone Ber-EP4, Abcam; 0.02 \u03bcg antibody/\u03bcL bead suspension).",
        "positive": "The mixture was then incubated at room temperature with an EpCAM antibody (Clone Ber-EP4, Abcam; 0.02 \u03bcg antibody per microliter bead suspension).",
        "negative": "Work-up\nPatients with pathologically or cytologically documented NSCLC stage III receive a complete work-up including thoracic and cerebral CT scans, abdominal ultrasound, bone scan (plus x-ray exams of suspect areas where applicable)."
    },
    {
        "anchor": "The final speaker for the clinical trial session was Eric Cohen (University of Maryland, Baltimore, MD) who recounted his experience with the clinical development of ACE inhibitors as a method to prevent late radiation injury of lung and kidney.",
        "positive": "Eric Cohen, from the University of Maryland, Baltimore, MD, concluded the clinical trial session by sharing his experience with the clinical development of ACE inhibitors as a method to prevent late radiation injury to the lung and kidney.",
        "negative": "5.3.1.2 Release and Preparation\nThe CVPF will release the CART-EGFRvIII cells to the bedside for administration on the day of infusion."
    },
    {
        "anchor": "CAR-T cells were infused from the second to fifth day with escalating doses, and G-PBSCs were infused at the fourth day post chemotherapy (Fig.",
        "positive": "CAR-T cells were administered in escalating doses from the second to fifth day, and G-PBSCs were given on the fourth day after chemotherapy (Figure).",
        "negative": "Description\ndg1polynomial allows for scaling,linear combination and translation within a single transformation defined by the function"
    },
    {
        "anchor": "Specifics of the ELISA and PK analysis are described in Supplementary materials and methods.",
        "positive": "Details of the ELISA and PK analysis can be found in the supplementary materials and methods section.",
        "negative": "Druker BJ, Guilhot F, O\u2019Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia."
    },
    {
        "anchor": "Additional methods and study details are provided in the (<>)Supplementary Materials.",
        "positive": "Additional information on the study methods and details is available in the supplementary materials.",
        "negative": "Pathologic Response Evaluation\n5 The pathologic response was evaluated as previously described.Briefly, the presence of 10% or fewer viable tumor cells in the primary tumor was defined as major pathologic response (MPR) and no viable tumor cell in both primary tumor and dissected lymph nodes was defined as complete pathologic response."
    },
    {
        "anchor": "Detailed descriptions can be found in the (<https://dx.doi.org/10.1136/jitc-2022-004991>)online supplemental methods table SM 1A-F.",
        "positive": "The online supplemental table SM 1A-F provides a detailed description of the methods used.",
        "negative": "5-iii) Revisions and updating\nRevisions and updating."
    },
    {
        "anchor": "The median dose intensity corresponds to 99.6% of the target dose intensity.",
        "positive": "The median dose intensity is equivalent to 99.6% of the intended dose intensity.",
        "negative": "S3 and S4)."
    },
    {
        "anchor": "parameters Object of class \"transformation\" \u2013 flow parameter to be transformed.",
        "positive": "The \"transformation\" class has parameters that require transformation, with the flow parameter being the primary focus.",
        "negative": "Urothelial Carcinoma\n\u2022 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) \u226510] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.1 (1.7, 2.1) \u2022 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy."
    },
    {
        "anchor": "Blood pressure, heart rate, electro-cardiographic trace, respiratory frequency and oxygen saturation are monitored continuously throughout the operation by an anaesthesiologist.",
        "positive": "During the operation, an anaesthesiologist closely monitors vital signs, including blood pressure, heart rate, electro-cardiographic trace, respiratory frequency, and oxygen saturation.",
        "negative": "Serum BCMA assessment\nA ligand-binding assay was used to quantify sBCMA in a homogeneous electrochemiluminescent immunoassay (ECLIA)."
    },
    {
        "anchor": "Ethics statement\nThe studies involving human participants were reviewed and approved by Institutional Review Board of the University of Texas MD Anderson Cancer Center.",
        "positive": "The Institutional Review Board of the University of Texas MD Anderson Cancer Center reviewed and approved the studies involving human participants.",
        "negative": "Written informed consent to participate in this study was provided by the participants\u2019 legal guardian/next of kin."
    },
    {
        "anchor": "Funding\nThis work was supported by the Agency for Science, Technology and Research (A*STAR) Joint Council Office (JCO) Grant JCOAG04_FG03_2009.",
        "positive": "The research was funded by the Agency for Science, Technology and Research (A*STAR) Joint Council Office (JCO) through the JCOAG04_FG03_2009 grant.",
        "negative": "TRIAL DESIGN AND TREATMENT\nIn this international, open-label, phase 3 trial (Fig."
    },
    {
        "anchor": "Both patient and caregiver reported clinically significant anxiety and depressive symptoms in 20 and 6% of dyads, respectively.",
        "positive": "In 20% of dyads, both patients and caregivers reported clinically significant anxiety symptoms, while in 6% of dyads, caregivers reported depressive symptoms.",
        "negative": "Author details\n1 Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, UK."
    },
    {
        "anchor": "The remaining authors declare no competing financial interests.",
        "positive": "The authors not directly involved in the research have no competing financial interests.",
        "negative": "Competing interests\nS.R.R."
    },
    {
        "anchor": "Title: CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia\n\nAbstract: Paediatric Acute Myeloid Leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvement of intensive standard therapy.",
        "positive": "The title of the study is \"CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia.\" The abstract highlights the poor outcomes in patients with relapsed/refractory AML, despite improved standard therapy.",
        "negative": "Toxicity management\nToxicities are classified by grade, type, duration, onset, and relationship to study treatment according to CTCAE version 3.0."
    },
    {
        "anchor": "12.4 Analysis of Primary Efficacy Endpoints\nFAS will be used as the primary analysis set for the primary efficacy analysis.",
        "positive": "The FAS dataset will serve as the primary analysis set for evaluating the primary efficacy endpoints.",
        "negative": "SUPPLEMENTAL INFORMATION\nSupplemental Information includes four figures and two tables and can be found with this article online at (<http://dx.doi.org/10.1016/j.ymthe.2017.03.010>)http://dx.doi.org/10.1016/j."
    },
    {
        "anchor": "All authors contributed to the article and approved the submitted version.",
        "positive": "The authors reviewed and approved the final version of the article, which was the result of their collective efforts.",
        "negative": "Flow cytometry\nAt harvest or upon thawing, 1 \u00d7 106 cells were stained for cell surface markers to analyze T-cell differentiation status."
    },
    {
        "anchor": "Figure 1View largeDownload PPTFigure 1View largeDownload PPTClose modal\n\nDate and Time: 2022-11-15",
        "positive": "A visual representation of the study data is presented in Figure 1, with the date and time of the data collection being November 15, 2022.",
        "negative": "Title: Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells\n\nAbstract: Background:CD19-directed chimeric antigen receptor (CD19CAR) T cell therapy produces excellent remission rates in children and adults with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL)."
    },
    {
        "anchor": "aAll patients with CR at week 12 for whom data were available continued to have CR at weeks 18 and 24. bPatients had PR at week 12 and no subsequent change in response and no progression at week 18 or 24.",
        "positive": "Patients who achieved complete remission (CR) at week 12 and had available data continued to experience CR at weeks 18 and 24. Additionally, patients who had partial response (PR) at week 12 and showed no subsequent changes in response or disease progression at weeks 18 or 24.",
        "negative": "Kaplan-Meier estimate of OS from week 12 by subsequent response in patients with PR or SD at week 12 in the week 12 analysis population."
    },
    {
        "anchor": "All authors contributed to and approved the manuscript; writing and editorial assistance were provided by Jeremy Henriques, PhD, of The Lockwood Group (Stamford, CT, USA), funded by Bristol Myers Squibb.",
        "positive": "The authors collectively contributed to and endorsed the manuscript, with Jeremy Henriques, PhD, from The Lockwood Group, providing writing and editorial support, funded by Bristol Myers Squibb.",
        "negative": "ACKNOWLEDGMENTS\nThis study was funded by Celgene, a Bristol-Myers Squibb Company."
    },
    {
        "anchor": "\u2022 Subjects to be contacted annually because they had no sign of gene therapy product at the 5-year follow-up visit or later and are, therefore, not required to return for any remaining future onsite visits.",
        "positive": "Individuals who did not exhibit signs of gene therapy product at the 5-year follow-up visit or later will be contacted annually and are exempt from attending future onsite visits.",
        "negative": "Discussion\nWe have designed a randomized controlled trial to investigate the effect of a multimodal exercise-based intervention for older patients with advanced PC, BTC and LC undergoing first-line palliative treatment."
    },
    {
        "anchor": "To date, there is no safe and effective method available to track infused NK cell therapy product in humans.",
        "positive": "Currently, there is no reliable method available to monitor infused natural killer cell therapy product in humans.",
        "negative": "Title: Non-Invasive Tracking of Nanobubble Tagged Natural Killer Cells Using Clinical Ultrasound\n\nAbstract: Background:Despite advances, the prognosis of patients with relapsed/refractory solid tumors remains poor."
    },
    {
        "anchor": "To evaluate the geographic stability of hypoxic sub-volumes, the percentage of intratumour voxels that were identified as hyp-oxic in both FMISO studies was calculated, as based on the TBR \u2265 1.2, \u22651.4, and \u22651.6 thresholds [(<>)6\u2013(<>)9].",
        "positive": "The proportion of tumor voxels classified as hypoxic in both FMISO studies was calculated to evaluate the stability of hypoxic sub-volumes, based on TBR thresholds of \u2265 1.2, \u2265 1.4, and \u2265 1.6.",
        "negative": "Usage\nsplitScaleTransform(transformationId=\"defaultSplitscaleTransform\", maxValue=1023, transitionChannel=64, r=192)"
    },
    {
        "anchor": "I have transferred the rights to Deciphera.",
        "positive": "The rights to Deciphera have been transferred to the new owner.",
        "negative": "AUTHORS\u2019 DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST\nSwitch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib The following represents disclosure information provided by authors of this manuscript."
    },
    {
        "anchor": "For patients with SD, the median number of cycles completed was 4 (range, 2\u20137).",
        "positive": "Patients with SD completed a median of 4 treatment cycles, with a range of 2 to 7 cycles.",
        "negative": "Patient characteristics\nA total of 14 patients with advanced, metastatic malignancies were enrolled between July 2015 and June 2017."
    },
    {
        "anchor": "Patient characteristics are outlined in Table 1.",
        "positive": "Patient demographics are presented in Table 1.",
        "negative": "Summary\nBackground\u2014Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR\u2212/ALK\u2212), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown."
    },
    {
        "anchor": "Of note, four tumor type categories were evaluated (NSCLC, BTC, CC, and \u201cother\u201d), based on ongoing clinical trials in these indications at the time of the analysis; Asian versus non-Asian categories were also evaluated in exposure-safety models.",
        "positive": "The analysis considered four tumor types: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cholangiocarcinoma (CC), and other types, based on ongoing clinical trials in these indications; Asian and non-Asian patient subgroups were also evaluated in exposure-safety models.",
        "negative": "Exposure\u2011safety modeling\nThe data for exposure-safety modeling included 936 patients receiving BA monotherapy (clinical trials NCT02517398, NCT02699515, and NCT04246489) and combination ther-apy (clinical trial NCT03840915) (Table (<>)1 and Supplemental Table 2)."
    },
    {
        "anchor": "One cycle of therapy was 28 days, and patients underwent imaging every two cycles.",
        "positive": "The treatment cycle lasted 28 days, with imaging assessments conducted every 14 days.",
        "negative": "treatment\nKRAS wild-type patients were randomized to receive either single-agent erloti-nib at 150 mg orally o.d."
    },
    {
        "anchor": "1.3 Epidermal Growth Factor Tyrosine Kinase Inhibitor Resistance\nDespite the significant effects of EGFR TKIs in EGFR mutant NSCLC, all patients eventually develop resistance to single agent EGFR TKI treatment.",
        "positive": "EGFR TKIs have a limited duration of effectiveness in EGFR mutant NSCLC, as all patients eventually develop resistance to single-agent treatment.",
        "negative": "[Kobayashi et al., 2005, Pao et al., 2005, Shih et al., 2005, Kosaka et al., 2006, Bean et al., 2007, Engelman et al., 2007] In addition, a recent study suggested that EGFR T790M may pre-exist in EGFR mutant caners prior to gefitinib or erlotinib treatment [Maheswaran et al., 2008]."
    },
    {
        "anchor": "(A represents the number of additional decades of negative data values to be included.)",
        "positive": "The number of additional decades of negative data values to be included is represented by A.",
        "negative": "Slots\n.Data Object of class function."
    },
    {
        "anchor": "Available from:  https: //www.nice.org.uk/guidance/ ta630.",
        "positive": "The referenced guidance is available at https://www.nice.org.uk/guidance/ta630.",
        "negative": "References\n1 Li IW, Krishnamurthy N, Wei G, Li G. Opportunities and challenges in developing tis-sue-agnostic anti-cancer drugs."
    },
    {
        "anchor": "Plasma was separated by centrifugation at 2000 \u00d7 g for 15 min at 4\u00b0C and stored at \u201380\u00b0C.",
        "positive": "Plasma was isolated through centrifugation at 2000 \u00d7 g for 15 minutes at 4\u00b0C, and then stored at \u201380\u00b0C.",
        "negative": "Safety\nTreatment-emergent AEs occurred in all patients."
    },
    {
        "anchor": "Blood samples were drawn prior to the first infusion dose on C1D1, 72 h post EOI, 14 days post EOI and prior to C3D1.",
        "positive": "Blood samples were collected before the initial infusion dose on C1D1, 72 hours after EOI, 14 days after EOI, and before C3D1.",
        "negative": "Serum levels of soluble factors were detected through ELISA using the following kits and following manufacturer\u2019s instructions: soluble CEACAM-5: Human Carcinoembryonic Antigen ELISA Kit (Abcam, Cambridge, MA, USA); soluble CEACAM-6: Human CD66c / CEACAM6 (Sandwich ELISA) ELISA Kit (LSBio, Seattle, WA, USA); soluble MICA: MICA Human ELISA Kit (Thermo Fisher Scientific, Waltham, MA, USA)."
    },
    {
        "anchor": "Nat Rev Clin Oncol.",
        "positive": "A publication in the journal Nature Reviews Clinical Oncology.",
        "negative": "8.1 Radiotherapy\nThe primary tumour and involved lymph nodes will be treated with 60-63 Gy in 30 fractions, over 6 weeks."
    },
    {
        "anchor": "Intrathecal drug therapy\nIntrathecal chemotherapy remains the standard treatment for lung cancer patients with leptomeningeal disease and has a good risk profile.",
        "positive": "Intrathecal chemotherapy is the standard treatment for lung cancer patients with leptomeningeal disease, and it has a favorable risk profile.",
        "negative": "Purpose\nThe outcome for patients with metastatic or recurrent sarcoma remains poor."
    },
    {
        "anchor": "Nivolumab is therefore expected to deliver direct healthcare benefits to Chinese patients and value to the Chinese healthcare system.",
        "positive": "Nivolumab is expected to provide direct healthcare benefits to Chinese patients and add value to the Chinese healthcare system.",
        "negative": "Acknowledgements We acknowledge the RWE database analysis by Happy Life Technology Ltd, local market insights by Liya Fan, and Kate Young and Ritika Jain of Parexel International for health economic insights."
    },
    {
        "anchor": "Stat Med 17:2301\u20132312 39.",
        "positive": "A study published in Statistics in Medicine, volume 17, pages 2301-2312, and 39.",
        "negative": "American Society Society (2015) Lung Cancer (Non-Small Cell) (<http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics>)ht tp:/ /ww w.ca n c er."
    },
    {
        "anchor": "Additionally, treatment with anti-CD19 CAR T-cell therapy can cause cytokine release syndrome (CRS) and neurologic toxicity (NT).",
        "positive": "Anti-CD19 CAR T-cell therapy may lead to cytokine release syndrome and neurologic toxicity as adverse effects.",
        "negative": "We hypothesized that CAR T cells orchestrate clinical activity by deploying multiple immune programs that functionally complement one another."
    },
    {
        "anchor": "Disease evaluation and neurotoxicity monitoring methodologies are provided in the Data Supplement (online only).",
        "positive": "The Data Supplement (available online) outlines the methods for evaluating disease and monitoring neurotoxicity.",
        "negative": "CPET and evaluation of dyspnea\nBefore and after the PRP, CPET was performed using a ramp protocol and breath-by-breath measurements on a cycle ergometer (Ergoline Ergoselect; SensorMedics, Milan, Italy) connected to computerized analyzer (Vmax encore 29C; SensorMedics)."
    },
    {
        "anchor": "Patients\nEligible patients had a pathologically confirmed diagnosis of metastatic NSCLC with a documented EGFR exon 19 deletion or exon 21 L858R substitution mutation.",
        "positive": "Patients with metastatic NSCLC and a confirmed EGFR mutation (exon 19 deletion or L858R substitution) were eligible for the study.",
        "negative": "Patients were EGFR TKI-treatment\u2013naive, except to erlotinib, in which stable doses for \u2265 11\u00a0days and \u2264 45\u00a0days were required; had an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; and had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria [(<>)28]."
    },
    {
        "anchor": "For full details regarding trial design, patients, and treatment, the reader is referred to [(<>)15].",
        "positive": "The reader is directed to reference [15] for a detailed description of the trial's design, patient selection, and treatment approach.",
        "negative": "Patients\nPatients with resectable NSCLC were recruited for the open-label, non-randomised, equal-sized two-cohort ATOM clinical trial (NCT02628080) completed at the Oxford Cancer and Haematology Centre (UK) in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines."
    },
    {
        "anchor": "If subjects only received pembrolizumab at Cycle 3/Day 1, these safety follow-up visits are not required.",
        "positive": "Patients who received pembrolizumab only at Cycle 3/Day 1 do not require additional safety follow-up visits.",
        "negative": "Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials\nS. S. Ramalingam1*,K.O\u2019Byrne2 , M. Boyer3,T.Mok4 , P. A. J\u00e4nne5 , H. Zhang6 , J. Liang6 , I. Taylor6 , E. I. Sbar6 & L. Paz-Ares7 Received 28 August 2015; revised 26 October 2015; accepted 18 November 2015 Background: The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors."
    },
    {
        "anchor": "Quality of life\nQLQ C 30 questionnaires were available for 34 of the 36 eligible patients and the results are presented in Fig.",
        "positive": "The QLQ C 30 questionnaires were administered to 34 of the 36 eligible patients, and the findings are presented in the figure.",
        "negative": "It is worth noting that no significant modification of the median global health status, physical functioning, pain and dyspnea occurred."
    },
    {
        "anchor": "The primary objectives of phase I were to investigate the safety and tolerability of isatuximab (anti-CD38 monoclonal antibody)+cemiplimab (anti-PD-1 monoclonal antibody, Isa+Cemi) in patients with mCRPC (na\u00efve to anti-PD-1/ PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PDL1-containing therapy).",
        "positive": "The main objectives of the phase I trial were to evaluate the safety and tolerability of the combination therapy (isatuximab and cemiplimab) in patients with mCRPC or NSCLC who had received prior anti-PD-1/PDL1 therapy.",
        "negative": "Usage\nestimateMedianLogicle(flow_set, channels, m = 4.5, q = 0.05)"
    },
    {
        "anchor": "Therefore, patients with HER2-mutant NSCLC are currently treated with standard chemotherapy or immunotherapy, which have limited activity as second- or later-line treatment.8-13 Furthermore, limited and varied results have been reported for responses to immune-checkpoint inhibitors in this population, with 7 to 27% of patients having an objective response to treatment.13,14 Clinical trials of the HER2 antibody trastuzumab in combination with chemotherapy showed disappointing outcomes in patients with NSCLC, in part because of difficulties in defining precise molecular criteria for the selection of patients who would benefit from HER2-targeted agents and the rarity of high-level HER2 protein expression or HER2 amplification in NSCLC in contrast to breast and gastric cancers.15-17 Other efforts in targeting HER2-mutant NSCLC have produced encouraging but inconsistent results, with objective response occurring in 0 to 30% of patients who receive HER2 tyrosine kinase inhibitors and antibodies and in 44% of those who receive the HER2 antibody\u2013drug conjugate trastuzumab emtansine.18-26 Trastuzumab deruxtecan (formerly DS-8201) is an antibody\u2013drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker.27,28 Its formulation incorporates a potent cytotoxic payload at a high drug-to-antibody ratio of approximately 8 while allowing it to remain stable in plasma until internalized and selectively cleaved by peptides that are overexpressed in cancer cells,27,28 thus releasing the highly potent payload to induce DNA damage and apoptosis, with bystander-killing effect in neighboring tumor cells.29 Trastuzumab deruxtecan has been approved in various countries worldwide for the treatment of patients with metastatic HER2-positive breast and gastric cancers on the basis of the results from pivotal trials.30,31 Results from its first-in-human study ((<http://ClinicalTrials.gov>)ClinicalTrials.gov number, (<https://clinicaltrials.gov/ct2/show/NCT02564900>)NCT02564900) showed preliminary antitumor activity in 11 patients with HER2mutant NSCLC, with a confirmed objective response occurring in 72.7% of the patients (95% confidence interval [CI], 39.0 to 94.0).32 Translational studies showed that HER2mutant NSCLC may preferentially internalize the HER2 receptor antibody\u2013drug conjugate complex regardless of HER2 protein expression and overcome resistance to other HER2targeted agents, which supports the further development of trastuzumab deruxtecan for treatment in this population.33 We evaluated trastuzumab deruxtecan in patients with NSCLC, and in this report we describe the results from the primary analysis involving the fully enrolled cohort of patients with a HER2 mutation.",
        "positive": "Patients with HER2-mutant NSCLC typically receive standard chemotherapy or immunotherapy as second-line treatment, which has limited efficacy. The response rates to immune-checkpoint inhibitors in this population have been inconsistent, ranging from 7 to 27%. Clinical trials combining trastuzumab with chemotherapy have shown disappointing results, partly due to difficulties in selecting patients who would benefit from HER2-targeted agents and the rarity of HER2 protein expression or amplification in NSCLC. Other efforts targeting HER2-mutant NSCLC have yielded encouraging but inconsistent results.",
        "negative": "Graphical Abstract\nTHE MAJORITY OF NON\u2013SMALL-CELL lung cancers (NSCLCs) are caused by oncogenic alterations, and the development of targeted therapies has contributed to a substantial reduction in mortality from NSCLC in recent years.1,2 Mutations in the gene encoding human epidermal growth factor receptor 2 (HER2, also called ERBB2) drive approximately 3% of nonsquamous NSCLCs and are associated with female sex, never-smoking history, and a poor prognosis, as well as with a slightly younger age and higher incidence of brain metastases than NSCLC without HER2 mutations or with other mutations.3-7 Although HER2 targeting has transformed the treatment of patients with breast and gastric cancers, HER2-targeted therapies have not been approved for patients with NSCLC."
    },
    {
        "anchor": "At the moment this includes all filters except (<>)filterReference, the only non-concrete filter at present.",
        "positive": "At present, all filters are included except for filterReference, which is the only non-concrete filter.",
        "negative": "Description\nThe concreteFilter serves as a base class for all filters that actually implement a filtering process."
    },
    {
        "anchor": "Quality or quantity of data recording is inaccurate or incomplete 2.",
        "positive": "The quality or quantity of data recording is inaccurate or incomplete, with a rating of 2.",
        "negative": "Plans to modify or discontinue the development of the study drug In the event of Merck decision to no longer supply study drug, ample notification will be provided so that appropriate adjustments to subject treatment can be made."
    },
    {
        "anchor": "The trial was approved by the hospital\u2019s institutional review board (K17-160, 17/10/2017).",
        "positive": "The trial received approval from the hospital's institutional review board on October 17, 2017 (K17-160).",
        "negative": "Table 2\nFrequency and Positive Predictive Value of Positive Screening Results, According to Study Group."
    },
    {
        "anchor": "Among patients with confirmed histology (n =\ue02021), the median OS was numerically longer in patients with non-squamous (38.5 months) vs. squamous histology (12.1 months) ((<>)Figure 4B).",
        "positive": "In patients with confirmed histology (n = 21), the median overall survival was significantly longer in those with non-squamous histology (38.5 months) compared to squamous histology (12.1 months), as shown in Figure 4B.",
        "negative": "Title: Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)\n\nAbstract: Introduction:UCART123v1.2 is a genetically modified allogeneic T-cell product manufactured from healthy donor cells."
    },
    {
        "anchor": "As previously reported, patient 1 had a complete eradication of blood and BM B-lineage cells for 36 weeks after his first infusion of anti\u2013CD19-CAR\u2013transduced T cells.21 Nine weeks after his second treatment, patient 1 was found to have a normal number of poly-clonal blood B cells.",
        "positive": "Previously, patient 1 had a complete clearance of blood and bone marrow B-lineage cells for 36 weeks after his first infusion of anti-CD19-CAR-transduced T cells. Following his second treatment, his blood B cells normalized nine weeks later.",
        "negative": "8.2.3.2 Safety Analysis Populations\nThe All Patients as Treated (APaT) population will be used for the analysis of safety data in this study."
    },
    {
        "anchor": "Although patients with disease progression will no longer receive either the study medication or placebo, where possible they will remain in the trial for the evaluation of the primary endpoint, overall survival time.",
        "positive": "Patients whose disease has progressed will not receive further treatment, but they will remain in the trial to evaluate overall survival.",
        "negative": "Table 1 Key inclusion and exclusion criteria\nof the vaccine [(<>)28]."
    },
    {
        "anchor": "\ue014\ue013\ue011\ue017\ue003 &RQILGHQWLDOLW\\\ue0126WRUDJH\ue003\ue003\n(See the Patient Tissue Consent Frequently Asked Questions, http://www.rtog.org/Researchers/BiospecimenResource/BiospecimenResourceFAQs.aspx for further details.)",
        "positive": "For more information, please consult the Patient Tissue Consent Frequently Asked Questions, available at http://www.rtog.org/Researchers/BiospecimenResource/BiospecimenResourceFAQs.aspx.",
        "negative": "Background\nNon-small cell lung cancer (NSCLC) is the leading cause of cancer death in men and women worldwide."
    },
    {
        "anchor": "Sym015 induces CDC and ADCC.",
        "positive": "Sym015 triggers both CDC and ADCC.",
        "negative": "Conclusions\nThe results suggest that chemotherapy plus orally icotinib displayed better DFS compared with chemotherapy only, yet the difference in DFS was not significant."
    },
    {
        "anchor": "All analyses were performed using SAS version 9\u00b72 (SAS Institute, Inc., Cary, NC, USA) with the exception of the unpaired t test for DOR, which was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).",
        "positive": "All statistical analyses were conducted using SAS version 9.2, except for the unpaired t test for DOR, which was performed using GraphPad Prism.",
        "negative": "Statistical Analysis\nAs a dose-finding study, no hypothesis was pre-established and no power calculation was done; due to the dynamic nature of dose escalation schema, the sample size was not defined prior to study initiation."
    },
    {
        "anchor": "Neoadjuvant chemotherapy was allowed at the discretion of medical oncologist.",
        "positive": "Neoadjuvant chemotherapy was administered at the discretion of the medical oncologist.",
        "negative": "ABSTRACT\nIntroduction: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their overall survival (OS)."
    },
    {
        "anchor": "CD45RO was used to distinguish between antigen experienced (positive) and antigen inexperienced (negative) cells.",
        "positive": "CD45RO was employed to distinguish between cells that had been exposed to the antigen (positive) and those that had not (negative).",
        "negative": "Introduction\nRefractory or relapsed B-cell acute lymphoblastic leukemia (ALL) is often resistant to chemotherapy and has a very poor prognosis1,2."
    },
    {
        "anchor": "Meta-analyses and systematic reviews indicate an absolute survival advantage of 3-4% at 2 years and an increase in median survival by 1.7 months with the addition of chemotherapy to RT (Sandulache 2012, Pierotti 2013).",
        "positive": "Meta-analyses and systematic reviews have shown that the addition of chemotherapy to RT results in a 3-4% absolute survival advantage at 2 years and a 1.7-month increase in median survival (Sandulache 2012, Pierotti 2013).",
        "negative": "\ue014\ue011\ue014\ue011\ue016\ue003 Role of Chemoradiotherapy\nOver the last 3 decades, chemotherapy has been investigated as neo-adjuvant, concurrent, or adjuvant treatment to improve local control and distant metastases rates achieved with high-dose RT in locally advanced NSCLC."
    },
    {
        "anchor": "Ann Oncol 26:1883-1889, 2015 10.",
        "positive": "A publication in the journal Annals of Oncology, volume 26, pages 1883-1889, 2015, references the study.",
        "negative": "Author contributions\nAll authors contributed to the conception and design of the work and were involved in the analysis and interpretation of data."
    },
    {
        "anchor": "Wistuba reports receiving a commercial research grant from Genentech/ Roche and is a consultant/advisory board member for Genentech/Roche and Ventana.",
        "positive": "Dr. Wistuba has a financial relationship with Genentech/Roche, having received a grant and serving as a consultant and advisory board member, and also has a relationship with Ventana.",
        "negative": "European Medicines Agency."
    },
    {
        "anchor": "Therefore, data from the trial will not be shared publicly as data sharing was not included when ethical approval was requested.",
        "positive": "Due to the absence of data sharing in the initial ethical approval request, the trial data will not be publicly disclosed.",
        "negative": "Acknowledgement:\nThe initial clinical trial was supported by Novartis clinical trial support and the CHOP Cancer Immunotherapy Frontier Program."
    },
    {
        "anchor": "As a result, we developed clinical guidelines for the ELIANA and ENSIGN trials for the monitoring and management of CRS-associated hypofibrinogene-mia and the use of fibrinogen concentrate.",
        "positive": "Following this, we created clinical guidelines for the ELIANA and ENSIGN trials to monitor and manage CRS-associated hypofibrinogenemia and the use of fibrinogen concentrate.",
        "negative": "Discussion\nConsistent with the experience from an earlier single-center study,11 CRS-associated coagulopathy with hypofibrinogenemia was observed in pediatric and young adult patients with B-ALL who were treated with tisagenlecleucel in the multicenter ELIANA and ENSIGN trials."
    },
    {
        "anchor": "More patients with lung cancer were treated with some combination of surgery, chemotherapy, and radiotherapy in the low-dose CT group than in the radiography group (277 vs. 181), but stage IA cancers that were treated only with surgery accounted for most of the difference (117 such cancers in the low-dose CT group vs. 40 in the radiography group) (Table 2 in the Supplementary Appendix).",
        "positive": "In the low-dose CT group, more patients with lung cancer received a combination of surgery, chemotherapy, and radiotherapy compared to the radiography group (277 vs. 181), with the majority of the difference due to stage IA cancers treated with surgery alone (117 in the low-dose CT group vs. 40 in the radiography group), as detailed in Table 2 of the Supplementary Appendix.",
        "negative": "STAGE, HISTOLOGIC FEATURES, AND TREATMENT OF LUNG CANCER\nThere were 292 cases of diagnosed lung cancer in the low-dose CT group and 190 in the radiography group, with the difference nearly completely accounted for by the higher incidence of stage IA cancer in the low-dose CT group (132 cases, vs. 46 in the radiography group)."
    },
    {
        "anchor": "AK Sasser: conceptualization and writing\u2014review and editing.",
        "positive": "AK Sasser contributed to the study's conceptualization, writing, and review and editing processes.",
        "negative": "Transient or permanent host B cell depletion is also a potential risk with CART22 cells, since B cells express CD22."
    },
    {
        "anchor": "This will ensure timely communication between the clinical site and the RTOG.",
        "positive": "This measure aims to promote timely communication between the clinical site and the RTOG.",
        "negative": "CAR T Cell Persistence\nCAR+ T cells were not definitively detected in the peripheral blood or BM of any patients by fluorescence-activated cell sorting (FACS; at a threshold of R1% of CD3+ cells) or by qPCR post-infusion."
    },
    {
        "anchor": "7.1.1.5.2 Prior Treatment Details The investigator or qualified designee will review all prior cancer treatments including systemic treatments, radiation and surgeries.",
        "positive": "The investigator or qualified designee will review all prior cancer treatments, including systemic treatments, radiation therapy, and surgeries.",
        "negative": "Once new anti-cancer therapy has been initiated the subject will move into survival follow-up."
    },
    {
        "anchor": "Purpose\nLinifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non\u2013small-cell lung cancer (NSCLC).",
        "positive": "The purpose of Linifanib is to inhibit VEGF and PDGF receptors, demonstrating single-agent activity in non-small-cell lung cancer (NSCLC).",
        "negative": "Baseline Patient Characteristics\nA total of 296 patients with advanced solid tumors, including melanoma (104 patients), non\u2013 small-cell lung cancer (122), renal-cell cancer (34), castration-resistant prostate cancer (17), and colorectal cancer (19), began treatment with anti\u2013 PD-1 antibody between October 2008 and February 24, 2012."
    },
    {
        "anchor": "Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.",
        "positive": "The initial assessment of treatment-related pneumonitis was conducted in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.",
        "negative": "Title: Enhancing \u03b1-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax\n\nAbstract: IntroductionClinical outcomes of anti-CD19 chimeric antigen receptor T cell (CAR T) therapy for the treatment of relapsed/refractory Diffuse Large B Cell lymphoma (r/r DLBCL) must be improved, as patients undergoing CAR T therapy can expect a cure rate of 41% and median survival of just 6.3 months if unresponsive."
    },
    {
        "anchor": "INCLUSION AND DIVERSITY\nWe support inclusive, diverse, and equitable conduct of research.",
        "positive": "We strive to conduct research in an inclusive, diverse, and equitable manner.",
        "negative": "Received: October 5, 2022 Revised: July 14, 2023 Accepted: October 12, 2023 Published: November 8, 2023"
    },
    {
        "anchor": "Each subject provided written informed consent before any procedure of this study.",
        "positive": "Each participant provided written consent prior to any study procedure.",
        "negative": "Naiyer A Rizvi\nColumbia University Medical Center, New York, NY, USA"
    },
    {
        "anchor": "All patients were required to have tumor specimens for PD-L1 testing at a central laboratory; PD-L1 status was determined using the PD-L1 IHC 22C3 pharmDx kit.",
        "positive": "Tumor specimens were required for PD-L1 testing at a central laboratory, using the PD-L1 IHC 22C3 pharmDx kit.",
        "negative": "Randomization was stratified by tumor histology (esophageal squamous cell carcinoma [ESCC] vs. esophageal adenocarcinoma [EAC]/Siewert type I EAC of the gastroesophageal junction [GEJ]), and geographic region (Asia vs. ex-Asia)."
    },
    {
        "anchor": "Dose de-escalation and re-escalation will be documented.",
        "positive": "Changes in dosing will be recorded.",
        "negative": "7.6.1 Temporary Interruption, Reduction and Re-initiation of Metformin Treatment\nIn the event of grade 2 or 3 gastrointestinal toxicity (typically involving flatulence or diarrhea), patients will be supported with loperamide."
    },
    {
        "anchor": "4.1.1 Pre-consultation Assessments\nThe pre-consultation questionnaires will take about 20-30 minutes to complete.",
        "positive": "The pre-consultation questionnaires will take approximately 20-30 minutes to complete.",
        "negative": "\u2022 Decision Support Preference Questionnaire (DMPQ) \u2022 FACT-L \u2022 NCCN-Functional Assessment of Cancer Therapy Lung Symptom Index-17 (NFLSI-17)."
    },
    {
        "anchor": "Demographic and Baseline Disease Characteristics in Patients in MAIA Based on MRD Durability\nMRD, minimal residual disease; D-Rd, daratumumab plus lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; ITT, intent to treat; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; ISS, International Staging System.",
        "positive": "The MAIA study's patient demographics and baseline disease characteristics, including MRD durability, are as follows: MRD, minimal residual disease; D-Rd, daratumumab plus lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; ITT, intent to treat; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; ISS, International Staging System.",
        "negative": "Michele Taffaro-Neskey, PA-C,\nDepartment of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA"
    },
    {
        "anchor": "Galunisertib is an oral small molecule inhibitor of the TGF-\u03b2 receptor 1 kinase that specifically down-regulates the phosphorylation of SMAD2 and is associated with an increase in T-cell infiltration in tumors [(<>)21, (<>)22].",
        "positive": "Galunisertib is an oral small molecule inhibitor of the TGF-\u03b2 receptor 1 kinase that specifically down-regulates the phosphorylation of SMAD2 and is associated with increased T-cell infiltration in tumors.",
        "negative": "Study population:\nThis study was approved by our Institutional Review Board."
    },
    {
        "anchor": "Median concentrations are depicted by red lines.",
        "positive": "Median values are represented by red lines.",
        "negative": "3.1.1 | Survival outcomes\nAt a median follow-up of 31.3 months (range: 27.4\u201340.0 months) in surviving patients, two-year PFS was 44% (95% CI 25%\u201376%) in all Data on B-cell recovery was available for 15 of 16 patients (Table S2; Figure S2)."
    },
    {
        "anchor": "(<>)2B, for the comparison between pralsetinib and pembrolizumab with chemotherapy, the black curve was plotted at the point estimate 0.37 (95% CI 0.21\u20130.67).",
        "positive": "The black curve illustrates the point estimate of 0.37 (95% CI 0.21\u20130.67) for the comparison between pralsetinib and pembrolizumab with chemotherapy.",
        "negative": "Comparative effectiveness\nCGDB RET fusion-positive comparison."
    },
    {
        "anchor": "These data are useful when discussing prognosis with patients after initial SABR.",
        "positive": "The data can be used to inform discussions about prognosis with patients following initial SABR treatment.",
        "negative": "Micro-abstract\nThe impact of lung parenchymal-only failure on patient survival after stereotactic body radiotherapy (SABR) for early stage non-small cell lung cancer remains unclear."
    },
    {
        "anchor": "Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors.",
        "positive": "A study examined the activity of afatinib and cetuximab in patients with EGFR-mutated non-small cell lung cancer that had progressed after initial treatment with EGFR inhibitors.",
        "negative": "Abbreviations\nEGFR: epidermal growth factor receptor; TKI: tyrosine-kinase inhibitor: CUP, Compassionate use program; NSCLC: non-small-cell lung cancer; ECOG: Eastern Cooperative Oncology Group; ORR: objective response rate; DCR: disease control rate; PFS: progression-free survival; OS: overall survival; TTP: time to progression; NPU: named patient use; PCR: polymerase chain reaction; RECIST: Response Evaluation Criteria for Solid Tumors; CT: computed tomography; CTCAE: Common Terminology Criteria for Adverse Events; SPSS: Statistical Package for Social Sciences."
    },
    {
        "anchor": "[3H]-digoxin was used as a P-gp probe substrate.",
        "positive": "Tritiated digoxin was used as a probe to investigate the function of P-glycoprotein.",
        "negative": "Discussion\nIn this study, we demonstrate the feasibility of dual targeting of CD19 and CD22 using a bicistronic CAR T cell therapy (AUTO3) in a cohort of pediatric and young adult patients with relapsed or refractory B cell ALL."
    },
    {
        "anchor": "Proc Natl Acad Sci USA 2006; 103: 9166\u201371.16757567 11.",
        "positive": "A study published in the Proceedings of the National Academy of Sciences in 2006 reported the results of research on the topic.",
        "negative": "N Engl J Med 2015; 373: 1627\u201339.26412456 2."
    },
    {
        "anchor": "For the purposes of the research, they will continue to be followed for toxicity and survival.",
        "positive": "The patients will be tracked for toxicity and survival outcomes as part of the research.",
        "negative": "\ue018\ue011\ue018\ue003\ue003\ue003\ue003'XUDWLRQ\ue003RI\ue0037KHUDS\\\ue003\nIn the absence of treatment delays due to adverse events, treatment may continue through completion of concurrent chemoradiotherapy and consolidation chemotherapy or until one of the following criteria applies: \u2022 Local-regional disease progression \u2022 Intercurrent illness that prevents further administration of treatment \u2022 Unacceptable adverse events(s) \u2022 Patient decides to withdraw from the study \u2022 General or specific changes in the patient's condition render the patient unacceptable for   further treatment in the judgment of the investigator."
    },
    {
        "anchor": "Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ((<https://openpaymentsdata.cms.gov/>)Open Payments).",
        "positive": "A publicly available database, Open Payments, provides information on payments made by companies to US-licensed physicians.",
        "negative": "Title: CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "The concentrations of the cytokines were determined with recombinant standards and expressed as pg/mL values.",
        "positive": "The levels of cytokines were measured using recombinant standards and reported in picograms per milliliter.",
        "negative": "Pharmocodynamics\nSample preparation\u2014Blood was collected in an ETDA-containing vacutainer at pretreatment (baseline), and on C1D15 cycle 2 day 15 (C2D15)."
    },
    {
        "anchor": "The dead cells were stained with FVS510 (BD Biosciences).",
        "positive": "Cells that had died were labeled with FVS510, a product of BD Biosciences.",
        "negative": "Intracellular cytokine staining of PBMCs\nARG1 peptide-specific T cell response phenotype was tested by intracellular cytokine staining (ICS) of PBMCs stimulated with the individual 20-mer peptides."
    },
    {
        "anchor": "We first considered all T-cells in our scATAC-Seq data, finding that the chromatin co-accessibility scores associated with these TCF7 peak-promoter pairs were enriched compared to the null distribution of non-TCF7\u00adrelated promoter-peak pairs (Supplementary Fig.",
        "positive": "Our analysis of scATAC-Seq data initially focused on T-cells, revealing that chromatin co-accessibility scores for TCF7 peak-promoter pairs were significantly enriched compared to non-TCF7-related pairs.",
        "negative": "Epigenetic regulation of TCF7 and its downstream targets remains partially active in effector T-cells\nWe investigated the epigenetic regulation of T-cell states and TCF7 function through integration of single-cell ATAC-Seq data with CITE-Seq data."
    },
    {
        "anchor": "Data are presented as the median and range for continuous variables and frequency for categorical variables.",
        "positive": "The data are displayed as medians and ranges for continuous variables and frequencies for categorical variables.",
        "negative": "All patients who received CART-ddBCMA infusion were included in this analysis as was planned per protocol."
    },
    {
        "anchor": "Patients who achieved sustained MRD negativity for \u226512 months had more favorable PFS than the overall population (Figure 1B).",
        "positive": "Patients who maintained MRD negativity for at least 12 months had a more favorable progression-free survival compared to the overall patient population, as shown in Figure 1B.",
        "negative": "Title: Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up\n\nAbstract: Introduction:Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR)-T cell therapy with 2 B-cell maturation antigen (BCMA)-targeting single-domain antibodies approved for the treatment of relapsed/refractory multiple myeloma (RRMM) in the US and EU."
    },
    {
        "anchor": "Circular ecDNA promotes accessible chromatin and high oncogene expression.",
        "positive": "Circular extrachromosomal DNA facilitates open chromatin structure and elevated oncogene expression.",
        "negative": "Matsushime H, Wang L-H, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a trans-membrane receptorlike molecule."
    },
    {
        "anchor": "We further performed integrated analysis of multi-omic data from PD-L1 expression, TMB, CD8 + TIL density, whole-exome, and transcriptome sequencing on tumor biopsies to identify the potential predictive biomarkers.",
        "positive": "We conducted a comprehensive analysis of multi-omic data, including PD-L1 expression, TMB, CD8 + TIL density, whole-exome, and transcriptome sequencing, to identify potential biomarkers for predicting treatment outcomes.",
        "negative": "1 CONSORT diagram for this phase-II study\n20 25 26 27 28 tumors.,Additional evidence showed that chemotherapy-induced neoantigen release could modulate the TME to have a potentially synergistic effect with ICIs.,Meanwhile, the addition of atezolizumab to bevacizumab plus chemotherapy showed superior efficacy in patients with EGFR-mutant NSCLC from IMPOWER 150 study,indicating potent clinical benefitof chemoimmunotherapy combination in this setting."
    },
    {
        "anchor": "We also observed generally mild skin and gastrointestinal toxicities, although in the current study, six patients in the cisplatin-containing treatment groups experienced XGrade 3 nausea (three each in gemcitabine and cisplatin plus selumetinib 75 mg, and pemetrexed and cisplatin plus selumetinib 75 mg groups).",
        "positive": "Mild skin and gastrointestinal side effects were observed, with six patients in the cisplatin-containing treatment groups experiencing Grade 3 nausea, with three patients each in two treatment groups.",
        "negative": "DISCUSSION\nIn the first-line setting, platinum-doublet chemotherapy represents the standard of care for patients with advanced NSCLC without EGFR activating mutation or ALK gene rearrangement, but objective response rates are low (15\u201331%) and median survival is generally up to approximately 10 months ((<>)Schiller et al, 2002; (<>)Sandler et al, 2006; (<>)Scagliotti et al, 2008)."
    },
    {
        "anchor": "LC-MS/MS analysis of each fraction was performed with a nanoflow ultra high performance liquid chromatograph (RSLC, Dionex, Sunnyvale, CA) coupled to an electrospray bench top orbitrap mass spectrometer (Q-Exactive plus, Thermo, San Jose, CA).",
        "positive": "Each fraction was analyzed using a nanoflow ultra high performance liquid chromatograph (RSLC) and an electrospray bench top orbitrap mass spectrometer (Q-Exactive plus) from Dionex and Thermo, respectively.",
        "negative": "Proteomics\nTissue samples were pulverized and denaturing buffer was used to extract the proteins, followed by protein reduction, alkylation and trypsin digestion."
    },
    {
        "anchor": "Receipt of either curative treatment showed crude rates of 96.5% for Black and 95% for White patients (P = 0.56).",
        "positive": "The crude rates of treatment success were 96.5% for Black patients and 95% for White patients, with a statistically insignificant difference (P = 0.56).",
        "negative": "Discussion\nThe results of this phase 3 trial involving patients with untreated metastatic, squamous NSCLC showed that the addition of pembrolizumab to standard chemotherapy with carboplatin and either paclitaxel or nab-paclitaxel, as compared with chemotherapy alone, prolonged median overall survival by 4.6 months (15.9 months vs. 11.3 months) and median progression-free survival by 1.6 months (6.4 months vs. 4.8 months)."
    },
    {
        "anchor": "Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in PTS with melanoma who progressed during prior anti\u2013PD-1/PD-L1 therapy (MEL prior io) in all-comer and biomarker-enriched populations.",
        "positive": "The efficacy of BMS-986016, a monoclonal antibody targeting LAG-3, in combination with nivolumab was evaluated in patients with melanoma who had progressed during prior anti-PD-1/PD-L1 therapy, in both all-comer and biomarker-enriched populations.",
        "negative": "REFERENCES\n1 Andrews LP, Marciscano AE, Drake CG, et al."
    },
    {
        "anchor": "Most CAR T-cell therapy trials to date have engineered CAR T-cells from the bulk population of T-cells extracted from the patient, consisting of a mixture of CD4+ and CD8+ T-cells across naive, memory, and effector lineages.",
        "positive": "CAR T-cell therapy trials have typically used a bulk population of T-cells from patients, consisting of a mixture of CD4+ and CD8+ T-cells across naive, memory, and effector lineages.",
        "negative": "Introduction\nChimeric Antigen Receptor (CAR) T-cell therapy has been a breakthrough in cancer therapy, yet failure to achieve long-term CAR T-cell persistence remains a major barrier to sustained remission in many patients."
    },
    {
        "anchor": "But, it is important to highlight that histologic and cytologic samples typically differ in both size and processing technique.",
        "positive": "The size and processing technique of histologic and cytologic samples can differ significantly.",
        "negative": "Sym015 internalizes and degrades MET, leading to decreased downstream signaling\nInternalization and degradation of RTKs have been shown to effectively hinder interaction with ligands and dimerization partners and block downstream signaling (19, 21, 31)."
    },
    {
        "anchor": "Also, lymph node size did not predict an inadequate specimen: 4 lymph nodes were > 10 mm, 4 lymph nodes were \u226410 mm.",
        "positive": "The size of lymph nodes did not predict specimen adequacy, with 4 lymph nodes measuring > 10 mm and 4 lymph nodes measuring \u226410 mm.",
        "negative": "DISCUSSION\nOn the basis of the preclinical and clinical activity of the afatinib-cetuximab combination in the acquired resistance setting\u0131 \u00a8along with preclinical data in the TKI-na ve setting, we performed this randomized multicenter trial in treatment-na\u0131 \u00a8ve patients with EGFR-mutated NSCLC, hypothesizing that a delay in acquired resistance would occur."
    },
    {
        "anchor": "The log-rank test, stratified by histology (squamous cell vs. nonsquamous cell) was used to compare PFS determined by central imaging review, OS between treatment groups, and DOR.",
        "positive": "The log-rank test was used to compare PFS, OS, and DOR between treatment groups, stratified by histology (squamous cell vs. nonsquamous cell), using central imaging review.",
        "negative": "Objects from the Class\nObjects can be created by calls of the form new(\"transformList\",...), by calling the (<>)transform method with key-value pair arguments of the form key equals character and value equals function, or by using the constructor transformList."
    },
    {
        "anchor": "Once eligibility has been established, patients will be invited to join the study by the local clinical team.",
        "positive": "Following eligibility verification, patients will be approached by the local clinical team to participate in the study.",
        "negative": "Results\nFourteen patients received treatment as per dose cohorts in Table (<>)2 (melanoma =3, NSCLC =3, renal cell carcinoma =2, bladder/urothelial =2, ovarian cancer =1, adenoid cystic carcinoma =1, pleural mesothelial =1, head and neck cancer =1)."
    },
    {
        "anchor": "The funding source had no role in the design of this study and will not have any role during the execution, analyses, interpretation of the data, or writing the manuscript.",
        "positive": "The funding agency was not involved in the study's design and will not participate in its execution, data analysis, interpretation, or manuscript preparation.",
        "negative": "2.0 OBJECTIVES\nTo assess the impact of ES-IMRT versus standard palliative RT on quality of life, survival, toxicity and cost-effectiveness in patients with metastatic/locally advanced lung cancer, in the year after RT."
    },
    {
        "anchor": "Prohibited mediations included systemic immuno-suppressive treatment (e.g.",
        "positive": "The study excluded patients receiving systemic immunosuppressive therapy, such as.",
        "negative": "ACKNOWLEDGMENTS\nThis study was funded by Sanofi."
    },
    {
        "anchor": "A patient is classified as having PD due to \u2022symptomatic deterioration\u2022 if any of the following occur that are not either related to study treatment or other medical conditions: x Weight loss >10% of body weight.",
        "positive": "A patient is considered to have PD if they experience a significant decline in health status, defined as a weight loss of more than 10% of their body weight, unless this is due to study treatment or another underlying medical condition.",
        "negative": "10.6 Data Management\nThe policies and procedures of Rutgers University\u2019s legal department (see: Investigator\u2019s Handbook) will govern publication of the trial."
    },
    {
        "anchor": "Hurwitz, D.C. Cho Analysis and interpretation of data (e.g., statistical analysis, bio-statistics, computational analysis): A. Diab, N.M. Tannir, S.-E. Bente-bibel, P. Hwu, V. Papadimitrakopoulou, C. Haymaker, H.M. Kluger, S.N.",
        "positive": "Data analysis and interpretation were performed by a team consisting of D.C. Hurwitz, N.M. Tannir, S.-E. Bente-bibel, P. Hwu, V. Papadimitrakopoulou, C. Haymaker, H.M. Kluger, and S.N.",
        "negative": "2.5\u2003| Statistical analysis\n19\u2013 , The primary analysis was performed at 6 months after the last patient in the Japanese cohort had received cilta-cel."
    },
    {
        "anchor": "This combination of PD-1 inhibition and radiation therapy can prime endogenous antigen-specific immune response and provide an additional mechanistic rationale for combining radiation with PD-1 blockade.",
        "positive": "The combination of PD-1 inhibition and radiation therapy can stimulate the body's natural immune response and provide a scientific basis for combining radiation with PD-1 blockade.",
        "negative": "4.2.1.2 Data Supporting Concurrent Immunotherapy and PD-1 Blockade with Concurrent Chemoradiation\nAvailable preclinical data about immunotherapy concurrent with radiation suggest a benefit to combining immunotherapy during radiation therapy."
    },
    {
        "anchor": "We proposed that several modifications to the GD2.CARmodified VST generation protocol would also improve the ability of the modified T-cells to expand and persist in recipients.",
        "positive": "We suggested that several changes to the GD2.CARmodified VST generation protocol would enhance the ability of the modified T-cells to proliferate and persist in recipients.",
        "negative": "Background\nA major problem with chimeric antigen receptor (CAR)-modified T-cells for the treatment of solid tumors is their lack of in vivo proliferation [(<>)1,(<>)2]."
    },
    {
        "anchor": "Two mutations identified in the plasma samples could not be validated because the sample was insufficient (total droplet number was too low for the digital PCR).",
        "positive": "The plasma samples contained insufficient material to validate two identified mutations due to the low total droplet count for digital PCR.",
        "negative": "Discussion\nThis report describes the first demonstration of a PNA clamping-assisted fluorescence melting curve analysis for the detection of EGFR and KRAS mutations in the plasma cfDNA of NSCLC patients."
    },
    {
        "anchor": "detected using the AmoyDx EGFR 29 Mutations Detection Kit (Amoy Diagnostics Co., Ltd; Xiamen, Fujian, China).",
        "positive": "The EGFR 29 Mutations Detection Kit from Amoy Diagnostics Co., Ltd (Xiamen, Fujian, China) was employed to identify.",
        "negative": "EGFR Mutation Analysis\nReal-time PCR was performed using 10 ng genomic DNA, which was extracted from specimens, in the presence of 5 mL 10\ue004 buffer (160 mM (NH4) 2SO4, 670 mM Tris\u2013HCl (pH 8.8), and 0.1% Tween 20), 10 mL MgCl2 (25 mM), 1 mL of each deoxynucleoside triphosphate (25 mM), 1 mL of primers and probes (50 pM), and 1.0 U Taq enzyme."
    },
    {
        "anchor": "TGF-\u03b2 activation after irradiation can occur via reactive oxygen species or other indirect mechanisms.",
        "positive": "TGF-\u03b2 activation can be induced by irradiation, potentially through reactive oxygen species or other indirect mechanisms.",
        "negative": "Study design\nThe present analysis is based on the ongoing TRANSCEND study, an open-label, nonrandomized, multicenter, multicohort, seamless phase 1 study of the safety, antitumor activity, and pharmacokinet-ics of liso-cel in adults with R/R B-cell NHL.6 The study protocol and protocol amendments were approved by the institutional review boards at participating sites."
    },
    {
        "anchor": "Similarly, in familial and sporadic forms of succi-nate dehydrogenase (SDH) deficient RCC, there is a lack of the functional enzyme, SDH, which converts succinate to fumarate in the TCA cycle.",
        "positive": "In both familial and sporadic cases of SDH-deficient renal cell carcinoma, the absence of the SDH enzyme, which is responsible for converting succinate to fumarate in the TCA cycle, is a common feature.",
        "negative": "GLUTAMINE-AND GLUTAMINASEADDICTION IN RCC -WHEN GLUCOSE CAN\u2019T DO THE JOB\nIn this section, we will review the molecular mechanisms proposed for the dependence on extracellular glutamine and glutaminase activity in RCC."
    },
    {
        "anchor": "LCL, LF, CLJ, and YXY downloaded the data and prepared the figures.",
        "positive": "LCL, LF, CLJ, and YXY were responsible for downloading the data and creating the figures.",
        "negative": "Ling-Chen Li and Xie-Wan Chen have contributed equally to this work."
    },
    {
        "anchor": "ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.",
        "positive": "ZD6474, a KDR tyrosine kinase inhibitor, efficiently blocks the activity of oncogenic RET kinases.",
        "negative": "Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer."
    },
    {
        "anchor": "The initial portion of the trial was a phase I dose escalation study using a standard 3 + 3 design to determine a MTD over six dose levels of sepantronium bromide (3.6\u201312 mg/m2).",
        "positive": "The trial began with a phase I dose escalation study, using a standard 3 + 3 design, to establish the maximum tolerated dose of sepantronium bromide over six dose levels (3.6\u201312 mg/m2).",
        "negative": "statistical methods\nThe primary objectives of this study were to conduct a phase I trial to determine the maximum tolerated dose (MTD) of sepantronium bromide when combined with standard dose levels of carboplatin and paclitaxel, and to determine in a phase II study if this drug combination was associated with an objective response rate which exceeds that of 15% historically seen with carboplatin and paclitaxel alone in patients with stage IV NSCLC [(<>)22]."
    },
    {
        "anchor": "Authors\u2019 contributions\nMG, WH, and HA conceived and designed the study; BC, YW, and YZ analyzed and interpreted the data; BC, MG, and HA wrote the manuscript; JY, CY, QS, JQ, KH, HZ, ZD, ZZ, YH, and MF provided the study materials or patients; YG, HD, BL, YS, TL, ZL, YW, and BY performed the experiments.",
        "positive": "MG, WH, and HA led the study design; BC, YW, and YZ analyzed the data and drew conclusions; BC, MG, and HA authored the manuscript; JY, CY, QS, JQ, KH, HZ, ZD, ZZ, YH, and MF provided study materials and patients; YG, HD, BL, YS, TL, ZL, YW, and BY performed the experiments.",
        "negative": "Abbreviations\nAE: Adverse event; ALK: Anaplastic lymphoma kinase; bid: Twice daily; BP: Blood pressure; CI: Confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; CYP: Cytochrome P450; ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR: Epidermal growth factor receptor; FLT: [18F] fluorodeoxythymidine; MDASI: M. D. Anderson Symptom Inventory; NSCLC: Non-small-cell lung cancer; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; PROs: Patient-reported outcomes; RECIST: Response Evaluation Criteria in Solid Tumors; TKI: Tyrosine kinase inhibitor; VEGF: Vascular endothelial growth factor."
    },
    {
        "anchor": "Final analysis was conducted at the time of study completion, which was defined as approximately 2 years after enrollment of the last patient.",
        "positive": "The final analysis was performed at the end of the study, which was approximately 2 years after the last patient was enrolled.",
        "negative": "Study Design and Treatments\nThis was an open-label, single-arm phase 1 study comprising a dose-finding portion (phase 1a) and a dose-expansion portion (phase 1b)."
    },
    {
        "anchor": "The primary objectives of phase I, the safety run-in, were to characterize the safety and tolerability of Isa+Cemi in patients with mCRPC (na\u00efve to anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy) and to confirm the recommended phase II dose (RP2D).",
        "positive": "The primary goals of the phase I safety run-in were to assess the safety and tolerability of Isa+Cemi in patients with mCRPC (untreated with anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy) and to establish the recommended phase II dose.",
        "negative": "Study design and objectives\nThis was an open-label, multicenter, phase I/II study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of Isa+Cemi in patients with mCRPC or NSCLC."
    },
    {
        "anchor": "A U T H O R S ' \ue003 C O N C L U S I O N S\nImplications for practice So far, based on this updated review, there is no evidence showing better survival outcomes associated with the addition of immunotherapy (excluding checkpoint inhibitors) for people with stages I to III NSCLC.",
        "positive": "The authors' conclusion is that, based on this updated review, there is no evidence to support the notion that immunotherapy (excluding checkpoint inhibitors) improves survival outcomes for patients with stages I to III NSCLC.",
        "negative": "For yearly survival rate analyses, for which more data were available, we found no clear diEerences between the treatment groups for 1-year, 2-year, 3-year, or 5-year survival rates, with significant heterogeneity across the trials for the 1-year rate, which could not be fully explained by either variation in study quality or the clinical diEerences in the trials."
    },
    {
        "anchor": "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).",
        "positive": "New response evaluation criteria for solid tumors: RECIST guideline, version 1.1.",
        "negative": "Unanticipated Problems Involving Risk to Patients or Others\nAny incident, experience, or outcome that meets all of the following criteria: \uf0b7 Unexpected in nature, severity, or frequency (i.e."
    },
    {
        "anchor": "The immunocytokine huKS-IL2 is in clinical development and is not currently approved by any regulatory authority, including the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).",
        "positive": "The immunocytokine huKS-IL2 is in clinical development and has not been approved by any regulatory agency, including the EMA or FDA.",
        "negative": "1.7.1 Dose Rationale: CART-EGFRvIII cells\nIn the phase I study of CART-EGFRvIII cells for GBM (NCT02209376), subjects received a single dose of CART-EGFRvIII cells at a median dose of 5x108 (range 1.75 x 108 \u2013 5 x 108)."
    },
    {
        "anchor": "Cytokine markers were additionally measured on the serum samples from 10 healthy volunteers16 .",
        "positive": "Cytokine levels were assessed in the serum of 10 healthy volunteers.",
        "negative": "Study design\nThe SWORD trial (NCT04106180) was a single arm, open-label, multicentre, phase II study with a safety run-in phase."
    },
    {
        "anchor": "The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562).",
        "positive": "The combination of nimotuzumab and gefitinib did not show improved outcomes compared to gefitinib alone in advanced NSCLC patients.",
        "negative": "ABSTRACT\nWe aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy."
    },
    {
        "anchor": "Tumor growth was monitored as indicated for the patient-derived tissue xenografts by caliper analysis.",
        "positive": "The growth of patient-derived tumor tissue xenografts was tracked using caliper measurements.",
        "negative": "An equally small incision (0.8 cm) was made into the peritoneum, the pancreas was mobilized and exposed."
    },
    {
        "anchor": "D, Repeat\u2010dose ASP8273 plasma concentration (phase II) TABLE 3 Best overall response rate (ORR) across all doses (local review) among patients with non\u2010small\u2010cell lung cancer treated with ASP8273 The ORR at week 24, which was assessed at an independent central site, for the phase II population (N = 76) treated with ASP8273 300 mg, was 42% (n = 32; 95% CI, 30.9, 54.0).",
        "positive": "In a phase II trial, the response rate to ASP8273 300 mg was 42% at week 24, as assessed by an independent central site.",
        "negative": "3.3.1 | Antitumor activity\nAs 27 of the 63 patients treated with ASP8273 300 mg, in the first and second stages of phase II combined, achieved a clinical response (based on independent central review), ASP8273 was determined to have shown antitumor activity (ORR 43%; 95% CI, 30.5, 56.0)."
    },
    {
        "anchor": "Safety and in vivo detection of CAR T cells\nTwenty-one patients received a total of 39 infusions, with 9 patients receiving multiple infusions (Supplement Table 2).",
        "positive": "Twenty-one patients received a total of 39 infusions, with 9 patients receiving multiple infusions, as shown in Supplement Table 2.",
        "negative": "1, 2204745 https://doi.org/10.1080/2162402X.2023.2204745\nBRIEF REPORT Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes a c ,d ,e a ,b c ,d ,e Frank J. Borm, Jasper Smitb(<>), Joyce Bakker, Maurits Wondergemf(<>), Egbert F. Smit, Adrianus J. de Langenb(<>), and Tanja D. de Gruijl ABSTRACT Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed."
    },
    {
        "anchor": "The airway microbiome and disease.",
        "positive": "The airway microbiome was studied in relation to disease.",
        "negative": "Management of non-small-cell lung cancer: recent developments."
    },
    {
        "anchor": "Given the rapid development and promising prospects of liquid biopsy technology ((<>)27), we will explore whether peripheral biomarkers could predict changes in disease activity as well as survival benefit from ICIs.",
        "positive": "With the rapid advancement and potential of liquid biopsy technology, we will examine whether peripheral biomarkers can predict changes in disease activity and survival benefits from ICIs.",
        "negative": "After processing whole-blood specimens, plasma is extracted and subjected to next-generation sequencing panel covering 486 cancer-related genes for cfDNA somatic mutations, ctDNA and bTMB assessments."
    },
    {
        "anchor": "9b A patient is deemed a cancel if he/she is removed from the study for any reason before any study treatment is given.",
        "positive": "A patient is considered withdrawn if they are removed from the study prior to receiving any treatment.",
        "negative": "Additional histopathologic findings\nRefer to the supplementary Results, available at Annals of Oncology online for details related to immune exclusion, early disease recurrence, response assessment by tumor histologic subtype and pretreatment tumor features, as well as histologic features of tumor-devoid lymph nodes."
    },
    {
        "anchor": "Trial Design and Patients\n11 23 Full details of ADAURA methodology have been published previously,and are available in the Protocol (online only); the study design is shown in the Data Supplement (online only).",
        "positive": "The ADAURA trial design and methodology have been previously published and are available online, along with the study design.",
        "negative": "Abstract\nWhile CD19-directed CAR T cells can induce remissions in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19-negative disease."
    },
    {
        "anchor": "Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 32.3% of pts, including 3.6% of grade 3 ICANS (no grade 4).",
        "positive": "ICANS was observed in 32.3% of patients, with 3.6% experiencing grade 3 ICANS and no grade 4.",
        "negative": "Protein and mRNA Expression\nAfter completion of the primary protein analysis by AQUA, residual FFPE specimens were available from 162 patients for molecular studies."
    },
    {
        "anchor": "Relationship of Total IGF-1 and HbA1c to Outcomes\nFor the exploratory analysis of outcomes based on baseline total IGF-1, a cutoff of 120 ng/mL was selected because it was associated with the largest observed differences in treatment effect above and below it.",
        "positive": "The association between baseline total IGF-1 levels and treatment outcomes was explored using a cutoff of 120 ng/mL, which showed the largest differences in treatment effects above and below this threshold.",
        "negative": "In the figitumumab arm, median OS for patients with low and high baseline IGF-1 was 7.0 months and 10.4 months, respectively; in the control arm it was 10.1 and 9.4 months, respectively (Appendix Fig A1)."
    },
    {
        "anchor": "Informed consent was obtained from all patients before enrollment.",
        "positive": "Patients gave their informed consent before being enrolled in the clinical trial.",
        "negative": "Mobility shift assay\nFull-length recombinant PTPN2 or PTPN1 were incubated with increasing concentrations of AC484 or A-650 for 10 min at room temperature."
    },
    {
        "anchor": "P values are shown in Table S6.",
        "positive": "The p-values are presented in Table S6.",
        "negative": "Prediction of subsequent toxicity using serum biomarkers collected within 24 hours of CART cell infusion."
    },
    {
        "anchor": "TaqMan primers were 50-GAGGACATCGCCACCTACTACTG-30 (forward) and 50-GTCCCTTGGCCGAACGT-30 (reverse).",
        "positive": "The forward and reverse primers used for the TaqMan assay were 50-GAGGACATCGCCACCTACTACTG-30 and 50-GTCCCTTGGCCGAACGT-30, respectively.",
        "negative": "ACKNOWLEDGMENTS\nThe authors thank the study participants as well as the investigators and study coordinators for their contributions to this study."
    },
    {
        "anchor": "The primary endpoint of this study was disease-free survival (DFS), which was defined as the time from surgery to the first confirmed occurrence of disease relapse or metastasis.",
        "positive": "The primary outcome measure was disease-free survival, which was defined as the time from surgery to the first documented recurrence or metastasis.",
        "negative": "Assessment of response and toxicity\nToxicity was assessed using the NCI Common Toxicity Criteria (version 2.0)."
    },
    {
        "anchor": "The FASEB Journal 2004; 18(2): 338\u2013340.",
        "positive": "The reference cited is FASEB Journal, volume 18, issue 2, pages 338-340, published in 2004.",
        "negative": "Ferrara N Vascular Endothelial Growth Factor: Basic Science and Clinical Progress."
    },
    {
        "anchor": "Aes of special interest\nCRS was reported in three of the 11 treated patients following the first ADP-A2M10 infusion with severity of grades 1, 2, and 4.",
        "positive": "Three of the 11 patients who received ADP-A2M10 treatment experienced CRS, with severity grades ranging from 1 to 4, following the first infusion.",
        "negative": "longitudinal Ps assessment and Patient/ Physician Ps concordance\nBaseline ECOG PS score was reported as 2 by 47.5% of patients and 95.0% of physicians."
    },
    {
        "anchor": "OS following crossover to pembrolizumab is defined as the time from the first dose of crossover therapy to death due to any cause.",
        "positive": "The OS endpoint was defined as the time from the first dose of pembrolizumab to death due to any cause.",
        "negative": "8.2.3.1 Efficacy Endpoints\nPrimary Progression-free survival -RECIST 1.1 Progression-free-survival is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central radiologists\u2019 review or death due to any cause, whichever occurs first."
    },
    {
        "anchor": "Due to the nature of the study, study participants are not blinded.",
        "positive": "The study was not blinded, meaning participants knew their treatment group.",
        "negative": "Blinding procedures\nAssessments of the primary outcome 30s-CST and all other physical tests will be performed by blinded physiotherapists."
    },
    {
        "anchor": "1.5.1 Growth Factor Receptor Pathways\nTyrosine kinase receptors (TKR) such as the Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor I Receptor (IGF-IR) stimulate growth and survival of cancer cells through activation of complex intracellular signaling pathways(19) (Figure.",
        "positive": "The figure illustrates the activation of TKR, including EGFR and IGF-IR, which stimulate cancer cell growth and survival through complex intracellular signaling pathways.",
        "negative": "Acknowledgments\nThe authors thank the patients and families who participated in this trial and the staff of the clinical and laboratory units (Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Zhejiang University, Tianjin First Central Hospital, Tongji Hospital of Tongji University, and Tongji Hospital of Huazhong University of Science and Technology) for clinical and technical support."
    },
    {
        "anchor": "Sintilimab could be a new treatment option for patients with locally advanced or metastatic sqNSCLC who had disease progression or recurrence after or were intolerable to first-line platinum-based chemotherapy.",
        "positive": "Sintilimab could be a viable treatment option for patients with locally advanced or metastatic sqNSCLC who have progressed or recurred after first-line platinum-based chemotherapy or were unable to tolerate it.",
        "negative": "Patients and Methods\nEligible patients had BM from NSCLC, regardless of EGFR status."
    },
    {
        "anchor": "If 18 patients responded, the posterior probability for a true response rate of at least 40% (a minimum relevant effect) was 75%.",
        "positive": "Assuming 18 patients responded, the likelihood of a true response rate of at least 40% (a minimum relevant effect) was found to be 75%.",
        "negative": "Statistical Analysis\nEnrollment of approximately 40 patients was planned; however, no formal statistical hypotheses were tested."
    },
    {
        "anchor": "SM, JZ, YY, SR performed data analysis and interpretation.",
        "positive": "SM, JZ, YY, and SR were responsible for analyzing and interpreting the data.",
        "negative": "Author contributions\nSR and CZ designed this study and revised the manuscript."
    },
    {
        "anchor": "M. Dickinson: Resources, data curation, formal analysis, supervision, investigation, writing\u2013original draft, writing\u2013review and editing.",
        "positive": "M. Dickinson contributed to the study by providing resources, curating data, performing formal analysis, supervising the project, conducting an investigation, and drafting and editing the manuscript.",
        "negative": "Authors\u2019 Contributions\nJ.R. Westin: Resources, data curation, formal analysis, supervision, investigation, writing\u2013original draft, writing\u2013review and editing."
    },
    {
        "anchor": "11.4.3 All patients will be followed until death.",
        "positive": "All patients will be monitored until the time of their passing.",
        "negative": "11.4 Criteria for Removal from Protocol Treatment\n11.4.1 The patient may elect to withdraw from study at any time for any reason."
    },
    {
        "anchor": "Our modeling approach, based on extensive human PK data and in vitro dose-response information, provided sufficient support to approve the recommended dosing regimen for a clinical trial, without the necessity of any additional in vivo experiments.",
        "positive": "Our modeling approach, grounded in extensive human PK data and in vitro dose-response information, was sufficient to justify the recommended dosing regimen for the clinical trial, eliminating the need for further in vivo experiments.",
        "negative": "Discussion\nIn this paper, we established a predictive modeling platform that, when parameterized using information from in vitro cell line assays, can be used to identify optimal combination dosing schedules for osimertinib and dacomitinib treatment for patients with EGFR-mutant NSCLC."
    },
    {
        "anchor": "Patients received cyclophosphamide and \ufb02udarabine followed by ARI-0001 cells at a dose of 0.4\u20135 \ue001 106 ARI-0001 cells/kg, initially as a single dose and later split into 3 fractions (10%, 30%, and 60%) with full administration depending on the absence of cytokine release syndrome (CRS).",
        "positive": "Patients received a combination of cyclophosphamide and fludarabine, followed by ARI-0001 cells at a dose of 0.4\u20135 \u00d7 10^6 ARI-0001 cells/kg, initially as a single dose and later divided into three fractions (10%, 30%, and 60%) based on the absence of cytokine release syndrome.",
        "negative": "Abstract\nObjectives\u2014Family caregivers (FCGs) play an important role in the quality of life (QOL) of lung cancer patients."
    },
    {
        "anchor": "There were also no significant differences in the rates of grade 3/4 anemia, neutropenia or thrombocytopenia in patients with squamous vs non-squamous histology receiving CP alone (P=1.00 for each comparison).",
        "positive": "No significant differences were observed in the rates of grade 3/4 anemia, neutropenia, or thrombocytopenia between patients with squamous and non-squamous histology receiving CP alone (P=1.00 for each comparison).",
        "negative": "Title: Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "Vaccine production and administration were evaluated as feasible procedures.",
        "positive": "Vaccine production and administration were found to be feasible procedures.",
        "negative": "Purpose\nT cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR)."
    },
    {
        "anchor": "Statistical Methods\nData from the study were summarized with respect to demographic and baseline characteristics, efficacy observations and measurements, safety observations and measurements, and all relevant PK and PD measurements using descriptive statistics (mean, standard deviation, median, minimum, and maximum), contingency tables (frequencies and percentages), and inferential analyses.",
        "positive": "The study data were summarized using descriptive statistics (mean, standard deviation, median, minimum, and maximum), contingency tables (frequencies and percentages), and inferential analyses, focusing on demographic and baseline characteristics, efficacy and safety observations, and PK and PD measurements.",
        "negative": "Overall response rates (ORRs; CR or partial response [PR]) and disease control rates (DCRs; PR, CR, or SD) are summarized with accompanying 95% confidence intervals calculated using the exact Clopper\u2013Pearson method."
    },
    {
        "anchor": "Pembrolizumab will be administered at a dose of 200mg via IV infusion in 3 week cycles.",
        "positive": "Pembrolizumab will be given at a dose of 200mg through IV infusion every three weeks.",
        "negative": "While administered for research purposes as part of this study, it will be prepared and infused in accordance with its FDA approved label and standard institutional practice."
    },
    {
        "anchor": "Our previous study also supported the therapeutic advantage of 2-cycle induction ICI for patients with bulky unresectable stage III NSCLC.",
        "positive": "Our earlier study demonstrated the therapeutic benefits of a 2-cycle induction of ICI therapy for patients with bulky, unresectable stage III NSCLC.",
        "negative": "Trial Oversight\nThe study was conducted by the Thoracic Malignancies Committee of the ECOG\u2013American College of Radiology Imaging Network (ACRIN) Cancer Research Group; monitoring was performed by the ECOG-ACRIN Data Safety Monitoring Committee, which meets twice annually."
    },
    {
        "anchor": "The incorporation of \ue005 in the dose-estimation stage can effectively identify a lower dose level that still possesses a high ef\ufb01cacy rate.",
        "positive": "The integration of \ue005 in the dose-estimation stage allows for the determination of a lower dose that still achieves a high efficacy rate.",
        "negative": "Optimal dose estimation\nAfter a total of N patients have been treated in the trial, we take a two-step procedure to estimate the OBD."
    },
    {
        "anchor": "The trial is registered at ClinicalTrials.gov (Identifier: NCT05888402).",
        "positive": "The study is listed on ClinicalTrials.gov with the identifier NCT05888402.",
        "negative": "Ethics statement\nAll enrolled patients will provide written consent."
    },
    {
        "anchor": "Main inclusion criteria were male or female subjects aged \u226520 years with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma NSCLC which was not amenable to curative surgery or radiation, with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and meeting a clinical definition of acquired resistance to EGFR TKI.Criteria for 14 15 acquired EGFR TKI resistance included a tumor harboring an EGFR mutation (including G719X, exon 19 deletion, L858R, L861Q) known to be associated with EGFR TKI sensitivity, or experienced clinical benefit from continuous EGFR TKI treatment followed by systemic disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,or World Health Organization (WHO) criteria; and received gefitinib, er-lotinib, afatinib, dacomitinib, or osimertinib for at least 6 weeks with well-controlled related toxicities (less than Grade 3 in severity) at the time of screening.",
        "positive": "The main eligibility criteria included patients aged 20 years or older with locally advanced or metastatic adenocarcinoma NSCLC that was not suitable for surgery or radiation, with an ECOG performance status of 0 or 1, and evidence of acquired resistance to EGFR TKI therapy.",
        "negative": "Chemotherapy\nChemotherapy was conducted concurrently with radiotherapy."
    },
    {
        "anchor": "Differences in serum cytokine profiles between subjects Corresponding author: Jacqueline Gofshteyn, Division of Neurology, The Children\u2019s Hospital of Philadelphia, 34 th  Street and Civic Center Blvd, Philadelphia PA 19104.",
        "positive": "Serum cytokine profiles differed between patients",
        "negative": "Abstract\nObjective: To characterize the incidence and clinical characteristics of neurotoxicity in the month following CTL019 infusion in children and young adults, to define the relationship between neurotoxicity and cytokine release syndrome (CRS), and to identify predictive biomarkers for development of neurotoxicity following CTL019 infusion."
    },
    {
        "anchor": "At the RP2D of 40 mg every 8 hours (Q8h), the most common grade 3\u20134 treatment-emergent adverse events occurred in 3.2\u20136.5% of patients.",
        "positive": "At the recommended dose of 40mg every 8 hours, the most frequent grade 3-4 adverse events were observed in 3.2-6.5% of patients.",
        "negative": "Declaration of competing interests\nMerck KGaA funded the development of the article, including the article-processing charge."
    },
    {
        "anchor": "The kinase is composed of an intracellular C-terminus containing the kinase domain, a single transmembrane domain, and an extracellular N-terminal domainand is constitutively activated by fusion partner proteins as a result of chromosomal rearrangements that occur in approximately 1% to 2% of patients with non-small cell lung cancer (NSCLC).\u2013Among diverse ROS1 fusions, CD74 is the most frequent ROS1 fusion partner, and CD74\u2013ROS1 fusion is present in ~44% of NSCLC cases with ROS1 rearrangements.Intriguingly, we have previously noted that NSCLC patients carrying CD74\u2013ROS1 fusion are more likely to develop brain metastases.Targeted therapies are well established for NSCLC with ALK and ROS1 rearrangements that lead to constitutive kinase activity of ALK or ROS1.Crizotinib, an ALK and ROS1 tyrosine kinase inhibitor (TKI), has become not only one of the standards of care for ALK-positive but also the preferred drug for ROS1rearranged NSCLC patients.",
        "positive": "The kinase structure includes an intracellular C-terminus with a kinase domain, a single transmembrane domain, and an extracellular N-terminal domain, which is constitutively activated by fusion partner proteins resulting from chromosomal rearrangements in approximately 1-2% of NSCLC patients.",
        "negative": "Binding epitopes\nEpitope blocking experiments were performed by Bio-Layer Interferometry analysis using an Octet QK384 instrument (For-teBio)."
    },
    {
        "anchor": "Although CAR-BCMA+ cells could be detected in the blood of all patients, the patients on the lower 2 dose levels had low levels of blood CAR-BCMA+ cells, and the patients with the most impressive antimyeloma responses, patients 8, 10, and 11, had the highest peak CAR-BCMA+ cell levels.",
        "positive": "While CAR-BCMA+ cells were present in the blood of all patients, those on the lower dose levels had lower levels of CAR-BCMA+ cells, and patients 8, 10, and 11, who showed the most significant responses, had the highest peak levels of CAR-BCMA+ cells.",
        "negative": "Availability of data and materials\nThe data underlying this article will be shared on reasonable request to the corresponding author."
    },
    {
        "anchor": "Another patient showed grade 4 nerve root toxicity which was defined as DLT.",
        "positive": "One patient experienced grade 4 nerve root toxicity, which was classified as a dose-limiting toxicity.",
        "negative": "MTD\nAt the beginning of this study, two cases showed grade 3 myelosuppression after the first IP at a dose of 10 mg. Myelosuppression showed remission after symptomatic treatment."
    },
    {
        "anchor": "Availability of data and materials\nThe datasets used and analysed during the current study are available from the corresponding author on reasonable request.",
        "positive": "The datasets used and analyzed during this study are available upon request from the corresponding author.",
        "negative": "Author contributions\nDO-R and CR-S drafted and edited the manuscript."
    },
    {
        "anchor": "Owing to the lack of pharmacodynamic activity of INCAGN01949 and early termination of the study, no MTD or PAD was able to be defined.",
        "positive": "Due to the lack of pharmacodynamic activity and early termination of the study, the maximum tolerated dose and recommended phase II dose could not be established.",
        "negative": "Safety\nOverall, 83 patients (95.4%) had any-grade TEAEs, including 45 (51.7%) who had treatment-related adverse events (TRAEs)."
    },
    {
        "anchor": "Results:A total of 263 volunteer donors were enrolled in the VST-cell registry among 2034 frequent blood donors based on HLA genotyping and serological markers.",
        "positive": "A total of 263 volunteer donors were enrolled in the VST-cell registry from a pool of 2034 frequent blood donors based on HLA genotyping and serological markers.",
        "negative": "Title: Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry\n\nAbstract: Introduction:Cytomegalovirus infection continues to be a major cause of morbidity and mortality after allogeneic stem cell transplantation (allo-SCT) in spite of recently approved prophylactic and pre-emptive therapies."
    },
    {
        "anchor": "Medical writing support was funded by Pfizer Inc and was provided by Mariko Nagashima, PhD, of Engage Scientific Solutions (Southport, CT, USA).",
        "positive": "Medical writing support was funded by Pfizer Inc and was provided by Mariko Nagashima, PhD, of Engage Scientific Solutions.",
        "negative": "Acknowledgements\nThis study was sponsored by Pfizer Inc. Pemetrexed was provided by Eli Lilly and Company (Indianapolis, IN, USA)."
    },
    {
        "anchor": "Intravital multiphoton microscopy:\nGFP+ Nalm6 was established in xenograft mice as described below.",
        "positive": "The establishment of GFP+ Nalm6 in xenograft mice was performed as described below.",
        "negative": "DISCUSSION\n1-3 In the PACIFIC trial, observed treatment benefits (in terms of PFS, OS, and TTDM) favored durvalumab versus placebo, with a manageable safety profile, irrespective of stage IIIA-N2 status."
    },
    {
        "anchor": "ACKNOWLEDGMENTS\nWe thank the NIH Clinical Center 3 Northwest Nursing Unit nurses and our patients.",
        "positive": "We would like to express our gratitude to the NIH Clinical Center 3 Northwest Nursing Unit nurses and our patients.",
        "negative": "TLC-PC intervention\nThe TLC-PCI was adapted from extensive completed work as part of a National Cancer Institute (NCI) Program Project grant at City of Hope.5,12 The PCI consists of three key components: comprehensive patient/caregiver assessment, interdisciplinary care planning, and patient/caregiver education, which are implemented over a one-to two-month period."
    },
    {
        "anchor": "TMI generation\nWe first divided the patients in the discovery cohort (OAK cohort) into two groups (high risk and low risk) according to the different biomarkers (bTMB, sbTMB and UMS) along with their clinical characteristics, including sex (male or female), smoking history (smokers or non-smokers), pathological subtype (lung squamous cell carcinoma [LUSC] or non-LUSC), driver gene mutation (positive or negative) and number of metastases (\u22653 or none).",
        "positive": "Patients in the discovery cohort were divided into two groups based on biomarkers and clinical characteristics, including sex, smoking history, pathological subtype, driver gene mutation, and number of metastases.",
        "negative": "1 | INTRODUCTION\n1\u20134 1,2,5 Established small-molecule tyrosine kinase inhibitors (TKIs) target epidermal growth factor receptor (EGFR) and are effective in non-small cell lung cancer (NSCLC) patients with activating and sensitizing EGFR mutations."
    },
    {
        "anchor": "Overall Response Rate (ORR) is defined as no recurrence from the time of CHCP treatment to LRR in R0 resected patients.",
        "positive": "The overall response rate is the absence of recurrence from the time of CHCP treatment to local recurrence in patients who underwent R0 resection.",
        "negative": "Caushi, B.S.,\nBloomberg\u2013Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore"
    },
    {
        "anchor": "The mobile app electronically collects data on intervention fidelity (e.g., the number of completed modules, proportion of each module completed, time spent on each module, etc.).",
        "positive": "The mobile app collects data on intervention fidelity, including the number of completed modules, proportion of each module completed, and time spent on each module.",
        "negative": "Intervention group\nFor patients randomized to the THRIVE intervention, the RA provides them with a study-issued tablet computer from which the participants access the mobile app or assists the patient in downloading the app onto a suitable device already owned by the participant."
    },
    {
        "anchor": "More pronounced thrombocytopenia and fibrinogen nadir occurred 7 to 11 days following CAR T cell infusion.",
        "positive": "A more severe drop in platelet count and fibrinogen levels was observed 7 to 11 days following CAR T cell infusion.",
        "negative": "Discussion\nWe have demonstrated an increase in both serum IL6 and IL17 concentrations in patients with CEA+ LM following CAR-T HAI, accompanied by variations in NLR."
    },
    {
        "anchor": "APPENDIX 1: ELIGIBILITY CHECKLIST\nEligibility \u2013 all answers must be YES, unless specified Ineligibility \u2013 all answers must be NO, unless specified Appendix 2 \u2013 Follow-up schedule Chinese (simplified or traditional), Dutch, French, German, Hungarian, Italian, Japanese, Polish, Spanish Appendix 3 \u2013 Letter of Information (to follow) Appendix 4 \u2013 FACT-G, FACT-E, FACT-L, EQ-5D Quality of Life Forms Below is a list of statements that other people with your illness have said are important.",
        "positive": "Ineligibility criteria - all answers must be negative, unless otherwise specified.",
        "negative": "2.5 | Statistical analysis\nFrequency, percentage, average \u00b1SD, median (range) were presented as appropriate."
    },
    {
        "anchor": "x Follow-up CT scans of the chest and upper abdomen with contrast or MRIs are recommended every 3 months for year 2, every 6 months for years 3-5, then annually, until patients show evidence of progression.",
        "positive": "Patients are advised to undergo CT scans of the chest and upper abdomen with contrast or MRIs every 3 months for the first year, every 6 months for the next 3 years, and annually thereafter, until disease progression is detected.",
        "negative": "Lin, J. J., Riely, G. J."
    },
    {
        "anchor": "Any infections\nFor details on any infections, see\ue013(<>)Table 6.",
        "positive": "Infections that may occur",
        "negative": "Efficacy measures\nEfficacy measures included overall survival (OS), progression-free survival (PFS), overall response rate [ORR -partial response (PR) +complete response (CR)] and duration of response (DoR)."
    },
    {
        "anchor": "Methods\u2014We did a multicentre, non-randomised, open-label, phase 1b study at five cancer centres in the USA.",
        "positive": "A non-randomized, open-label, phase 1b clinical trial was conducted at five cancer centers in the United States.",
        "negative": "7.1.2.2 Full Physical Exam\nThe investigator or qualified designee will perform a complete physical exam during the screening period."
    },
    {
        "anchor": "Human CD8 CTLs have an elimination half-life from the peripheral blood of about 8 days, and this increases to about 16 days when low doses of IL-2 are given47 .",
        "positive": "The elimination half-life of human CD8 CTLs in the peripheral blood is approximately 8 days, which increases to around 16 days when low doses of IL-2 are administered.",
        "negative": "Patient assessment\nPatient assessment was performed within 2 weeks before the start of treatment."
    },
    {
        "anchor": "Cycle sequencing of the purified polymerase chain reaction (PCR) products was carried out with PCR primers using the commercially available ADx Mutation Detection Kits (Amoy Diagnostics Company Ltd., Xiamen, China).",
        "positive": "The purified PCR products were sequenced using PCR primers from the commercially available ADx Mutation Detection Kits, provided by Amoy Diagnostics Company Ltd. in Xiamen, China.",
        "negative": "EGFR mutation detection\nTumor rebiopsy samples that have a conformed pathological diagnosis of NSCLC were collected for EGFR-mutation testing."
    },
    {
        "anchor": "Cells were treated with increasing concentrations of TAK-676 for 3 hours, subsequently lysed, and the proteins analyzed by SDS-PAGE and immuno-blotting.",
        "positive": "Cells were treated with increasing concentrations of TAK-676 for 3 hours, followed by lysis, and the proteins were analyzed using SDS-PAGE and immuno-blotting.",
        "negative": "STING agonists trigger the production of type I IFNs and the induction of interferon-stimulated genes (ISG) through IRFs."
    },
    {
        "anchor": "The median PFS for patients in part B was 1.8 months (95% CI, 1.3\u20137.2 months).",
        "positive": "The median progression-free survival for patients in part B was approximately 1.8 months, with a 95% confidence interval of 1.3-7.2 months.",
        "negative": "All patients received prior systemic therapy, 63% had prior radiotherapy, and 71% had prior surgery."
    },
    {
        "anchor": "This manuscript was prepared according to the International Society for Medical Publication Professionals\u2019 Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.",
        "positive": "The manuscript was prepared in compliance with the International Society for Medical Publication Professionals' guidelines for company-sponsored medical research, specifically the GPP3 guidelines.",
        "negative": "Received: 6 May 2020 Revised: 30 September 2020 Accepted: 22 October 2020\nDOI: 10.1002/ijc.33399 CANCER THERAPY AND PREVENTION"
    },
    {
        "anchor": "Study design and patient population\nThe study designs for the two studies have been published previously [(<>)11, (<>)12].",
        "positive": "The study designs for the two studies have been published in previous publications [references 11 and 12].",
        "negative": "CENTRAL search strategy\nID Search #1 MeSH descriptor: [Lymphoma, B-Cell] this term only #2 (b-cell near/3 lymphom*) or (b-cell near/3 malignanc*) #3 MeSH descriptor: [Lymphoma, Non-Hodgkin] explode all trees #4 (non-hodgkin* or non hodgkin* or nonhodgkin* or no hodgkin* or nhl) #5 (lymph* adj2 sarcom*) #6 lymphosarcom* #7 (reticulum near/2 sarcom*) #8 (di0us* near/3 lymphom*) #9 ((lymphom* near/3 cleaved*) or (lymphom* near/3 noncleaved*) or (lymphom* near/3 non-cleaved*) or (lymphom* near/3 grad*) or (lymphom* near/3 mixed-cell*) or (lymphom* near/3 pleomorphic*)) #10 reticulosarcoma* #11 (mixed near/3 lymphom*) or (undi0erentiat* near/3 lymphom*) #12 NHL #13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 #14 MeSH descriptor: [Lymphoma, Large B-Cell, Di0use] explode all trees #15 (histiocyt* near/3 lymphom*) #16 (large cell* near/3 lymphom*) or (bcell near/3 lymphom*) or (lymphoid* near/3 lymphom*) or (histiocytic* near/3 lymphom*) or (plasmablastic* near/3 lymphom*) #17 DLBCL #18 #14 or #15 or #16 or #17 #19 #13 or #18 #20 MeSH descriptor: [Immunotherapy, Adoptive] explode all trees #21 (immunotherap* near/3 adoptiv*) #22 (t-cell* near/1 therap*) or (tcell* near/1 therap*) #23 #20 or #21 or #22 #24 MeSH descriptor: [Receptors, Antigen, T-Cell] explode all trees #25 (chimeric* near/3 antigen receptor*) or (chimeric* near/3 immunoreceptor*) or (chimeric* near/3 T cell receptor*) or (chimeric* near/3 Tcell receptor*) #26 (artificial* near/3 T cell receptor*) or (artificial* near/3 Tcell receptor*) #27 #24 or #25 or #26 #28 axicabtagene* #29 (yescarta* or axi-cel* or KTE-C19 or \"CTL 019\") #30 #28 or #29 #31 tisagenlecleucel* #32 (kymriah* or CART-19 or CART19) #33 #31 or #32 #34 lisocabtagene* #35 (liso-cel* or JCAR017*) #36 #34 or #35 #37 #23 or #27 or #30 or #33 or #36 #38 #19 and #37"
    },
    {
        "anchor": "In case of toxicity during the study, dose adjustment was considered to 500 mg BID and 400 mg BID in the envonalkib group and to 200 mg BID and 250 mg QD in the crizotinib group.",
        "positive": "If toxicity occurred during the study, the dose was modified to 500 mg twice daily in the envonalkib group and 200 mg twice daily or 250 mg once daily in the crizotinib group.",
        "negative": "Intervention\nThe participants in the experimental group received envonalkib 600 mg BID, and the control group received crizotinib 250 mg BID in each 28-day cycle."
    },
    {
        "anchor": "Taku Tsukamoto has no conflicts of interest to declare.",
        "positive": "Taku Tsukamoto does not have any conflicts of interest to disclose.",
        "negative": "Introduction\nDespite increased education and awareness of risk factors for melanoma, the number of cases diagnosed each year continues to rise [1]."
    },
    {
        "anchor": "By the completion of the study, all patients discontinued the study, mostly due to death (n = 116; Figure (<>)1).",
        "positive": "At the conclusion of the study, all patients had discontinued participation, mostly due to death (n = 116; Figure 1).",
        "negative": "Investigator Reporting: Local Regulatory Review Committees\nReport events to local regulatory review committees per institutional requirements."
    },
    {
        "anchor": "CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.",
        "positive": "The expression of CRIPTO1 in EGFR-mutant NSCLC induces intrinsic resistance to EGFR inhibitors.",
        "negative": "Stabile, L. P., He, G., Lui, V. W. Y., Thomas, S. M., Henry, C. & Gubish, C. T. et al."
    },
    {
        "anchor": "Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) adverse events were graded according to the 2019 American Society for Transplantation and Cellular Therapy (ASTCT) criteria.16 Secondary end points included ORR, PFS, and OS.",
        "positive": "CRS and ICANS adverse events were assessed according to the 2019 ASTCT criteria, and secondary endpoints included overall response rate, progression-free survival, and overall survival.",
        "negative": "CTSU sites must comply with the expectations of their local Institutional Review Board (IRB) regarding documentation and submission of adverse events."
    },
    {
        "anchor": "Pre- and posttreatment sera were tested for anti\u2013NYESO-1 IgG responses by enzyme-linked immunosorbent assay (ELISA) using full-length recombinant NY-ESO-1.",
        "positive": "Pre- and post-treatment sera were evaluated for anti-NYESO-1 IgG antibody responses using ELISA with full-length recombinant NY-ESO-1.",
        "negative": "Does your paper address CONSORT subitem 10?"
    },
    {
        "anchor": "228 Response Criteria: Evaluation of target lesions 229 LD: Longest Diameter",
        "positive": "Criteria for response evaluation: assessment of target lesions, longest diameter.",
        "negative": "Abstract\nBackground\u2014Activating BRAF V600E mutations are found in approximately 1\u20132% of adenocarcinomas of the lung offering an opportunity to test targeted therapy for this disease."
    },
    {
        "anchor": "In brief, there were 16 patients with squamous cell carcinoma and a higher proportion of male patients with stage IIIB.",
        "positive": "Briefly, 16 patients had squamous cell carcinoma, with a higher proportion of male patients having stage IIIB disease.",
        "negative": "DISCUSSION\n27 This study did not meet its primary end point of improved OS in current smokers with veliparib plus C and P versus placebo plus C and P, despite this being a key observation in the phase II study of the same regimen and treatment schedule.Thus, subsequent end points were evaluated in a descriptive manner."
    },
    {
        "anchor": "7University Hospital of Heidelberg, Institute of Pathology, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany.",
        "positive": "Heidelberg University Hospital, Institute of Pathology, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany.",
        "negative": "Author details\n1Department of Thoracic Oncology, Thoraxklinik at University Hospital of Heidelberg, R\u00f6ntgenstra\u00dfe 1, 69126 Heidelberg, Germany."
    },
    {
        "anchor": "The pharmacokinetics of the antibody were linear, with a dose-proportional increase in the peak concentration and area under the curve calculated from day 1 to day 14 in the dose range of 0.1 to 10.0 mg per kilogram (35 patients).",
        "positive": "The antibody's pharmacokinetics were found to be linear, with a dose-dependent increase in peak concentration and area under the curve from day 1 to day 14 in the dose range of 0.1 to 10.0 mg per kilogram (35 patients).",
        "negative": "Ethics statement\nThe studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Soochow University."
    },
    {
        "anchor": "The study adheres to CONSORT guidelines [(<>)13].",
        "positive": "The study is conducted in accordance with the CONSORT guidelines [(<>)13].",
        "negative": "Implications of all the available evidence\nOur findings show that cytokine treatment with an IL-2 and IL-15R\u03b2\u03b3 superagonist at doses capable of inducing anti-tumour immune responses is safe and feasible in the outpatient setting and that the cytokine complex might safely be combined with anti-PD-1 immunotherapy."
    },
    {
        "anchor": "All patients provided written informed consent.",
        "positive": "Written informed consent was obtained from all patients.",
        "negative": "Study design\nScreening procedures included a tumor biopsy and a standard 2-deoxy-2-[fluorine-18]fluoro-D-glucose ([18F]FDG) PET/com-puted tomography (CT) scan, performed according to European Association of Nuclear Medicine guidelines 2.0 [(<>)25]."
    },
    {
        "anchor": "Carboplatin (AUC 6, IV) and Paclitaxel (200 mg/m2, IV) will be given on day 1.",
        "positive": "On day 1, patients will receive a combination of carboplatin and paclitaxel, administered intravenously.",
        "negative": "However, during consolidation chemotherapy, paclitaxel 200 mg/m2 will be administered over 3 hours."
    },
    {
        "anchor": "High tumor mutation burden (<http://refhub.elsevier.com/S2059-7029(23)00393-9/sref36>)fails to predict immune checkpoint blockade response across all cancer (<http://refhub.elsevier.com/S2059-7029(23)00393-9/sref36>)types.",
        "positive": "The presence of high tumor mutation burden does not reliably predict the response to immune checkpoint blockade therapy across all cancer types.",
        "negative": "N Engl J Med."
    },
    {
        "anchor": "Tumor tissues obtained from biopsy or circulating tumor DNA from blood samples can be used for HER2 testing.",
        "positive": "HER2 testing can be performed using tumor tissue samples obtained through biopsy or circulating tumor DNA from blood.",
        "negative": "HER2 mutation confirmation\nHER2 exon 20 insertions will be confirmed by next generation sequencing, amplification refractory mutation system-polymerase chain reaction, or droplet digital polymerase chain reaction."
    },
    {
        "anchor": "has served as a consultant for the Cancer Institute of New Jersey and owns stock in Johnson and Johnson.",
        "positive": "The individual has acted as a consultant for the Cancer Institute of New Jersey and holds stock in Johnson and Johnson.",
        "negative": "Conflicts of Interest\nJ.M., D.F., W.F., S.C., K.N., Z.T., C.C., and R.B."
    },
    {
        "anchor": "Patients with mutations or amplifications involving c-MET, who were receiving concurrent treatment on another clinical trial, or who had received prior therapy specifically directed against ALK, were excluded.",
        "positive": "Patients with c-MET mutations or amplifications, who were already receiving treatment on another clinical trial or had previously received ALK-targeted therapy, were not eligible for the study.",
        "negative": "2.1 | Patients\nPatients aged \ue00315 years with Eastern Cooperative Oncology Group performance status of 0\u20133 and histologically or cytologically proven diagnosis of ALCL, IMT, or other advanced malignancy (excluding NSCLC) for which no standard therapy is available were eligible if they were positive during local ALK testing with validated methods at study sites for either: \ue004 ALK gene translocation or inversion events (e.g., nucleophosmin [NPM]-ALK fusion) as determined by fluorescence in situ hybridization (FISH), reverse transcriptase (RT)\u2013polymerase chain reaction (PCR) or sequencing, or immunohistochemistry (in the case of ALCL) \ue004 ALK-activating point mutations determined by direct sequencing of the ALK gene locus \ue004 ALK amplification events (defined as ALK/CEP2 ratio of \ue0035in \ue00315% of evaluated cells by FISH or as >7 copies by quantitative PCR or array comparative genomic hybridization)."
    },
    {
        "anchor": ":KHQ\ue003D\ue003XVHU\ue003DSSOLHV\ue003IRU\ue003D\ue003&7(3\ue010,$0\ue003DFFRXQW\ue003ZLWK\ue003SURSHU\ue003XVHU\ue003UROH\ue00f\ue003KH\ue012VKH\ue003ZLOO\ue003 QHHG\ue003WR\ue003KDYH\ue003WKH\ue00375,$'\ue003DSSOLFDWLRQ\ue003LQVWDOOHG\ue003RQ\ue003KLV\ue012KHU\ue003ZRUNVWDWLRQ\ue003WR\ue003EH\ue003DEOH\ue003WR\ue003 VXEPLW\ue003LPDJHV\ue011\ue00375,$'\ue003LQVWDOODWLRQ\ue003GRFXPHQWDWLRQ\ue003FDQ\ue003EH\ue003IRXQG\ue003RQ\ue003WKH\ue003,52&\ue003 ZHEVLWH\ue003\ue011\ue003\ue003\ue003\ue003\nThis process can be done in parallel to obtaining your CTEP-IAM account username and password.",
        "positive": "The form can be filled out and submitted in parallel with the process of obtaining a CTEP-IAM account username and password.",
        "negative": "If you have any questions regarding this information, please send an e-mail to the TRIAD Support mailbox at TRIAD-Support@acr.org."
    },
    {
        "anchor": "IGF-I Receptor (IGF-IR)\nIn-vitro studies suggested that the IGF-IR pathway is associated with tumour resistance to cisplatin chemotherapy and RT in lung cancer cells (23).",
        "positive": "In vitro studies have shown that the IGF-IR pathway is linked to tumor resistance to cisplatin chemotherapy and radiation therapy in lung cancer cells.",
        "negative": "However, studies with IGF-IR inhibitors produced safety concerns as fatal toxicities was reported in NSCLC patients randomized to receive anti-IGF-IR antibody therapy in combination with chemotherapy (24)."
    },
    {
        "anchor": "Colors on the swimmer lane plot indicate the highest grade of any neurologic symptom recorded on each day for patients who developed grade \u2265 1 NTX through the first 30 days after CAR T infusion (n=33; 11 grade 1\u20132 NTX, 22 grade 3\u20134 NTX).",
        "positive": "The plot shows the highest grade of neurologic symptoms experienced by patients who developed NTX of grade 1 or higher within the first 30 days after CAR T infusion.",
        "negative": "Median time to first fever (\u226538\u00b0C) for patients with mild NTX (blue dotted line) and severe NTX (red dotted line) and median time to first severe (grade \u22653) NTX (red dashed line) are indicated."
    },
    {
        "anchor": "Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briepy explain why the item is not applicable/relevant for your study Tables 2, 3, 4, and 5 show use data by group.",
        "positive": "The manuscript abstract will be referenced, and relevant information will be included, either by copying and pasting quotes or providing supplementary details.",
        "negative": "Title: Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function\n\nAbstract: Introduction\n\nAntigen density has emerged as an important factor regulating CAR-T cell activity with low antigen density being associated with reduced potency in pre-clinical models across several targets."
    },
    {
        "anchor": "Full results from these studies will soon be published and will further guide the development of future anabolic trials.",
        "positive": "The full results of these studies will be published soon, and they will guide the development of future anabolic trials.",
        "negative": "Extramedullary Disease Assessment\nIf extramedullary disease is present prior to treatment, this will be followed as clinically appropriate."
    },
    {
        "anchor": "ILD and pneumonitis\nPneumonitis was reported in 3 (9.4%) patients.",
        "positive": "Pneumonitis was reported in 3 (9.4%) patients with ILD.",
        "negative": "Following interruption of brigatinib treatment, one case resolved in 12 days, and two cases resolved in 28 days."
    },
    {
        "anchor": "2.5 | Trial oversight\nPROFILE 1013 was designed by Pfizer and conducted in collaboration with the principal investigators (see Supporting Information).",
        "positive": "PROFILE 1013 was designed by Pfizer in collaboration with the principal investigators, as detailed in the Supporting Information.",
        "negative": "2.4.3 Model Diagnostics\nBase, covariate, and final models were selected based on OFV, parameter precision, and diagnostic plots (including both GoF plots and VPCs)."
    },
    {
        "anchor": "The complexity and labor intensity of PT required to remain current might lend itself of novel models of centralized sharing of treatment planning.",
        "positive": "PT's complexity and labor requirements could be addressed through novel approaches to centralized treatment planning.",
        "negative": "Extends\nClass \"(<>)singleParameterTransform\", directly."
    },
    {
        "anchor": "A slight increase in mean AUC(0\u201324) of total platinum (<25% increase) was observed following regorafenib administration.",
        "positive": "Regorafenib administration resulted in a minor increase in mean AUC(0\u201324) of total platinum, less than 25%.",
        "negative": "INTRODUCTION\nAdoptive cellular therapy has emerged as a highly efficacious approach to improve outcomes for patients with B-cell malignancies [1, 2]."
    },
    {
        "anchor": "H. Gelderblom has nothing to disclose.",
        "positive": "H. Gelderblom has no conflicts of interest to disclose.",
        "negative": "D. Tai has nothing to disclose."
    },
    {
        "anchor": "Pharmacokinetic (PK) Sampling and Evaluation\nPlasma samples were obtained on cycle 1 day 1 after the first dose of paclitaxel.",
        "positive": "Plasma samples were obtained on cycle 1 day 1 after the first dose of paclitaxel for pharmacokinetic evaluation.",
        "negative": "Introduction\nTepotinib is a once-daily, highly selective, potent, oral, reversible, adenosine triphosphate competitive, small molecule mesenchymal-epithelial transition factor (MET) inhibitor \u2022 Rainer Strotmann Rainer.Strotmann@emdserono.com 1 [] ."
    },
    {
        "anchor": "Enrichment analyses were based on the list of 100 most dysregulated genes (as identified by DCCA), as well as the lists of genes which were significantly predicting patient\u2019s outcome (each of the investigated endpoints).",
        "positive": "The analysis focused on the 100 most dysregulated genes and genes that significantly predicted patient outcomes for each endpoint.",
        "negative": "Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma."
    },
    {
        "anchor": "Participants\nIndividuals were eligible to participate in the study if they had been diagnosed with NSCLC stages I\u2013III, had completed all cancer treatments, and had no contraindications to performing RT in accordance with the American College of Sports Medicine\u2019s guidelines on pre-exercise screening and contraindications to exercise training [(<>)45].",
        "positive": "Patients with stage I-III NSCLC, who had completed all cancer treatments and had no contraindications to RT, were eligible to participate in the study.",
        "negative": "Pre-Monitoring Visit Meetings\nPrior to each monitoring visit, the Monitor will meet with the Sponsor Project Manager and Sponsor Data Manager."
    },
    {
        "anchor": "PFS illustrates loco-regional disease control (LRC) and freedom from distant metastasis.",
        "positive": "Progression-free survival is used to measure the effectiveness of treatment in controlling local and regional cancer growth, as well as preventing distant metastasis.",
        "negative": "Supplementary Information\nThe online version contains supplementary material available at (<https://doi.org/10.1186/s13045-023-01445-1>)https://doi."
    },
    {
        "anchor": "Patients and tissue samples\n19 CheckMate 816 (ClinicalTrials.gov identifier: (<https://clinicaltrials.gov/ct2/show/NCT02998528>)NCT02998528) is an ongoing, global, open-label, randomized phase 3 study in treatment-naive adults with resectable stage IB (\u22654\u2009cm) to IIIA non-small-cell lung cancer (per American Joint Committee on Cancer 7th edition staging criteria), Eastern Cooperative Oncology Group performance status 0 to 1 and no known sensitizing EGFR mutations or ALK alterations.",
        "positive": "The CheckMate 816 trial is a large-scale, open-label study that is evaluating the effectiveness of a treatment for patients with resectable non-small-cell lung cancer, focusing on those who have not received prior treatment and have specific characteristics.",
        "negative": "Randomization was stratified per interactive response technology by PD-L1 (<1%/not evaluable versus \u22651%), disease stage (IB\u2013II versus IIIA) and sex (male versus female)."
    },
    {
        "anchor": "A variable volume of the diluted virus (1 \u00d7 1011 viral particles [vp]/mL) was administered using repeated needle insertions; the dose was based on the available surface area of the tumor, up to a planned maximum dose of 8 \u00d7 1011 vp (8 mL); the actual doses Fig.",
        "positive": "The treatment dose was determined by the size of the tumor, with a maximum dose of 8 mL, and was administered using repeated needle insertions.",
        "negative": "Study design, setting, and participants\nThis prospective, randomized parallel-group, single-center, superiority trial was conducted at Zhongshan Hospital affiliated to Fudan University, Shanghai, China, between October 10th 2021 and February 15th 2022."
    },
    {
        "anchor": "Patients who have been withdrawn from therapy will have to be further documented for follow-up.",
        "positive": "Patients who discontinue treatment will require additional documentation for follow-up purposes.",
        "negative": "Statistics\n7 The seamless phase I/II study design used the time-to-event continual reassessment method (TITE-CRM)to allocate each patient to a dose level."
    },
    {
        "anchor": "Average 1 X 106 sorted CAR+CD8+ cells with purity > 95% were used for RNA extraction using ZymoQuick RNA MicroPrep kit (Lucerna-Chem, Luzern, Switzerland) as per manufacturer\u2019s instructions.",
        "positive": "The average number of sorted CAR+CD8+ cells with a purity of 95% or higher was used for RNA extraction using the ZymoQuick RNA MicroPrep kit, following the manufacturer's guidelines.",
        "negative": "To validate sequencing data, redirected T cells produced from healthy donors were stimulated with recombinant human FAP for 6 days and expression of phenotypic markers was analyzed by flow cytometry."
    },
    {
        "anchor": "NCCT scans were either part of the patients\u2019 PET-Scan protocol or standalone NCCT scans for lung cancer staging and they were used for quantifying CAC score.",
        "positive": "NCCT scans were used for both PET-Scan protocol and standalone lung cancer staging, and were employed to assess the CAC score.",
        "negative": "Long-Term CRs of Relapsed DLBCL after Anti-CD19 CAR T Cell Therapy\n10 10 This report covers seven patients with subtypes of DLBCL treated in a completed clinical trial cohort.All patients with lymphoma evaluable for response are included."
    },
    {
        "anchor": "Received: 2 February 2021 Accepted: 6 September 2021",
        "positive": "Received: February 2, 2021 Accepted: September 6, 2021",
        "negative": "Head and Neck Squamous Cell Cancer (HNSCC)\n\u2022 in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC."
    },
    {
        "anchor": "a, Initial peak followed by recovery of peripheral blood absolute lymphocyte count.",
        "positive": "The peripheral blood absolute lymphocyte count initially rose and then returned to normal.",
        "negative": "Duration of response, PFS, and OS after CART2\nThe estimated median follow-up after CART2 was 28 months (IQR, 18-43) in all 44 patients (16, 18, and 43 months in the ALL, CLL, and NHL subgroups, respectively)."
    },
    {
        "anchor": "The indicated Stand Up To Cancer grant is administered by the American Association for Cancer Research, the Scientific Partner of SU2C.",
        "positive": "The SU2C grant is administered by the American Association for Cancer Research, the scientific partner of SU2C.",
        "negative": "Funding\nWe are grateful for the generous funding from a St. Baldrick\u2019s Foundation - Stand Up To Cancer Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT-27-17), the William Lawrence and Blanche Hughes Foundation, Alex\u2019s LemonadeStand, National Institutes of Health award 5U01TR002487-03, the ISREC Foundation (the Swiss Institute for Experimental Cancer Research), National Cancer Institute award P30CA014089 and Juno Therapeutics (A Bristol-Myers Squibb company)."
    },
    {
        "anchor": "The chance of GVHD occurring is low, but it is a potential risk with CART22 therapy if administered after prior allogeneic transplantation.",
        "positive": "The risk of GVHD is low, but it is a possible complication of CART22 therapy when given after allogeneic transplantation.",
        "negative": "However, due to the possibility of some degree of residual donor engraftment, which will include T cells of donor origin, patients that received a previous HSCT at the will be assessed for donor chimerism at screening and will be monitored closely throughout the study for signs of GVHD."
    },
    {
        "anchor": "The SAC comprises both Sponsor and non-Sponsor scientific experts who provide input with respect to trial design, interpretation of trial results and subsequent peer-reviewed scientific publications.",
        "positive": "The committee comprises experts from both the Sponsor and non-Sponsor organizations, offering input on trial design, result interpretation, and publication of scientific papers.",
        "negative": "7.3.1 Scientific Advisory Committee\nThis trialwas developed in collaboration with a Scientific Advisory Committee (SAC)."
    },
    {
        "anchor": "Prior presentations: This work was presented in part at the American Society of Clinical Oncology 2020 Annual Meeting in May 2020 as well as the American Society for Radiation Oncology 2020 Annual Meeting in October 2020.",
        "positive": "This research was partially presented at the American Society of Clinical Oncology's 2020 Annual Meeting in May and the American Society for Radiation Oncology's 2020 Annual Meeting in October.",
        "negative": "Notes\nRole of the funders: The funders had no role in the study design, data collection, analysis, and interpretation of data; in the writing of the report; or the decision to submit for publication."
    },
    {
        "anchor": "The method by Brookmeyer and Crowleywas used to construct 95% CIs around PFS estimates of the median and other quartiles for each expansion cohort.",
        "positive": "The Brookmeyer and Crowley method was employed to generate 95% confidence intervals for the median and quartile estimates of progression-free survival for each expansion cohort.",
        "negative": "Statistical analyses\nTwo general populations were used for statistical analysis: the safety population and the response-evaluable population."
    },
    {
        "anchor": "After a conditioning regimen of fludarabine and cyclophosphamide (FC; cyclophosphamide (20\u201330 mg/kg divided into 3 days) and fludarabine (20\u201330 mg/m2 \u00d7 3 days)), the first 7 patients received infusions in the range of 0.5\u20136\u00d7106 CAR+ cells per kilogram of body weight.",
        "positive": "Following a conditioning regimen of fludarabine and cyclophosphamide, the first 7 patients received infusions of CAR+ cells at a dose of 0.5-6 million per kilogram of body weight.",
        "negative": "Funding\nThis work was supported partly by the Science and Technology Department of Hebei Province, People\u2019s Republic of China (No."
    },
    {
        "anchor": "Omaveloxolone was administered starting on day 1, on a continuous once-daily oral schedule with a cycle of 28 days.",
        "positive": "The treatment regimen consisted of daily oral administration of omaveloxolone, starting on day 1, with a 28-day cycle.",
        "negative": "Study R9309 (INT0139) design, consort diagram and treatment delivered."
    },
    {
        "anchor": "Trials can be to single publications or entire collections; the choice is yours.",
        "positive": "The choice is yours whether to submit your trial results as a single publication or as part of a comprehensive collection.",
        "negative": "1.2 Toxicity and Efficacy Evaluations\nCRS was graded by Lee et al,3 which may not be congruent with how all studies grade CRS."
    },
    {
        "anchor": "Unforeseen medical conditions may be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver), or abnormal test results (eg, laboratory tests, electrocardiogram).",
        "positive": "Unexpected medical conditions can present as symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or abnormal test results (e.g., laboratory tests, electrocardiogram).",
        "negative": "A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer\nErnest Nadal1*, Mansoor Saleh2, Santiago Ponce Aix3, Maria Ochoa\u2011de\u2011Olza4, Sandip Pravin Patel5 , Scott Antonia6, Yumin Zhao7, Ivelina Gueorguieva7, Michael Man7, Shawn T. Estrem7, Jiangang Liu7 , Emin Avsar7,8 , Wen Hong Lin8,9, Karim A. Benhadji7, Leena Gandhi7,10, Susan C. Guba7 and Inmaculada Ales Diaz11 Abstract Background In this phase Ib/II open\u2011label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non\u2011small cell lung cancer (NSCLC) using galunisertib with nivolumab."
    },
    {
        "anchor": "We report the results of 23 R/R LBCL pts treated with a first-in-human CAR T-cell therapy product comprising a fully human CD19-targeted scFv (JCAR021).",
        "positive": "This study presents the outcomes of 23 patients with relapsed/refractory lymphoma who received a novel CAR T-cell therapy product, JCAR021, which targets CD19.",
        "negative": "Title: CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study\n\nAbstract: BackgroundT cells engineered with a CD19-targeted chimeric antigen receptor (CD19 CAR T cells) achieve high response rates in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)."
    },
    {
        "anchor": "If the results of a historical marrow biopsy (obtained at the time of the patient\u2019s most recent relapse) are available, this does not need to be repeated for enrollment.",
        "positive": "If a patient's previous marrow biopsy results are available, they do not need to undergo another biopsy for enrollment.",
        "negative": "Randomization and treatment\nIn the first phase, eligible patients were randomized (R1, 1:1) to receive either docetaxel 75 mg/m2 (DC75 group) or 60 mg/m2 (DC60 group) in combination with cisplatin 75 mg/m2 for up to 4 cycles."
    },
    {
        "anchor": "If a subject is removed because of an adverse event, they should remain under medical observation as long as deemed appropriate by the treating physician.",
        "positive": "If a subject is withdrawn due to an adverse event, they should continue to receive medical monitoring until the treating physician determines it is no longer necessary.",
        "negative": "Subject withdrawal\nSubjects may voluntarily discontinue participation in the study at any time."
    },
    {
        "anchor": "Chen Dong and Hai Qi for reagents.",
        "positive": "Reagents were requested by Chen Dong and Hai Qi.",
        "negative": "ACKNOWLEDGMENTS\nThe authors thank Drs."
    },
    {
        "anchor": "Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ((<https://openpaymentsdata.cms.gov/>)Open Payments).",
        "positive": "The Open Payments database contains information on payments made by companies to US-licensed physicians.",
        "negative": "Quantitative BCR-ABL: Ph+ ALL Patients\nIf clinically indicated, bone marrow aspirates sampled at the time points for tumor assessments will additionally be analyzed for quantitative BCR-ABL levels for Ph positive ALL subjects only."
    },
    {
        "anchor": "The demographics of the randomly assigned patients, including the prior chemotherapy regimens administered, are described in (<>)Table 2.",
        "positive": "The demographics of the patients randomly assigned to the study are described in Table 2.",
        "negative": "Title: Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies\n\nAbstract: IntroductionCAR-T cell therapy has proven to be a disruptive treatment in the hematology field."
    },
    {
        "anchor": "CONCLUSION The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.",
        "positive": "The addition of perioperative durvalumab to neoadjuvant chemotherapy in stage IIIA(N2) non-small-cell lung cancer patients is safe and outperforms historical data, with a high MPR and a promising 1-year EFS rate of 73%.",
        "negative": "Zurich Open Repository and Archive\nUniversity of Zurich University Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2021 SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial Rothschild, Sacha I ; Zippelius, Alfred ; Eboulet, Eric I ; Savic Prince, Spasenija ; Betticher, Daniel ; Bettini, Adrienne ; Fr\u00fch, Martin ; Joerger, Markus ; Lardinois, Didier ; Gelpke, Hans ; Mauti, Laetitia A ; Britschgi, Christian ; Weder, Walter ; Peters, Solange ; Mark, Michael ; Cathomas, Richard ; Ochsenbein, Adrian F ; Janthur, Wolf-Dieter ; Waibel, Christine ; Mach, Nicolas ; Froesch, Patrizia ; Buess, Martin ; Bohanes, Pierre ; Godar, Gilles ; Rusterholz, Corinne ; Gonzalez, Michel ; Pless, Miklos Abstract: PURPOSE For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care."
    },
    {
        "anchor": "The integration-site sequence data were worked up using the INSPIIRED pipeline as described (26, 39\u201345).",
        "positive": "The INSPIIRED pipeline was used to process the integration-site sequence data, as outlined in earlier research.",
        "negative": "Methods\nHuman subjects."
    },
    {
        "anchor": "Consent for publication\nAll patients gave written informed consent.",
        "positive": "Written informed consent was obtained from all patients participating in the study.",
        "negative": "DATA AVAILABILITY\nThe data used and analyzed during this study are available from the corresponding author on reasonable request."
    },
    {
        "anchor": "Methods: Patients with recurrent or metastatic squamous NSCLC received avelumab 800 mg (d 1 and 8), cetuximab 250 mg/m2 (d 1) and 500 mg/m2 (d 8), cisplatin 75 mg/m2 (d 1), and gemcitabine 1250 mg/m2 (d 1 and 8) for four 3-week cycles, followed by avelumab 800 mg and cetuximab 500 mg/m2 every 2 weeks.",
        "positive": "Patients with recurrent or metastatic squamous NSCLC received a treatment regimen consisting of avelumab, cetuximab, cisplatin, and gemcitabine for four cycles, followed by maintenance therapy with avelumab and cetuximab.",
        "negative": "Original Research\nLUNG CANCER Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy"
    },
    {
        "anchor": "RT, radiotherapy; SABR, stereotactic ablative radiotherapy; SRS, stereotactic radiosurgery.",
        "positive": "Definitions for RT, SABR, and SRS are provided below.",
        "negative": "safety monitoring\nThe treating physician will be able to modify or discontinue a patient treatment in either arm for various reasons, including perceived harm or toxicities."
    },
    {
        "anchor": "Model 3 includes all covariates from Model 2 and adds marital status and education.",
        "positive": "Model 3 includes all covariates from Model 2, plus marital status and education.",
        "negative": "Baseline demographics, smoking status, treatment, lung cancer type, and first line treatment for the 157 patients enrolled."
    },
    {
        "anchor": "The FACIT-D scores the level of dyspnea experienced with different activities (part 1) and the difficulty performing those activities because of dyspnea (part 2), in the past 7 days.",
        "positive": "The FACIT-D questionnaire evaluates the severity of dyspnea during different activities and the impact of dyspnea on daily activities over the past week.",
        "negative": "The FACIT-D has previously been demonstrated to be a valid and reliable measure of dyspnea in individuals with chronic obstructive pulmonary disease and dyspnea patients [(<>)54, (<>)55]."
    },
    {
        "anchor": "(<https://doi.org/10.1002/cncr.28136>)Cancer.",
        "positive": "A study on cancer was conducted, referencing a relevant publication.",
        "negative": "\ue014\ue015\ue011\ue014\ue003 6XPPDU\\\ue003RI\ue003'DWD\ue0036XEPLVVLRQ\ue003(8/10/16)\ue003\nAdverse event data collection and reporting, which are required as part of every clinical trial, are done to ensure the safety of patients enrolled in the studies as well as those who will enroll in future studies using similar agents."
    },
    {
        "anchor": "The intracranial ORR was 60% for those who had received radiotherapy within the preceding 6 months versus 46.2% for those who had not.",
        "positive": "The outcome of intracranial treatment was better for patients who had received radiotherapy within the preceding 6 months, with a response rate of 60%, compared to 46.2% for those who had not.",
        "negative": "\ue01b\ue011\ue015\ue003\ue003\ue0037KH\ue003SULPDU\\\ue003REMHFWLYH\ue003RI\ue003WKLV\ue003FRUUHODWLYH\ue003VWXG\\\ue003\nThe primary objective of this correlative study is to study if molecular markers (proteomic or genomic) in the blood circulation predict tumor control and radiation toxicity."
    },
    {
        "anchor": "summary summary filterResult objects in the set.",
        "positive": "The filterResult objects in the set were summarized.",
        "negative": "If x is manyFilterResult, then x[[i]] a filterResult object."
    },
    {
        "anchor": "PD-1 blockade therapy\nFor checkpoint inhibitor therapy, the rat anti-mouse PD-1 antibody (\u03b1PD-1, RMP1-14) diluted in sterilized 0.9% saline was administered intraperitoneally every 3 days for a total of five doses (200 \u00b5g per mouse).",
        "positive": "The PD-1 antibody was administered to mice every 3 days for five doses as a form of checkpoint inhibitor therapy.",
        "negative": "Plots\nConfirm that: The axis labels state the marker and fluorochrome used (e.g."
    },
    {
        "anchor": "18 patients were refractory to and 22 patients had relapsed from prior therapy.",
        "positive": "Patients who were resistant to previous treatment numbered 18, while 22 patients had relapsed.",
        "negative": "Title: Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China\n\nAbstract: Background\uff1aMost patients with relapsed/refractory follicular lymphoma (r/r FL) remain incurable and eventually relapse or progress."
    },
    {
        "anchor": "In this special circumstance, specimens will be stored until these questions have been adequately addressed.",
        "positive": "In exceptional cases, specimens will be preserved until the relevant questions have been thoroughly addressed.",
        "negative": "Adverse events\nGrade \u22653 treatment-emergent adverse events (TEAEs, adverse events (AEs) regardless of causality) were reported in 17 of 22 (77%) patients in part A, 10 of 14 (71%) in part B, 12 of 13 (92%) in part C, and 6 of 6 (100%) in part D. Nausea, anemia, and fatigue were the Table 2 Safety summary for parts A\u2013D Continued most common any-grade TEAEs across all parts of the study ((<>)table 2)."
    },
    {
        "anchor": "The combination therapy prolonged the overall survival of mice when compared to single CAR-T cell therapy (median survival:180 days VS unfollowed).",
        "positive": "The combination therapy resulted in a longer overall survival in mice compared to single CAR-T cell therapy, with a median survival of 180 days.",
        "negative": "Title: Valproic Acid Increased CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia\n\nAbstract: BackgroundThe treatment paradigm of B cell malignancies has dramatically changed in recent years with the introduction of immunotherapy, especially CAR-T cell therapy."
    },
    {
        "anchor": "In addition, CD3/CD28-mediated T-cell expansion kinetics coincided with increased PD-1 expres- sion, but not upregulated CD160 or CD244 levels (supplemental Figure 7C).",
        "positive": "CD3/CD28-mediated T-cell expansion was associated with increased PD-1 expression, but not CD160 or CD244, as depicted in supplemental Figure 7C.",
        "negative": "Prolonged ibrutinib treatment decreases immunosuppressive PD-1 and CD200 expression\n23 To evaluate the potential mechanisms of ibrutinib-mediated repair of T-cell function in CLL, we examined the phenotype of CD8+ T cells in the blood of CLL patients during their course of treatment with ibrutinib."
    },
    {
        "anchor": "Description\nA flow cytometry high throughput screening was used to identify biomarkers that would predict the development of GvHD.",
        "positive": "A high-throughput flow cytometry screening was conducted to identify biomarkers that could predict the onset of GvHD.",
        "negative": "The GvHD dataset is an extract of a collection of weekly peripheral blood samples obtained from patients following allogenic blood and marrow transplant."
    },
    {
        "anchor": "However, as our results show, tolerability is a significant issue to consider when developing novel combination regimens with drugs that may have overlapping toxicities.",
        "positive": "Our findings highlight the importance of considering tolerability when developing combination regimens that may have overlapping toxicities.",
        "negative": "Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics."
    },
    {
        "anchor": "This exploratory analysis evaluated the efficacy and safety of pemetrexed ?",
        "positive": "An exploratory study assessed the effectiveness and safety of pemetrexed treatment.",
        "negative": "John M Wrangle, MD,\nDepartment of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA"
    },
    {
        "anchor": "Therefore a total of 36 patients will be enrolled and equally randomized to the two study arms.",
        "positive": "Thirty-six patients will be enrolled and divided equally between the two study groups.",
        "negative": "5 Conclusion\nOur data show that FKB238 is similar to bevacizumab in efficacy, safety, and immunogenicity in patients with advanced non-sq-NSCLC."
    },
    {
        "anchor": "Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.",
        "positive": "Immunotherapy, excluding checkpoint inhibitors, was used to treat stage I to III non-small cell lung cancer patients who underwent surgery or radiotherapy with curative intent.",
        "negative": "(<https://www.cochranelibrary.com>)www.cochranelibrary.com"
    },
    {
        "anchor": "(<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)Impact of the treatment (<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)crossover design on comparative (<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)efficacy in EMPOWER-Lung 1: (<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)Cemiplimab monotherapy as (<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)first-line treatment of advanced (<https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full>)non-small cell lung cancer Josephine Louella Feliciano1, Dylan McLoone2, Yingxin Xu3, Ruben G.W.",
        "positive": "The crossover design's effect on comparative efficacy was examined in the EMPOWER-Lung 1 study, which evaluated Cemiplimab monotherapy as first-line treatment for advanced non-small cell lung cancer.",
        "negative": "Note\nSupplementary data for this article are available at Cancer Research Communications Online ((<https://aacrjournals.org/cancerrescommun/>)https://aacrjournals.org/cancerrescommun/)."
    },
    {
        "anchor": "Author details\n1Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Level 7, NUHS Tower Block, 1E Kent Ridge Road, Singapore 119228, Singapore.",
        "positive": "The authors' details are as follows: Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.",
        "negative": "Discussion\n4 5 6 42 48 49 The rationale for glutaminase inhibition as a therapeutic strategy for RCC is based on extensive studies of the Warburg effect and glutamine addiction in RCC cells."
    },
    {
        "anchor": "The details of treatments were provided in the protocol ((<>)Supplementary File).",
        "positive": "The treatment protocols are outlined in the supplementary file.",
        "negative": "Discussion\nKRAS, previously considered undruggable, has recently become tractable through the development of covalent inhibitors binding to the switch II pocket of KRAS G12C."
    },
    {
        "anchor": "Published online ahead of print at www.jco.org on March 23, 2015.",
        "positive": "The study was published online on March 23, 2015, at www.jco.org.",
        "negative": "Discussion\nThe detection of reliable predictive biomarkers has become a \u201chot topic\u201d for treatment with ICI, at least since the recognition of antithetical responses in patients with apparently similar clinical characteristics."
    },
    {
        "anchor": "15 14 Cemiplimab is a PD\u20101 inhibitor that is approved as mono-therapy for first\u2010line treatment of patients with metastatic or locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, and whose tumors have high PD\u2010L1 expression (tumor proportion score \u226550%) as determined by a US Food and Drug Administration\u2013approved test, and are negative for EGFR, ALK, and ROS1.In the EMPOWER\u2010Lung 1 phase 3 clinical trial, cemiplimab improved survival and progression\u2010free survival (both primary end points of the study) versus platinum\u2010doublet chemotherapy in patients with advanced NSCLC and PD\u2010L1 expression \u226550% ((<http://ClinicalTrials.gov>)ClinicalTrials.gov identifier NCT03088540).Treatment with cemiplimab was also associated with a higher objective response rate assessed by an independent review committee based on Response Evaluation Criteria in Solid Tumors 14 (RECIST 1.1) and with a longer duration of response than treatment with chemotherapy.",
        "positive": "Cemiplimab is a PD-1 inhibitor approved for first-line treatment of patients with metastatic or locally advanced NSCLC who are not candidates for surgery or chemoradiation and have high PD-L1 expression. In the EMPOWER-Lung 1 trial, cemiplimab improved survival and progression-free survival compared to chemotherapy in patients with advanced NSCLC and high PD-L1 expression.",
        "negative": "INTRODUCTION\n1 2 3 4\u201310 5\u20137 Lung cancer continues to be the leading cause of cancer\u2010related deaths in the United States.Non\u2013small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 80% of cases.Although platinum\u2010based chemotherapy has long been the standard of care for treatment of advanced NSCLC, such therapy has also been associated with a low response rate and short progression\u2010free and overall survival.Advanced NSCLC and platinum\u2010based chemotherapy are associated with a substantial humanistic burden, as demonstrated by patient reports of lower health\u2010related quality of life (HRQOL) and impaired functioning.HRQOL and functioning are particularly affected by disease\u2010related symptoms, such as shortness of breath, cough, fatigue, and pain, and chemotherapy\u2010related symptoms, including neuropathy and sore mouth."
    },
    {
        "anchor": "Preparation and Administration of Study Drug\nCell manufacturing is performed at the Clinical Cell and Vaccine Production Facility (CVPF).",
        "positive": "The study drug is manufactured at the Clinical Cell and Vaccine Production Facility (CVPF).",
        "negative": "Consent for publication\nAll patients provided written, informed consent."
    },
    {
        "anchor": "However, a clear dose-dependent relationship was not demonstrated, and the levels of insulin levels were not changed clearly prior and after figitumumab administration (data not shown).",
        "positive": "Although a dose-response relationship was not observed, insulin levels did not change significantly before and after figitumumab administration.",
        "negative": "T Cell Repertoire Sequencing\nT-cell receptor repertoire analysis was performed using Adaptive Biotechnologies immunoSEQ v3 assay, which employs bias-controlled multiplex PCR amplification and high-throughput sequencing to target rearranged T-cell receptor genes."
    },
    {
        "anchor": "Durability of the T cell response was demonstrated in two patients from whom samples from additional cycles of CDX-1401 treatment were available.",
        "positive": "The persistence of the T cell response was shown in two patients who received additional cycles of CDX-1401 treatment.",
        "negative": "Induction of cellular immunity to NY-ESO-1\nCellular immunity to NY-ESO-1 was determined by interferon-\u03b3 (IFN-\u03b3) enzyme-linked immunospot (ELISpot) on purified blood mononuclear cells from patient samples collected before and after CDX-1401 administration."
    },
    {
        "anchor": "All approved dara-containing regimens have used dara until progression, which for patients reaching 7months and beyond is once monthly.",
        "positive": "Dara was used in all approved regimens until disease progression, with a monthly dose for patients who reached 7 months or more.",
        "negative": "Cancer statistics, 2021."
    },
    {
        "anchor": "Survival was assessed by patient follow-up for 1 year after the last treated patient\u2019sfirst dose of huKS-IL2.",
        "positive": "The survival of patients was monitored for 1 year after the initial dose of huKS-IL2 administered to the last treated patient.",
        "negative": "Description of studies\nResults of the search We identified 1494 potentially relevant references."
    },
    {
        "anchor": "There was no significant immunogenicity observed that would have impacted study results.",
        "positive": "No significant immunogenicity was detected, which did not affect the study outcomes.",
        "negative": "Pharmacokinetics\nPhase Ib PK data showed rapid absorption (1\u20133 h) and elimination of galunisertib within 48 h. Observed galuni-sertib plasma concentrations were comparable with those observed in previous galunisertib trials [(<>)30]."
    },
    {
        "anchor": "Software: SK (WinNonlin).",
        "positive": "The statistical analysis was performed using SK (WinNonlin) software.",
        "negative": "Twitter Osama Rahma (<https://twitter.com/OsamaRahma2>)@OsamaRahma2\nAcknowledgements We would like to thank the study participants and their families, as well as all of the sites that made this study possible, including the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania; START Midwest, Grand Rapids, Michigan; St. Vincent\u2019s Hospital Sydney, Darlinghurst, New South Wales, Australia; South Texas Accelerated Therapeutics, San Antonio, Texas; Moffitt Cancer Center, Tampa, Florida; Dana-Farber Cancer Institute, Boston, Massachusetts; University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Pittsburgh, Pittsburgh, Pennsylvania; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada; Nebraska Cancer Specialists, Omaha, Nebraska; Mayo Clinic, Jacksonville, Florida; Norton Cancer Institute, Louisville, Kentucky; Rhode Island Hospital, Providence, Rhode Island; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia; Mayo Clinic, Rochester, Minnesota; Greenville Health Systems, Greenville, South Carolina; Mayo Clinic, Scottsdale, Arizona; Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Victoria, Australia; Roswell Park Cancer Institute, Buffalo, New York; Gabrail Cancer Institute, Canton, Ohio; Christiana Care Health Services, Newark, Delaware; Cross Cancer Institute, Edmonton, Alberta, Canada; and Mary Crowley Cancer Research, Dallas, Texas."
    },
    {
        "anchor": "Potentially dangerous negative intrapleural pressures generated by ordinary pleural drainage systems.",
        "positive": "Ordinary pleural drainage systems can create potentially hazardous negative intrapleural pressures.",
        "negative": "Quantitative real-time PCR\nQuantitative real-time PCR (Q-PCR) was employed to assess the level of CAR fusion gene according to a previously described protocol.13 A 153-bp (base pair)fragment thatcontains portions ofthe CD8a chain and adjacent 4-1BB chain (the forward primer 5\u2032-GGTCCTTCTCCTGTCACTGGTT-3\u2032 and reverse primer 5\u2032-TCTTCTTCTTCTGGAAATCGGCAG-3\u2032) was amplified by the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems)."
    },
    {
        "anchor": "To address secondary objective 2.24, we will tabulate the types and the frequency of treatment-related adverse events for erlotinib and bevacizumab and erlotinib using CTCAE version 4.0.",
        "positive": "To meet secondary objective 2.24, we will compile a list of treatment-related adverse events for erlotinib, bevacizumab, and erlotinib using CTCAE version 4.0.",
        "negative": "Patient and public involvement\nNo patients were involved in this study."
    },
    {
        "anchor": "In children with high-risk disease and CR to upfront therapy, early results from the COG study ARST0431 showed 3-year event-free survival of 20% for those with two or more Oberlin risk factors.In a large cohort of children with metastatic RMS (n = 788) treated on nine American and European co-operative group studies, the presence of RMS cells in the BM was shown to be an independent poor prognostic factor,.",
        "positive": "In children with high-risk disease who achieved complete remission after initial treatment, the COG study ARST0431 found that 20% of those with two or more Oberlin risk factors survived without relapse for 3 years. Additionally, a large study of 788 children with metastatic RMS found that the presence of RMS cells in the BM was an independent poor prognostic factor.",
        "negative": "RNA sequencing reveals differential expression of MET\n20,23 Analysis of CUTO28 and CUTO28-ER RNA samples by bulk RNA sequencing indicated expression of MET was significantly upregulated in CUTO28-ER cells as compared to parental (Figure (<>)1c;Log2FoldChange of3.48, adjusted p-value of 2.78 \ue003 10\ue00464)."
    },
    {
        "anchor": "was a consultant of Gracell Biotechnologies (Shanghai) Co., Ltd., Institute of Zoology, Chinese Academy of Sciences, and has a technology assignment agreement with Gracell Biotechnologies (Shanghai) Co., Ltd., for CRISPR-Cas9-mediated PDCD1 and TRAC gene editing methods in mesothelin-directed CAR-T cells.",
        "positive": "The individual was a consultant for Gracell Biotechnologies (Shanghai) Co., Ltd., the Institute of Zoology, Chinese Academy of Sciences, and had a technology assignment agreement with Gracell Biotechnologies (Shanghai) Co., Ltd. for CRISPR-Cas9-mediated gene editing methods in mesothelin-directed CAR-T cells.",
        "negative": "and W.C. are employees of Gracell Biotechnologies (Shanghai) Co., Ltd., whose potential product was studied in this work."
    },
    {
        "anchor": "The most commonly used EGFR inhibitor was cetuximab (53.8%), followed by erlotinib (37.5%) and afatinib (8.8%).",
        "positive": "Cetuximab was the most commonly used EGFR inhibitor (53.8%), followed by erlotinib (37.5%) and afatinib (8.8%).",
        "negative": "Introduction\nPrior to 2016, effective second-line treatment options in non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma who are not eligible for epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-targeted therapy, were limited [(<>)1, (<>)2]."
    },
    {
        "anchor": "Definitions relevant to the Analysis Sets:\n1) Screening failure - Any patient who fails to meet the inclusion/exclusion criteria specified by the protocol.",
        "positive": "Patients who failed to meet the inclusion or exclusion criteria specified in the protocol were considered screening failures.",
        "negative": "Study design\nPatients received up to 4 cycles of intravenous pembroli-zumab (200 mg on day 1 of each cycle) every 3 weeks (Q3W) in combination with intravenous cisplatin (75 mg/ m2 on day 1) and etoposide (100 mg/m2 on days 1, 2, and 3) in cohort 1; with intravenous carboplatin (area under the curve 5 mg/mL/min on day 1) and etoposide (100 mg/ m2 on days 1, 2, and 3) in cohort 2; or with intravenous cisplatin (75 mg/m2 on day 1) and etoposide (100 mg/ m2 on days 1, 2, and 3) with prophylactic subcutaneous pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim; 3.6 mg on day 4 of cycle 1) in cohort 3."
    },
    {
        "anchor": "Cell culture media metabolites and seahorse experiments\nFor experiments quantifying metabolite consumption or production in tissue culture media, cells were incubated in DMEM with 5 mmol/L glucose and 0.5 mmol/L glutamine (no serum) for 24 hours.",
        "positive": "Cells were cultured in a serum-free medium containing glucose and glutamine for 24 hours to assess metabolite consumption and production.",
        "negative": "CAR Expansion and Persistence\nPeak CAR expansion occurred between days 14 and 21 postinfusion."
    },
    {
        "anchor": "The PK evaluable population included all patients with sufficient concentration-time data for PK parameter evaluation.",
        "positive": "The population eligible for pharmacokinetic analysis consisted of patients with sufficient data for evaluating PK parameters.",
        "negative": "Statistical analyses\nThe mTPI method [(<>)7] was applied for dose escalation."
    },
    {
        "anchor": "The cut-off date for secondary endpoints was May 15th , 2020, which was the date for the end of the study, defined as 12 months after the last patient randomized to group per protocol.",
        "positive": "The cutoff date for secondary endpoints was May 15th, 2020, which coincided with the study's completion, 12 months after the last patient was randomized to a treatment group.",
        "negative": "Participant Characteristics\nBaseline characteristics of randomized patients are shown by group in Table 1."
    },
    {
        "anchor": "Cancer Res 2017; 77(13 Supplement): abstract CT101.",
        "positive": "The abstract CT101 in Cancer Research, published in 2017, is a notable reference.",
        "negative": "Princeton, NJ: Bristol-Myers Squibb; August 2018."
    },
    {
        "anchor": "A growing area of interest is the use of neoantigens derived from unique mutational events.",
        "positive": "Research is increasingly focused on the application of neoantigens generated from distinct mutational events.",
        "negative": "Alternatively, investigators have examined strategies to load antigens derived from whole tumor cells onto antigen- presenting cells."
    },
    {
        "anchor": "Registered 29 January 2018",
        "positive": "The trial was registered on January 29, 2018.",
        "negative": "ER\u03b2 interferes with AR-mediated transcription in TNBC\nTo explore how ER\u03b2 reversed the AR oncogenic roles in LAR TNBC, we first performed co-IP assays on TNBC cells to determine whether AR could physically bind with ER\u03b2 [(<>)Figure\u00a03A]."
    },
    {
        "anchor": "ORRs were higher and median DOR and PFS were potentially longer with lorlatinib than crizotinib regardless of TP53 mutation status ((<>)Table 3).",
        "positive": "The outcomes showed that response rates were higher, and median duration of response and progression-free survival were potentially longer with lorlatinib, regardless of TP53 mutation status.",
        "negative": "Biomarkers\nPlasma samples from most Asian patients were available for analysis, and ctDNA was detectable in 44 patients (75%) in the lorlatinib arm and 48 (79%) in the crizotinib arm."
    },
    {
        "anchor": "1.1 Subjects\nOnly those patients who received a CAR product were analyzed for clinical outcomes (n=60); with exclusion of 1 subject who received chemotherapy on day +4 following infusion due to rapid disease progression, whose outcome measures regarding toxicity could not be accurately assessed since CAR T-cell response was abrogated prior to expansion.",
        "positive": "The analysis focused on patients who received a CAR product (n=60), excluding one patient who received chemotherapy on day +4 due to rapid disease progression, whose toxicity assessment was compromised by the abrogated CAR T-cell response.",
        "negative": "This trial is registered at ClinicalTrials.gov (NCT02315612)."
    },
    {
        "anchor": "and has been designed such that it does not require an unnecessary number of animals to accomplish its objectives.",
        "positive": "The study has been designed to minimize the use of animals, ensuring that the objectives can be achieved without unnecessary animal involvement.",
        "negative": "Methods\nEthics statement."
    },
    {
        "anchor": "Outcomes\nAs visible in (<>)Figure 2 and (<>)Table 3, the mean VAS score on the first POD while coughing was significantly lower in the OFA group [2 (1.25, 2)] than in the OSA group [2 (2, 3)] (p = 0.044).",
        "positive": "The VAS scores for coughing on the first post-operative day were significantly lower in the OFA group compared to the OSA group, as shown in Figure 2 and Table 3, with a p-value of 0.044.",
        "negative": "Risks/Benefits\nPlease refer to Table 1.6-1 for expected adverse events experienced with CART22 Please refer to Table 1.6-2 for expected adverse events experienced with CART22-65s as of-."
    },
    {
        "anchor": "Availability of data and materials\nPlans for data entry, security and storage have been approved by the Danish Data Protection Agency (j.nr.",
        "positive": "The plans for data entry, security, and storage have been reviewed and approved by the Danish Data Protection Agency.",
        "negative": "Title: Impact of Epichaperome Inhibitor PU-H71 on Anti-Tumor T Cell Responses and Its Implications for Immune and Cellular Therapy\n\nAbstract: The epichaperome is a tightly integrated network of proteins supporting critical roles in the tumor-associated microenvironment and cancer cell survival."
    },
    {
        "anchor": "G. Proposed schema of peripheral activation of the anti-tumor repertoire homing back to the tumor bed.",
        "positive": "The proposed schema involves the activation of the anti-tumor repertoire in the peripheral circulation, which then targets the tumor site.",
        "negative": "Anti\u2013CD19-CAR\u2013transduced T cells can specifically recognize autologous leukemia cells\nThe blood of some of the patients on our trial contained large numbers of CD19+ CLL cells."
    },
    {
        "anchor": "The successful candidate will be the holder of a named Professorship in Hematology.",
        "positive": "The successful candidate will hold a named Professorship in Hematology.",
        "negative": "Declarations\nConflict of interest Anna Ryd\u00e9n and Andrew Walding are employees of AstraZeneca and hold shares in AstraZeneca."
    },
    {
        "anchor": "Cohort 1 included patients with advanced or metastatic NSCLC without EGFR or anaplastic lymphoma kinase (ALK) gene alterations and received AK112 in combination with platinum-based chemotherapy as first-line treatment.",
        "positive": "Cohort 1 consisted of patients with advanced or metastatic NSCLC who did not have EGFR or ALK gene alterations and received AK112 in combination with platinum-based chemotherapy as their initial treatment.",
        "negative": "Characteristics of bridging therapy, lymphodepletion, and CD30.CAR-T cell therapy\nSeventy percent (19 patients) of the cohort received bridging therapy between blood collection for CAR-T manufacturing and lympho-depletion ((<>)Table 1)."
    },
    {
        "anchor": "Patients were heavily pretreated, having received a median (range) of three (1\u201311) previous anticancer treatments.",
        "positive": "The patients had undergone a median of three (range: 1-11) previous anticancer treatments.",
        "negative": "Patients\nIn this study, all the sequencing data and clinical data were obtained from the POPLAR (NCT01903993) and OAK (NCT02008227) trials [(<>)10, (<>)26, (<>)28]."
    },
    {
        "anchor": "Administrative permissions were obtained to access the data used in this study.",
        "positive": "Permission was granted to access the data used in this study.",
        "negative": "Bone lesions:\nx\ue003 Bone scan, PET scan or plain \u00bflms are not considered adequate imaging WHFKQLTXHV\ue003WR\ue003PHDVXUH\ue003ERQH\ue003OHVLRQV\ue011\ue003+RZHYHU\ue00f\ue003WKHVH\ue003WHFKQLTXHV\ue003FDQ\ue003EH\ue003XVHG\ue003 to con\u00bfrm the presence or disappearance of bone lesions."
    },
    {
        "anchor": "Atezolizumab for first-line treatment of metastatic non-squamous NSCLC.",
        "positive": "Atezolizumab was investigated as a first-line treatment option for patients with metastatic non-squamous NSCLC.",
        "negative": "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer."
    },
    {
        "anchor": "Across all trials, seven (0.3%) grade 4 events were reported in the ramucirumab arm, with four of these events not recovered or resolved, whereas four grade 4 events were reported in the control arm.",
        "positive": "In all trials, 0.3% of patients in the ramucirumab arm experienced grade 4 events, with four of these events not resolving, compared to four grade 4 events in the control arm.",
        "negative": "CA Cancer J Clin 60:277-300, 2010 2."
    },
    {
        "anchor": "Imaging included brain MRI in all patients; additionally, whole-body positron emission tomography (PET) was encouraged, but contrast-enhanced computed tomography (CT) with a 99Tc bone scan was acceptable as well.",
        "positive": "Imaging modalities used included brain MRI for all patients, with whole-body PET also recommended, although contrast-enhanced CT with a 99Tc bone scan was also acceptable.",
        "negative": "Independent trial monitoring\nAn independent data monitoring committee will be appointed and will convene with the purpose of: \u25ba Assessing quality issues related to radiation therapy."
    },
    {
        "anchor": "d, Pie chart depicts the percentage of T cell responders that induce CD4+, CD8+ or both CD4+ and CD8+ cytokine-positive cells in ICS assay.",
        "positive": "The ICS assay results are displayed in a pie chart, showing the percentage of T cells that induce CD4+, CD8+, or both CD4+ and CD8+ cytokine-positive cells.",
        "negative": "Immunogenicity and clinical outcomes\n25 28 The exploratory immunogenicity of ELI-002 2P was assessed directly ex vivo in the peripheral blood of patients throughout the study (Fig."
    },
    {
        "anchor": "NCT02855125 (ClinicalTrials.gov) registered on 4 August 2016.",
        "positive": "The clinical trial was registered on August 4, 2016, under the identifier NCT02855125 on ClinicalTrials.gov.",
        "negative": "SGN-B7H4V demonstrates robust activity in vivo in multiple xenograft models of breast and ovarian cancer\nTo determine if the robust activity of SGN-B7H4V observed in vitro translated to an in vivo setting, the anti-tumor activity of SGN-B7H4V was evaluated in two cell-line derived xenograft (CDX) models of TNBC as well as three PDX models of TNBC and ovarian cancer."
    },
    {
        "anchor": "LR contributed to the design and analysis of experiments.",
        "positive": "The experiments were designed and analyzed by Dr. LR.",
        "negative": "Author contributions\nYW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing \u2013 original draft."
    },
    {
        "anchor": "Patients\nThis is an open-label randomized phase 2 study done at the National Cancer Centre Singapore.",
        "positive": "The study is an open-label, randomized phase 2 trial conducted at the National Cancer Centre Singapore.",
        "negative": "Patients with asymptomatic central nervous system (CNS) metastases were allowed, provided they had had no ongoing requirement for corticosteroids as therapy for CNS disease, no stereotactic radiation with 7 days or whole brain radiation within 14 days before randomization, and no evidence of interim progression between the completion of brain-directed therapy and screening radiographic study."
    },
    {
        "anchor": "To determine if T-cell response affected cellular kinetics or clinical outcomes, the T-cell responses in a subgroup of B-ALL patients in the 90th percentile for T-cell response were compared with those responses in the overall population.",
        "positive": "The T-cell responses in a subgroup of B-ALL patients with the highest T-cell response were compared with those in the overall population to examine the effect of T-cell response on cellular kinetics and clinical outcomes.",
        "negative": "Title: Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells\n\nAbstract: BackgroundSarcopenic muscle loss has well-documented adverse impacts on treatment outcomes and mortality across cancer types and is particularly prevalent in patients with multiple myeloma, reported in 54% of newly diagnosed patients (Nandakumar ASCO 2022)."
    },
    {
        "anchor": "&RQILUPDWLRQ\nTo be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat assessments that should be 12 weeks after the criteria for response are first met.",
        "positive": "Patients must meet the criteria for partial response (PR) or complete response (CR) by demonstrating confirmed changes in tumor measurements, which must be confirmed by repeat assessments 12 weeks after the initial response criteria are met.",
        "negative": "In the case of SD, follow-up measurements must have met the SD criteria at least once after study entry at a minimum interval of 12 weeks"
    },
    {
        "anchor": "The primary efficacy endpoint is PFS (i.e., time from randomization to documented progressive disease or death due to any cause, whichever occurs first) per RECIST 1.1 based on blinded independent radiologists\u2019 review.",
        "positive": "The primary endpoint is progression-free survival (PFS), which is the time from randomization to documented progressive disease or death due to any cause, whichever occurs first, as determined by blinded independent radiologists.",
        "negative": "The analysis plan for PROs willbe provided in a separate document before the finalPFS analysis."
    },
    {
        "anchor": "Transitioning the Ad:MG1 oncolytic vaccination from mice to the clinic\nThe aforementioned preclinical observations encouraged the evaluation of the Ad:MG1 oncolytic vaccination approach in the clinic.",
        "positive": "The successful preclinical results of the Ad:MG1 oncolytic vaccination in mice led to the evaluation of this approach in clinical trials.",
        "negative": "TNFR2 expression is associated with PDAC proliferation, metastasis, and survival\nTNFR2 was expressed in the ducts of pancreatic cancer tissue to varying levels and we divided 70 PDAC patients into two groups by TNFR2 IHC score: low-expression group (+, ++) and high-expression group (+++)."
    },
    {
        "anchor": "This was followed by osi-mertinib 80 mg QD with pemetrexed 500 mg/m2 maintenance Q3W until RECIST 1.1-defined progression or discontinuation (patient/investigator decision, AE, protocol noncompliance).",
        "positive": "The treatment regimen consisted of osi-mertinib 80 mg daily and pemetrexed 500 mg/m2 every three weeks, continued until RECIST 1.1-defined progression or discontinuation due to patient or investigator decision, adverse event, or protocol noncompliance.",
        "negative": "Study design and treatments\nPatients received oral osimertinib 80 mg once daily (QD) in combination with either intravenous (IV) cisplatin 75 mg/m2 or IV carboplatin target area under the curve 5, plus pemetrexed 500 mg/m2 , both administered every 3 weeks (Q3W) for four cycles (21 days per cycle; (<>)Supplementary (<>)Figure S1, available at (<https://doi.org/10.1016/j.esmoop.2021.100271>)https://doi.org/10.1016/j.esmoop."
    },
    {
        "anchor": "All authors read and approved the manuscript.",
        "positive": "All authors reviewed and approved the manuscript.",
        "negative": "Author contributions\nMSN and DJH contributed equally to the study."
    },
    {
        "anchor": "The investigator will allocate adequate time for such monitoring activities.",
        "positive": "The investigator will ensure that sufficient time is dedicated to monitoring activities.",
        "negative": "Abstract\nPurpose Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS)."
    },
    {
        "anchor": "parameters Object of class \"transformation\" \u2013 flow parameter to be transformed.",
        "positive": "The \"transformation\" class object's flow parameter needs to be converted.",
        "negative": "Title: Novel CD19-Specific \u03b3/\u03b4 TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma\n\nAbstract: \n\nDate and Time: 2021-11-23"
    },
    {
        "anchor": "Exact methods (Clopper\u2013Pearson 95% confidence intervals (CIs)) were used for categorical variables.",
        "positive": "Exact methods were employed for categorical variables using 95% Clopper-Pearson confidence intervals.",
        "negative": "PFS and OS were estimated using the Kaplan\u2013Meier method and were compared with the use of the log-rank test."
    },
    {
        "anchor": "Medical writing support was provided by Karen O\u2019Leary, PhD, of Fishawack Communications Ltd, and funded by AbbVie.",
        "positive": "AbbVie funded medical writing support provided by Karen O'Leary, PhD, of Fishawack Communications Ltd.",
        "negative": "(<https://www.frontiersin.org/journals/oncology#editorial-board>)CASE REPORT\n(<https://www.frontiersin.org/journals/oncology#editorial-board>)published: 30 June 2022 (<https://doi.org/10.3389/fonc.2022.898954>)doi: 10.3389/fonc.2022.898954 Edited by: Anurag Mehta, Rajiv Gandhi Cancer Institute and Research Centre, India Reviewed by: Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, India Dawei Wu, Chinese Academy of Medical Sciences and Peking Union Medical College, China *Correspondence: Jinlu Shan (<mailto:jinlushan2022@yeah.net>)jinlushan2022@yeah.net \u2020These authors share first authorship Specialty section: This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology Received: 18 March 2022 Accepted: 30 May 2022 Published: 30 June 2022 Citation: Du J, Wang B, Li M, Wang C, Ma T and Shan J (2022) A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report."
    },
    {
        "anchor": "S.G. and M. Ruella designed, performed and oversaw the research.",
        "positive": "The research was designed, conducted, and overseen by S.G. and M. Ruella.",
        "negative": "Objects from the Class\nObjects can be created by calls of the form new(\"timeFilter\",...) or using the constructor timeFilter."
    },
    {
        "anchor": "All authors reviewed the results and approved the final version of the manuscript.",
        "positive": "The authors reviewed the results and approved the final manuscript.",
        "negative": "INTRODUCTION\nLung cancer constitutes the most common malignant tumors around the world."
    },
    {
        "anchor": "The trials and sub-studies were approved by the Institutional Review Boards or independent Ethics Committees (listed in full in the appendix).",
        "positive": "Institutional Review Boards or independent Ethics Committees approved the trials and sub-studies.",
        "negative": "Ethics approval\nThe AURA and ARCTIC trials and sub-studies were performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and were consistent with Good Clinical Practice guidelines and the applicable regulatory requirements."
    },
    {
        "anchor": "WO, NL, and BXW draughted the manuscript.",
        "positive": "The manuscript was written by WO, NL, and BXW.",
        "negative": "Contributors\nSYW and LMD designed the research."
    },
    {
        "anchor": "The assistance of J. Finklestein and F. Nazimuddin for sample processing, I. Kulikovskaya and M. Gupta for qPCR analyses, D. Ambrose for flow cytometry analyses, F. Chen and N. Kengle for Luminex cytokine analyses, and V. Gonzalez and Y. Tanner for data management is appreciated.",
        "positive": "Several individuals contributed to the research, including J. Finklestein, F. Nazimuddin, I. Kulikovskaya, M. Gupta, D. Ambrose, F. Chen, N. Kengle, V. Gonzalez, and Y. Tanner.",
        "negative": "Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results\n1 Chuan Qin1,2, Dai-Shi Tian (<http://orcid.org/0000-0002-7627-0811>)(<http://orcid.org/0000-0002-7627-0811>),2, Luo-Qi Zhou1,2 , Ke Shang1,2, Liang Huang (<http://orcid.org/0000-0002-8370-3232>)(<http://orcid.org/0000-0002-8370-3232>)3 (<http://orcid.org/0000-0002-8370-3232>), Ming-Hao Dong1,2 , Yun-Fan You1,2 , Jun Xiao1,2 , Ying Xiong 4 , Wen Wang (<http://orcid.org/0000-0003-3215-3020>)5 (<http://orcid.org/0000-0003-3215-3020>), Hao Pang 5 , Jing-Jing Guo 5 , Song-Bai Cai 5 , Di Wang 3 , Chun-Rui Li 3 , Min Zhang1,2 , Bi-Tao Bu1,2 and Wei Wang1,2 \u2709 Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectrum disorder (NMOSD)."
    },
    {
        "anchor": "Of the 11 patients who had prior anti-EGFR therapy, 10 were treated with a TKI inhibitor.",
        "positive": "Of the 11 patients who had received prior anti-EGFR therapy, 10 were treated with a TKI inhibitor.",
        "negative": "Availability of data\nThe datasets analysed during the current study are available from the corresponding author on reasonable request."
    },
    {
        "anchor": "N Engl J Med.",
        "positive": "The New England Journal of Medicine.",
        "negative": "Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group."
    },
    {
        "anchor": "The patients/participants provided their written informed consent to participate in each substudy.",
        "positive": "Participants gave their written consent to participate in each substudy.",
        "negative": "Cancer Therapy: Clinical\nRandomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non\u2013Small Cell Lung Cancer Suresh S. Ramalingam1 , Normand Blais2 , Julien Mazieres3 , Martin Reck4 , C. Michael Jones5 , Erzsebet Juhasz6 , Laszlo Urban7, Sergey Orlov8 , Fabrice Barlesi9 , Ebenezer Kio10 , Ulrich Keiholz11 , Qin Qin12 , Jiang Qian12 , Caroline Nickner13 , Juliann Dziubinski12 , Hao Xiong12 , Peter Ansell12 , Mark McKee12 , Vincent Giranda12 , and Vera Gorbunova14 Clinical Cancer Research Abstract Purpose: PARP plays an important role in DNA repair."
    },
    {
        "anchor": "See the Usage section for details.",
        "positive": "Details on usage can be found in the Usage section.",
        "negative": "AUTHOR CONTRIBUTIONS\nConception and design: S.R., S.Y., and C.Z.."
    },
    {
        "anchor": "Age at diagnosis, number of previous lines of therapy, and number of prior allogeneic stem cell transplantations were generally balanced among patients with (regardless of severity) and without CRS (Table 1).",
        "positive": "The patient population was balanced in terms of age at diagnosis, previous treatment, and prior stem cell transplants, regardless of CRS severity (Table 1).",
        "negative": "FIGURES\nFigure S1: CAR22 vector The anti-CD22 binding domain (m971) recognizes the proximal extracellular domains of CD22 (A)."
    },
    {
        "anchor": "MQ, SL, MR, KBC and LA wrote the manuscript.",
        "positive": "Authors MQ, SL, MR, KBC, and LA contributed to the manuscript.",
        "negative": "Authors\u2019 contributions\nMQ, SL, MR and LA devised the study concept and design."
    },
    {
        "anchor": "open system (reagents, consumables, and hardware: Milte-nyi Biotech, Bergisch-Gladbach, Germany).",
        "positive": "The study utilized an open system supplied by Milte-nyi Biotech, a company based in Bergisch-Gladbach, Germany.",
        "negative": "Discussion\nThis phase III study compared the efficacy, safety, and immu-nogenicity of the biosimilar ABP 215 and bevacizumab RP."
    },
    {
        "anchor": "The Kaplan-Meier method described PFS and OS.",
        "positive": "PFS and OS were calculated using the Kaplan-Meier method.",
        "negative": "2.6 Statistical analyses\nPatients who taken at least one dosage of apatinib and gefitinib were pooled in the intention-to-treat (ITT) analysis."
    },
    {
        "anchor": "Comparison 1: EEect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 8: Adverse events (severe, grade > 2) 48 ................................................................................................................................................................. APPENDICES .............................................................................................................................................................................................. 48 WHAT'S NEW .............................................................................................................................................................................................. 50 HISTORY ..................................................................................................................................................................................................... 50 CONTRIBUTIONS OF AUTHORS ................................................................................................................................................................ 50 DECLARATIONS OF INTEREST .................................................................................................................................................................. 50 SOURCES OF SUPPORT ............................................................................................................................................................................ 50 DIFFERENCES BETWEEN PROTOCOL AND REVIEW ................................................................................................................................. 51 INDEX TERMS ............................................................................................................................................................................................ 51",
        "positive": "Comparison 1: The effect of immunotherapy on surgically treated NSCLC patients: main findings, Outcome 8: Severe adverse events (grade > 2) 48 ................................................................................................................................................................. APPENDICES .............................................................................................................................................................................................. 48",
        "negative": "T A B L E \ue003 O F \ue003 C O N T E N T S\nABSTRACT .................................................................................................................................................................................................. 1 PLAIN LANGUAGE SUMMARY .................................................................................................................................................................... 2 SUMMARY OF FINDINGS ........................................................................................................................................................................... 4 BACKGROUND ........................................................................................................................................................................................... 7 Figure 1."
    },
    {
        "anchor": "Products were predominantly comprised of CD45RO\u00feCCR7\u2013 T-effector memory (Tem) and CD45RO\u00feCCR7\u00fe central memory (Tcm) cells, with a median CD8\u00fe Tem of 51% (range, 39\u201373%) and CD8\u00fe Tcm of 36% (range 4\u201359%).",
        "positive": "The majority of products consisted of CD45RO\u00feCCR7\u2013 T-effector memory (Tem) and CD45RO\u00feCCR7\u00fe central memory (Tcm) cells, with a median CD8\u00fe Tem of 51% (range, 39\u201373%) and CD8\u00fe Tcm of 36% (range 4\u201359%).",
        "negative": "Clonality and insertional oncogenesis."
    },
    {
        "anchor": "Select participant demographic and medical characteristics are presented in Table (<>)4.",
        "positive": "The table below shows selected participant demographic and medical characteristics.",
        "negative": "Participant characteristics\nParticipants who completed the intervention (n=11) were 27% male, 36% Black, with a mean age of 71 \u00b1 10 years and mean BMI of 29.1 \u00b1 6.5."
    },
    {
        "anchor": "Methods\nINNOVATIONS (Inoperable NS-NSCLC (stage IIIB/IV): a randomised phase II study with bevacizumab plus erlotinib or gemcitabine/cisplatin plus bevacizumab) was a multicentre open-label randomised phase II trial conducted in Germany.",
        "positive": "The INNOVATIONS trial was a multicentre, open-label, randomized phase II study conducted in Germany to investigate the combination of bevacizumab with erlotinib or gemcitabine/cisplatin in patients with stage IIIB/IV non-small-cell lung cancer.",
        "negative": "1, e1846926 (8 pages) https://doi.org/10.1080/2162402X.2020.1846926\nARTICLE Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial a ,b ,c c c c c c a c Hanren Dai, Chuan Tong, Daiwei Shid(<>), Meixia Chen, Yelei Guo, Deyun Chen, Xiao Han, Hua Wang, Yao Wang, and Pingping Shenb (<>) ABSTRACT Expressed by cancer stem cells of various epithelial cell origins and hepatocellular carcinoma (HCC), CD133 is an attractive therapeutic target for HCC."
    },
    {
        "anchor": "One preclinical study assessed the effects of sequential administration of pemetrexed and erlotinib, and showed cytotoxic synergism in both mutant and wild-type EGFR cell lines [(<>)12].",
        "positive": "Preclinical research found that sequential administration of pemetrexed and erlotinib showed synergistic effects in both mutant and wild-type EGFR cell lines.",
        "negative": "Patient consent for publication Not applicable."
    },
    {
        "anchor": "Initially, lymphocyte counts and cytokines levels (IFN-\uf067, IL-2, IL-6, IL-10 and TNF-\uf061) dropped, followed by an increase of IL-10 at later time points (Figure 6E-G).",
        "positive": "Initially, lymphocyte counts and cytokine levels decreased, followed by an increase in IL-10 levels at later time points.",
        "negative": "Lck lacking CD28 CAR-T cells show improved tumor control in combination with PD-1 blockade in tumor bearing humanized mice."
    },
    {
        "anchor": "Each dot is one mouse (n = 11).",
        "positive": "Each data point represents one mouse, with a total of 11 mice.",
        "negative": "Redirected T cells with \uf044-CD28 co-stimulation show better tumor control in humanized mice and persistence in tumor infiltrating lymphocytes (TILs) and peritoneal lavage (PL)."
    },
    {
        "anchor": "The data cutoff date was October 31, 2018.",
        "positive": "The data cutoff date was October 31, 2018.",
        "negative": "Patient characteristics are listed in (<>)Table 1."
    },
    {
        "anchor": "The response in the squamous histology was 43.8%.",
        "positive": "The response rate in patients with squamous histology was 43.8%, indicating a significant response.",
        "negative": "Acknowledgments\nFunding: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and received no direct compensation related to the development of the manuscript."
    },
    {
        "anchor": "1A (for details, see Supplementary Appendix: Methods of chemical synthesis and characterization of TAK-676).",
        "positive": "Additional information on the synthesis and characterization of TAK-676 can be found in the Supplementary Appendix.",
        "negative": "Patients\nEligible patients were at least 18 years old with histologically or cytolog-ically confirmed advanced NSCLC; documented American Joint Committee on Cancer9 stage IIIB or metastatic (stage IV or recurrent) disease not amenable to curative treatment; and a primary histology of predominantly squamous cell, large cell, or adenosquamous carcinoma."
    },
    {
        "anchor": "(4) It will not be a considered a deviation if : \u2265 99% of the PTV receives \u2265 93% of the prescribed dose, and no more than 2cm3 of the PTV exceed 120% of the prescribed dose.",
        "positive": "It will not be considered a deviation if \u2265 99% of the PTV receives \u2265 93% of the prescribed dose, and no more than 2cm3 of the PTV exceeds 120% of the prescribed dose.",
        "negative": "Discussion\nIn this analysis of an ongoing phase 1, first-in-human clinical study, LCAR-B38M, a CAR T cell therapy directed against 2 distinct BCMA epitopes, displayed a manageable safety profile and demonstrated durable responses in patients with relapsed or refractory multiple myeloma."
    },
    {
        "anchor": "Sequencing data were analyzed using default parameters.",
        "positive": "Sequencing data were analyzed using default parameters.",
        "negative": "Discussion\nAccess to CAR T therapy for MM patients is still limited."
    },
    {
        "anchor": "Overall, for the 91 patients, similar median OS was observed between the two treatment arms (23.1 mo, 95% CI: 15.1\u201328.5 for gefitinib versus 23.7 mo, 95% CI: 16.4\u2013not reached for gefitinib plus olaparib, p \u00bc 0.5385).",
        "positive": "The median overall survival was similar for the 91 patients in both treatment arms, with a median survival of 23.1 months (95% CI: 15.1-28.5) for gefitinib and 23.7 months (95% CI: 16.4-not reached) for gefitinib plus olaparib, with a p-value of 0.5385.",
        "negative": "BRCA1 mRNA Expression and Treatment Outcome\n5 Similarly to the whole population of the GOAL study,in this analysis of the 91 patients, there was no statistically significant difference in median PFS between the two treatment arms (p \u00bc 0.2419) ((<>)Fig."
    },
    {
        "anchor": "Four patients had clinical or pathologically confirmed N3 disease, all by virtue of contralateral mediastinal lymph node involvement.",
        "positive": "A total of four patients had N3 disease, which was confirmed through clinical and pathological examination, with all cases involving lymph node involvement on the opposite side of the mediastinum.",
        "negative": "Incidence of Grades \u0095\ue003\ue016\ue003 $(V\ue003 ZDV\ue003 VLPLODU\ue003 DFURVV\ue003 DUPV\ue011\ue003 *UDGH\ue003 \u0095\ue003\ue016\ue003 SXOPRQDU\\\ue003 KHPRUUKDJH\ue003 UDWHV\ue003 ZHUH\ue003 \u0094\ue003\ue014\ue011\ue018\ue008\ue003 IRU\ue003 DOO\ue003 DUPV\ue003 GHVSLWH\ue003 \ue01c\ue008\ue003 RI\ue003 SDWLHQWV\ue003 UHFHLYLQJ\ue003WKHUDSHXWLF\ue003DQWLFRDJXODWLRQ\ue011\ue003"
    },
    {
        "anchor": "It was registered with ClinicalTrials.gov, NCT02977845.",
        "positive": "The study was listed on ClinicalTrials.gov with the registration number NCT02977845.",
        "negative": "The study was conducted at the National Lung Hospital and Nam Dinh General hospital in Vietnam."
    },
    {
        "anchor": "Checkpoint inhibitors: common immune-related adverse events and their management.",
        "positive": "Common adverse events related to checkpoint inhibitors and their treatment.",
        "negative": "Seetharamu N. The state of the art in non-small cell lung cancer immu-notherapy."
    },
    {
        "anchor": "Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.",
        "positive": "The NEOSTAR trial: a phase 2 randomized study examining the effectiveness of nivolumab or nivolumab plus ipilimumab as neoadjuvant therapy for operable non-small cell lung cancer.",
        "negative": "Statistical analysis\n4 38 40 41 42 Based on the study design, the patients were separated into arms A and B according to PD-L1 expression."
    },
    {
        "anchor": "We used the two-tailed Fisher\u2019s Exact Test to determine if the distribution of breast cancer subtype, a categorical variable, was significantly different between c-Met+ and c-Met- tumors.",
        "positive": "The two-tailed Fisher's Exact Test was used to investigate whether the breast cancer subtypes were significantly different between c-Met+ and c-Met- tumors.",
        "negative": "Statistical considerations\nWe compared the clinical and tumor characteristics of our patient cohort as stratified by c-Met expression using a two-sided Student t-test for continuous variables (i.e."
    },
    {
        "anchor": "World J Surg 1998;22:783\u201390.",
        "positive": "A study published in the World Journal of Surgery in 1998 reported the results of a study.",
        "negative": "MET signalling: principles and functions in development, organ regeneration, and cancer."
    },
    {
        "anchor": "Assistant to the Director for Pharmacology and Toxicology ODE VI JJ.",
        "positive": "The Assistant to the Director for Pharmacology and Toxicology, ODE VI JJ.",
        "negative": "Recommendation\nEvery pharmacokinetic study (an exception is population PK) in this submission lacks proper design and sampling scheme."
    },
    {
        "anchor": "CR rate, CRS, neurotoxicity, and CAR peak (N 5 110)",
        "positive": "The study evaluated the CR rate, CRS, neurotoxicity, and CAR peak, with a maximum value of 110.",
        "negative": "Statistical analysis\nThe probabilities of OS and LFS were estimated by using the Kaplan-Meier method and were compared with the log-rank test by using GraphPad Prism 5 software."
    },
    {
        "anchor": "We used exact McNemar\u2019s tests to investigate diagnostic yield and molecular adequacy differences between 19g and 22g needles.",
        "positive": "Exact McNemar's tests were used to compare the diagnostic yield and molecular adequacy of 19g and 22g needles.",
        "negative": "We used a logistic regression estimated by Generalized Estimating Equations to investigate whether the needle effect on diagnostic yield differed between \u201ccore biopsy\u201d and cytology smear & cell block (i.e."
    },
    {
        "anchor": "Among the adverse events that were reported in at least 10% of patients, alopecia and pruritus occurred more frequently in the pembro-lizumab-combination group than in the placebo-combination group, whereas back pain occurred more frequently in the placebo-combination group; after adjustment for exposure, rates of alopecia and pruritus were similar in the groups (Fig.",
        "positive": "In the study, alopecia and pruritus were more common in the pembro-lizumab-combination group compared to the placebo-combination group, while back pain was more common in the placebo-combination group; after adjusting for exposure, the rates of alopecia and pruritus were found to be similar between the groups.",
        "negative": "Safety\nAdverse events of any grade, regardless of attribution to a trial regimen by an investigator, occurred in 98.2% of the patients in the pembrolizumab-combination group and in 97.9% of the patients in the placebo-combination group (Table 2)."
    },
    {
        "anchor": "Statistical analyses\nStatistical analysis was applied to biologically independent mice or technical replicates for each experiment.",
        "positive": "For each experiment, statistical analysis was conducted on independent biological samples or technical replicates.",
        "negative": "Endpoints\nThe two primary endpoints were the objective response rate (ORR), which was defined as the proportion of patients achieving a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 assessed by the investigator, and safety."
    },
    {
        "anchor": "Purpose\nABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity.",
        "positive": "ABT-751 is a potent anticancer agent that inhibits cell division and disrupts blood vessels.",
        "negative": "We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non\u2013small-cell lung cancer (NSCLC)."
    },
    {
        "anchor": "Author details\n1Department of Hematology and Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing 100071, China.",
        "positive": "The authors are based at the Department of Hematology and Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.",
        "negative": "2 Department of Immunology/Department of Bio-therapeutic, Institute of Basic Medicine, School of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China."
    },
    {
        "anchor": "Following completion of their sixth dosing cycle, patients who experienced a response (CR or PR) or had remained stable (SD) were eligible to continue on maintenance therapy receiving BTH1677 and cetuximab (BTH1677 arm) or cetuximab alone (Control arm).",
        "positive": "Following six cycles of treatment, patients who achieved a response (CR or PR) or remained stable (SD) were eligible to continue receiving maintenance therapy with either BTH1677 and cetuximab or cetuximab alone.",
        "negative": "Tumour challenges and analyses of tumour growth\nFor subcutaneous tumour challenges, mice were inoculated in the lower flank with 6\u2009\u00d7\u2009104 (B16, KPC or 4T1) or 1\u2009\u00d7\u2009105 (EMT-6, MC38 or CT26) cells resuspended in Hanks balanced salt solution (HBSS, Gibco) mixed 1:1 by volume with Matrigel (Corning, BD Biosciences) on day\u20090."
    },
    {
        "anchor": "For example, if a threshold of at least a 5% risk of cancer is used with the parsimonious model including spiculation (Table 2, model 1b), the sensitivity, specificity, positive predictive value, and negative predictive value are 71.4%, 95.5%, 18.5% and 99.6%, respectively.",
        "positive": "Using a 5% risk of cancer threshold with the parsimonious model that includes spiculation (Table 2, model 1b), the sensitivity, specificity, positive predictive value, and negative predictive value are 71.4%, 95.5%, 18.5%, and 99.6%, respectively.",
        "negative": "APPLICATION IN THE SCREENING SETTING\nIn the screening setting, one of the most difficult decisions is whether CT or another investigation is needed before the next annual low-dose CT study."
    },
    {
        "anchor": "We thank Y. Wang for project management of this study.",
        "positive": "We would like to express our gratitude to Y. Wang for overseeing the project management of this study.",
        "negative": "efficacy\nOf the 22 subjects treated on the phase I study, 16 were assessable for response as they had completed at least two cycles of therapy and had a restaging CT post cycle 2."
    },
    {
        "anchor": "The study protocol was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines What is already known about this subject \u2022 Standard paclitaxel dosing is based on body surface area (BSA); however, BSA alone may not adequately describe the variability of paclitaxel response sufficient to achieve the narrow safety and efficacy margins.",
        "positive": "The study protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Prior knowledge suggests that standard paclitaxel dosing is based on body surface area (BSA), but BSA may not fully capture the variability in paclitaxel response, which is critical for achieving the narrow safety and efficacy margins.",
        "negative": "T-cell enrichment and cell sorting\nT-cells were enriched from apheresis samples by negative selection using EasySep\u2122 Human T Cell Enrichment Kit (#19051; StemCell Technologies) according to the manufacturer\u2019s instructions."
    },
    {
        "anchor": "Similar results were obtained when the population was restricted to those with NSCLC.",
        "positive": "When the analysis was limited to patients with non-small cell lung cancer (NSCLC), similar results were observed.",
        "negative": "Study population\nA total of 42 patients were screened, of which 26 were enrolled and allocated to feladilimab/tremelimumab 8/75 mg (n = 1), 24/75 mg (n = 1), 8/225 mg (n = 5), 80/75 mg (n = 3), 24/225 mg (n = 16), respectively (Supplementary Fig."
    },
    {
        "anchor": "Please refer to the Schedule of Evaluations (<>)(Appendix 1) for additional information.",
        "positive": "Additional details can be found in the Schedule of Evaluations (<>)(Appendix 1).",
        "negative": "STUDY PROCEDURES\nThe study consists of (1) a screening phase, (2) a manufacturing phase consisting of apheresis and preparation of the CART-EGFRvIII cell product(s), (3) a treatment phase, and (4) follow-up."
    },
    {
        "anchor": "Full-length cDNA was synthesized and amplified using SMART-Seq V4 Ultra Low Input RNA Kit (Cat #: 634891, Takara) from 1 ng total RNA per sample.",
        "positive": "The SMART-Seq V4 Ultra Low Input RNA Kit (Cat #: 634891, Takara) was used to synthesize and amplify full-length cDNA from 1 ng of total RNA per sample.",
        "negative": "Libraries were sequenced on an Illumina Hiseq 2500 in paired-end mode with the read length of 100 nt."
    },
    {
        "anchor": "[Published 3 Dec 2017].",
        "positive": "The publication date was December 3, 2017.",
        "negative": "Acknowledgements\nThe authors thank F. Chen and N. Koterba for technical assistance with cytokine quantification assays, and J. Schug for assistance with RNA sequencing."
    },
    {
        "anchor": "This potential conflict of interest has been reviewed and managed by Oregon Health & Science University.",
        "positive": "Oregon Health & Science University managed the potential conflict of interest.",
        "negative": "Authorship\nContribution: R.T.M., S.J.S., D.G.M., and F.L.L."
    },
    {
        "anchor": "Most common treatment-emergent adverse events included diarrhea, dry skin, fatigue, and decreased appetite; the vast majority being grades 1\u20132.",
        "positive": "The most common side effects reported during treatment were diarrhea, dry skin, fatigue, and decreased appetite, with most being mild to moderate.",
        "negative": "Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial\nHuiwen Jiang1,2 (<https://orcid.org/0000-0001-9973-4335>)| Chenggong Li1,2 | Ping Yin3 | Tao Guo1,2 | Lin Liu1 | Linghui Xia1 | Yaohui Wu1,2 | Fen Zhou1,4 | Lisha Ai1 | Wei Shi1 | Xuan Lu1 | Huafang Wang1 | Lu Tang1,2 | Qiuzhe Wei1 | Jun Deng1,2 | Runming Jin1,4 | Wei Xiong2 | Jian Dong2 | Heng Mei1,2* (<https://orcid.org/0000-0001-7941-2443>)|Yu Hu1,2* (<https://orcid.org/0000-0002-2815-4568>)"
    },
    {
        "anchor": "Taking into account eventual losses (patients lost to follow-up or deceased before 1 year), at least 40 patients needed to be included.We reported confidence intervals for a 95% two-sided confidence-level (95% CI), estimated using the binomial approach.",
        "positive": "A minimum of 40 patients were required to be enrolled to account for potential losses.",
        "negative": "Statistical analysis\nThe number of patients to include was assessed following a binomial law, considering a 5% type-one error and 85% statistical power."
    },
    {
        "anchor": "To view a copy of this licence, visit (<http://creativecommons.org/licenses/by/4.0/>)http://creativecommons.org/licenses/by/4.0/.",
        "positive": "To view the terms of this license, visit the Creative Commons website.",
        "negative": "Additional information\nSupplementary Information The online version contains supplementary material available at (<https://doi.org/10.1038/s41598-022-26199-7>)https://doi.org/ (<https://doi.org/10.1038/s41598-022-26199-7>)10.1038/s41598-022-26199-7."
    },
    {
        "anchor": "When evaluated against melanoma metastatic models, the Ad-DCT:MG1-DCT prime-boost not only extended median survivals in comparison to Ad-DCT-treated animals but also cured 20% and 30% of the animals bearing brain and lung metastases, respectively.",
        "positive": "The Ad-DCT:MG1-DCT prime-boost treatment not only extended the median survival of animals with melanoma metastases but also achieved a 20% and 30% cure rate in animals with brain and lung metastases, respectively.",
        "negative": "INTRODUCTION\nUntil the advent of immunotherapy, \ufb01rst-line treatment of patients with advanced nonsquamous non\u2012small-cell lung cancer (NSCLC) without an EGFR/ALK alteration was platinum-based chemotherapy, with addition of bevacizumab as an option in select patients.1,2 The introduction of pembrolizumab, an anti\u2012programmed death-1 (PD-1) monoclonal antibody, has altered the treatment paradigm for patients with NSCLC."
    },
    {
        "anchor": "Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.",
        "positive": "Liquid biopsies were used to track trastuzumab resistance in patients with metastatic HER2-positive gastric cancer.",
        "negative": "Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made."
    },
    {
        "anchor": "S4 Time course studies on expression of activation and checkpoint proteins in Descartes-08 vs control T cells in co-cultures\n(A-E) Descartes-08 and the paired control (ctrl) CD8+ T cells (n = 3) were co-cultured with various target MM cells (solid black symbols) or no target cells (open gray diamond) (E:T = 1:10) (Fig.",
        "positive": "A time course analysis was performed to investigate the expression of activation and checkpoint proteins in Descartes-08 and control T cells co-cultured with target MM cells or no target cells.",
        "negative": "(F) Fold changes of MFI values for CD38 in Descartes-08 vs the paired ctrl CD8+ T cells at the same indicated time periods."
    },
    {
        "anchor": "Molecular analysis of tumor specimens was conducted in Dr Alice Shaw\u2019s laboratory and funded by an RO1 grant from the National Institutes of Health.",
        "positive": "Molecular analysis of tumor specimens was conducted in Dr. Alice Shaw's laboratory, funded by an RO1 grant from the National Institutes of Health.",
        "negative": "Statistical Analysis\n17 18 Descriptive statistics were computed to summarize patient and disease characteristics."
    },
    {
        "anchor": "This combination warrants further investigation in MpBC, with special attention to understanding mechanism of action, and carefully designed to weigh against the significant risks of irAEs.",
        "positive": "The combination therapy requires further study in MpBC, with a focus on elucidating its mechanism of action and carefully balancing the risks of irAEs.",
        "negative": "Abstract\nPURPOSE: Metaplastic breast cancer (MpBC) is a rare aggressive subtype that responds poorly to cytotoxics."
    },
    {
        "anchor": "The MTD was defined as a safe dose with the highest probability of DLT in the targeted toxicity interval (20%\u201335%).",
        "positive": "The maximum tolerated dose was established as the safest dose with a 20-35% likelihood of severe adverse effects.",
        "negative": "Guidelines for Screening, Early Diagnosis and Early Treatment of Lung Cancer in China (Beijing, 2021)."
    },
    {
        "anchor": "Tumor mutational burden (TMB) was assessed by whole-exome sequencing.",
        "positive": "Whole-exome sequencing was used to determine the tumor mutational burden.",
        "negative": "Conclusion\nSubjective toxicities are at high risk of under-reporting by physicians, even when prospectively collected within randomized trials."
    },
    {
        "anchor": "These assessments will be performed prior to the pembrolizumab infusion unless otherwise indicated.",
        "positive": "Pembrolizumab infusion will be preceded by assessments, unless otherwise instructed.",
        "negative": "Nested PCR for detection of free AdCCL21 from patients\u2019 plasma\nTo detect free adCCL21, DNA was extracted from patient\u2019s plasma using a kit (QIAGEN, Valencia, CA) and used for PCR."
    },
    {
        "anchor": "Cell proliferation assay\nWe seeded 2000 PDAC cells/well in 96-well plates for 24 hours.",
        "positive": "The cell proliferation assay involved seeding 2000 PDAC cells per well in 96-well plates for 24 hours.",
        "negative": "The 96-well plates were cultured at 37\u00b0C in 5% CO2 for 2 hours."
    },
    {
        "anchor": "Overall, 84.3% were men, median age was 61 years [39.5-73.8] and median KPS was 90% [80-100%].",
        "positive": "The demographic data showed that 84.3% of participants were male, with a median age of 61 years and a median KPS of 90% (80-100%).",
        "negative": "Tocilizumab: IV infusion over 1 hour\n\u2022 Patient weight < 30 kg: 12 mg/kg i.v."
    },
    {
        "anchor": "Inclusion criteria\n\ue001 Age of 70 years or older \ue001 Pre-operation criteria (contrast-enhanced computed tomography (CT) scan) \u25aa Suspected peripheral NSCLC.",
        "positive": "Eligibility criteria included being 70 years or older and meeting pre-operative criteria, including a contrast-enhanced CT scan, with suspected peripheral NSCLC.",
        "negative": "Multidisciplinary patient-centered management of brain metastases and future directions."
    },
    {
        "anchor": "[35] During the study, a requirement for a baseline MRI of the brain with contrast was added.",
        "positive": "The study protocol was updated to include a baseline MRI of the brain with contrast.",
        "negative": "French regulatory framework\nIn addition to GDPR, the transfer of this data by Centre Jean Perrin is a processing in itself that is subject to Chapters IX and XII of the updated Law no."
    },
    {
        "anchor": "At doses of 120\u2009mg Q2W and above, tebotelimab demonstrated complete and sustained PD-1 occupancy in CD4 and CD8 T cells, based on peripheral blood flow cytometry analyses (Extended Data Fig.",
        "positive": "At doses of 120\u2009mg Q2W and above, tebotelimab occupied PD-1 receptors on CD4 and CD8 T cells, as measured by peripheral blood flow cytometry.",
        "negative": "Safety, pharmacokinetics, pharmacodynamics of tebotelimab in solid tumors\n35 The MTD (primary endpoint) was not defined up to 1,200\u2009mg Q2W."
    },
    {
        "anchor": "For the detailed statistics analysis plan, see supplemental Methods.",
        "positive": "The detailed statistics analysis plan is provided in the supplemental Methods section.",
        "negative": "ACKNOWLEDGEMENTS\nWe would like to acknowledge all investigators, coordinators, and study site personnel, as well as patients and their families for their participation in this study."
    },
    {
        "anchor": "Only record in each case report form record data of a clinical study subject.",
        "positive": "Data for each clinical study participant should be recorded in the case report form.",
        "negative": "4.12.7 Case report form\nThe investigator must ensure that the electronic case report form is completed and accurately completed."
    },
    {
        "anchor": "1 | Trial schema for the interventional second stage of the BR.36 study.",
        "positive": "The trial schema for the interventional second stage of the BR.36 study is outlined below.",
        "negative": "Additional information\nExtended data is available for this paper at (<https://doi.org/10.1038/s41591-023-02598-9>)https://doi.org/10.1038/s41591-023-02598-9."
    },
    {
        "anchor": "C-CL: Abbvie, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, PharmaEngine, and Roche.",
        "positive": "The following pharmaceutical companies are involved in the study: Abbvie, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, PharmaEngine, and Roche.",
        "negative": "AI: Epizyme, Lilly, Merck Sharp & Dohme, Novartis, Pharmamar, Roche, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Pfizer."
    },
    {
        "anchor": "All patients were required to sign an informed consent form before enrollment.",
        "positive": "Patients were required to give their informed consent prior to participating in the study.",
        "negative": "Ethics approval and consent to participate\nThis trial has been approved by the institutional review boards (ID: 2016-XY-023) and the independent ethics committees of Sun Yat-sen University Cancer Center (Ethic approval ID: 5010-2016-03)."
    },
    {
        "anchor": "These findings highlight the ongoing importance of validation studies before CTVI technology can be widely translated from academic centers to the clinic.",
        "positive": "The results emphasize the need for validation studies to ensure the successful translation of CTVI technology from academic centers to clinical practice.",
        "negative": "CONCLUSIONS\nCT ventilation imaging (CTVI) research has focused extensively on clinical validation, but until now there has been little in the way of common validation tools for CTVI researchers."
    },
    {
        "anchor": "Seven patients (n \u00bc 2 at 22.5 mg; n \u00bc 5 at 30 mg) received GCSF, most often in the first cycle.",
        "positive": "GCSF was administered to 7 patients, with 2 receiving 22.5 mg and 5 receiving 30 mg, primarily in the first cycle.",
        "negative": "3.6 | Immunological studies\nPBMCs were available to measure antigen-specific T-cell responses prior to and during therapy from three patients in C1, and one patient in C2 who were treated at the NCI."
    },
    {
        "anchor": "In the linifanib 12.5-mg arm, median PFS Fig 3.",
        "positive": "The median progression-free survival in the linifanib 12.5-mg arm is shown in Fig 3.",
        "negative": "5.7 Subject Replacement Strategy\nSubjects who receive at least 1 dose of Pembrolizumab will be considered evaluable and will not be replaced."
    },
    {
        "anchor": "Our web collection on statistics for biologists contains articles on many of the points above.",
        "positive": "Our online collection of statistics for biologists covers many of the points mentioned above.",
        "negative": "Statistics\nFor all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section."
    },
    {
        "anchor": "Analyzed the data: CL DJS JJL LJ RR GJ MIN IIW JJE MEH",
        "positive": "The data analysis was conducted by a team consisting of CL, DJS, JJL, LJ, RR, GJ, MIN, IIW, JJE, and MEH.",
        "negative": "Author Contributions\nConceived and designed the experiments: CL DJS JJL LJ GJ MIN IIW EAG JMR JAR."
    },
    {
        "anchor": "In vitro and in vivo activity of lucitanib in FGFR1/2 amplified or mutated cancer models.",
        "positive": "The in vitro and in vivo activity of lucitanib was evaluated in FGFR1/2 amplified or mutated cancer models.",
        "negative": "Comparison of nivolumab exposures\nCavgss values were comparable (<6% difference) between 480 mg Q4W and 3 mg/kg Q2W (Table (<>)1)."
    },
    {
        "anchor": "In our preclinical murine models, CCL21 treatment resulted in an increase in CD4, CD8, and CD11c+DEC205+ dendritic cell infiltrates into the tumor creating a lymphoid-like microenvironment [12].",
        "positive": "Treatment with CCL21 in our preclinical murine models resulted in an influx of CD4, CD8, and CD11c+DEC205+ dendritic cells into the tumor, generating a lymphoid-like microenvironment.",
        "negative": "Introduction\nLung cancer is the leading cause of cancer death in the United States, and immunotherapy with checkpoint inhibitors is transforming therapeutic approaches [1, 2]."
    },
    {
        "anchor": "Medical writing support was provided by Paul Shepherd, MA, CMPP of Engage Scientific Solutions and was funded by Pfizer.",
        "positive": "Engage Scientific Solutions, with funding from Pfizer, provided medical writing support for the study, courtesy of Paul Shepherd.",
        "negative": "5 Conclusions\nIn conclusion, this study in patients with advanced non-squamous NSCLC demonstrated similarity between PF-06439535 and bevacizumab-EU in terms of the primary efficacy endpoint of ORR, when each was administered in combination with paclitaxel and carboplatin as first-line treatment."
    },
    {
        "anchor": "R Herbst has no potential conflicts of interest.",
        "positive": "R Herbst has no personal or professional interests that could influence the study's outcome.",
        "negative": "Competing interests\nG Bigley, A Dale, S Fan, H Fu, Q Ji, A Platt, J Read, X Su, V Williams, Q Ye, L Zheng and T Zhang are employed (other than primary affiliation; e.g., consulting) by AstraZeneca."
    },
    {
        "anchor": "Esophagitis does not constitute a reason to interrupt or delay RT or chemotherapy provided oral intake is sufficient to maintain hydration.",
        "positive": "Esophagitis is not a valid reason to pause or delay radiation therapy or chemotherapy, as long as patients can maintain hydration through oral intake.",
        "negative": "Esophagitis\nEsophageal complaints are common with concurrent CRT."
    },
    {
        "anchor": "Trial treatment should begin on the day of enrollment or as close as possible to the date on which treatment is allocated/assigned.",
        "positive": "The trial treatment should commence on the day of enrollment or at the earliest opportunity after treatment assignment.",
        "negative": "5.2.1.1 Dose Selection (Preparation)\nThe rationale for selection of doses to be used in this trial is provided in Section 4.0 \u2013 Background & Rationale."
    },
    {
        "anchor": "Gastonguay MR (2011) Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies.",
        "positive": "Gastonguay's 2011 review examined the methodology and 42 case studies on the application of full covariate models in place of statistical significance for covariate effect analysis.",
        "negative": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.3.2022."
    },
    {
        "anchor": "Data for select patients are shown in (<>)Figure 3, and data for all patients is shown in (<>)Supplementary Figure S2.",
        "positive": "Data for a selection of patients is depicted in Figure 3, and data for all patients is presented in Supplementary Figure S2.",
        "negative": "Swimmer\u2019s plot displays each individual patient\u2019s time in the study (in months), their disease diagnosis, and outcomes."
    },
    {
        "anchor": "ECOG, Eastern Cancer Oncology Group.",
        "positive": "The Eastern Cancer Oncology Group (ECOG) is a recognized organization.",
        "negative": "Table 2\nPatient demographics and clinical characteristics (N = 21)."
    },
    {
        "anchor": "Accordingly, we noted that TRAIL-engineered NK cells express significantly higher levels of NKp30 and CD16 with a trend for increased NKG2D expression (panel A).",
        "positive": "The study found that TRAIL-engineered NK cells displayed significantly higher levels of NKp30 and CD16, with a trend towards increased NKG2D expression, as depicted in panel A.",
        "negative": "Will my medical information be kept private?"
    },
    {
        "anchor": "inoperable Stage II disease requiring chemoradiation therapy or stage IIIA or IIIB NSCLC based on appropriate staging studies including brain MRI or head CT, CT Chest, and FDG-PET/CT scan.. 5.",
        "positive": "Patients with inoperable Stage II disease requiring chemoradiation therapy or Stage IIIA or IIIB NSCLC, as determined by staging studies including brain MRI, head CT, CT Chest, and FDG-PET/CT scan, were included in the study.",
        "negative": "5.1.2 Subject Inclusion Criteria\n1."
    },
    {
        "anchor": "Analogous to the arginine deplete microenvironment found in patients at diagnosis, administration of recombinant arginase led to a signi\ufb01cant reduction in serum arginine (p = 0.001; Fig.",
        "positive": "Similar to the arginine-depleted microenvironment present at patient diagnosis, recombinant arginase administration resulted in a significant reduction in serum arginine levels (p = 0.001; Figure).",
        "negative": "The failure to address the low arginine microenvironment impairs anti-CTAG clinical responses\nArginine metabolism is a pathway which is aberrant in AML blasts and can influence the immune microenvironment.4,9 Using an immunocompetent, syngeneic model of AML, we showed that significant numbers of AML blasts (CD45.2+) were detectable in the bone marrow (median 80%) and spleens (median 40%) of mice, analogous to presentation of AML in patients (Supporting Information Fig."
    },
    {
        "anchor": "Most patients were male (63.1%) and either Caucasian (57.1%) or Asian (29.9%) race.",
        "positive": "The patient population was predominantly male (63.1%), with a mix of Caucasian (57.1%) and Asian (29.9%) ethnicities.",
        "negative": "Exposure\u2013safety analyses\nA total of 499 patients from five clinical trials who received multiple doses of tepotinib monotherapy ranging from 30 to 1400 mg/day were included in the exposure\u2013safety analyses (Supplementary Table S2)."
    },
    {
        "anchor": "Efficacy and safety analyses were conducted on the intent-to-treat (ITT) population, which comprised all patients who received at least one dose of study medication.",
        "positive": "The entire patient population, including those who received at least one dose of the study medication, was evaluated for efficacy and safety.",
        "negative": "Time-to-event endpoints (overall survival, progression-free survival and duration of response) were estimated using Kaplan-Meier survival analysis."
    },
    {
        "anchor": "Following incubation at 37 \u00b0C for 1 h, 100 \u00b5l of biotinylated IFN\u03b3 detection antibody (BAF-285, R&D systems, MN, USA) was added to each well for a further hour at 37 \u00b0C.",
        "positive": "The biotinylated IFN\u03b3 detection antibody (BAF-285) was added to each well after a 1-hour incubation at 37 \u00b0C and left for another hour at the same temperature.",
        "negative": "www.impactjournals.com/oncotarget/\nOncotarget, 2017, Vol."
    },
    {
        "anchor": "5 Four cycles of platinum-based chemotherapy are considered optimal for advanced NSCLC.The use of maintenance therapy after combination chemotherapy 6 7 8 results in improved overall survival (OS) and has been adopted in routine clinical practice.",
        "positive": "Four cycles of platinum-based chemotherapy are widely accepted as the optimal treatment for advanced NSCLC, and the addition of maintenance therapy after combination chemotherapy has been found to enhance overall survival.",
        "negative": "Consequently, the regimens of cisplatin/carboplatin and pemetrexed followed by pemetrexed maintenance and carboplatin, paclitaxel, and bevacizumab followed by bevacizumab maintenance are used in routine care for patients with advanced nonsquamous NSCLC."
    },
    {
        "anchor": "Exclusion criteria\n(1) Small cell lung cancer (including lung cancer mixed with small cell carcinoma and non-small cell carcinoma); (2) Those with multiple factors that affect oral medications (such as inability to swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal obstruction); (3) Known symptomatic brain metastasis, spinal cord compression, cancerous meningitis, or brain or pia mater disease detected by CT or MRI; (4) Those with a history of psychotropic substance abuse who are unable to quit or have mental disorders; (5) Patients participating in other clinical studies; (6) Patients with autoimmune diseases or immunodeficiency diseases; (7) Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.",
        "positive": "Patients with the following conditions were excluded: small cell lung cancer, certain medical conditions affecting oral medication absorption, brain metastases, and a history of substance abuse or mental disorders.",
        "negative": "Methods\nidentifier<- signature(object = \"normalization\", value = \"character\"): Set method for the identifier slot."
    },
    {
        "anchor": "Site investigators screened preoperative patient-counselling clinics daily and invited patients to participate in the trial.",
        "positive": "Patients were identified and invited to participate in the trial through daily screenings at preoperative counseling clinics conducted by site investigators.",
        "negative": "Usage\nlogicleTransform(transformationId=\"defaultLogicleTransform\", w = 0.5, t = 262144, m = 4.5, a = 0) estimateLogicle(x, channels,...)"
    },
    {
        "anchor": "There was also no difference in OS between patients who previously received ipilimumab and nivolumab in combination (n\u2009=\u200914) and those who were CPI treatment-na\u00efve (n\u2009=\u20094) (hazard ratio 1.31, 95% confidence interval (0.23, 2.81), P\u2009=\u20090.68).",
        "positive": "The study found no significant difference in overall survival between patients who had received ipilimumab and nivolumab in combination and those who had not received CPI treatment before.",
        "negative": "Efficacy\nOS was analyzed as a planned secondary endpoint of the trial."
    },
    {
        "anchor": "[PubMed: 11325483] 24.",
        "positive": "According to a study published in PubMed (reference 11325483), the following results were observed.",
        "negative": "10.1 Study Monitoring Plan\nThis study will be monitored according to the Sponsor Data and Safety Monitoring Plan."
    },
    {
        "anchor": "There was no significant difference in overall survival between treatment groups (table 2, figure 2).",
        "positive": "The analysis found no significant difference in overall survival between the treatment groups, as shown in Table 2 and Figure 2.",
        "negative": "After a series of meetings between June 14, 2010, and Jan 31, 2011, the independent data monitoring committee recommended that study enrolment be stopped, and necitumumab treatment discontinued in patients who had not completed two cycles of treatment."
    },
    {
        "anchor": "The patient population had a median age of 64 years, with 59% male and 87% white, 84% current or former smokers, and 67% with adenocarcinoma tumors (Table 1).",
        "positive": "The patient population had a median age of 64 years, with a mix of demographics, including 59% male, 87% white, 84% current or former smokers, and 67% with adenocarcinoma tumors.",
        "negative": "Study Population\nA total of 132 patients from North America, Asia, and Europe were enrolled between November 2012 and March 2013 to the phase II study group A and randomized to receive ser-ibantumab plus erlotinib (n = 85) or erlotinib alone (n =44; Fig."
    },
    {
        "anchor": "For patients with multiple lesions, graphs of each lesion were grouped into separated panels to show tumor volume changes over time after CD19-BBZ(86) CAR-T cell therapy.",
        "positive": "Tumor volume changes for each lesion were visualized in separate panels for patients with multiple lesions, illustrating the impact of CD19-BBZ(86) CAR-T cell therapy over time.",
        "negative": "Consent for publication Not applicable."
    },
    {
        "anchor": "Eligible patients were assigned to a cohort and received intratumoral vaccine injections in conjunction with tumor sampling and patient monitoring (Figure 1A).",
        "positive": "Patients who met the eligibility criteria were grouped into cohorts and received a combination of intratumoral vaccine injections, tumor sampling, and patient monitoring, as depicted in Figure 1A.",
        "negative": "ABSTRACT\nIntroduction: Using mathematical modelling allows to select a treatment\u2019s regimen across infinite possibilities."
    },
    {
        "anchor": "Patients\nEligible patients had documented advanced solid tumors; an age of 18 years or older; a life expectancy of 12 weeks or more; an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 (on a scale from 0 to 5, with 0 indicating that the patient is asymptomatic, 1 that the patient is restricted in strenuous activity, and 2 that the patient is ambulatory but unable to work)17; measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0,18 with modification (see Methods S1 in the Supplementary Appendix, available at NEJM.org; and the protocol); adequate hematologic, hepatic, and renal function; and a history of one to five systemic treatment regimens.",
        "positive": "Patients who qualified for the study had to meet a set of criteria, including having advanced solid tumors, being at least 18 years old, having a life expectancy of at least 12 weeks, and having a performance status of 0, 1, or 2, as well as measurable disease, adequate organ function, and a history of one to five systemic treatment regimens.",
        "negative": "Quality of life\nThe Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) was used to assess lung cancer-specific quality of life [(<>)52]."
    },
    {
        "anchor": "Among patients with documented ALK/ROS1 positivity, 41 (77%) of 53 patients had ALK-positive NSCLC, while 12 (23%) had ROS1-positive NSCLC; one patient had an unconfirmed ALK/ROS1 status (ALK FISH analysis was negative with 6% split signals; ROS1 testing was not performed) and was omitted from the ITT population.",
        "positive": "Among patients with confirmed ALK/ROS1 positivity, 41 (77%) had ALK-positive NSCLC and 12 (23%) had ROS1-positive NSCLC, with one patient omitted from the ITT population due to an unconfirmed ALK/ROS1 status.",
        "negative": "DATA AVAILABILITY STATEMENT\nNovartis will not provide access to patient-level data if there is a reasonable likelihood that individual patients could be re-identified."
    },
    {
        "anchor": "The gating strategy for immunophenotyping is shown in Extended Data Fig.",
        "positive": "The Extended Data Figure illustrates the gating strategy used for immunophenotyping.",
        "negative": "N Engl J Med 381(21):2020\u20132031."
    },
    {
        "anchor": "We investigated the additional benefit of perioperative treatment with durvalumab.",
        "positive": "The study explored the benefits of incorporating durvalumab into perioperative treatment.",
        "negative": "The primary end point was 1-year EFS."
    },
    {
        "anchor": "The study drug should be stored in accordance with the storage conditions and should be stored in its original container, which should be consistent with that on the drug label.",
        "positive": "The study medication should be stored in accordance with the recommended storage conditions and in its original packaging, which should match the label instructions.",
        "negative": "5 Study Drug\n5.1 Name: Camrelizumab Manufacturer: Suzhou Suncadia Biopharmaceuticals Co., Ltd."
    },
    {
        "anchor": "Auditing and Inspecting\nThe investigator will permit study-related monitoring, audits, and inspections by the IRB, the Sponsor, government regulatory bodies, and University compliance and quality assurance groups.",
        "positive": "The investigator will allow monitoring, auditing, and inspection of the study by the IRB, Sponsor, government regulatory bodies, and University compliance and quality assurance groups.",
        "negative": "Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable University compliance and quality assurance offices."
    },
    {
        "anchor": "[4, 5] The degranulation activity was evaluated by flow cytometry analysis and determined as the percentage of CD107a+ CD8+ cells.",
        "positive": "Flow cytometry analysis was used to evaluate degranulation activity, which was quantified as the percentage of CD107a+ CD8+ cells.",
        "negative": "Degranulation assay (CD107a mobilization)\nDescartes-08 or the paired control CD8+ T cells were incubated in 96-well plates (100,000 cells/well), together with MM cell lines (H929, U266, MM1S, MM1R), bone marrow mononuclear cells (BMMC) or purified CD138+ cells from MM patients."
    },
    {
        "anchor": "Similarly, survival analysis was repeated from 32 to 29 EGFR-mutant NSCLC patients for GSE11969 and GSE72094.",
        "positive": "The survival analysis was repeated for 32 to 29 EGFR-mutant NSCLC patients in the GSE11969 and GSE72094 datasets.",
        "negative": "YAP1 Is Not a Prognostic Factor of LUAD."
    },
    {
        "anchor": "This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Conference on Harmonisation.",
        "positive": "In accordance with the Declaration of Helsinki and the International Conference on Harmonisation's Good Clinical Practice Guidelines, this study was conducted.",
        "negative": "Study Oversight\nThis study was approved by the institutional review boards at 4 study centers in the United States prior to commencement."
    },
    {
        "anchor": "No parameters were identified as significant prognostic factors for OS.",
        "positive": "No variables were found to be significant predictors of overall survival.",
        "negative": "ACKNOWLEDGMENT\nThis work was supported in part by a Cancer Institute NSW Early Career Fellowship, the Cancer Australia Priority-driven Collaborative Cancer Research Scheme Grant APP1060919 as well as National Institute of Health Grants R01HL079406, R01CA166703 and P01CA059827."
    },
    {
        "anchor": "A review of two regulatory approved anti-CD19 CAR T-cell therapies in di0use large B-cell lymphoma: why are indirect treatment comparisons not feasible?",
        "positive": "A study examining two approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: the limitations of indirect treatment comparisons.",
        "negative": "CAR-T cell therapy in cancer: tribulations and road ahead."
    },
    {
        "anchor": "Acknowledgements\nThe authors would like to thank the patients, their families, and all investigators involved in these studies.",
        "positive": "We would like to express our gratitude to the patients, their families, and the investigators who participated in these studies.",
        "negative": "Baseline Clinical and Post Treatment Biological Characteristics Associated with Neurotoxicity\nIn order to identify clinical and biological factors that are associated with severe neurotoxicity, we examined age, gender, weight, body mass index, number of prior therapies, pretreatment disease burden, Philadelphia chromosome positive (Ph+) ALL, CAR T cell doses, prior hematopoietic stem cell transplant (HSCT) status, conditioning chemotherapy regimen, and infused CAR T cell product characteristics."
    },
    {
        "anchor": "Gut Microbial Signature in Lung Cancer Patients\nThe multi-level LEfSe was used to analyze biomarkers between the lung cancer patients with di\ue013erent histopathology and the healthy controls.",
        "positive": "A multi-level LEfSe analysis was conducted to identify biomarkers in lung cancer patients with varying histopathology compared to healthy controls.",
        "negative": "(B) PCoA analysis of intestinal flora in four groups of samples."
    },
    {
        "anchor": "Eight patients with high-level MET amplification NSCLC had rapid progression, underlying that it is an independent poor prognostic factor.",
        "positive": "Rapid disease progression was observed in eight patients with high-level MET amplification in NSCLC, suggesting that MET amplification is an independent poor prognostic factor.",
        "negative": "DISCUSSION\n22 23 30 In this study, tepotinib provided antitumor activity in patients with NSCLC with high-level MET amplification detected by liquid biopsy: ORR was 41.7%, CBR was 45.8%, and median DOR was 14.3 months."
    },
    {
        "anchor": "Isodose coverage of the PTV was near protocol requirements for most patients, as was dose spillage and adherence to protocol-recommended limits for OAR doses.",
        "positive": "Most patients had isodose coverage of the PTV that met protocol requirements, with similar results for dose spillage and adherence to OAR dose limits.",
        "negative": "*\nCopy and paste relevant sections from the manuscript (include quotes in quotation marks \"like this\" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briepy explain why the item is not applicable/relevant for your study The paper reports on responses participants (caregivers) gave to weekly Check-Ins in the online intervention."
    },
    {
        "anchor": "PBMCs were stimulated with 50 ng/ml anti-CD3 MoAb (Takara, Japan) and 500 U/ ml recombinant human interleukin-2 (Peprotech, USA) in GT-T551 medium (Takara).",
        "positive": "PBMCs were activated using a combination of 50 ng/ml anti-CD3 monoclonal antibody (Takara, Japan) and 500 units per milliliter recombinant human interleukin-2 (Peprotech, USA) in GT-T551 medium (Takara).",
        "negative": "SUPPLEMENTAL INFORMATION\nSupplemental Information can be found online at (<https://doi.org/10.1016/j.ymthe.2020.09.027>)https://doi.org/10."
    },
    {
        "anchor": "This analysis included 5,555 patients from 21 different cohorts including breast, cervical and prostate cancer.",
        "positive": "This study analyzed data from 5,555 patients across 21 different cohorts, including breast, cervical, and prostate cancer.",
        "negative": "Results\nA total of 4996 randomized patients received at least one dose of the study drug (safety population of 2748 received ramucirumab and 2248 received placebo)."
    },
    {
        "anchor": "Patient population\nA total of 29 patients with TRK fusion-positive TC were identified at the data cut-off of 20 July 2020.",
        "positive": "As of July 20, 2020, a total of 29 patients with TRK fusion-positive TC were identified in the patient population.",
        "negative": "Two patients classified as ATC by the local investigators had poorly differentiated TC (PDTC), as did one patient classified as PTC (Supplementary Table 1)."
    },
    {
        "anchor": "Learn more biomedcentral.com/submissions",
        "positive": "Visit biomedcentral.com for submission guidelines.",
        "negative": "Publisher\u2019s Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
    },
    {
        "anchor": "Support for third-party editorial support for this manuscript was provided by Shanghai Roche Pharmaceuticals Limited.",
        "positive": "This manuscript received editorial support from Shanghai Roche Pharmaceuticals Limited.",
        "negative": "Acknowledgements\nWe thank all patients who participated in this study."
    },
    {
        "anchor": "A confidence interval for the median survival time.",
        "positive": "The median survival time was estimated with a confidence interval.",
        "negative": "Ethics, informed consent and safety\nThe final protocol was approved by the ethics committee of the University of Heidelberg, Germany [] and the Bun-desinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM-registration number 4031656)."
    },
    {
        "anchor": "Perioperative conditions\nEfficacy was evaluated after patients received 2 treatment cycles; with the exception of two control group patients with in which tumors progressed to stage IV and were surgically unresectable, the remaining 24 patients underwent standard radical lung cancer resection (lung lobectomy and regional lymph node dissection).",
        "positive": "After two treatment cycles, treatment efficacy was evaluated in patients, excluding those with advanced tumors who required surgery; the remaining patients underwent standard lung cancer surgery.",
        "negative": "There were no significant differences in intraoperative blood loss, number or groups of lymph dissected nodes, duration of postoperative indwelling catheter use, mean daily chest drainage volume, or mean duration of postoperative hospitalization between the control and test groups (Table 3)."
    },
    {
        "anchor": "If drug destruction on site is not feasible, OCOG will provide instruction for the return of the drug.",
        "positive": "If on-site drug destruction is not possible, OCOG will provide guidance on returning the drug.",
        "negative": "7.5 Accountability Procedures\nBARL will be responsible for procuring and storing the study supply of Metformin."
    },
    {
        "anchor": "ASCO in Action provides key details for the cancer community on critical issues affecting the delivery of care, including federal funding for cancer research, the ongoing response to COVID-19, physician reimbursement, and more.",
        "positive": "ASCO in Action offers crucial information to the cancer community on key issues impacting cancer care, such as federal funding, COVID-19 response, and physician reimbursement.",
        "negative": "ASco\u00b7 in Action\nYour Source for Cancer Policy and Practice News ASCO in Action provides the latest news and analysis on cancer policy and practice issues through a frequently updated newsfeed and biweekly newsletter."
    },
    {
        "anchor": "Main secondary endpoints include treatment-related toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0), frequency of major anatomical changes on daily MRI, local tumor control, patterns of tumor recurrence, progression-free survival, overall survival, patient-reported outcomes and pulmonary function.",
        "positive": "Secondary endpoints included treatment toxicity, MRI changes, local tumor control, tumor recurrence patterns, patient-reported outcomes, and pulmonary function.",
        "negative": "Study design and participants\nThis was a multicenter, randomized, open-label, active-controlled phase III trial, which enrolled patients with advanced ALK-positive NSCLC in 44 centers in China from August 21, 2019 to July 13, 2020."
    },
    {
        "anchor": "Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.",
        "positive": "In a mouse melanoma model, CD25-targeted photodynamic therapy led to the depletion of regulatory T cells within tumors, resulting in antitumor immune responses.",
        "negative": "Exceptions to Expedited Reporting: EXPECTED Serious Adverse Events\nAn expedited report may not be required for specific Grade 1, 2 and 3 Serious Adverse Events where the AE is listed in Section 15.0 of the protocol as EXPECTED."
    },
    {
        "anchor": "Ningbo Clinical Medicine Research Center Project (Grant No.",
        "positive": "The Ningbo Clinical Medicine Research Center Project (Grant Number.",
        "negative": "Outcomes\nThe primary endpoint was overall survival, defined as the time from randomisation to death from  any cause."
    },
    {
        "anchor": "Reasons for treatment interruptions should be documented in the patients chart.",
        "positive": "Treatment interruptions should be recorded in the patient's medical chart.",
        "negative": "PK Analysis\nOverall, 59 patients in the Asian population had at least one PK assessment and were included in the PK analysis set."
    }
]